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ABSTRACT 
 
 
Arteriovenous fistula (AVF) are widely considered to be the optimal form of vascular 
access for haemodialysis incurring fewer complications, superior patency, better dialysis 
quality and a lower mortality than tunnelled central venous catheters (TCVCs). The use of 
TCVCs is associated with a six-fold increase in the risk of systemic sepsis, long-term 
morbidity from central vein stenosis and a higher risk of cardiovascular and all-cause 
mortality compared to AVF. 
 
Despite the relative success of strategies such as “Fistula First” and the best practice target 
in England and Wales (with simultaneous improvement in prevalent autologous access 
use) there has been no such associated improvement in incident vascular access rates.  
The importance of “getting it right from the start” cannot be overemphasised. Patients who 
start dialysis via a line are more likely to remain with a line. Data from the UK Renal 
Registry indicate that 59.8% of patients starting on a TCVC remain dialysing via a TCVC 
at 3 months and >40% still have their TCVC after 1 year. The legacy of poor early 
vascular access decision-making remains with the patient throughout their life on dialysis. 
This thesis sought to evaluate methods for improving vascular access within the incident 
patient cohort. A multifaceted approach was taken to address several key themes: 
1. TCVC complications and central vein stenosis: avoiding problems for the future. 
2. Predicting maturation in incident dialysis patients. 
3. Promoting maturation: strategies to optimise maturation. 
4. Right access, right patient, right time: individualised, patient-centred care. 
5. ‘Crashlanders’: managing patients who present without prior warning. 
The emphasis of this work was directed towards finding pragmatic, patient-focussed 
solutions to clinically relevant problems. The dogma of “Fistula First at all costs” is 
challenged. 
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ERA- EDTA European Renal Association- European Dialysis and Transplant Association 
ERF  established renal failure 
ESRD  end stage renal disease 
ESVA  end stage vascular access 
FDA  United States Food and Drug Administration 
FFBI  Fistula First Breakthrough Initiative 
FTM  failure to mature 
G  gauge 
HD   haemodialysis 
HLA  human leucocyte antigen 
HeRO  Haemodialysis Reliable Outflow 
HR  hazard ratio 
HSP  Henoch Schonlein Purpura 
IHD  ischaemic heart disease 
IQR  interquartile range 
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ISD  Information Service Department 
k  thousand 
KAG  Kidney Advisory Group 
Kt/V a marker of dialysis adequacy determined by pre- and post-dialysis urea 
levels 
LA  local anaesthesia 
m million 
MDRD-4 Modifications of Diet in Renal Disease-4 
MDT Multidisciplinary Team 
MI myocardial infarction 
MRSA methicillin resistant Staphylococcus aureus 
MSSA methicillin sensitive Staphylococcus aureus 
NHS National Health Service 
NHS-BT National Health Service-Blood and Transplant 
NICE National Institute of Clinical Excellence 
NKF-KDOQI National Kidney Foundation- Kidney Disease Outcomes Quality Initiative 
NR not reported 
NTCVC non-tunnelled central venous catheter 
o.d. once daily 
OR odds ratio 
PbR payment by results 
PD peritoneal dialysis 
pmp  per million population 
PRD  primary renal disease 
Pre-D  pre-dialysis 
pt  patient 
PTFE   polytetrafluoroethylene 
PVD  peripheral vascular disease 
Qa  vascular access blood flow 
QALY  quality adjusted life year 
QDS  four times per day 
QI  Quality Improvement 
QoL  quality of life 
RCF  radiocephalic fistula 
RCT  randomised controlled trial 
RUDI  revision using distal inflow 
rr  risk ratio 
RR  relative risk 
RRT  renal replacement therapy 
SD  standard deviation 
SERPR Scottish Electronic Renal Patient Registry 
SLE  systemic lupus erythematosus 
SRR  Scottish Renal Registry 
TCVC  tunnelled central venous catheter 
tPA  tissue plasminogen activator 
UK  United Kingdom 
UK-RR United Kingdom Renal Registry 
URR  urea reduction ratio 
US  United States 
USRDS United States Renal Data System 
VSM  vascular smooth muscle 
y.o.  years old 
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SUMMARY 
Arteriovenous fistula (AVF) are considered the ‘gold standard’ vascular access for 
haemodialysis (HD) and are recommended as first line by both the Renal Association and 
Vascular Access Society. AVF have superior patency rates and provide better quality HD 
than alternative access modalities. The use of TCVCs is associated with a six-fold increase 
in the risk of systemic sepsis, long-term morbidity from central vein stenosis and a higher 
risk of cardiovascular and all-cause mortality compared to AVF. For these reasons there 
has been significant drive to improve rates of autologous vascular access, both through the 
“Fistula First” Campaign in the USA and best practice (PbR) targets in England and 
Wales. Quality improvement drives have resulted in significant increase in autologous 
vascular access rates among prevalent HD patients; however, to date, there has been no 
associated improvement in the number of functional AVF in incident patients. 
  
The importance “getting it right from the start” cannot be overemphasised. Patients who 
start dialysis via a line are more likely to remain with a line. Data from the UK Renal 
Registry indicate that 59.8% of patients starting on a TCVC remain dialysing via a TCVC 
at 3 months and >40% still have there TCVC after 1 year. Successful AVF maturation is 
poorer in patients who have already commenced dialysis. The legacy of poor early 
vascular access decision-making remains with the patient throughout their life on dialysis. 
This thesis seeks to evaluate methods for improving vascular access within the incident 
patient cohort. A multifaceted approach was taken to address several key themes: 
1. TCVC complications and central vein stenosis: avoiding problems for the future. 
2. Predicting maturation in incident dialysis patients 
3. Promoting maturation: strategies to optimise maturation. 
4. Right access, right patient, right time: individualised, patient-centred care. 
5. ‘Crashlanders’: managing patients who present without prior warning. 
The emphasis of the work was directed towards finding pragmatic, patient-focussed 
solutions to clinically relevant problems. The dogma of “Fistula First at all costs” is 
challenged. 
Chapter 2 describes the extent of the problem of TCVC usage locally in the West of 
Scotland and the impact of a Quality Improvement project to reduce prevalent TCVC 
usage. Aggressive strategies to create autologous access resulted in one-fifth of patients 
with prevalent TCVCs successfully having an AVF created, but this was offset against the 
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morbidity of a high fistula failure rate in patients already dialysing via TCVC and no 
overall reduction in prevalent TCVC usage rates. The complexities of autologous access 
creation in a long-standing prevalent population are highlighted, demonstrating the 
importance of targetting incident autologous access creation. 
Chapter 3 focusses on central vein stenosis as a consequence of long-term TCVC use. The 
significant personal and economic costs are highlighted: multiple and frequent 
interventions to relieve symptoms, loss of vascular access, and poor outcomes for all 
access modalities in patients with bilateral central venous occlusion and “end stage” 
vascular access. A novel strategy of expedited renal transplantation with extended criteria 
organs from donation after circulatory death (DCD) donors for patients with “end stage” 
vascular access is described. 
Chapter 4 evaluates some factors predictive of autologous AVF maturation. It is the first 
clinical study to evaluate the relationship between renal function and AVF outcome. No 
association was found between eGFR at the time of access creation and either short or 
long-term patency. However increasing serum urea was associated with worse clinical 
patency at 6 weeks and poorer long-term outcomes from RCF, highlighting that in incident 
patients timing of AVF creation (to avoid the significant uraemia late in the pre-dialysis 
period) may actually influence AVF outcome. 
Chapters 5 and 6 report randomised controlled trials (RCTs) of operative and peri-
operative techniques aimed to improve autologous AVF early patency rates. An interrupted 
suturing technique yielded higher immediate (92.9% vs. 66.6%; p<0.001) and 6 week 
(71.4% vs. 47.2%; p=0.01) primary patency rates for RCF than a continuous suturing 
technique.  It is hypothesised that the interrupted suturing technique improves anastomotic 
compliance and reduces the narrowing and puckering that can occur upon suture tightening 
in small calibre vessels. Similarly, Chapter 6 details a RCT comparing regional anaesthesia 
(brachial plexus block) and local anaesthesia for primary AVF creation. Primary patency at 
3 months was higher in the brachial plexus block cohort (84.1%  (73.0%, 91.3%) vs. 
61.9% (49.5%, 72.3%); P=0.005; OR 2.1). 
Finally, Chapters 7-9 evaulate the role of early cannulation arteriovenous grafts (ecAVGs) 
as novel devices to provide vascular access for patients in imminent need of 
haemodialysis. Chapter 7 presents observational data of the early local experience with 
ecAVGs. A relatively high complication rate (thrombosis and local infection) was 
observed. A description of the subsequent experiential learning and interventions to 
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improve graft outcomes is provided. Chapter 8 proposes the novel concept of ecAVG as an 
alternative to TCVC in “crashlanders”. Prospective observational data and a cost-
consequence analysis demonstrate that ecAVG are a practical, acceptable and cost-
effective alternative to TCVC in this patient cohort. Chapter 9 confirms similar findings in 
a randomised controlled trial. A reduction in both systemic bacteraemia (16.4% vs. 3.3%; 
rr 0·2 95% CI 0·12, 0.56; P=0·02) and mortality (16·4% vs. 5.0%; rr 0·3 95% CI 0·08, 
0·45; P=0·04) at 6 months in patients requiring “urgent vascular access for haemodialysis” 
treated with ecAVG compared to TCVC was shown.  
In conclusion, the work presented in this thesis has highlighted the importance of 
optimising vascular access provision in incident haemodialysis patients and the importance 
of timely autologous access creation whenever possible. Several strategies to target the 
traditionally poor AVF maturation rates, which limit autologous access use, have been 
outlined (interrupted suturing techniques and regional anaesthesia). However, it is 
recognised that autologous vascular access is not always the best option for every patient. 
In incident patients presenting without vascular access, ecAVG have been shown to be a 
viable and cost-effective alternative to TCVC. A planning strategy that targets vascular 
access to the individual in order to find a “personal vascular access solution” is essential. 
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INTRODUCTION 
 
1.1.  END STAGE RENAL DISEASE 
 
1.1.1. Definition 
 
Chronic kidney disease (CKD) is defined as an estimated glomerular filtration rate (eGFR) 
<90mL/min/1.73m2 (The Renal Association, 2013; KDOQI, 2000) . It is a common and 
progressive condition that affects >15% of the population in the United States (Archer et 
al. 2013; USRDS, 2014). A smaller proportion of patients (0.5%) will progress to end 
stage renal disease (ESRD) (Archer et al. 2013). The terms end stage renal disease, chronic 
kidney disease stage V and established renal failure (ERF) are used, largely 
interchangeably, to describe patients with eGFR <15mL/min/1.73m2 or a requirement for 
haemodialysis (The Renal Association, 2013; KDOQI, 2000). 
 
1.1.2.  The Burden of End Stage Renal Disease  
 
The incidence of ESRD has increased exponentially over the past 30 years (Scottish Renal 
Registry, 2015). United States Renal Data System (USRDS) figures indicate a 43% 
increase in the number of incident haemodialysis (HD) patients in 2006 compared to 1991 
(USRDS, 2006). The prevalence of patients with ESRD is doubling every 10 years in the 
United States (US) and it is projected that there will exceed half a million patients on 
dialysis in America by 2020 (Finn 2008; Collins et al. 2009). In the United Kingdom (UK), 
the incident rate of patients starting renal replacement therapy (RRT) increased from 109 
per million population (pmp) in 2014 to 115ppm in 2015 (UK Renal Registry, 2016). 
Similarly, there was a 4% absolute increase in the number of prevalent RRT patients 
between December 2015 and the same time the previous year (UK Renal Registry, 2016). 
United Kingdom Renal Registry (UK-RR) figures (December 2014) indicate that there are 
58,968 adult patients on RRT on the UK, 4,900 of whom are in Scotland (Scottish Renal 
Registry, 2015). Even acknowledging inaccuracies in international data collection, there 
are approximately 2 million people worldwide currently receiving RRT (Daugirdas, 2012; 
Kimmel & Rosenberg, 2014). 
 
ESRD has a significant negative impact on both longevity and quality of life (Kimmel & 
Rosenberg, 2014). Survival from ESRD is worse than that of most cancers (USRDS, 2014; 
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Cancer Research UK, 2014). The 5-year survival with ESRD in Scotland is 36%, 
compared to 59% in patients with bowel cancer, 87% for breast cancer and 85% in prostate 
cancer (Cancer Research UK, 2014; Scottish Renal Registry, 2015). In the US, only half of 
patients survive for 3 years after commencing dialysis (USRDS, 2014). Adjusted all cause 
mortality rates are 6.5-7.9 times greater in dialysis patients than for individuals in the 
general population (USRDS, 2014). A 25-year old diabetic commencing dialysis in 
Scotland has only 50% chance of living beyond 5 years (Scottish Renal Registry, 2015).  
Similarly, a female dialysis patient in her 30s is likely to survive just a quarter as long as a 
counterpart without ESRD (median life expectancy: 12.1 vs. 47.1 years) (USRDS, 2014).  
 
A high incidence of both cardiovascular disease (Go et al. 2004; USRDS, 2014) and 
infection (Henrich, 2012; USRDS, 2014) in the ESRD population leads to frequent 
hospitalisation and poor quality of life (Valderabano et al. 2001; Iliescu, 2003; Terada & 
Hyde, 2012; USRDS, 2014). Mean health-related quality of life (QoL) scores for patients 
recently commenced on HD corresponded to the lowest 10-15% of scores within the 
general population across all domains of function, whilst elderly HD patients demonstrate 
a physical function QoL score almost half of that observed amongst an age-matched cohort 
of non-ESRD patients (Rebello et al. 1998; Parkerson & Gutman, 1997). 
 
Notwithstanding the personal burden of ESRD, the disease also places considerable 
demand on healthcare resources. Patients with ESRD have an average of 1.84 hospital 
admissions annually and 11.7 bed days are utilised per year for patients on HD (USRDS, 
2014). Frequent hospitalisation, coupled with the cost of RRT (out-patient haemodialysis 
costs between £30 000 and £35 000/ patient/ year) means that 3% of the NHS budget 
intended for a population of 65 million is utilised on kidney failure services for just 50,000 
patients (NKF-KDOQI, 2013; NICE, 2011). Similarly within the US, in 2009 the overall 
Medicare expenditure for people with ESRD totaled $33.8 billion (6% of the total 
Medicare budget on less than 1% of the population) (American Kidney Fund, 2013). As a 
result of these financial and societal costs, CKD and ESRD are a significant public health 
concern (Henrich, 2012). 
 
1.1.3. Changing demographics of the RRT population 
 
In recent years, more inclusive acceptance policies for RRT have resulted in changing 
demographics of the ESRD population (Thomson, 2009; Vacharanjani et al. 2014). 
Increasingly elderly and co-morbid patients are now sustained on RRT (UK Renal 
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Registry, 2016; Scottish Renal Registry, 2015). The median age for starting RRT in 
Scotland was 64 years in 2012, compared to 61 years in 1995 and just 32 years old in 1978 
(Scottish Renal Registry, 2013). Similarly, the elderly (64-75 year-old) now represent the 
fastest growing group of prevalent RRT patients, with the median age of prevalent HD 
patients in the UK 66 years old (UK Renal Registry, 2016).  The number of extreme 
elderly (>85 year old) patients accepted onto RRT in the UK has doubled between 2006 
and 2011, whilst the percentage of patients aged >70 years has increased from 19.2% in 
2000 to 24.9% in 2012 (UK Renal Registry, 2014). Figure 1.1 highlights a similar, though 
less extreme, trend in Scotland (Scottish Renal Registry, 2013).  
 
 
 
Figure 1.1: Age specific prevalence of RRT patients in Scotland by year. Reproduced 
with permission from Information Service Department (ISD), Scotland (Scottish Renal 
Registry, 2013) 
 
 
With advancing age comes additional co-morbidity. The most recent UK Renal Registry 
Report (2016) highlights that 49.8% of patients with ESRD had one or more co-
morbidities (13% had more than 3 co-morbidities). In the ≥65 year-old age group, this 
proportion increases to 63% of patients with one or more co-morbidity.   
 
Due to a shared pathogenesis and clustering of risk factors, ESRD, IHD, diabetes, 
hypertension and peripheral vascular disease (PVD) commonly co-exist (Go et al. 2004; 
Sahay 2012; USRDS, 2014).  Reduced kidney function is associated with increased levels 
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of inflammatory mediators, abnormal apoliporotein levels, elevated plasma homocystine, 
enhanced coagulability, anaemia, left ventricular hypertrophy, increased arterial 
calcification and endothelial dysfunction, all of which are risk factors for cardiovascular 
disease (Go et al. 2004). 19% of patients in the UK with ESRD also have IHD (defined as 
angina, myocardial infarction or prior coronary artery bypass grafts). Like other co-
morbidities, the prevalence of ischaemic heart disease (IHD) in patients with ESRD also 
increases exponentially with advancing age (UK Renal Registry, 2016.).   
 
Prior to 1980, it was practically unheard of for diabetic patients with ESRD to receive 
RRT. Now nearly a quarter of patients commencing RRT in Scotland have diabetes as their 
primary renal disease (PRD) (Figure 1.2) (Scottish Renal Registry, 2016). In 2012, 35% of 
patients in the UK with ESRD had diabetes either as their PRD or additional co-morbidity 
and in the US diabetes is now the leading cause of ESRD (USRDS, 2014; American 
Kidney Fund, 2013; UK Renal Registry, 2016). The well publicised “diabetes explosion” 
is likely to see 4 million people in the UK with diabetes by 2025, 40% of whom will 
develop CKD, making diabetes the leading cause of ESRD in the UK within the next 10 
years (Gray, 2011; British Broadcasting Corporation, 2009; Diabetes UK, 2014; Diabetes 
Leadership Initiative, 2012). 
 
 
 
Figure 1.2: Percentage of patients in each diagnosis group starting RRT by year in 
Scotland. Reproduced with permission from Information Service Department (ISD), 
Scotland (Scottish Renal Registry, 2015) 
 
The implications of an aging, increasingly co-morbid population are significant. Data from 
the Scottish Renal Registry supports an association between age, co-morbidity and adverse 
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clinical outcome (Metcalfe et al. 2000; Metcalfe et al. 2003). Median survival of a patient 
<20 years old on RRT is 27.5 years, but only 1.3 years if the patient is >75 years old 
(Scottish Renal Registry, 2013). Likewise, the 5-year survival after starting RRT for a 45 
year old patient with diabetic nephropathy is only 31%, compared to 67% in a similar 
patient whose PRD is glomerulonephritis (Scottish Renal Registry, 2016). 
 
Despite the changing population of patients with ESRD, the overall mortality for incident 
patients remains static and prevalent mortality is declining (USRDS, 2014; Scottish Renal 
Registry, 2015; UK Renal Registry, 2016). This is testament to improvements in RRT and 
the quality of care provided for patients with ESRD (Alwall et al. 1949; Fernandez-Martin 
et al. 2015; Iseki, 2015). Nevertheless, an ever increasing number of patients with ESRD 
coupled with growing numbers of aged, co-morbid patients (with their additional 
challenges and complexities) exemplifies that the burden of ESRD and the impact of the 
disease on healthcare resources is likely to continue to escalate for the foreseeable future. 
 
1.2.    RENAL REPLACEMENT THERAPY 
 
1.2.1.  Methods of renal replacement therapy 
 
Renal replacement therapy (RRT) serves as a substitute for many of the functions of a 
native kidney and prolongs survival in patients with ESRD. It may be delivered in the form 
of renal transplantation, haemodialysis (either within the hospital or at home) or peritoneal 
dialysis (PD). Of the 4,561 patients currently on RRT in Scotland, 1,920 (39%) are on HD, 
226 (4%) are on PD and 2,773 (56%) have a functioning renal transplant (Scottish Renal 
Registry, 2015). (Figure 1.3) A similar distribution in the provision of RRT is seen 
elsewhere within the UK, with a small but steady growth of the HD population in England 
and Wales (2.6% pmp annually) (UK Renal Registry, 2014). 
 
Renal transplantation is the optimal form of RRT with better survival rates and improved 
QoL than dialysis (Wolfe et al. 1999; Port et al. 1993; Ojo et al. 2000; Laupacis et al. 
1996). It is also the most cost-effective form of RRT costing just £17 000 in the first year 
and £5 000 for each subsequent year following transplantation compared to the average 
£30 800 per patient/ year for dialysis (de Wit et al. 1998; NKF-KDOQI, 2013; Organ 
Donation Taskforce, 2008).  Unfortunately however, transplantation is not an option for 
every patient. Advancing age and multiple co-morbidities are relative contraindications 
which preclude transplantation in many cases (Knoll, 2013; Schold, 2014; Schold et al. 
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2009). In Glasgow, only 226 (32.6%) of the 694 patients on RRT are currently active on 
the renal transplant waiting list, with 152 patients transplanted in 2015 (M. Clancy, 
personal communication). Due to an imbalance between supply and demand of organs, 
there are currently 7,000 people on the cadaveric renal transplant waiting list in the UK 
and median wait time for a cadaveric kidney is 3.6 years (Hudson & Curnow, 2013). As a 
result, dialysis is the reality for most patients with ESRD (at least in the short-term). 
 
 
Figure 1.3: Growth in number of patients by treatment modality 1960-2015. 
Reproduced with permission from Information Service Department (ISD), Scotland 
(Scottish Renal Registry, 2015).  
 
1.2.2.  Haemodialysis 
 
Although not a true replacement for native renal function, haemodialysis serves to remove 
waste solutes and body water and restore biochemical and acid-base balance akin to a 
normally functioning kidney (Thomson, 2009). In the longer term it may also assist in the 
control of blood pressure (BP) and the prevention of uraemic complications (Kirk & 
Tattersall, 2015). It is a life prolonging treatment for patients with ESRD (Thomson, 
2009). 
 
To permit haemodialysis blood must be removed from the intravascular component of the 
patient’s circulation, passed through an extracorporeal circuit into the “dialyser” where 
waste solutes and excess water are removed, and then returned to the patient’s venous 
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circulation (Figure 1.4) (Kirk & Tattersall, 2015; Hamilton, 1999). There are many 
different dialysis treatment regimens, however most patients in the UK will receive 
hospital haemodialysis for 4 or 5 hours three times per week (NHS Choices, 2013). 
 
 
 
Figure 1.4: Haemodialysis circuit demonstrating extra-corporeal circuit and 
“dialyser”. Reproduced with permission from Adam Kirk. 
 
Dialysis works on the principles of diffusion (of solutes) and ultrafiltration (of fluid) across 
a semi-permeable membrane. Diffusion is the process whereby substances dissolved in 
water will move from an area of high to low concentration across a semi-permeable 
membrane, while ultrafiltration is the movement of fluid across the membrane created by a 
transmembrane pressure gradient (Hamilton, 1999; Freemesm, 2013). By altering the 
hydrostatic pressure within the dialysate compartment, water and some dissolved solutes 
can be encouraged to cross the membrane. These processes are analogous to those 
occurring within the glomerulus of the native kidney. The characteristics of the semi-
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permeable membrane e.g. membrane permeability (pore size) and surface area will 
determine exactly what substances can cross the membrane (Hamilton, 1999). A larger 
pore size (high-flux membrane) will allow larger molecules to be removed by dialysis 
(Ambalavanan et al. 1999). Like the nephron of a native kidney, haemodialysis utilise a 
countercurrent mechanism whereby the dialysate is flowing in one direction and the blood 
within the extracorporeal circuit flowing in the opposite direction to maximise the 
concentration gradient and increase the efficiency of dialysis (Hamilton, 1999). All these 
functions occur within the “dialyser” of the circuit. 
 
Adequacy of dialysis i.e. how well the waste is being removed is influenced by a number 
of factors including rate of blood flow, membrane resistance and recirculation 
(Ambalavanan et al. 1999; Kapoian et al. n.d.). In most cases a rapid blood flow 
(>250mL/min) will be required to achieve adequate dialysis (Kapoian et al. n.d.). Dialysis 
adequacy can be assessed by monitoring the patient’s urea reduction ratio (URR) and Kt/V 
(Kapoian et al. n.d.; Mactier et al. 2013). 
 
1.3.    VASCULAR ACCESS 
 
1.3.1.  What is vascular access? 
 
An entry point into the patient’s circulatory system must be provided to permit the removal 
and return of blood from the extracorporeal dialysis circuit. This entry point to the 
bloodstream is the “vascular access”. Successful haemodialysis is entirely reliant on the 
provision of safe, efficient and durable vascular access (Fluck & Kumwenda, 2011). The 
vascular access serves as the patient’s ‘lifeline to the dialysis machine’ (Riella et al, 2013, 
pp.348). 
 
Vascular access provision is the ‘cornerstone to providing adequate haemodialysis’ 
(Hammes, 2014, pp.105) and a ‘fundamental aspect of the treatment of haemodialysis 
patients’ (Fluck & Kumwenda, 2011, pp.3). Good quality vascular access saves more lives 
in patients with ESRD than the targetted treatment of anaemia and phosphate metabolism 
combined (DOPPS Collaborators, 2012). However the provision of good quality vascular 
access can prove challenging to achieve, both for the individual patient and for the overall 
delivery of renal services (Thomson, 2009). Several authors acknowledge these 
difficulties, describing vascular access as the ‘Achilles’ heel’ of haemodialysis (Konner, 
1999, pp.2094). 
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20% of all hospital admissions and one-third of all in-patient bed days utilised by patients 
on HD are the result of problematic vascular access (Akoh & Hakim, 2001; Hirth, 1996; 
DOPPS Collaborators, 2012; Pisoni et al. 2009; Rayner et al. 2004). Half of all hospital 
admissions in the first year of dialysis are access-related (Vassalotti et al. 2012). In the last 
decade, prevalent hospitalisation rates for infection in patients with ESRD have almost 
doubled (Lok, 2007; USRDS, 2014; Collins et al. 2009). Infection is now the leading cause 
of hospitalisation and the second commonest cause of death (after cardiac events) for 
patients on HD (USRDS, 2014). Access-related bacteraemia is responsible for nearly 30% 
of all infections in the HD population and is the leading cause of preventable hospital 
admission (Collins et al. 2009).  
 
Frequent hospitalisation can have a significant negative impact on QoL and the patient’s 
perception of the “burden of dialysis” (Afsar et al. 2012; Wasse et al. 2007).  Furthermore, 
access-related complications are associated with significant financial costs to the 
healthcare system. The average cost for treatment for a single episode of line sepsis is  
£20 000, whilst the morbidity associated with vascular access complications costs 
Medicare approximately $1 billion annually in the US (Feldman et al. 1993; Taylor et al. 
2002; Allon et al. 2011; Ramanathan et al. 2007; Allon & Robbin, 2002). 
 
1.3.2.  Which vascular access to choose? 
 
The National Kidney Care Vascular Access Report (2012, pp.10) states that: 
 
‘The ideal form of vascular access should be safe and efficient. It should be easy to 
use. It should provide effective therapy. It should minimise the risk of complications 
related to its use and presence.’  
 
However, there is no single “ideal” vascular access that is long-lasting and permits safe 
and reliable haemodialysis for every patient. As a result, a range of access modalities exist. 
 
Early attempts at providing vascular access, developed in parallel with haemodialysis 
because vascular access provision was integral to the success of maintenance HD. Initially, 
vascular access methods relied on repeated peripheral cannulation to deliver arterial blood 
to the dialysis machine and return it via an accompanying vein (Thomson, 2009). This 
method led to the rapid exhaustion of the peripheral vasculature and did not prove 
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sustainable outwith an acute setting. In 1949, Alwall made the first attempt to directly 
connect an artery and vein using glass cannulae and rubber tubing. This device was 
intended to allow blood to be diverted into an extracorporeal circuit for dialysis as 
required. His attempt was unsuccessful, however it provided the template for the ‘Scribner 
shunt’ developed by Quinton, Dillard and Scribner in 1960 (Quinton et al. 1962). Their 
device consisted of two Teflon cannulae inserted at the wrist, one into the radial artery and 
one into the cephalic vein. The external ends of the cannulae could then be connected to 
the extracorporeal circuit by flexible tubing. Whilst the Scribner shunt has subsequently 
been subjected to multiple refinements and ultimately superseded by other forms of 
vascular access, its development was instrumental in permitting the provision of 
maintenance haemodialysis to the chronic ERSD population. 
 
In 1966, Brescia and colleagues published their experience of arteriovenous fistulae (AVF) 
for vascular access in the New England Journal of Medicine (Brescia et al. 1966).  By 
using native vessels in an entirely subcutaneous configuration, the thrombotic, infectious 
and dislodgement complications of the Scribner shunt were significantly reduced. An AVF 
is an artificial connection between artery and vein. The vein is divided and anastomosed 
onto the artery. This vein can then be directly cannulated with needles to permit HD 
(Figure 1.5). Although troubled with a high primary failure rate (Wong et al. 2011; 
Dember et al. 2008), matured AVF have excellent long-term patency with a low rate of 
infectious complications (Akoh & Hakim, 2001; Hoen et al. 1995; Huijbregts et al. 2008; 
Kinnaert et al. 1977).  
 
Like AVF, arteriovenous grafts (AVG) also provide a man-made subcutaneous connection 
between artery and vein. However in AVG the cannulatable segment is not formed by 
native vessel, rather a foreign implant to bridge the gap between artery and vein (Figure 
1.5). This non-native segment may be biological (autologous vein from an alternative site, 
allogeneic vein, umbilical cord vein or bovine carotid artery) or, more commonly, 
synthetic (Dacron® or polyterafluroethylene (PTFE)) (May et al. 1969; Kester, 1978; 
Moshe Haimov, 1974; Windus, 1993; Morgan & Lazarus, 1975). AVGs have the 
advantage that they obviate the need for maturation and the risk of early failure associated 
with AVF use (Windus, 1993). However, like all prosthetics, they are associated with 
higher rates of infection (Bell & Rosental, 1988).   
 
Tunnelled central venous catheters (TCVC) were first used for HD in 1969 following the 
successful use of silastic catheters for chemotherapy and parenteral nutrition (Erben et al. 
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1969). A double-lumen catheter (or previously two single lumen catheters) is inserted into 
a central vein (subclavian, internal jugular or femoral) and venous blood removed into the 
extracorporeal dialysis circuit via one lumen and returned via the other (Figure 1.5). 
TCVCs are simple and easy to insert and can be used immediately and conveniently for 
dialysis (Akoh & Hakim, 2001). Their use has revolutionised the practice of acute HD. 
However again, infection rates are considerably higher that those observed in autologous 
access (Kessler et al. 1993; Hoen et al. 1998). 
 
Arteriovenous fistulae are widely considered to be ‘the best form of vascular access for 
HD’ (Lok et al, 2007, pp.1043) incurring fewer complications, superior patency, better 
dialysis quality and a lower mortality than TCVCs (Lok, 2007; Thomson et al. 2007; Fluck 
& Kumwenda, 2011). The use of TCVCs is associated with a significantly increased risk 
of systemic sepsis, long-term morbidity from central vein stenosis and a higher risk of 
cardiovascular and all-cause mortality compared to AVF (Bray et al. 2012; Thomson et al. 
2007; Agarwal et al. 2007; Lok, 2007). 
 
The enduring patency of AVF is superior to other access modalities, with long-term access 
survival of approximately 90% for AVF compared to 60% for AVG (Fluck & Kumwenda, 
2011; Crowther et al. 2002; Rayner et al. 2003). AVF also require fewer remedial actions 
to maintain patency. Approximately 0.2 interventions are required annually to maintain the 
patency of an AVF, compared to 1.0 interventions per patient per year in AVG (Ifudu et al. 
1998). CVCs demonstrate similar patency rates to AVG with a median thrombosis-related 
malfunction rate of 0.3 events/ patient/ year (Donati et al. 2012). 
 
The risk of sepsis attributable death in a HD patient is 100 times that of the general 
population and TCVC use is the greatest risk factor for infection-related mortality (Lok et 
al. 2014). The systemic bacteraemia rate in patients dialysing via an AVF is approximately 
0.03 per 1,000 dialysis days, compared to 0.06 per 1,000 dialysis days for an AVG and 1.4 
per 1,000 catheter days for TCVC (Taylor et al. 2002). Local data from the West of 
Scotland demonstrates TCVC use to be associated with a hazard ratio (HR) for 
bacteraemia of 5.4 compared to AVF (Thomson et al. 2007). The time to first episode of 
bacteraemia was also significantly longer in patients with AVF compared to AVG or 
central venous catheter (CVC) (Figure 1.6) (Thomson et al. 2007). Given that each episode 
of bacteraemia confers a 2.8 times relative risk (RR) of death in a dialysis patient 
(Bloembergen et al. 1996), infections in this patient cohort cannot be considered trivial 
events.  
 33 
 
 
 
 
Figure 1.5:  Forearm arteriovenous fistula (top), arteriovenous graft (middle) and 
tunnelled central venous catheter (bottom). Adapted from National Institute of Diabetes, 
Digestive and Kidney Diseases, 2014.  
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Figure 1.6: Kaplan Meier survival plot of the time to bacteraemia by vascular access 
type (CVC= central venous catheter, AVF=arteriovenous fistula, AVG= arteriovenous 
graft). Reproduced with permission from Dr. Peter Thomson. (Thomson et al. 2007). 
 
 
Several large studies have shown reduced survival in patients dialysing via a TCVC 
(Bradbury et al. 2007; Bray et al. 2012; Astor et al. 2005). Ravani and colleagues (2013b) 
recently conducted a systematic review of over half a million patients. They found a higher 
rate of all-cause (risk ratio (rr) =1.53, 95% confidence interval (CI)=1.41–1.67), infectious 
(2.12, 1.79–2.52), and cardiovascular (1.38, 1.24–1.54) mortality in patients dialysing via 
TCVC compared to AVF.  Similarly, compared with AVGs, patients with TCVCs had a 
higher risk of mortality (1.38, 1.25–1.52), fatal infections (1.49, 1.15–1.93) and 
cardiovascular events (1.26, 1.11–1.43). AVGs conferred a higher risk of all-cause 
mortality (1.18, 1.09-1.27) and fatal infection (1.36, 1.17-1.58) than AVF but no difference 
in cardiovascular death was observed (Ravani et al. 2013a). Similarly, Bradbury and 
colleagues (2007) observed a higher mortality rate at both 120 and 365 days in patients 
commencing dialysis via a catheter. A recent national Scottish study of 2,666 patients 
revealed a 2-3 fold increased risk of both all-cause and cardiovascular mortality and 7- fold 
increase in death from septicaemia in patients receiving HD via a TCVC (Bray et al. 2012). 
These findings mirror those observed in our unit where TCVC usage conferred nearly three 
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times the risk of all-cause mortality than dialysis via an AVF (HR 2.75) (Thomson et al. 
2007). 
 
It is for these reasons that AVF are widely regarded as the ‘gold standard’ vascular access 
for HD (Smith et al, 2012, pp.84). The National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative Clinical Practice Guidelines for Vascular Access (NKF-
KDOQI, 2006) in the USA, European Renal Association-European Dialysis and 
Transplant Association (ERA-EDTA) Best Practice Guidelines (Tordoir et al. 2007), 
Caring for Australasians with Renal Impairment (CARI) (KHA-CARI, 2012) and Renal 
Association (UK) Vascular Access Guidelines (Fluck & Kumwenda, 2011) all advocate 
that AVF should be the access modality of choice wherever possible (Table 1.1).  
Table 1.1; Recommendations regarding choice of access modality from renal advisory 
groups around the world (ERA-EDTA= European Renal Association- European Dialysis 
and Transplant Association; CARI= Caring for Australasians with Renal Impairment; 
KDOQI= Kidney Disease Outcomes Quality Initiative) (Oxford CEBM, 2009).  
Advisory 
group 
 
Recommendation Level of 
Evidence  
The Renal 
Association 
(UK)(Fluck & 
Kumwenda, 
2011) 
 
ERA-EDTA  
(Tordoir et al. 
2007) 
 
 
 
 
 
CARI  
(KHA-CARI, 
2012) 
 
 
 
 
KDOQI 
(National 
Kidney 
Foundation, 
2006) 
‘We recommend that any individual who commences haemodialysis 
should do so with an arteriovenous fistula as the first choice, 
arteriovenous graft as second choice, a tunnelled central venous catheter 
as third choice and a non-tunnelled central venous catheter as an option 
of necessity’ (pp.63) 
 
‘Every chronic renal failure patient who have opted for haemodialysis 
should start dialysis via a functioning vascular access’ (p.88) 
 
‘Autogenous AVF should be preferred over AV grafts and AV grafts 
should be preferred over catheters’ (pp.92) 
 
‘No recommendation possible based on level I and II evidence’ (pp.1) 
 
‘Wherever possible it is suggested that a native arteriovenous fistula is 
superior to an arteriovenous graft and to central venous catheter’ (pp.1) 
 
‘When a native arteriovenous fistula is not possible, an artificial 
arteriovenous graft should be used in preference to a central venous 
catheter’ (pp.1) 
 
‘The access should be placed distally and in the upper extremities 
whenever possible. Options for fistula placement should be considered 
first, followed by prosthetic grafts if fistula placement is not possible. 
Catheters should be avoided for HD and used only when other options 
listed are not available’ (pp.8) 
 
‘The order of preference for placement of fistulae in patients with kidney 
failure who choose HD as their initial mode of KRT should be (in 
descending order of preference): 
• Preferred: Fistulae 
• Acceptable: AVG of synthetic or biological material 
• Avoid if possible: Long-term catheters’ (pp.8) 
 
1B  
 
 
 
 
 
III  
 
 
III 
 
 
 
 
III 
 
 
III 
 
 
 
IV 
 
 
 
 
 
1B 
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Despite this, of the 478 patients who commenced on dialysis in Scotland during 2015, only 
42.1% started HD via an AVF, the rest via a CVC. 71.8% of prevalent patients currently 
receive HD via an AVF or AVG and 28.2% via a CVC (Scottish Renal Registry, 2015). 
Nationally in the UK, during a similar time period, 80% of prevalent patients received HD 
via an AVF, 4% via an AVG and only 16% via a TCVC (UK Renal Registry, 2016).  
 
Globally, there is considerable variation in practice. The Dialysis Outcomes and Practice 
Patterns Study (DOPPS) is a large-scale study of dialysis practice, which began in 1996 
and now collects data from over 20 countries worldwide. Most recent DOPSS data 
indicates that 92% of prevalent patients in Russia and 91% in Japan are dialysing via AVF, 
compared to only 68% in the US (Figure 1.7) (DOPPS Collaborators, 2012; Pisoni et al. 
2015). In the 1990s this difference was even more marked with fewer than 20% of 
prevalent patients in the US dialysing via an AVF compared to almost 80% in Europe 
(DOPPS Collaborators, 2012.; Allon & Lok, 2010). These international variations in 
practice likely reflect disparities in both the provision of pre-dialysis and vascular access 
services, as well as differences between the dialysis populations, with the patients in the 
US being significantly more co-morbid than those in Japan or Europe (Pisoni et al. 2015; 
Ethier et al. 2008). 
 
 
 
Figure 1.7:  Prevalent vascular access in DOPPS 4 countries in 2012. Reproduced with 
permission from the Arbor Research Collaborative for Health (DOPPS, 2012). 
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1.4.     ARTERIOVENOUS FISTULAE 
 
1.4.1.  What is an arteriovenous fistula? 
 
As previously described, arteriovenous venous fistulae (AVF) are regarded as the ‘gold 
standard’ vascular access (Smith et al, 2012, pp.84). They have the lowest infection rate 
and best long-term patency of any form of vascular access (National Kidney Care Vascular 
Access Report, 2012), making them the vascular access of choice according to British, 
European and American Renal Advisory Groups (NKF-KDOQI, 2013; Fluck & 
Kumwenda, 2011; Tordoir et al. 2007). Patients dialysing via an AVF are three times less 
likely to be admitted to hospital (for any reason) than their counterparts with TCVCs 
(National Kidney Care Vascular Access Report, 2012). The recent Dialysis Outcomes 
Practice and Patterns Study (DOPPS) reported a relative risk of death of 1.19 for TCVC 
and 1.08 for AVG compared to AVF (Pisoni et al. 2015). AVF are able to deliver a higher 
dialysis dose and are believed to provide better quality dialysis than TCVCs (a fact which 
may, in part, explain the lower cardiovascular mortality rate observed in patients dialysing 
via AVF) (KDOQI, 2012; Bray et al. 2012).  
 
AVF are created by anastomosing an artery and vein together during a minor surgical 
procedure. Almost universally they are created in the upper limb under either local or 
regional anaesthesia. They may be created at a variety of sites, but a distal site in the non-
dominant arm is preferred (Fluck & Kumwenda, 2011). Wherever possible, a wrist 
(radiocephalic (RCF)) fistula should be created between the radial artery and cephalic vein. 
Second choice would be an elbow brachiocephalic fistula (BCF), followed by the more 
complex brachiobasilic fistula (BBF) (Figure 1.8) (Allon & Robbin, 2002). In actual fact, a 
fistula can be created at any site where the artery and vein are in close proximity. In most 
cases an end-to-side anastomosis of the cut end of the main draining vein onto the side of 
the artery is performed; however the original side-to-side anastomoses described by 
Brescia; and Gracz fistulae (using the deep perforating veins) are alternatives (Konner, 
1999; Allon & Robbin, 2002). 
 
Following creation of the anastomosis, the low-pressure outflow vein is exposed to the 
higher flow rates, higher pressures and shear stresses of arterial blood and, with time, the 
vein too will become ‘arterialised’. This process of arterialisation is referred to as 
maturation. The blood flow rate in the radial artery, which is typically 20-30mL/min prior 
to AVF creation, immediately increases to 200-300mL/min (as the blood flows into a low 
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resistance venous system) and, following complete maturation, flow rates of 600-
1200mL/min will typically be established (Schuman et al. 2007). The immediate increase 
in laminar blood flow (with fast flow down the centre of the vessel and slower flow at the 
edges) results in increased shear stress within the vessel wall. In response to the shear 
stress, the vascular endothelium releases nitric oxide and prostacyclin, which promote 
vascular smooth muscle cell relaxation, vasodilatation and inhibit platelet aggregation and 
thrombosis (Riella & Roy-Chaudhury, 2013). Outward vascular remodeling then occurs as 
a homeostatic process (to reduce vascular shear stresses) and is responsible for the 
maturation process (Browne et al. 2015). Maturation typically takes between 6-8 weeks 
before the vein is suitable for cannulation for dialysis. 
 
1.4.2.  Complications of AVF 
 
Unfortunately, a significant number of AVF fail to complete the maturation process and 
with never develop into an access suitable to sustain HD. This is the principal limitation to 
their universal use (Lok, 2007; Dember et al. 2008). Other complications associated with 
AVF occur less commonly than in other forms of vascular access. 
 
1.4.2.1.  Failure to mature (FTM) 
 
Failure to mature (FTM) and early thrombosis is the ‘Achilles’ heel’ of autologous fistula 
use (Riella et al, 2013, pp.348). Exact rates of non-maturation range from 10-50% 
depending on the definition of primary failure, with worse outcomes observed in 
contemporaneous cohorts (Miller et al. 1999; Dixon et al. 2002; Dember et al. 2008). Most 
authors will report an immediate thrombosis rate of approximately 20%, with a 
substantially larger proportion of patients having fistulae that mature suboptimally, never 
achieving functional patency (Allon & Robbin, 2002). For example, the widely cited 
randomised controlled Dialysis Access Consortium (DAC) study found that 60% of all 
AVF created had “failed to attain suitability for dialysis” (i.e. maintain a pump flow rate of 
>300mL/min during 8 of 12 dialysis sessions) five months after creation (Dember et al. 
2008). Similarly the recently published Fish oil and Aspirin in Vascular access OUtcomes 
in REnal Disease (FAVOURED) study demonstrated a fistula failure rate of 50% at one-
year in both control and intervention arms of the trial (Irish et al. 2017). A high early 
failure rate necessitates further attempts at AVF creation with associated morbidity and 
prolonged catheter dependence (Leake et al. 2015). This has latterly lead a number of 
authors to advocate the use of AVGs as an alternative to AVF (Allon & Lok, 2010; Lok, 
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2007), citing comparable cumulative patencies rates up to 2 years for the two access 
modalities when the early AVF failure rate is accounted for (Lok et al. 2013) (Figure 1.9). 
KDOQI guidelines advocate the use of objective criteria to assess the maturation of AVF 
and suitability for cannulation (NKF-KDOQI, 2006). They describe “the rule of 6s”: 
fistulae must be able to support a blood flow of 600mL/min; be a maximum of 6mm from 
the skin surface; and have a diameter of >6mm to permit cannulation. In reality, as long as 
the Qa is at least 100mL/min greater than the pump speed on the dialysis machine, the 
AVF should be capable of sustaining haemodialysis without recirculation (American 
Society of Nephrology, n.d.) . Most clinicians will wait 6-8 weeks prior to attempting the 
first cannulation, however data from the DOPPS study indicate that, for suitably mature 
AVF, there was no significant difference in outcome between AVF cannulated within 15-
28 days and those which had a longer maturation period (43-82 days) prior to initial 
cannulation (Pisoni et al. 2002). 
 
A number of risk factors for FTM have been identified. Lok and colleagues (2006) 
identified that age >65 years old, coronary artery disease, peripheral vascular disease and 
non-Caucasian ethnicity were associated with high early failure rates of AVF. Many 
observational studies also show a higher FTM rate in diabetics (Feldman et al. 1996). 
Small, calcified vessels are also implicated in AVF failure, with most authors advocating 
minimum arterial diameters of 2mm and minimum venous diameters of 2.5mm before 
attempting AVF creation (Sidawy et al. 2008; Silva et al. 1998). 
 
Successful maturation depends upon appropriate increases in blood flow through the fistula 
(Tessitore et al. 2014b), increased diameter of the vein (Allon et al. 2016) and vein wall 
thickness (Jaberi et al. 2011) following creation. Mean fistula diameters of >4mm are seen 
at day 1 in 85% and by 6 weeks in 87% upper arm AVF, but only 40% and 77% of forearm 
AVF respectively (Allon et al. 2016) . Similarly, access flow rates (Qa) <400-500mL/min 
are associated with an increased risk of thrombosis (Tessitore et al. 2014b). Studies of 
perioperative blood flow found brachial artery blood flow of <120-160mL/min to be 
highly predictive of early thrombosis (Saucy et al. 2010), highlighting the importance of 
the immediate blood flow through the fistula in the maturation process. In most successful 
AVF, the blood flow rates necessary to sustain dialysis are seen immediately, with one 
study of 602 AVF confirming that in at least 50% of AVF the six-week blood flow 
measurement was achieved at day 1 (Bay et al. 1998). Ladenheim and colleagues (2016) 
recently demonstrated a similar pattern in RCF with functional AVF having a mean blood 
flow of 753mL/min at 1 week compared to 121mL/min in non-functional AVF. No fistula 
 40 
in this study with a blood flow <200mL/min after 1 week ever achieved functional 
patency. It may be that an inability of vessels to adapt and dilate to increase early flow 
rates explains the higher FTM rate observed in elderly patients and diabetics with high 
resistance, mediacalcinosis and heavily calcified vessels (Riella & Roy-Chaudhury, 2013)
 
 
 
 
Figure 1.8: Diagram of radiocephalic (top left), brachiocephalic (top right) and 
brachiobasilic fistulae (bottom). Adapted from Allon and Robbin (2002). 
 Recent years have seen a plethora of ideas to try and improve poor early patency rates. 
Operative techniques that focus on modifying the flow dynamics of the anastomosis have 
shown theoretical promise, but have not yet translated into improvements in clinical 
outcomes (Rajabi Jagahrgh et al. 2013; Ene-Iordache et al. 2001). Similarly, attempts at 
topical treatment of the AVF anastomosis either with antispasmodics (e.g. papaverine) or 
enzymes to reduce intimal hyperplasia (e.g. PRT-201 pancreatic elastase) have not shown 
any improvement in early patency rates (Hye et al. 2014). Even in the DAC study, which 
did show a reduction in early AVF thrombosis with clopidogrel (12.2% versus 19.5%; 
P=0.018) (Dember et al. 2008), this was not translated into any meaningful difference in 
functional patency.  
 
If a patent fistula can be established however, it may be that an angiographic procedure to 
dilate up the venous outflow of the AVF  (balloon assisted maturation) can then be used to 
improve blood flow and permit maturation of a suboptimal fistula into one capable of 
sustaining dialysis (Roy-Chaudhury et al. 2012a). Early results with this technique appear 
promising with Miller and colleagues (2011) successfully maturing 118 of 122 suboptimal 
in AVF to the extent that they were capable of sustaining dialysis. This technique does, 
however, lead to intimal injury, recurrent intimal hyperplasia, rapid restenosis and need for 
additional interventions to maintain patency (Allon et al. 2016; Allon et al. 2013). 
 
1.4.2.2. Stenosis and thrombosis 
 
Long-term patency of AVF is superior to other forms of vascular access (Allon & Robbin, 
2002). Primary unassisted patency rates in mature AVF of 75-90% at one-year are 
commonly quoted in the literature (Coburn, 1994; Silva et al. 1998). In their large study of 
nearly 500 patients, Huijbregts and colleagues (2008) found 6, 12 and 18 month secondary 
and functional patency of 75%, 70%, 67% and 90%, 88% and 86% respectively. 
Nevertheless, if AVF thrombosis does occur, thrombectomy/ declotting is often technically 
challenging and associated with poor outcomes (Aitken et al. 2012a). 
 
Nearly all AVF thrombosis occurs on the background of a pre-existing stenosis. A stenosis 
is a narrowing of the blood vessel which will progress and limit blood flow through the 
fistula, ultimately resulting in occlusion. The stenosis can occur at any site in the fistula, 
but the outflow vein and juxta-anastomotic areas are most common. Stenoses tend to occur 
at the site of vascular injury (either surgical insult, injury from needling or at areas of the 
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outflow vein where turbulent blood flow exists e.g. the cephalic arch). The pathognomonic 
feature of AVF stenosis is neointimal hyperplasia (Rothuizen et al. 2013). In response to 
injury, there is an influx of proinflammatory cells and cytokines into the vessel wall. There 
is differentiation of fibroblasts into myofibroblasts and synthetic type vascular smooth 
muscle (VSM) cells, which in turn leads to smooth muscle proliferation within the media 
and neointimal hyperplasia (Lee & Roy-Chaudhury, 2009; Roy-Chaudhury et al. 2007; Li 
et al. 2007). When the rate of this process exceeds the rate of outward remodeling, the 
vessel will stenose and ultimately occlude (Rothuizen et al. 2013). 
 
A number of antiproliferative drugs e.g. paclitaxel and sirolimus have been trialled in an 
attempt to reduce treat neointimal hyperplasia and prevent stenosis with some early 
promise (Kelly et al. 2006; Roy-Chaudhury et al. 2007; Iyem, 2011), however they have 
no routine role in clinical practice currently.  
 
Given that the progression from stenosis to thrombosis is well recognised and angioplasty 
or stenting is very effective in treating stenosis to prevent subsequent thrombosis (unlike 
thrombectomy after thrombosis) (Miquelin et al. 2008; Roy-Chaudhury et al. 2012a), much 
attention has been focussed on surveillance of AVF. The hope is that by intervening early 
on an asymptomatic stenosis, future thrombosis will be prevented. Surveillance is 
advocated by most sets of clinical practice guidelines (Fluck & Kumwenda, 2011; NKF-
KDOQI, 2006), however in reality, the majority of observational data fails to support this 
rationale (Tonelli et al. 2001). 
 
1.4.2.3. Steal/ distal hypoperfusion ischaemic syndrome 
 
Distal hypoperfusion ischaemic syndrome (DHIS) is a condition in which hand ischaemia 
occurs following vascular access placement. It affects between 5-10% of vascular accesses 
to varying degrees (Malik et al. 2008), presenting initially with pain and pallor in the hand 
and digits. In extreme cases it can result in tissue and even limb loss if not treated.  The 
peripheral nerves as particularly vulnerable to ischaemia and an irreversible ischaemic 
monomelic neuropathy can rapidly develop (Thermann & Kornhuber, 2011). Many cases 
of DHIS result from distal arterial disease and inadequate inflow to the arm that is 
exacerbated by creation of a vascular access. However, true “steal syndrome” occurs in the 
absence of intrinsic arterial disease. The high blood flow within the fistula (commonly a 
BCF) leads to reverse blood flow in the distal (radial) artery and blood that is literally 
“stolen” from the hand.  For this reason, steal is more common in elderly patients and in 
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female diabetics with small distal vessels (Tordoir & van der Sande, 2004). Diagnosis is 
made by ultrasound or angiography. Treatment strategies are principally operative, either 
by ligation of the fistula; proximalisation (to a large vessel e.g. axillary artery inflow) 
(Zanow et al. 2006); or distalisation (via either a distal revascularisation and interval 
ligation (DRIL) procedure or a revision using distal inflow (RUDI) procedure (Minion et 
al. 2005; Roh, 2012; Walz et al. 2007). 
 
1.4.2.4. Infection 
 
Infection accounts for approximately 20% of AVF complications, however the rate 
remains significantly lower than for TCVCs or AVGs (Stolic, 2012). Most infections are 
localised perivascular cellultis presenting as erythema and oedema that can be easily 
treated with antibiotics. Systemic infection is rare with a rate of 0.03 bacteraemic episodes 
per 1,000 access days commonly quoted (Taylor et al. 2002). It is postulated that systemic 
bacteraemia arising from fistulae may be the result of poor cannulation technique (NKF-
KDOQI, 2006). In particular buttonhole cannulation (a technique in which two fixed tracts 
are created for repeated cannulation of the AVF at the same site) may be associated with a 
higher bacteremia rate (O'Brien et al. 2012). 
 
1.4.2.5. Aneurysm 
 
An aneurysm is a pathological, localised dilatation of a blood vessel. In AVF they occur 
for two reasons: upstream stenosis and repeated area cannulation and vessel trauma at the 
same site (Stolic, 2012). A true aneurysm involves all layers of the vessel wall. 
Conversely, pseudoaneurysms (false aneurysms) may only involve part of the vessel wall 
with haematoma lying outside the vessel, and almost invariably occur at the site of 
cannulation where an injury to the vessel wall has occurred. The skin over an aneurysmal 
area commonly is thinned and they carry a risk of rupture. Surgical revision or ligation is 
necessitated in such cases to prevent life-threatening haemorrhage (Stolic, 2012). 
 
1.4.2.6. Impact on cardiovascular function 
 
The Vascular Access Society defines “high-flow” AVF as those with Qa >1000-
1500mL/min (Huijbregts et al. 2008). In actuality, much higher access flow rates 
commonly occur without complication. High vascular access blood flow (Qa) is believed 
to increase cardiac output and may (in rare cases) lead to high output cardiac failure 
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(MacRae et al. 2004). It is conjectured that creation of an AVF results in reduction in 
systemic vascular resistance (SVR), leading to compensatory increases in stroke volume 
(SV), heart rate (HR) and cardiac output (CO) in order to maintain blood pressure (BP) 
(MacRae et al. 2004; Válek et al. 2010; Korsheed, 2011); however the evidence for such 
theories comes principally from animal studies (Guyton & Sagawa, 1961) and a few small 
case series (Savage et al. 2002; Isoda et al. 1994). There is anecdotal evidence that high 
flow AVF can cause symptomatic heart failure with orthopnoea, paroxysmal nocturnal 
dyspnoea and peripheral oedema (MacRae et al. 2004; Isoda et al. 1994), however many 
patients tolerate very high Qa i.e.>5L/min with minimal symptoms.  
 
1.5.     TUNNELLED CENTRAL VENOUS CATHETERS 
 
1.5.1.  What is a tunnelled central venous catheter? 
 
Tunnelled central venous catheters are dual-lumen catheters made from silastic or silicon 
elastomer, which are inserted percutaneously using a Seldinger technique into a large 
central vein either in the neck (internal jugular or subclavian), groin (femoral) or directly 
into the inferor vena cava via lumbar vessels (translumbar) (Klein et al. 2016). Unlike 
temporary catheters, a cuff is used to secure their position and reduce the risk of 
introducing infection. TCVCs are simple and easy to insert and can conveniently be used 
immediately for dialysis. For this reason, their use has revolutionalised acute HD and, in 
2011, 59% of all incident patients in the England and Wales commenced dialysis via a 
TCVC (National Kidney Care Vascular Access Report, 2012). Conversely however, CVCs 
are the leading cause of healthcare-associated bloodstream infection and confer a 
significantly higher risk of bacteraemia than any other form of vascular access (Taylor et 
al. 2002). 
 
1.5.2.  Complications of central venous catheters 
 
Patients dialysing via central venous catheters are more likely to be hospitalised as a result 
of access related complications than patients dialysing via another modality (National 
Kidney Care Vascular Access Report, 2012). UK data indicate that TCVC use confers a 
six-fold increased risk of systemic sepsis and three-fold higher all-cause mortality 
compared to AVF (Thomson et al. 2007; Bray et al. 2012), whilst DOPPS data report a 
32% increased risk of death in HD patients with a CVC worldwide (Pisoni et al. 2009). 
Central vein stenosis can have significant and underrecognised long-term adverse 
 45 
consequences (Agrawal, 2013). Furthermore, catheter use appears to be associated with a 
chronic catabolic state, malnutrition, weight loss and hypoalbuminaemia (Yeun & Depner, 
2000). 
 
1.5.2.1. Catheter-related bloodstream infection (CRBSI) 
 
CRBSI is the most common infection in patients on HD with an estimated incidence 0.6-
6.5 per 1,000 catheter days observed in most studies (Lata et al. 2016; Lok & Mokrzycki, 
2011), although the exact rates vary with reporting and definition practices. A local study 
reports systemic bacteraemia rates of 1.77 per 1,000 catheter days for TCVCs, 6.3 per 
1,000 catheter days for internal jugular NTCVC and 13.5 per 1,000 catheter days from 
femoral NTCVCs (Thomson et al. 2010). Healthcare associated bacteraemia is associated 
with an increased risk of death (HR 2.8 [95% CI 1.5-5.1]) (Lata et al. 2016) and increased 
length of hospital stay from an average of 7 to 21 days (Stone et al. 2005). An average 
CRBSI costs $37 000 to treat with catheter-related bacteraemia costing the healthcare 
system over $2 billion annually in the USA (Stone et al. 2005). 
 
A patient on haemodialysis should expect to be hospitalised twice a year on average. 1 in 
10 of these admissions will be due to vascular access infection (Ravani et al. 2013b). 
Whilst, the overall number of hospital admissions attributable to vascular access appear to 
have fallen in recent years, infection as a cause for hospital admission continues to rise 
(USRDS, 2014). In the USA, the number of hospital admissions due to vascular access 
infection more than doubled between 1993 and 2005 (Lok & Mokrzycki, 2011). This rise 
in infective admissions (to 903 admissions per 1,000 patient years) is disproportionate for 
patients on HD compared to the other RRT modalities and is widely attributed to catheter 
related-complications (USRDS, 2014). A prospective cohort study of over 100 000 patients 
in Canada found that the relative risk of bloodstream infection with TCVCs was 15.5 and 
with uncuffed CVCs was 22.5 compared to AVF (Taylor et al. 2002).  Similarly within a 
local cohort, catheter use was found to be an independent risk factor for both bacteraemia 
and death compared to AVF (HR 5.4 and 2.8 respectively) (Thomson et al. 2007).  
 
Most cases of catheter-related bacteraemia are uncomplicated and can be treated simply 
with antibiotics with or without catheter removal (Ashby et al. 2009; Lata et al. 2016), 
however others can result in metastatic infection. Approximately 10% of CRBSI in dialysis 
patients are associated with infective endocarditis (Lok & Mokrzycki, 2011). Endocarditis 
in this context carries a mortality rate of 25% (Lata et al. 2016). Discitis, spinal epidual 
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abscess, septic pulmonary emboli and osteomyelitis can all occur as secondary 
complications. Mortality rates from CRBSI in HD patients range between 6-34% in the 
literature (Lok & Mokrzycki, 2011). Whilst prevalent mortality on HD is reducing, 
incident death rates remain static (UK Renal Registry, 2016), at least in part explained by 
early catheter-related bacteraemia (Thomson et al. 2010). 
 
Most catheter-related bacteraemic episodes are the result of infection from skin 
commensals e.g. Staphylococcus aureus or Staphylococcus epidermidis. Staph.aureus is 
normally methicillin sensitive (MSSA). However methicillin-resistant Staph.aureus 
(MRSA) is more common amongst dialysis patients and vancomycin forms the mainstay 
of treatment of both systemic and local exit site infection (Lata et al. 2016; Lok & 
Mokrzycki, 2011). 
 
Given that infection is so costly, both in terms of the economic burden and morbidity for 
the patient (most cases necessitating line change), recent research has focussed on 
strategies to reduce infection. Education, strict asepsis, catheter care bundles and “scrub 
the hub” regimens with chlorhexidine skin cleansing and “no touch” technique have been 
very effective in reducing bacteraemia rates (Simmons et al. 2011). Topical antibiotics e.g. 
mupirocin/ polysporin (Lok et al. 2003), recombinant tissue plasminogen activator (tPA) 
(Hemmelgarn et al. 2006) and antimicrobial locks e.g. taurolidine/ sodium citrate have also 
proven effective. For example the Haemodialysis Infection Prevention with PolyspOrin 
(HIPPO) study demonstrated significant reduction in catheter-related bacteraemia rates 
with a combined topical antibiotic (polysporin) ointment, with bacteraemia rates <1 per 
1,000 maintained out beyond 6 years (Lok et al. 2003; Battistella et al. 2011). In clinical 
practice, multimodal and combination preventative strategies have been employed with 
greatest effect. 
 
1.5.2.2. Thrombosis and catheter malfunction 
 
In reaction to vessel damage and platelet activation, a fibrin sheath will form around many 
TCVCs shortly after insertion (Napalkov et al. 2013). This fibrin sheath can complicate the 
line in several ways: it may become colonized with bacteria and form a biofilm or can 
directly occlude the catheter causing malfunction and poor flows through the catheter. The 
KDOQI guidelines define catheter dysfunction as the inability of achieve volumetric blood 
flow >300mL/min during the first 60 minutes of dialysis (NKF-KDOQI, 2006). Reported 
rates of catheter malfunction or thrombosis range between 0.6 and 33% or 0.06 to 21 
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episodes per 1,000 catheter days (Napalkov et al. 2013). In the event of catheter occlusion 
of malfunction, forceful flushing is contraindicated as it may lead to catheter rupture. 
Recombinant tPA and intraluminal lock or infusion of lytic enzyme (e.g. urokinase) may 
assist in dissolution of acute thrombosis (Hemmelgarn et al. 2006; NKF-KDOQI, 2006), 
and in some cases it is possible for the fibrin sheath to be stripped from the catheter under 
radiological guidance (Funaki, 2012). However in many cases the catheter cannot be 
salvaged as evidenced by local data demonstrating that 7% of TCVCs needed replaced due 
to occlusion during 1 year follow-up (Aitken et al. 2014a). 
 
1.5.2.3. Central venous stenosis 
 
Of all the catheter-related complications, central vein stenosis (CVS) or occlusion carries 
the greatest long-term morbidity and is the most difficult to manage (Agarwal et al. 2007). 
Trauma to the vein wall during and following TCVC insertion leads to upregulation of 
proinflammatory transcription factors and profibrotic genes, which in turn, cause smooth 
muscle proliferation, intimal hyperplasia, smooth muscle proliferation and subsequent 
thickening and fibrous changes within the intima of the central veins.(Agarwal, 2013) The 
resulting venous outflow stenosis and obstruction causes venous hypertension and presents 
with arm or facial swelling or access dysfunction of an ipsilateral fistula. In extreme cases, 
patients may present with bilateral central venous occlusion precluding both upper limb 
autologous access or further CVCs. Very rarely complete access failure may result with 
patients unable to dialyse as a result of access loss (Aitken et al. 2014b). 
 
The prevalence of central vein stenosis varies depending on the diagnostic criteria (i.e. 
symptomatic versus angiographic), however most of the literature would suggest that 
between 10-40% of central lines are affected (MacRae et al. 2005). Risk factors for CVS 
include increasing number of TCVCs, longer duration of TCVC, a subclavian approach to 
vessel puncture and the presence of a cardiac pacemaker device (Agarwal, 2013). 
 
Its widely accepted that asymptomatic CVS should not be treated (Agarwal, 2013; 
Agarwal et al. 2007). Symptoms may improve as venous collaterals develop (Agarwal et 
al. 2007). Symptomatic CVS can be managed by endovascular intervention (angioplasty or 
stenting) (Bakken et al. 2007), however it is notoriously difficult to treat. Lesions are 
susceptible to elastic recoil and commonly recur (Beathard, 1992).They require repeated 
intervention, the benefit of which is often short-lived (Bakken et al. 2007), and are 
associated with significant personal and economic burden (Jackson et al. 2014). 12-month 
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unassisted patency rates for angioplasty of CVS range from 12-50%, with cumulative 
patency rates as low as 13% in some studies (Beathard, 2015; Quinn et al. 1995; Dammers 
et al. 2003a). National Kidney Foundation-KDOQI (2006) guidelines recommend stenting 
of the central veins in cases of elastic recoil with significant residual stenosis following 
angioplasty or in cases of recurrence after < 3months. Patency rates of stenting vary and 
are improving as technology advances, however primary patency rates at 1-year remain 
approximately 50-60% (Rajan et al. 2007). In most cases, intervention for CVS is a 
temporising measure that will ultimately fail leading to access loss.  
 
“End-stage” vascular access (ESVA) with imminent vascular access failure and the 
inability to dialyse is an uncommon but devastating problem (Aitken et al. 2014b). The 
exact prevalence of access failure is poorly described in the literature, however most 
clinicians involved in caring for patients with renal failure will be aware of a handful who 
have died as a result of complete access failure due to central venous occlusion (Jackson et 
al. 2014). Bilateral central vein occlusion precludes any future upper limb access (either 
peripherally or with further catheter into the neck vessels). Lower limb access or 
translumbar lines can be attempted, but the outcomes are suboptimal (Power et al. 2010) 
and ultimately occlusion of the iliac vessels and inferior vena cava will occur also. There 
are no good treatment solutions to this problem, which commonly affects younger dialysis 
patients, and can prove fatal. For this reason, perhaps more than any other, unnecessary 
catheter use should be avoided to prevent the initial occurrence of CVS. 
 
1.6.     ARTERIOVENOUS GRAFTS 
 
1.6.1.  Traditional arteriovenous grafts 
 
Arteriovenous grafts (AVGs) are artificial conduits between artery and vein. A synthetic 
material is utilised to create the graft, which is implanted subcutaneously, and then 
cannulated for dialysis. AVGs in their modern-day guise were first utilised in 1972 
(Konner, 2005). Three different graft materials were used at this time: one biological 
(bovine carotid artery) and two synthetic (expanded polytetrafluoroethylene (ePTFE) and 
Dacron® (Chinitz et al. 1972; Dunn et al. 1972)). Ultimately, ePTFE was found to be a 
more effective material of dialysis grafts than Dacron® due to its ease of handling, lower 
risk of aneurysm formation with repeated cannulation and lower infection rates (Konner, 
2005). 
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An arteriovenous graft can theoretically be implanted at any site in the body between an 
artery and vein, however the most common configurations are brachio-basilic forearm 
loops and brachioaxillary in the upper limb (Figure 1.9) and common femoral artery to 
femoral vein in the lower limb (Akoh, 2009). 
 
 
Figure 1.9: Common configurations of upper limb arteriovenous grafts.  
1: brachioaxillary; 2: axillo-axillary; 3: forearm loop (brachiobasiic or brachiocephalic); 4: 
straight forearm (radial to median cubital or cephalic). Reproduced with permission from 
Wichtig Publishing (Akoh, 2009). 
 
The benefits and limitations of an AVG lie somewhere between those of a TCVC and an 
AVF: they require significantly more initial cost in surgical expertise, time, and finance but 
have rates of complication and infection lower than a TCVC.  
 
As previously described, systemic bacteraemia rates of AVGs are 0.5-0.6 per 1,000 
dialysis days compared to 1.77 per 1,000 catheter days for TCVC and 0.3 per 1,000 
dialysis days for an AVF (Taylor et al. 2002; Thomson et al. 2010).  
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It is well recognised that the long-term patency of a functioning AVF is significantly better 
than an AVG, with the need for fewer interventions to maintain that patency. In a large 
Canadian cohort study of 1,140 accesses created between 2000-2010, Lok and colleagues 
(2013) found that, once primary failures were excluded, median cumulative patency for 
AVFs was 61.9 months compared to 23.8 months for AVGs (HR 0.56, 95% CI: 0.43-0.74; 
P<0.001). They also concluded, however, that AVGs are more likely to establish initial 
function than AVF. The primary failure rate for AVGs in their series was half that of AVF 
(19% vs 40%; P<0.001). Furthermore, accounting for the high primary failure rate of 
autologous access, the cumulative patency did not differ between fistulae and grafts for 
either first or subsequent accesses (7.4 vs.15 months; P=0.85 and 7.0 vs. 9.0 months; 
P=0.39 respectively). In most contemporary series the primary patency rates for AVGs 
range from 40-60% (Schild et al. 2007). However with aggressive management of 
thrombosis and re-intervention, secondary patency rates of as high as 90% at 1 year have 
been achieved in some cases (Akoh, 2009). 
 
Besides “failure to mature”, AVGs obviate several other of the problems associated with 
autologous access use: lack of native vessels and prolonged maturation time (Allon & Lok, 
2010; Lok, 2007). Standard ePTFE AVG can be cannulated two weeks after implantation 
(allowing just a short period of time for the graft to be incorporated into the surrounding 
tissue) (Akoh, 2009; Saran et al. 2005), avoiding the delays associated with prolonged or 
inadequate AVF maturation and the need for repeated interventions to achieve functional 
patency. In one observational study, only 16% of AVG required intervention to achieve 
functional patency, compared to 42% of AVF (Lee et al. 2007). 
 
The Renal Association, NKF-KDOQI and European Best Practice Guidelines in Vascular 
Access advocate the use of AVG only as a second line vascular access in patients in whom 
no autologous options exist (citing poor patency rates and infectious complications 
associated with AVG usage). Despite this however, AVGs were still the most prevalent 
form of vascular access in the United States until the early 1990s, with 70-80% prevalence 
(Hirth, 1996). 
 
1.6.2.  Early cannulation arteriovenous grafts (ecAVGs) 
 
Unlike standard AVGs, which need to be left approximately two weeks from insertion 
prior to first cannulation in order to allow them to incorporate into the surrounding tissue, 
 51 
early cannulation arteriovenous grafts (ecAVGs) are suitable for immediate cannulation. 
This property of ecAVGs means that, instead of principally being used in patients with no 
native vessels for autologous access, these grafts can be marketed as an alternative to 
TCVC in patients requiring immediate haemodialysis (Ottaviani et al. 2016). 
 
The first attempt at producing an early cannulation graft was in 1997 (Perma-Seal® (Possis 
Medical Inc., Minneapolis, MN, USA)). The role of and application of the graft was never 
recognised by the surgical community and the graft did not obtain FDA approval 
(Glickman, 2016). Since this time, an increased recognition of the mortality and morbidity 
associated with unnecessary catheter use (Thomson et al. 2007) and greater appreciation of 
the burden of AVF non-maturation necessitating TCVC use (Xue et al. 2010; Lacson et al. 
2007; Dember et al. 2008) lead to a revival in interest of ecAVG as an alternative to 
TCVC. In fact the 2006 KDOQI Vascular Access Update advocates the use of 
arteriovenous grafts as a “planned bridge” to AVF creation in selected cases based on 
clinical need.  
 
Initially the Vectra® (Bard, Murray Hill, NJ, USA) graft was licensed for early 
cannulation, and subsequently the three currently commercially available products 
(Rapidax™ (Vascutek Ltd, Renfrewshire, UK), Gore®ACUSEAL (W.L. Gore Associates, 
Flagstaff, AZ, USA) and Flixene™ (Maquet-Atrium Medical, Hudson, NH, USA) were 
developed. Both the Gore®ACUSEAL and Flixene™ grafts are made from ePTFE with 
unique tri-layer structures that give the grafts “low bleed” properties. The 
Gore®ACUSEAL graft is composed of two layers (outer and inner layer) of ePTFE 
separated by a central elastomeric membrane, designed to give the graft its self-sealing 
properties and limit pseudoaneurysm and seroma formation (Glickman, 2016) (Figure 
1.10). The median time to first cannulation in most case series is 2 days (Tozzi et al. 
2014a; Berard et al. 2015), however the grafts may be cannulated as early as 30 minutes 
post-operatively (Tozzi et al. 2014b; Al-Shakarchi et al. 2015a). 
 
Published data on the outcomes of ecAVGs remains limited. Patency rates in observational 
studies of both Flixene™ and Gore®ACUSEAL are comparable to those of standard 
ePTFE (Tozzi et al. 2014a; Glickman et al. 2015; Berard et al. 2015; Chiang et al. 2014). 
Much of the data reflect small, single-centre experiences with short follow-up. 
Nevertheless secondary patency rates for Gore®ACUSEAL range from 60-90% at 12 
months in every series (Table 1.2). In the only prospective multicentre study of early 
cannulation grafts, 1-year cumulative patency was 79% (95% CI: 71-85%), with a primary 
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unassisted patency rate of 35% (95% CI: 27-44%) (Glickman et al. 2015). Complications 
in this series were higher than in other cohorts with 6 patients experiencing haematoma 
formation, 15 graft infections and 15 cases of steal syndrome amongst 138 patients 
(Glickman et al. 2015). Overall infection rates for ecAVGs are comparable to those of 
standard AVGs, ranging from 0-18% in the published series (Al-Shakarchi et al. 2015b). 
 
 
 
Figure 1.10: Trilayer construction of Gore®ACUSEAL early cannulation graft. 
Magnification 500x. Reproduced with permission from W.L.Gore Associates. 
 
Despite published data on over 1 000 ecAVGS (Al-Shakarchi et al. 2015b), the exact role 
of ecAVG in clinical practice remains unclear and poorly defined. This is reflected by the 
large variety and range of patients treated with ecAVG in the literature: patients with no 
autologous upper limb options for vascular access (Glickman et al. 2015; Berard et al. 
2015); failure of previous vascular access (Tozzi et al. 2014b); need for urgent vascular 
access and TCVC avoidance (Berard et al. 2015; Aitken et al. 2014b) and complex or “end 
stage” vascular access solutions (Aitken et al. 2014b; Chemla et al. 2011). Chemla and 
colleagues (2011) present a series of early cannulation axillo-axillary grafts for patients 
with complex vascular access needs quoting 6 weeks and 1 year primary patency rates of 
93% and 66% respectively. Due to the diverse patient populations and characteristics it is, 
however, difficult to draw direct comparisons between the existing series of ecAVGs. 
 
 
 
Author Number 
of 
patients 
Multi/single- 
centre 
Indications Time to first 
cannulation 
Median 
follow-up 
Primary 
patency at 
12 months 
 
Secondary 
patency at 
12 months 
Infection 
rate 
Tozzi et al..2014a 30 Single centre Median age: 60+/-12 years  
“poor candidate for 
autologous access”  90% upper limb  
Median: 2.4+/-1.2 days 6.3 months 68% 93.3% 0% 
Aitken et al. 2014c 37 Single centre Median age: 42+/-17 years “allcomers”  46% bilateral central vein stenosis  65% lower limb  
Mean: 30.4+/-23.4 hours 6.5 months 32% 40% 16% 
Maytham et al. 2015  55 Single centre Median age: 64+/-17 years  
“native options not possible or exhausted”  
73% within 24 hours 17.5 months 46% 61% 0.2 per 1,000 dialysis days Glickman et al,.2015 138 Multicentre Median age: 63+/-14 years  
“upper arm vascular access in patients not suitable for 
AVF”  
Median 15 days 12 months 33% 78% 11% 
 
Table 1.2: Summary of published studies of Gore®ACUSEAL early cannulation graft.
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1.6.3. Novel arteriovenous grafts 
 
The relatively poor outcomes in vascular access provide the prime opportunity for 
innovation to improve results. As a result, recent years have seen an explosion of new 
technologies, in many cases outpacing the current evidence or experience (Inston & Jones, 
2014). This rapid expansion is largely driven by industry with novel interventions targetted 
to each of the clinical problems encountered. Graft geometry and flow modification e.g. 
spiral laminar flow grafts aim to counter the problems with venous outflow stenosis 
(Kokkalis et al. 2015); graft drug coatings e.g. heparin (Glickman, 2016), paclitaxel (Baek 
et al. 2012) and sirolimus (Paulson et al. 2012) have all been proposed as interventions to 
reduce in-graft stenosis and thrombosis (Allon et al. 2016); and new electrospinning 
technologies have been employed to control the size, density and orientation of graft fibres 
with the intention of giving them specific self-sealing properties to permit early 
cannulation (Ferraresso et al. 2013). The development of novel biological grafts more akin 
to autologous vessels may improve patency rates (Dukkipati et al. 2013; Peck et al. 2011), 
while devices such as the haemodialysis reliable outflow (HeRO) device have been 
designed to manage a specific clinical problem (central vein stenosis) (Glickman, 2011). 
The pace at which technology has developed and the overwhelming influence of industry 
has limited the head-to-head evidence available for any of these new products, most of 
which are described as case reports or small case series in the literature (Inston & Jones, 
2014). 
 
1.6.3.1. Biological grafts 
 
Synthetic arteriovenous grafts are universally plagued by neointimal hyperplasia and 
stenosis leading to subsequent thrombosis and poor patency rates (Peck et al. 2011). The 
rationale for biological grafts therefore is that, by avoiding artificial material, the foreign 
body reaction is also prevented. 
 
Biological grafts are not new. In fact, at the same time as modern era synthetic grafts were 
being developed, both xenogenic and allogenic biological grafts were also employed for 
vascular access. Bovine carotid artery, mesenteric vein and ureteric grafts (Darby et al. 
2006; Katzman et al. 2005; Kaplan et al. 1976) were all found to form effective 
arteriovenous conduits with at least comparable patency to ePTFE. Unfortunately however, 
high rates of both pseudoaneurysm formation and rupture limited their long term use (Peck 
et al. 2011). Cryopreserved saphenous and femoral vein homografts remain commercially 
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available, however the hypothesis that such grafts would reduce infection rates was not 
supported in practice and cumulatively the clinical application of these grafts is limited to 
very niche situations (e.g. implanting into an area of existing infection) (Peck et al. 2011). 
 
Recent work has focussed on developing scaffolds for biological grafts (either 
bioengineered resorbable scaffolds that permit cellular ingrowth (Shinoka et al. 2001) or 
completely biological in vivo tissue-engineered grafts  (Campbell et al. 1999). Like the 
xenografts previously, bioengineered grafts form excellent bypass conduits, but concern 
regarding their ability to maintain sustainable integrity at cannulation sites is always a 
concern for dialysis vascular access  (Tillman et al. 2012). The best-established biological 
graft is the biosynthetic Omniflow® graft (LeMaitre, Toronto, Canada), which utilises 
ovine collagen grown around a polyester mesh template. Retrospective analysis of 720 
vascular accesses (59 ovine grafts) found the bioengineered grafts to have 1-year 
secondary patency comparable to autologous AVF (71%) and substantially better than 
ePTFE (54%). The infection rate of the ovine graft was 2% (Edwards & Ramshaw, 1995). 
More recently results of the multicentre phase II trial of the human acellular vessel 
(Humacyte® (Humacyte Inc., Morrisville, NC, USA)) have been published and show 
significant promise. Six-month primary and secondary patencies of 63% and 93% were 
observed, with no evidence of aneurysm formation and only one infection in 60 patients 
(median follow-up 16 months)  (Lawson et al. 2016) . The decellularised collagen scaffold, 
has theoretical benefits of producing less inflammation and lower immune reactions. A 
phase III trial is underway. To date this has recruited 190 patients. One of the major 
limitations in the implementation of tissue bioengineered grafts into clinical practice is cost  
(Tillman et al. 2012).  It therefore follows that a graft, such as Humacyte®, which could in 
the future be produced to be freely available off the shelf, might have significant benefit. 
 
1.6.3.2. Haemodialysis Reliable Outflow (HeRO) Device  
 
 The Haemodialysis Reliable Outflow (HeRO) device is a unique innovation in vascular 
access, designed to manage the problem of central vein stenosis, in patients who have no 
venous outflow to drain a standard AVG, but in whom there is a desire to avoid TCVC. 
The device is a hybrid of a venous outflow component (akin to a central venous catheter) 
that is placed in the central vessels under image-guidance and drains much is a line would 
and an inflow graft component that is anastomosed onto the artery and tunnelled and 
cannulated as would be a standard graft. The graft component and outflow component then 
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connect together to permit venous drainage (Glickman, 2016; Glickman, 2011; Al-
Shakarchi et al. 2015c) . 
 
In an era where there is increased survival on haemodialysis, the number of patients who 
have exhausted all traditional vascular access options are increasing. Central venous 
occlusion poses a very difficult problem to manage. The HeRO device provides one 
potential solution for this complex patient cohort. Given the complexities involved in 
managing these patients and the lack of alternative treatment strategies, published 
outcomes from the HeRO device are commendable.  A recent review of the literature  (Al-
Shakarchi et al. 2015c)  identified eight studies with a total of 409 patients, mainly in 
North America. Pooled primary and secondary patency rates of 21.9% and 59.4% at one-
year were obtained. Systemic bacteraemia rates of 0.13-0.7 per 1,000 dialysis days have 
been observed. 
 
1.6.4.  Complications of AVGs 
 
The complication rates of AVGs lie somewhere between those of AVF and TCVC. 
Bacteraemia and local infection are more common in AVG than AVF, but less common 
then in TCVC. Similarly, graft thrombosis occurs more frequently than AVF thrombosis, 
however it is easy to treat and re-establish patency with a graft. 
 
1.6.4.1. Venous stenosis and thrombosis 
 
The majority of grafts occlude due to venous outflow stenosis. Like in AVF, a process of 
vascular injury, neointimal hyperplasia, stenosis and then thrombosis occurs. The process 
is particularly aggressive at the graft-vein anastomosis, although can also occur at sites of 
needle injury within the graft  (Roy-Chaudhury et al. 2012b). The venous anastomosis is 
especially vulnerable to endothelial and smooth muscle cell injury due to a combination of 
haemodynamic stressors (non-laminar and turbulent blood flow and low shear stress)  (Van 
Tricht et al. 2005)  surgical injury and PTFE graft-induced macrophage accumulation  
(Roy-Chaudhury et al. 2001). Injury can also occur at the time of angioplasty  (Lee et al. 
2010). As a result, the rates of venous stenosis and subsequent thrombosis are higher in 
AVGs than autologous AVF, though it is easier to re-establish patency following 
thrombosis in prosthetic (Sgroi et al. 2013; Lok et al. 2013). 
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Twelve-month primary and secondary patency rates of AVGs range from 22-65% (Sgroi et 
al. 2013; Keuter et al. 2008) and 58-81% (Gibson et al. 2001; Kakkos et al. 2008) in 
historical series of standard PTFE. Secondary patency rates as high as 93% have been 
quoted in some contemporaneous series of ecAVG (Tozzi et al. 2014a). In their large 10-
year cohort study comparing AVF and AVG, Lok and colleagues (2013) found that whilst 
overall cumulative patency for AVF and AVG did not differ, AVG had significantly 
poorer cumulative patency (23.8 vs. 61.9 months; P<0.001) after exclusion of primary 
failures. Thrombosis occurs in 50% of all grafts within 1 year of placement, necessitating a 
salvage procedure in 75% (Schwab, 1999; Miller et al. 2000). 
 
Recent years have seen multiple interventions directed at attempting to improve graft 
patency. To date most have failed to convincingly or consistently reduce thrombosis rates 
(Diskin, 2003; Kaufman et al. 2003; Sreedhara et al. 1994; Moufarrej et al. 2016). 
Pharmacological therapies have been both local and systemic. A large multicentre 
randomised trial of dipyridamole plus low-dose aspirin demonstrated modest improvement 
in graft patency (28% vs. 23% primary unassisted patency at 1-year) but poor cumulative 
AVG survival (Dixon et al. 2009). The Cochrane review published in 2008 (Osborn et al. 
2008) identified ten studies that evaluated the role of anti-platelet or anticoagulant drugs in 
maintaining patency of AVGs. A modest improvement in graft thrombosis was observed 
with anti-platelet agents (asprin, clopidogrel and ticlopidine), however the single study of 
warfarin (Crowther et al. 2002) was halted early due to an increased rate of haemorrhagic 
complications in the treatment arm. A recent randomised controlled trial of fish oil 
supplementation found lower rates of graft failure in the fish oil supplementation arm (3.43 
vs. 5.95 per 1,000 access days; P<0.001), however was probably underpowered to detect 
any difference in the primary endpoint (proportion of patients experiencing thrombosis or 
need for intervention in the first 12 months) (Lok et al. 2012). Finally, there have been 
multiple attempts made at modifying the venous outflow of the graft in an attempt to 
improve the haemodynamics and minimise neointimal hyperplasia. These adaptations have 
been driven by industry and include a spiral graft aimed at inducing spiral laminar flow 
(Stonebridge et al. 2012); tapered grafts designed in an attempt to widen the venous 
outflow and control flow rates through the graft (Krueger et al. 2004); the Optiflow™ 
(Bioconnect Systems, Ambler, PA, USA) anastomotic connector to obviate the need for 
suturing and surgical trauma (Manson et al. 2013) and the Gore®Hybrid graft with nitinol 
reinforced stent to cross the venous anastomosis (Jones & Inston, 2015). The theoretical 
benefits of such products are evident, however to date there is no evidence that any one 
results in superior patency (Roy-Chaudhury et al. 2012b). 
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1.6.4.2. Graft infection 
 
Systemic infection rates of AVGs are higher than AVF but significantly lower than TCVCs 
in most published series. The systemic bacteraemia rate for AVG is commonly reported as 
0.06 per 1,000 access days (Schild et al. 2007). In actuality, the infection rates quoted in 
the literature vary significantly (Table 1.3) and there is no standardised definition of what 
constitutes an infection, making comparison of incidence, intervention and outcome 
difficult (Ryan et al. 2004). Most case series are small, involve heterogenous patient 
groups and variable sites for AVGs (upper and lower limb). Follow-up is poorly defined 
and there are no clear reporting methods for infection rates (Kingsmore, 2016). Some 
series report infection rates as a percentage of the total population at end of the follow-up 
period (Schild et al. 2007; Allemang et al. 2014), others report per year (Ram et al. 2010) 
or per 1,000 access days (Aitken et al. 2014b). As a result, widely variable infection rates 
are quoted (Kingsmore, 2016).  
 
Although systemic bacteraemia is uncommon (and metastatic infection practically unheard 
of) localised infection and infected haematoma of AVGs is significantly more common, 
affecting 10-15% of all grafts (Al-Shakarchi et al. 2015b). The natural history and timing 
of infection is also important, with most infections occurring early (presumably the result 
of infected haematoma at the operative site) (Kingsmore, 2016). Such infections tend to 
result in local problems and may ultimately necessitate explant of the graft, but rarely 
result in a systemic bacteraemia. Later (secondary) infections commonly result from poor 
cannulation technique and lack of asepsis. The organism is normally a skin commensal and 
systemic bacteraemia is more common (Kingsmore, 2016; Harish & Allon, 2011) (Figure 
1.11). Often a prolonged course of antibiotics will effectively treat these infections, 
although practice is variable and without an established evidence base (Ryan et al. 2004). 
Standardised definitions of graft infection including methods of quoting incidence, severity 
of local (i.e. degree of local cellulitis/ abscess formation) and systemic infection (i.e. 
positive blood cultures or suspected systemic infection), and need for intervention are 
required for effective comparison between products and centres and to facilitate future 
research (Kingsmore, 2016).  
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Table 1.3: Infection rates of arteriovenous grafts in published case series and 
randomised controlled trials 
 
Author Study 
type 
Number 
of grafts 
Follow-up Graft type Site of graft Infection 
rate 
Wang et 
al.1996 
Case 
series 
109 18 months Omniflow 
Standard PTFE 
63% upper limb 1%/yr 
2.3%/yr 
Glickman et 
al. 2001 
RCT 142 12 months Vectra 
PTFE 
100% upper limb 5.6% 
5.6% 
Dammers et 
al. 2003 
RCT 109 12 months Tapered PTFE 
Standard PTFE 
100% upper limb 0.12/ yr 
0.03/ yr 
Ryan et al. 
2004 
Case 
series 
1441 - Standard PTFE 100% upper limb 3.5% 
Rooijens et 
al. 2005 
RCT (vs 
RCF) 
84 12 months Standard PTFE 100% upper limb 0.13/yr 
Schild et al. 
2007 
Case 
series 
702 Median: 10 
months 
Standard PTFE 95% upper limb 9.5% 
Kakkos et al. 
2008 
Case 
series 
76 18 months Vectra 100% upper limb 6.6% 
Keuter et al. 
2008 
RCT  (vs 
BBF) 
51 325 days Standard PTFE 100% upper limb 15% 
Palumbo et 
al. 2009  
Case 
series 
38 Median:38 
months 
Omniflow - 0% 
Ko et al. 2009  RCT 89 2 years Cuffed PTFE 
Standard PTFE 
100% upper limb 4% 
5% 
Ram et al. 
2010  
Case 
series 
268 - Standard PTFE 79% upper limb 
21% thigh 
0.5/pt/yr 
0.1/pt/yr 
Sala et al. 
2011  
Case 
series 
30 - Standard PTFE 100% upper limb 10% 
Mistry et al. 
2011  
Case 
series 
48 - Flixene 100% upper limb 6.25% 
Lioupis et al. 
2011  
Case 
series 
48 - Flixene 100% upper limb 6% 
Morosetti et 
al. 2011 
RCT (vs 
BBF) 
27% 2 years Omniflow II 100% upper limb 0% 
Harish & 
Allon, 2011 
Case 
series 
1309 - Standard PTFE 78% upper limb 
22% thigh 
9% 
14% 
Kennealey et 
al. 2011  
RCT 53 33 months Standard PTFE 
Bovine carotid 
artery graft 
100% upper limb 0.1/yr 
0.13/yr 
Bachleda et 
al. 2012  
Case 
series 
53 - Standard PTFE - 28.3% 
Lok et al. 
2012  
RCT (fish 
oil) 
201 12 months Standard PTFE 95% upper limb 8.4% 
Davoudi et al. 
2013  
RCT (vs 
BBF) 
30 - Standard PTFE 100% upper limb 17% 
Allemang et 
al. 2014  
Case 
series 
265 Up to 4 
years 
Standard PTFE 92% upper limb 9% 
Scarritt et al. 
2014  
Case 
series 
78 - Flixene 100% upper limb 9% 
Harlander-
Locke et al. 
2014 
Case 
series 
17 18 months Bovine carotid 
artery 
Previous infection 
or high risk 
6% 
Tozzi et al. 
2014a 
Case 
series 
30 6.3 months Acuseal 90% upper limb 0% 
Chiang et al. 
2014 
Case 
series 
64 18 months Flixene 
Standard PTFE 
100% upper limb 20% 
40% 
Nassar et al. 
2014  
RCT 72 18.5 months Standard PTFE 
HeRO 
21% 
20% 
 
Maytham et 
al. 2015 
Case 
series 
52 17.5 months Acuseal 100% upper limb 16% 
Glickman et 
al. 2015 
Case 
series 
138 12 months Acuseal 100% upper limb 11% 
Berard et al. 
2015 
Case 
series 
46 Median: 
223.5 days 
Flixene 73% upper limb 2% 
Shemesh et 
al. 2015 
RCT 160 23.5 months Standard PTFE 
Propaten 
100% upper limb 3.8% 
3.8% 
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Figure 1.11: Time to graft infection in days (thigh and upper extremity (UE)), 
highlighting two distinct time periods for onset of infection- primary (likely the result 
of infected haematoma at the time of surgery) and secondary (likely resulting from 
inoculation of organisms due to poor cannulation technique. Adapted from Harish & 
Allon, 2011. Reproduced with permission from Mr David Kingsmore. 
 
Graft infections are notoriously difficult to treat. Once prosthetic has become infected 
systemic antibiotics (even prolonged courses) and often ineffective and often operative 
drainage or explant of the grafts is the only treatment option (Ryan et al. 2004; Benrashid 
et al. 2017). Prevention therefore is the mainstay of management. Strict asepsis and good 
cannulation technique is vital (Bachleda et al. 2012; Parisotto et al. 2014); prophylactic 
antibiotic at the time of implant may be helpful (Kingsmore, 2016); and, finally, graft 
modifications (antibiotic impregnated or bioengineered grafts) may have a role in the 
future (Inston & Jones, 2014). 
 
1.6.4.3. Other graft complications 
 
Like AVF, AVG can also be complicated by pseudoaneurysm formation and steal (Al-
Shakarchi et al. 2015b; Sgroi et al. 2013). As with graft infection, the reporting of other 
graft complications in literature is variable and non-standard. Quoted rates of 
pseudoaneurysm formation range from 0-17% (Al-Shakarchi et al. 2015b; Kakkos et al. 
2008; Sgroi et al. 2013). They are commonly associated with clustering of cannulation 
sites (area cannulation) and rotation of needle sites can assist in preventing this 
complication (Tozzi et al. 2014b; Al-Shakarchi et al. 2015b). 
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Theoretically steal syndrome should be more common in patients with AVGs than AVFs 
due to the diameter of the graft (6mm internal diameter in most AVGs vs. 2-3mm outflow 
vein in AVF). In reality, rates reported in the literature (0-11%) (Glickman, 2016; Al-
Shakarchi et al. 2015b) don’t differ significantly from autologous access, though the 
clinical symptoms are more likely to manifest soon after surgery due to the fixed outflow 
of the AVG and higher flow rates observed immediately. 
 
1.7. PROMOTING THE USE OF AUTOLOGOUS ACCESS  
Conventional opinion supporting AVF as the ‘gold standard’ vascular access (Smith et al. 
2012, pp.849) has led to a number of strategies, targets and initiatives promoting 
autologous access use. 
1.7.1.  “Fistula First” 
The “Fistula First Breakthrough Initiative” (FFBI) is a multi-faceted, American, 
continuous quality improvement project that was established in 2003 with the aim of 
achieving the KDOQI targets of 50% incident and 40% prevalent AVF use by 2005 (Lok, 
2007).  The goal of 40% prevalent AVF use was rapidly surpassed with an increase in 
AVF use from 24% in 2000 to 52% in 2008 (Pisoni et al. 2002; Spergel, 2008; Lynch et al. 
2011a; Lynch et al 2011b; Allon & Lok, 2010). The new target of 66% prevalent AVF use 
is fast approaching. The initiative has however failed to influence incident AVF use. Until 
last year (when DOPPS-5 observed slight improvements in incident AVF usage to 28%) 
incident AVF use in the US has been <15% compared to 60-70% in most of Europe 
(Pisoni et al. 2015; Ethier et al. 2008; Allon & Lok, 2010). 
Furthermore, unfortunately the increase in prevalent AVF usage has unfortunately not been 
accompanied by a concomitant reduction in catheter use (Lok, 2007). Conversely, the rate 
of prevalent TCVC usage has actually increased from 17% to 26% (perhaps due to a high 
primary failure rate of AVF created through an aggressive fistula primacy policy 
necessitating prolonged TCVC dependence) (Allon & Lok, 2010; Pisoni et al. 2015). 
Instead of a switch from TCVC to AVF, the post-FFBI era has seen a switch from AVG to 
AVF with no, or in fact negative, influence on catheter usage (Figure 1.12) (Gomes et al. 
2013; Vassalotti et al. 2012). Although reduction in CVC use was never a primary goal of 
the FFBI, many now recognise the need for ‘a concurrent approach to AVF promotion and 
CVC reduction’ (Lok, 2007, pp.1045). The KDOQI standard of ≤10% prevalent catheter 
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use has now been widely adopted into the FFBI campaign and latterly there has been a 
shift in focus from “Fistula First” to “Catheter Last” (NKF-KDOQI, 2006; Lacson et al. 
2007; Fulton, 2009). 
  
  
Figure 1.12: Prevalent vascular access use in the US highlighting the impact of the 
FFBI (increasing numbers of AVF, reducing numbers of AVGs and no significant 
change in TCVC use.) Reproduced with permission from National Kidney Foundation 
Fistula First Breakthrough Initiative. (Gomes et al. 2013). 
 
 
So has “Fistula First” actually achieved its aims? Certainly, the improvement in prevalent 
autologous access use must be commended, as should the heightened awareness of 
vascular access as a key determinate of outcomes for patients on HD that has been 
promoted by the campaign. However there is currently no evidence to suggest that the 
observed increase in AVF usage has actually resulted in any improvement in dialysis-
related outcomes (either reduction in infection rate or improved survival) (Malas et al. 
2015). Furthermore ‘current incident practice [still] falls exceedingly short years after 
recommendations, [with] a change in current policies and structured multidisciplinary 
efforts needed to ameliorate this deficit’ (Malas et al. 2015, pp.441). Additionally, whilst 
DOPPS data confirm that drives to improve autologous access use have resulted in more 
AVF being created (more than twice as many AVF were created per head of the dialysis 
population in 2012 compared to 2002), the proportion of those AVF that are subsequently 
used for dialysis has actually reduced in recent years (Rayner et al. 2003; Pisoni et al. 
2009). These observations have led some to observe that perhaps the drive should not be 
simply to have 65% of patients on HD with a fistula, or even that 65% of patients on HD 
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have a “functioning” fistula, rather that 65% of patients on HD have an AVF capable of 
sustaining dialysis (Lok, 2007). 
1.7.2.  Targets in the United Kingdom 
In the UK, The Renal Association has set even more stringent targets, advocating that 65% 
of incident patients and 85% of prevalent patients should have autologous vascular access 
(Fluck & Kumwenda, 2011). Recently a controversial best practice tariff was established 
in England and Wales with the aim of creating a rules-based framework that financially 
rewards efficiency and best practice (Department of Health, 2010). The Payment by 
Results (PbR) tariff was calculated based on 75% of prevalent haemodialysis occurring via 
an AVF or AVG in 2011/2012; 80% in 2012/2013 and 85% by 2013/2014, with trusts 
financially recompensed for achieving these goals (Department of Health, 2010; Sharif & 
Baboolal, 2011).  
Although contentious, the best practice tariffs have rekindled the drive for definitive 
vascular access this side of the Atlantic. Like in the US, prevalent AVF rates have 
increased year-on-year with 67% prevalent AVF use in DOPPS-1, 74% in DOPPS-4 and 
80% in DOPPS-5, with a corresponding reduction in catheter-dependence (unlike the US, 
baseline prevalent AVG use was low and therefore improvements in AVF use in the UK 
have resulted in concurrent reduction in TCVC use) (Robinson & Port, 2010; DOPPS 
Collaborators, 2012; Ethier et al. 2008; Pisoni et al. 2015). Practice around the UK is 
diverse however, with some units having upwards of 60% of patients dialysing via an AVF 
after only 6 months, while others have less than 10% (UK Renal Registry, 2014). 
Furthermore, like in the US, the incentivised practice has not translated into improvement 
in autologous access use in incident patients to date (UK Renal Registry, 2016). The recent 
DOPSS-5 data show that incident AVF use in the UK is only 53% compared to 85% in 
Japan (Pisoni et al. 2015). 
1.7.3. The Local Problem 
Healthcare in Scotland is a devolved power, therefore the best practice tariff does not apply 
within the National Health Service (NHS) in Scotland. There is now a significant 
discrepancy in autologous access rates North and South of the border (73% prevalent AVF 
rate in Scotland compared to 80% in England and Wales) (UK Renal Registry, 2016; 
Scottish Renal Registry, 2015), with concerns that the disparity will further increase 
without incentivisation in Scotland (Thomson 2015, personal communication). 
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There is also significant variation in prevalent vascular access use within Scotland (Figure 
1.13) (Scottish Renal Registry, 2015). Units in the West of Scotland are falling well below 
the national average. In 2015, Glasgow’s dialysis units only achieved 63% prevalent AVF 
use, compared to 81% in Edinburgh and 94% in Aberdeen (Scottish Renal Registry, 2015). 
These shortcomings have lead to a drive to improve vascular access provision locally. 
 
Figure 1.13: Percentage of prevalent haemodialysis patients in Scotland dialysing via 
autologous AVF 2012-2016. Reproduced with permission from Information Service 
Department (ISD), Scotland (Scottish Renal Registry, 2015). 
 
1.7.4.  How do you improve autologous access use? 
Attaining a functioning fistula is a complex process ‘akin to running a hurdle race’ (Allon, 
2007, pp. 786). There are multiple steps (referral to a nephrologist, surgical assessment, 
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creation of AVF, maturation and maintenance) that need to be performed in a sequential 
order. Failure in any of the steps results in the patient initiating dialysis via a catheter 
(Allon, 2007). Input is required from a range of specialists within the multidisciplinary 
team (nephrologists, surgeons, interventional radiologists, vascular access nurses) (Lok, 
2007). It is therefore vital that a co-ordinated team-based approach is adopted with 
everyone working towards a common goal (Lok & Davidson, 2012).  
The factors associated with a suboptimal start onto HD are both patient- and centre-
specific. Each unit and every patient will present unique challenges and barriers to AVF 
creation that need to be addressed at a local level as well as through national targets 
(Wilson et al. 2013). Root-cause analysis of TCVC usage however repeatedly highlights 
common problems. Assuming that TCVC avoidance is the aim, a better understanding of 
the reasons for catheter usage can be used to inform a strategy to optimise autologous 
access (Wish, 2010). Lee and colleagues (2005) found that nearly half of patients (43.5%) 
dialysing via a TCVC did so as they were still awaiting AVF creation (either after starting 
HD or following failure of a previous AVF). 28.7% were waiting for an AVF to mature; 
18.5% had no native option and 9.2% did so through patient choice (Lee et al. 2005). Nica 
and colleagues (2013) highlighted that patient factors and deficiencies in the systems and 
processes of vascular access provision were major determinants of TCVC use, with patient 
refusal, late referral, wait for surgery, lack of operating room space and poor cannulation 
quoted as relatively consistent problems. Good access outcomes require both reliable 
systems and attention to the human factors (National Kidney Care Vascular Access Report, 
2012). 
The strategies required to improve autologous vascular access rates differ between incident 
and prevalent patients. In prevalent patients, the aim must be to prevent access loss through 
thrombosis. Failure to recognise and treat dysfunctional access is the principal cause for 
loss of a functioning vascular access (Vassalotti et al. 2012). Although the role of 
radiological surveillance of fistulae remains controversial, clinical monitoring with prompt 
recognition of stenosis and timely intervention for failing AVF is essential to prevent 
thrombosis (Sharma & Ranjan, 2014; Polkinghorne, 2006; Salman, 2014; Allon & Robbin, 
2002; Fluck & Kumwenda, 2011). Education of dialysis nursing staff and good 
cannulation practice is also vital to minimise complications. A single episode of infiltration 
prolongs TCVC dependence by 3 months (Allon & Lok, 2010; Lee et al. 2006). Finally, 
there is a growing body of evidence to suggest that pharmacological manipulation at 
various of stages in the stenosis-thrombosis pathway may assist in preventing access loss 
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(Jackson et al. 2012). Fish oils, clopidogrel, aspirin and dipyridamole have all been shown 
to have a modest benefit in prolonging patency of both AVF and AVG in clinical trials 
(Lok, 2012; Dember et al. 2008; Tanner & DaSilva, 2015). Whether or not this translates 
into clinically significant benefit to the patient remains a matter of debate. The Dialysis 
Access Consortium (DAC) trial of aspirin and dipyridamole only prolonged graft survival 
by 6 weeks (Dixon et al. 2009). 
Incident patients should be the focus of efforts to improve autologous access creation (Lok, 
2007). An optimal start on dialysis with functioning AVF is associated with better short- 
and longer term survival (Mendelssohn et al. 2006; Malas et al. 2015). Starting dialysis via 
a TCVC sets a precedent for ongoing future catheter use (Weber et al. 2009).  40% of 
patients who started on a line are still with TCVC (with or without AVF) after a year on 
HD (Lok, 2007; Ethier et al. 2008).  The vestige of poor access planning and early line 
usage remains with the patient for their lifetime on dialysis in the form of lost access sites 
and central vein stenosis (Agarwal et al. 2007; Aitken et al. 2014a).  
Late referral is cited as the commonest reason for failure to start dialysis via an AVF (Lok, 
2007; Wish, 2010; UK Renal Registry, 2014.). The recommendation from the UK Renal 
Association is that referral for vascular access should occur when the patient enters CKD 
IV (taking into account comorbidities, rate of declines in renal function and the surgical 
pathway) (Fluck & Kumwenda, 2011). Similarly, the National Kidney Foundation 
advocates AVF creation at least 6 months before the anticipated need for dialysis (NKF-
KDOQI, 2006). Despite this, even in patients known to nephrology services >90 days, only 
50% were referred to the surgical team for autologous access creation prior to starting on 
HD (National Kidney Care Vascular Access Report, 2012). Of those assessed by a surgeon 
at least three months prior to starting dialysis, 70.4% started dialysis on an AVF whereas 
only 9.7% of those who had not seen a surgeon did (UK Renal Registry, 2014.). 
A recent Dutch study identified a number of bottlenecks in the referral pathway for AVF 
creation: delayed referral (failure of nephrologist to recognise decline in renal function); 
delay to surgical assessment (suboptimal accessibility OF surgical clinic); delay to surgery 
(lack of surgical capacity) (van der Veer et al. 2015). Several years ago, a Joint Working 
Party Group of The Renal Association, Vascular Society of Great Britain and Ireland and 
British Society of Interventional Radiology (2006) identified minimum physical 
requirements that were required to provide a vascular access service. Despite this, many 
units still fall short of their recommendations of one theatre list per week for every 120 
prevalent dialysis patients, a two-week waiting time for fistuloplasty and the ability to 
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perform thrombectomy within 48 hours. 
In addition to these material requirements, integration of the individual components within 
vascular access service infrastructure is essential since ‘fragmentation of care’ has been 
identified as major barrier to AVF placement (Wish, 2010, pp.615). Clear referral 
pathways and processes are essential as lack of a structured referral pathway is recognised 
as an obstacle to autologous access creation (Lopez-Vargas et al. 2011). However rigid 
strategies can put unnecessary delays into the system (for example the recommendation of 
“Fistula First” that every patient must have a pre-operative vein mapping ultrasound) (Lok, 
2007). A degree of flexibility, and perhaps redundancy, is required so that the process of 
care is fluid and can be adapted for the individual patient. Currently inherent delays created 
by a methodical surgical referral pathway in many centres (clinical assessment, then 
imaging, then wait listing prior to surgery) (Lok & Oliver, 2003) means that only 8% of 
patients who are referred for surgery “late” (i.e. after starting on dialysis) have a 
functioning AVF after 6 months on dialysis (UK Renal Registry, 2014). 
Approximately one third of patients are known to a nephrologist for <90 days prior to the 
initiation of HD. Obviously it will not be possible to create and mature an AVF within this 
time period, therefore these “crashlanders” present unique management challenges. They 
are often critically unwell, grossly fluid overloaded or hyperkalaemic. Many have 
experienced a significant hypotensive insult to precipitate their renal failure and many have 
poor cardiac function. Repeated cannulation and venesection in this patient cohort will 
destroy native vessels and limit autologous options for the future. For these reasons, the 
default position for such patients is for TCVC, with nearly 90% starting dialysis via a line 
(Chao, 2013; UK Renal Registry, 2016). However, it is essential that autologous access 
planning begins at the initial recognition of acute kidney injury (AKI) with preservation of 
vessels for future vascular access. Despite the fact that the patient is acutely unwell and 
TCVC may be the simplest and easiest option, alternatives including urgent PD, ecAVG, 
and early cannulation of native AVF should be considered as means of avoiding damage to 
the central veins and compromising autologous options for the future (Ponce & Balbi, 
2011; Blake, 2012; Tozzi et al. 2014b; Berard et al. 2015; Saran et al. 2005). Such options 
require a degrees of flexibility within the surgical service and cannot be managed on the 
“next available” theatre list. Locally, there has been some success with a policy of semi-
urgent vascular access creation where required (Aitken et al. 2012C).  
The best way to manage “crashlanders” remains to avoid them by identifying patients early 
enough to allow access planning prior to an urgent need to commence HD. Hughes and 
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colleagues (2013) found that 31.2% of patients classified as “crashlanders” actually had 
somewhat predictable acute-on-chronic renal failure in which a foreseeable trajectory of 
renal decline was not adequately anticipated or recognised, necessitating avoidable TCVC 
insertion for the start of HD.  
Early identification of patients soon to require HD also allows for pre-dialysis education. 
Pre-dialysis education has a very important role in preservation of vessels for native 
access. Patients told to avoid phlebotomy from their non-dominant arm are twice as likely 
to successfully have creation of a native AVF (Lok & Oliver, 2003). Additionally, pre-
dialysis education is important to influence and inform opinion about the value of 
autologous access (Lok, 2007). Nephrologists consider patient refusal to be one of the 
principal barriers to AVF creation and it’s well recognised that the longer a patient spends 
dialysing via a line, the harder it is to convince them as to the benefits of AVF (Xi et al. 
2010.; Nica et al. 2013). Many patients who have a catheter enjoy the ease of dialysis 
(quicker to get on and off the machine, no needles etc.) and become reluctant for AVF 
creation (Xi et al. 2010.; Lacson et al. 2011). 
Finally, non-maturation of AVF is a significant problem. If a fistula is created, but not 
matured by the time a patient starts on dialysis, the default is a TCVC. 81% of patients 
known to renal services have AVF surgery attempted prior to commencing on HD, but the 
number of patients actually starting HD via an AVF is less than 50% in the UK (Pisoni et 
al. 2015; UK Renal Registry, 2016; Scottish Renal Registry, 2015).  Despite pre-operative 
vein mapping to choose the optimal site and balloon-assisted maturation, only about half of 
AVF created mature sufficiently for dialysis (Dageforde et al. 2013; Mendes et al. 2002; 
Roy-Chaudhury et al. 2012b; Zangan & Falk, 2009; Dember et al. 2008). As previously 
highlighted, the challenge is therefore not in creating an AVF, it is in creating a 
functioning AVF (Lok, 2007). Two-thirds of patients in the Dialysis Access Consortium 
(DAC) study of AVF maturation, had AVF that were patent but still unsuitable for use at 
the time the patient needed to commence of dialysis (Pisoni et al. 2009). It is therefore 
important that attention to access is maintained throughout pre-dialysis care (even after 
creation) as a culture of “create and forgot” can result in an otherwise adequate AVF being 
unsuitable for use at the start of dialysis because no one checked to ensure it was maturing 
adequately (Nica et al. 2013; Lok & Oliver, 2003). Ultimately every hurdle is of equal 
importance. The most complex system and robust infrastructure will fail if no-one 
remembers to check for a thrill in the Low Clearance Clinic. It is therefore essential that 
vascular access remains foremost in the mind of every clinician caring for patients with 
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ESRD and is considered at each and every consultation. 
 
1.8. CHALLENGING THE ‘GOLD STANDARD’ ARTERIOVENOUS FISTULA  
 
In recent years the doctrine of AVF primacy has been challenged. There is, in fact, no level 
I or II evidence to support the use of AVF over other access modalities, and international 
vascular access guidelines, which universally advocate AVF as the modality of choice 
(Fluck & Kumwenda, 2011; KHA-CARI, 2012; Tordoir et al. 2007; NKF-KDOQI, 2006), 
are based on data from large (albeit good quality), retrospective case series. The high 
primary failure rate of autologous accesses and increasingly frail, comorbid dialysis 
population have led a number of authors to question whether AVF really are the panacea 
that they are reputed to be or whether TCVCs are a necessary evil in some situations 
(Drew & Lok, 2014; Lok, 2007; Allon & Lok, 2010). “Fistula First” and other similar 
initiatives promote autologous access use at all costs. However, latterly some authors have 
questioned if failure to achieve a functioning AVF by the time of HD initiation really does 
reflect poor quality care? Or whether the well-recognised benefits of having an AVF need 
to be balanced against the burden of trying to achieve a functioning AVF and the likely 
gain that the patient is likely to obtain in terms of dialysis-years via that access? (O'Hare et 
al, 2010; Moist et al. 2012; Drew & Lok, 2014). 
 
1.8.1.  Evidence for AVF as ‘gold standard’ 
 
1.8.1.1. Randomised controlled trials 
 
There is minimal level I evidence comparing vascular access modalities. No randomised 
controlled trials (RCTs) exist comparing TCVC to either AVF or AVG. There are four 
RCTs comparing AVF and AVG. These are summarised in Table 1.4. The two multicentre 
studies were conducted by the same research team in the Netherlands, compare autologous 
AVF to prosthetic PTFE in very specific patient cohorts, and have differing conclusions. 
Rooijens and colleagues (2005) found forearm PTFE grafts superior to RCF in patients 
having primary AVF creation with suboptimal vessels (79% vs. 52% secondary patency at 
1-year; p=0.001), while Keuter and colleagues (2008) found transposed BBF to have 
superior patency to forearm loop grafts (46% vs. 26% primary patency at 1-year; P=0.005) 
in patients unsuitable for or with failed RCF or BCF fistulae. In both studies the prosthetic 
arm required more interventions to maintain patency than the autologous arm.  Both 
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studies are well-conducted RCTs, but their clinical applicability is limited by the fact that 
neither address the true dilemmas faced by the clinician in practice: BCF or forearm loop 
AVG following failed RCF? BBF or brachio-axillary AVG following failed BCF? Is there 
a role for lower limb prosthetic? (Allon & Lok 2010) For this reason, neither of the studies 
are mentioned in either the American or European Vascular Access Guidelines, which 
draw on large, observational cohort studies for evidence instead (Tordoir et al. 2007; NKF-
KDOQI, 2006). The other two studies are small single-centre trials comparing AVG and 
BBF with conflicting results (Morosetti et al. 2011; Davoidi et al. 2013). Morosetti and 
colleagues (2011) found primary patency rates at 6, 12 and 24 months of 81%, 61% and 
60% respectively in the BBF cohort and 55%, 32% and 21% in the AVG cohort, whilst 
Davoudi et al. (2013) found no difference in mean primary patency time in transposed 
BBF and AVG (244.13 ± 103.65 and 264.97 ± 149.28 days respectively). Both studies 
have fewer than 30 patients in each arm, no description of where the AVG were sited and 
add little to the existing body of evidence. 
 
1.8.1.2. Observational cohort studies 
 
All of the large registry studies show an association between AVF and improved survival 
compared to TCVC or AVG (Table 1.5) (James et al. 2009). Registry data is supported a 
plethora of single-centre, retrospective cohort studies that are summarised in two 
systematic reviews (Huber et al. 2003; Murad et al. 2008). For the most part these studies 
support, not only a survival benefit with AVF, but also lower infection rates, 
hospitalisation rates and improved cost-effectiveness (Huber et al. 2003; Murad et al. 
2008; Lok, 2007; Pisoni et 2015) (Figure 1.14).  
 
The retrospective registry studies carry inherent selection and indication bias (Allon & 
Lok, 2010). The data collected is often limited in breadth and missing data is not 
infrequent. For example, in the UK Registry Report (2014) six centres needed to be 
excluded as the data return for was less than 50%. Selection bias in large cohort studies 
systematically favours the outcomes of AVF over TCVC. Critically ill patients starting 
haemodialysis urgently and those too frail for AVF creation will be included for analysis in 
the TCVC cohort, increasing the risk of adverse outcome in this group (Quinn & Ravani, 
2014). Patients who are not eligible for AVF creation have a 3-year survival of 26% vs. 
81% in those deemed eligible for AVF creation (Blake et al. 2013). The eligibility criteria 
for AVF placement in the retrospective studies are poorly defined (Ravani et al. 2013a). 
Additionally, new starts onto dialysis (particularly “crashlanders”) are more likely to 
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dialyse via TCVCs. It is well recognised that individuals who start dialysis urgently have 
twice the risk of adverse events, including death (OR 2.09) (Mazonakis et al. 2009). In an 
analysis of incident patients Quinn and colleagues (2011) found that, although the hazard 
for death was 70% higher in patients treated with catheters compared to those with 
autologous access, when those starting dialysis urgently were removed there was no 
significant difference in outcome. Large registry datasets do not include such data and 
therefore their interpretation is limited by indication bias. Likewise, most authors will 
consider outcomes by ‘access achieved’ not ‘access intention’ (Windus, 1993, pp.460). 
Given that most failed AVF attempts occur in frail, elderly, diabetics, such a per protocol 
analysis will also favour AVF outcomes (Quinn & Ravani, 2014). Finally, it must be taken 
into account that, in many cases, retrospective data on patency rates and access outcomes 
are over 30 years old (Lok, 2007). The dialysis population has changed significantly during 
this time, as have access practices and outcomes (Scottish Renal Registry, 2016; USRDS, 
2014; Fernstrom et al. 1988; Golledge et al. 1999; Dember et al. 2008; Lok et al. 2006). 
Inferences and recommendations based on historical data may not hold true in the 
contemporary dialysis population.  
 
 
 
 
Figure 1.14: Forrest plot of 12-month cumulative access patency (from observational 
study data) comparing arteriovenous fistula and arteriovenous grafts (including 
primary fistula failures).  
Author Study 
design 
Population Comparison Primary 
end point 
Secondary end 
points 
Primary outcome Secondary outcomes Conclusions Keuter et al. 2008  Randomised, muticentre trial in Netherlands 
Patients with failed RCF/ BCF or vessels unsuitable for either fistula type (n=105) 
Transposed BBF vs. forearm loop graft 
Primary patency at 1 year Primary aand secondary patencies at 1 year  Number of interventions necessary to maintain patency 
Primary patency at one year was superior in BBF than forearm PTFE loop grafts (46% vs. 22%; P=0.005) 
Primary assisted patency was also superior in BBF (87% vs 71%; ; P=0.04).  Secondary patency at 1 year was comparable between the groups (89% vs. 85%; P=0.86)  Fewer interventions were required in the BBF to maintain patency (1.7/ pt. vs. 2.7/pt)  
BBF are superior to forearm PTFE loop grafts in patients unsuitable for primary RCF or BCF with superior primary and primary assisted patency rates and fewer interventions required to maintain patency. 
Rooijen et al. 2005 Randomised, muticentre trial in Netherlands 
Patients requiring de novo primary vascular access with marginal forearm vessels (radial artery diameter 1-2mm and/or cephalic vein at wrist <1.7mm) (n=383)  
RCF vs. forearm graft Primary patency at 1 year Primary assisted and secondary patencies at 1 year  Number of interventions necessary to maintain patency 
Primary patency at 1 year was superior in prosthetic forearm grafts compared to RCF (44% vs. 33%; P= 0.03) 
Primary assisted patency and secondary patency were also superior in forearm grafts (63% vs. 48%; P=0.03 and 79% vs. 52%; P=0.001 respectively).  Fewer interventions were required in the RCF cohort for access salvage(0.5/ pt./yr vs. 0.94/pt/yr; P=0.08) 
Forearm PTFE grafts are superior to RCF in patients with poor forearm vessels with better primary, primary-assisted and secondary patency rates. More intervention were required to maintain this patency however. Morosetti et al. 2011 Single centre randomised  controlled trial in Italy 
‘Complex’ patients (failed RCF/ BCF, exhausted superficial veins or suitable vessels) (n=57) 
BBF vs, Omniflow Ii Vascular prosthesis 
Primary and secondary patency (time-point for primary outcome unclear) 
Operation time, length of hospital stay, rescue procedures 
Primary patency at 6, 12 and 24 months for BBF were 81%, 61% and 60% and for AVG were 55%, 32% and 21% respectively. Secondary patency at 6, 12 and 24 months for BBF were 86%, 76% and 66% and for AVG were 72%, 52% and 34% respectively.  
Total operation time was 91+/-15minutes in the AVG arm and 105+/-28minutes in the BBF arm. Mean length of hospital stay was 4+/-1 days in the AVG arm vs. 5+/- days in the BBF arm 
BBF should be the first choice in patients with good life expectancy who can rely on a temporary vascular access. However, given the shorter time to use AVG could be used in those with shorter life 
expectancy or who can’t have temporary vascular access. Davoudi et al. 2013 Single centre randomised controlled trial 
No suitable forearm veins (n=60) BBF with transposition vs. AVG Primary patency time Secondary patency at 1 year; access related complications 
Mean primary patency times in 
the BBF and AVG groups were 
244.13 ± 103.65 and 264.97 ± 
149.28 respectively 
 
Access failure rates at 1 year 23.3% in BBF cohort vs. 30% in AVG cohort AVG offer similar patency and complication rates to 
BBF, thus they should be 
considered the preferred 
haemodialysis access when 
there are no suitable forearm 
veins. 
Table 1.4: A summary of randomised controlled trials comparing AVG to AVF. 
Author Registry Population Access status Crude mortality Adjusted mortality Confounders adjusted for Dhingra et al. 2001 USRDS Random sample of prevalent haemodialysis patients in the United States December 1993 (n=5507) At study start date NR Diabetics: AVF: reference; AVG: RR 1.41; TCVC: RR 1.54 Non-diabetics: AVF: reference; AVG: RR 1.08; TCVC: RR 1.7 
Age, gender, race, BMI, smoking, CAD, PVD, cancer, ability to walk, education level Pastan et al.. 2002 ESRD Network 6 All prevalent haemodialysis patient in North Carolina, South Carolina and Georgia  April 1998 (n=7,497) At study start date AVF: 7.3% AVG: 9.1% TCVC: 15.2% NTCVC: 16.8% 
AVF: reference; AVG: OR 1; TCVC: OR: 1.4 Age, gender, race, diabetes, functional status, serum albumin, angina, CHF, MI, delivered time, blood flow, URR, time since onset of ESRD Xue et al. 2003 Medicare All Medicare incident haemodialysis patients >66y.o. commencing haemodialysis 1995-1997 (n=66,595) At time of first dialysis 1 year mortality: AVF: 24.9% AVG 28.1% CVC: 41.5% 
AVF: reference; AVG: RR 1.16; TCVC: RR 1.7  Age, gender, race, diabetes, initial access type, BMI, days from first access placement to initial dialysis date, albumin and creatinine Polkinghorne et al. 2004 ANZDATA All adult patients starting haemodialysis in Australia and New Zealand 1999-2002 (n=3,749) At time of first ANZDATA study Deaths per 1,000 access days: AVF: 86 AVG: 146 CVC: 261 
AVF: reference; AVG: HR 1.39; CVC (by duration of dialysis): <60 days: HR: 2.53; 60-120 days: HR: 1.66; >120 days: HR: 2.77  
Age, gender, late referral, PVD, CAD, PRD, smoking, hypertension, lung disease, geographical location, year of entry 
Astor et al. 2005 CHOICE study Subpopulation of incident HD patients in the United States who were recruited for the CHOICE study (n=616) Access treated as a time dependant variable 
Annual mortality AVF: 11.7% AVG 14.2% CVC: 19.9% 
AVF: reference; AVG: HR: 1.2; TCVC: HR: 1.5 Age, gender, race, PVD, cardiovascular disease, diabetes, index of coexisting disease, BMI, smoking, education, timing of referral to a nephrologist, insurance  Bradbury et al. 2007 DOPPS I and II Selected incident HD patients in the United States , Europe, Japan, Australia, New Zealand and Canada 1996-2004 (n=4,802) At time of first dialysis 1 year mortality: AVF: 11.0% AVG 11.8% CVC: 19.9% 
AVF: reference; AVG: HR: 0.97; TCVC: HR: 1.49 Age, gender, race, BMI, PRD, comorbid conditions, albumin, calcium, haemoglobin, phosphate, pre-ESRD nephrology care Pisoni et al. 2009  DOPPS I and II Selected prevalent HD patients in the United States , Europe, Japan, Australia, New Zealand and Canada 1996-2004 (n=3,786) At date of study sample NR AVF: reference; AVG: RR: 01.15; TCVC: RR: 1.32 Age, gender, race, BMI, PRD, comorbid conditions, albumin, calcium, haemoglobin, phosphate, pre-ESRD nephrology care, dialysis centre Grubbs et al,.2013  USRDS Incident haemodialysis patients in the United States aged 67-90 years 2005-2007 At time of first dialysis NR AVF: reference; AVG: HR: 1.2; TCVC: HR: 1.95 Age, gender, health status, functional health status, place of residence DeSilva et al. 2013  USRDS Medicare Selected incident haemodialysis patients in the United States aged ≥ 67y.o. (n=115,425 At time of first dialysis NR AVF: reference; AVG: HR: 1.05; TCVC: HR: 1.77 Age (stratified), gender, race, diabetes, initial access type, BMI, CAD, PVD, PRD Hicsk et al. 2015 USRDS All prevalent haemodialysis patients in the United States 2006-2010 (n=507,791) At time of first dialysis NR TCVC reference; AVG: HR: 0.83; AVF: HR:0.63 Age 18-48y.o.: TCVC reference; AVG: HR: 0.92; AVF: HR:0.53 Age 49-89y.o. TCVC reference; AVG: HR: 0.81; AVF: HR:0.63 Age >89y.o.: TCVC reference; AVG: HR: 1.24; AVF: HR:0.76 
Age (stratified), gender, race, diabetes, initial access type, BMI, comorbidities 
Table 1.5: Summary of Registry Data comparing mortality on dialysis between AVF, AVG and TCVC.
1.8.1.3. The evidence in context 
 
Many of the more recent registry studies acknowledge the significance and implications of 
an aged, co-morbid dialysis population on vascular access choice. The conclusions of these 
latter series differ with regards to the role of AVF. For example, DeSilva and colleagues 
(2013) demonstrated no survival benefit of AVF over AVG in incident patients over 67 
years old (HR 1.05) and several authors have actually shown superior patency of AVGs in 
the first 18 months after insertion (Chan et al. 2007; Moist et al. 2012). Such observations 
have led some to advocate for an approach of preferential graft placement in those patients 
with a life expectancy of less than 2 years on dialysis (Moist et al. 2012;  Lee et al. 2005). 
 
Contrary to widely held belief, the 1-year cumulative patency is actually comparable for 
AVF and AVG, with the caveat that grafts need additional interventions to maintain 
patency (Allon, 2007; Allon & Robbin, 2002). After exclusion of primary AVF failures, 
the perceived improved access survival of AVF over AVG is nullified, with comparable 
patencies for both AVF and AVG out to 10 years (Lee et al. 2006; Allon & Lok, 201; Lok 
& Foley, 2013; Lok et al. 2013) (Figure 1.15). Rosas and colleagues (2012) found a 
strategy of AVF primacy to be cost-effective over prosthetic only if the AVF maturation 
rate was >69%. A recent systematic review found the pooled AVF maturation rate in 
contemporaneous studies to be only 59% (Al-Jaisji, 2013). 
 
Perhaps patency is the wrong end-point with which to compare access modalities 
altogether? AVG are associated with a less frequent need for early intervention (Roy-
Chaudhury et al. 2012) and earlier catheter removal than AVF (Leake et al. 2015). In a 
recent retrospective series, Disbrow and colleagues (2013, pp.680) question: ‘Is a 
reappraisal of the Fistula First Initiative indicated?’ after finding that in patients dialysing 
via a catheter at time of definitive access placement (AVF or AVG), the maturation time, 
risk of non-maturation and number of interventions required to achieve a functioning AVF 
negated its potential benefits. The authors suggest that the aim of definitive vascular access 
should be to minimise the number of catheter-dependent days. 
 
Finally, interpretation of the literature must be undertaken within the context of local 
resources and practice. For example, Kumbar et al. (2012) concluded that, with appropriate 
surveillance, AVGs have similar long-term primary-assisted patency to AVFs. Even 
TCVCs, with appropriate care and maintenance, have been shown to have excellent 
outcomes in the right setting. The West London group recently published enviable catheter 
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outcomes with 1-year patency rates of 76% and a bacteraemia rate of 0.34 per 1,000 
catheter days (Power et al. 2011) (lower than that quoted for many studies of AVF) again 
illustrating the role of a “horses for courses” approach to vascular access. 
 
 
 
 
Figure 1.15: Survival curves of cumulative access patency of AVF and AVG in 
haemodialysis patients with forearm access. A. AVF vs. AVG after including primary 
failures. B. AVF vs. AVG excluding primary failures.  Reproduced with permission 
from The Clinical Journal of the American Society of Nephrology (Lok et al. 2013). 
 
 76 
1.8.2.  Are arteriovenous fistulae right for everyone? 
 
As previously discussed, the dialysis population is changing. Elderly, diabetic patients 
have poor AVF outcomes, shorter survival on HD and increased risk associated with 
access creation (Scottish Renal Registry, 2015; Lok et al. 2005; Miller et al. 1999). The 
utility and benefit of a functioning AVF must be weighed against the futility and morbidity 
associated with multiple failed attempts at access creation. Whilst a functioning AVF may 
well be preferable to a functioning AVG, a non-functioning AVF isn’t (Allon, 2007). 
Three factors need to be taken into account when considering whether “Fistula First” is 
really the right approach: 
 
1. The likelihood of successful AVF maturation. 
2. The morbidity associated with attempted AVF creation. 
3. The benefit that is likely to be gained from having AVF creation (i.e. 
anticipated survival on dialysis or likelihood of needing dialysis). 
 
Access planning requires an understanding and balance of these factors. 
 
1.8.2.1. Balancing the risks and benefits of AVF creation (likelihood of maturation 
versus morbidity) 
 
The likelihood of successful maturation must be balanced against the morbidity associated 
with AVF creation or, perhaps even more importantly, the morbidity of failed AVF 
creation. An elderly and increasingly comorbid dialysis population means that the 10% 
FTM rate quoted a decade ago is obsolete and now approaches 50% (Drew & Lok, 2014). 
Despite a 2-3-fold increase in AVF and AVG creation noted in the most recent Dialysis 
Outcomes and Practice Patterns Study (DOPPS) study, initial feedback indicates that this 
does not appear to have translated into more usable accesses (Pisoni et al. 2015) 
 
AVF created in obese patients are less likely to be successfully cannulated, with the patient 
often subjected to multiple revisional and superficialisation procedures in an attempt to 
achieve functional patency (Evans et al. 2015; Chan et al. 2008). Advancing age, coronary 
artery disease, peripheral vascular disease and diabetes are all associated with increased 
chance of FTM (Lin et al. 1998; Lok et al. 2006; McGrogan et al. 2015a). Lok and 
colleagues (2006) found advancing age to confer a 2-fold greater chance of non-
maturation. Lazarides and colleagues (2007) concluded from their meta-analysis that the 
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non-maturation rate of RCF in the elderly was so high, that distal AVF should not be 
considered in those >70years. Similarly a recent meta-analysis found small (<2mm) 
vessels, low intra-operative arterial blood flow and late referral for access creation were 
also associated with non-maturation (Smith et al. 2012). However, despite multiple 
predictive tools, it remains very difficult to acutely predict whether an individual fistula 
will mature (McGrogan,et al. 2015b). 
 
Diabetics, especially women, have small, diseased arteries. (Chen & Moe, 2003) This is 
associated, not only with a high primary failure rate of autologous access (Jankovic et al. 
2015), but also a higher than average risk of steal syndrome (Malik et al. 2008). The 
balance of risk-benefit in this patient cohort in therefore altered. Furthermore, the median 
survival of a 65 year-old diabetic commencing on dialysis is only 1.6 years (Scottish Renal 
Registry, 2013), leading some to question the value of AVF in this patient cohort (Lee et 
al. 2007).  
 
AVF creation is not a benign procedure: 5-10% of patients will develop steal syndrome 
(Malik et al. 2008); high output cardiac failure is a recognised complication (Wasse et al. 
2007); severe chronic neuropathic pain occurs in 3.2% whether or not the fistula ever 
successfully matures (Aitken et al. 2013). Given that most patients who undergo AVF 
creation have not yet started dialysis and the procedure is being performed 
prophylactically, the need to minimise unnecessary complications is paramount (O'Hare et 
al. 2007). 
 
Perhaps more significant than complications (and commonly overlooked), is the burden of 
failed or suboptimal maturation. Less than half of AVF created are suitable to use for HD 
five months after creation (Dember et al. 2008). The rest either fail early necessitating a 
second or subsequent surgery with diminishing returns from each attempt (Aitken et al. 
2014a; Gibyeli Genek et al. 2015; Lok et al. 2006), or require multiple interventions e.g. 
balloon assisted maturation to promote development (Roy-Chaudhury et al. 2012a). 
Multiple interventions are associated with the need for repeated hospitalisation and 
negatively impact on QoL (Afsar et al. 2012). Again, many of these interventions are 
performed on patients not yet on dialysis, increasing the burden of disease in an otherwise 
relatively asymptomatic cohort of patients. Furthermore, surgical fatigue can also result in 
reluctance for second or subsequent attempts at access creation, which are perceived to be 
futile (Gibyeli Genek et al. 2015). The costs associated with an unused fistula are much 
higher than perceived (Malas et al. 2015). Some authors advocate AVG as an alternative to 
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multiple failed AVF attempts to obviate this problem (Allon & Lok, 2010; O’Hare et al. 
2010). 
 
1.8.2.2. Predicting the decline to end-stage and survival on dialysis: the benefit of 
fistula creation 
 
Aside from the access itself, two major factors influence the benefit, or otherwise, that a 
person might obtain from an AVF: 
 
1. The likelihood of that patient ever requiring dialysis. 
2. The anticipated life expectancy on dialysis. 
 
These factors are heavily influenced by co-morbidity, nature of the primary renal disease 
and age, therefore they are constantly changing with the evolving demographic of the 
ESRD population (Toussaint et al. 2015). 
 
AVF creation in the pre-dialysis setting differs from any other any other preventative or 
preparatory healthcare intervention (O’Hare et al. 2010). Unlike vaccination it does not 
confer public heath benefits, nor is it a potentially life-saving procedure akin to elective 
abdominal aortic aneurysm repair. More like purchasing a life insurance policy, the 
benefits of AVF placement are only accrued if the event (i.e. dialysis initiation) actually 
occurs (O’Hare et al. 2010). Prior to this, the burden and morbidity associated with 
attempting to achieve functioning vascular access is incurred without any tangible gain.  
 
One of the most challenging aspects of pre-emptive access placement is determining when, 
or if, a patient is likely to need dialysis.  Vascular access planning guidelines fall into two 
categories: those which suggest that an absolute eGFR should be used for referral for 
access creation e.g. a creatinine clearance <15-20ml/min (Canadian Society of 
Nephrology, 2006) and those which advocate that time to need for dialysis should be 
predicted and utilised to determine referral i.e. within 6 months of anticipated need for 
dialysis (NKF-KDOQI, 2006). They all assume linearity of progression in renal function 
decline (Rosansky, 2012). In reality, prediction of the trajectory of renal function decline is 
poorly understood and very difficult to forecast.  
 
O’Hare and colleagues (2012) identified four different patterns of decline to end-stage. The 
majority of patients had a persistently low level of eGFR <30mL/min/1.73m2 (mean eGFR 
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slope 7.7 ± 4.7 mL/min/1.73m2/ year). However 9.5% had accelerated loss from eGFR >60 
mL/min/1.73m2 (mean eGFR slope 32.3 ± +/-13.4 mL/min/1.73m2/year) and 3.1% 
demonstrated catastrophic loss (Figure 1.16), highlighting the difficulties both in 
predicting when dialysis might be required and in applying a fixed cut-off for any 
intervention (Schell & O’Hare, 2013).  Nearly half of patients with CKD stage V will have 
stable renal function at 2 years follow-up (O’Hare et al. 2012) and over a quarter of elderly 
patients (average age 75 years) with stage IV CKD showed no decline in eGFR after 10 
years follow-up (Eriksen & Ingebretsen, 2006), making many pre-emptive AVF creation 
attempts in these patients extraneous.  
 
 
Figure 1.16: Estimated glomerular filtration rate (eGFR) trajectories in patients 
approaching end stage renal disease.  
Trajectory group 1 (63%): persistently low eGFR (<30 mL/min/1.73m2);  
Trajectory group 2 (25%): progressive loss from baseline 30-59 mL/min/1.73m2; 
Trajectory group 3 (9%): accelerated loss in eGFR from levels >60 mL/min/1.73m2; 
Trajectory group 4 (3.1%): catastrophic loss from levels >60 mL/min/1.73m2 within 6 
months or less.  
Reproduced with permission from National Institute of Health. (O’Hare et al. 2012) 
 
It is well recognised that elderly patients will have a slower rate of decline in renal 
function (Van Pottelbergh et al. 2012; Vachharajani, 2011; O'Hare et al. 2007) and a 
shorter life expectancy (Kurella et al. 2007), therefore the potential for unnecessary 
vascular access procedures in this cohort is particularly salient. O’Hare et al. (2007) 
Figure 1. eGFR trajectories and 95% confidence intervals defined by trajectory modeling.
Dotted lines denote 95% confidence intervals
Trajectory Group 1 (persistently low levels of eGFR): 63% of patients with a mean
probability of assignment 0.88 (±0.24)
Trajectory Group 2 (progressive loss of eGFR): 25% of patients with a mean probability of
assignment 0.86 (±0.27)
Trajectory Group 3 (accelerated loss of eGFR): 9% of patients with a mean probability of
assignment 0.91 (±0.25)
Trajectory Group 4 (catastrophic loss of eGFR): 3% of patients with a mean probability of
assignment 0.99 (±0.11)
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evaluated a US Department of Veterans Affairs population and created a hypothetical 
model in which all patients with advanced CKD were assumed to received vascular access 
surgery. They used their model to calculate the proportion of patients in whom AVF 
creation would be necessary (the patient initiated dialysis within 2 years) or unnecessary 
(the patient died prior to starting dialysis or remained alive and dialysis free). They 
observed that in patients >85 years with eGFR <15ml/min/1.73m2 only 25% of patients 
started dialysis within 6 months and only 1 in 3 started within a year. The authors 
extrapolated this data to calculate that among 85 year old patients referred for access 
surgery at an eGFR <15ml/min/1.73m2,, with predicted 6 months survival, three accesses 
have to be created for every one used for dialysis (O'Hare et al. 2007).  
 
The rate of decline of renal function and likelihood of needing dialysis also needs to be 
balanced against the likelihood of dying prior to ever requiring dialysis. Figure 1.17 
highlights this problem, demonstrating the relative frequency by which ESRD exceeds that 
of death by patient age. For example, the likelihood that a 70 year-old man will survive to 
commence dialysis does not exceed the risk that he will die from other causes until his 
eGFR falls below 15mL/min/1.73m2 (O’Hare et al. 2010). 
 
  
 
Figure 1.17: Graphical representation of the eGFR at which the relative frequency of 
ESRD exceeds that of death by patient age. Reproduced with permission from John 
Wiley & Sons Ltd. (O’Hare et al. 2010). 
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More than one percent of patients will die within 30 days of access creation (Jorna et al. 
2016) and almost 30% of patients >74 years do not survive 12 months after AVF creation 
(McGrogan et al. 2014). Nearly two-thirds of patients over 80 years old die within 18 
months of commencing on dialysis (Vacharanjani et al. 2014), with the median survival of 
patients aged 65-79 years at initiation of maintenance haemodialysis only 2 years (Kurella 
et al. 2007). There is however considerable heterogeneity and variation around this 
observation with an interquartile range of 8.3 months to more than 4 years (Kurella et al. 
2007), which (like the prediction of decline in renal function) makes prediction of survival 
on HD difficult, with few good objective measures to help prognosticate. Moss and 
colleague (2008) describe the utility of the “surprise question” i.e. ‘would I be surprised if 
this patient died in the next year?’ for predicting short-term mortality. In practice, this 
subjective measure is likely to prove just as valid as more complex algorithms in 
determining where the futility of unnecessary access procedures is likely to lie (McGrogan 
et al. 2014).  
 
Approximately 30% of patients remain pre-dialysis one year following creation of their 
AVF (Morsy et al. 2011) and a recent Canadian study found that 9% of incident patients 
who had AVF created died before the AVF was ever used (median follow-up 8 months) 
(Oliver et al. 2012). Recently several authors have utilised analytical models in an attempt 
to minimise gratuitous AVF creation. Shechter and colleagues (2014) used a Markov 
model to calculate that referral 15 months prior to initiation of dialysis would result in 34% 
of patients starting dialysis via a TCVC with 14% unnecessary AVF, while referral at 
eGFR threshold of <20mL/min/1.73m2 would result in 38% incident TCVCs and 20% 
unnecessary AVFs. Similarly, Hiremath and colleagues (2011) found a policy of watchful 
waiting until dialysis started was associated with better life expectancy (66.6 vs. 65.9 
months) and quality adjusted life expectancy (38.9 vs. 38.5 quality adjusted life months) 
than immediate AVF creation in all patients with CKD stage IV. Data from our own centre 
demonstrates that one-third of brachiobasilic fistulae are never used for dialysis (Hameed 
et al. 2016), a finding that needs to be considered in the context of the morbidity 
(rehospitalisation and reintervention to achieve patency particularly in BBF). Some authors 
would advocate that, in this patient cohort with no simple autologous option, an AVG at 
the time a patient requires to start HD is favourable to pre-emptive AVF creation (Allon & 
Lok, 2010; Moist et al. 2012; Lok, 2007). 
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1.8.2.3. Elderly patients 
 
Recently published Italian vascular access guidelines acknowledge that, in the context of 
shorter life expectancy and slower decline to end-stage disease, elderly patients must be 
considered as a unique patient cohort (Lomonte et al. 2016). As a patient group they 
provide a useful example to highlight a number of the issues already described and the 
need to consider these factors in individualised vascular access planning. 
 
Increasing age is associated with a higher chance of non-maturing fistula, with patients 
>65 years having a more than doubling of the chance of primary non-function (OR 2.23; 
95% CI 1.25, 3.96) (Lok et al. 2006). A recent observational study found cumulative 
fistula survival at 12 months to be 68% in patients ≤70 years old compared to 39% in 
patients over the age of 70 (Olsha et al. 2015). Similarly in their meta-analysis, McGrogan 
and colleagues (2015a) found pooled 12-month primary and secondary patency rates in the 
elderly of 53.6% and 71.6% respectively. Vascular calcification, oxidative stresses and 
poor endothelial function limit the ability of vessels to vasodilate and are postulated to be 
responsible for the higher failure rate of AVF that is observed in the elderly (Moist et al. 
2012) with distal radiocephalic fistulae most likely to fail (OR 1.52 at 12 months) 
(Lazarides et al. 2007). 
 
Vascular access procedures and their complications represent an important cause of 
morbidity and mortality in the elderly haemodialysis population (Feldman et al. 1996). 
Age greater than 65 years has also been identified as a risk factor for dialysis-associated 
steal syndrome (Zamani et al. 2009), and elderly patients require more frequent 
endovascular interventions to assist in achieving and maintaining access patency (Lok et 
al. 2005). Furthermore, frailty and malnutrition often lead to thin skin that bruises and tears 
easily. Such “minor” complications and the morbidity associated with them are often not 
documented or reported in studies (Moist et al. 2012). 
 
The median life expectancies for a 65 year old and an 80 year old patient commencing 
haemodialysis are 2.5 and 1.3 years respectively (Cherukuri et al. 2016). In the United 
States, a quarter of octogenarians starting dialysis never return to independent living 
(Vacharanjani et al. 2014) and commencing dialysis is associated with significant decline 
in functional status such that only 13% of elderly patients starting on dialysis will have a 
preserved functional state after 1 year (Combs & Davison, 2015). More than a third of 
elderly patients who commence dialysis opt to discontinue within the first six months 
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(Rosansky, 2012). In patients over the age of 70, survival is comparable with 
haemodialysis and conservative care (Lazenby et al. 2016). 
 
As earlier described, many elderly patients with significant reduction in their eGFR will 
never go on to initiate dialysis, therefore efforts to secure a functioning fistula prior to 
commencing dialysis may result in harm of a procedure from which they will never benefit 
(O’Hare et al. 2010; Schell & O’Hare, 2013; Oliver et al. 2012). A recent study found that, 
following AVF creation, up to two-thirds of elderly patients died before their fistula was 
ever used for dialysis (Richardson et al. 2009). Lee and colleagues (2015) recently 
published a large cohort study of over 3,000 elderly patients (>70 years) with access placed 
in the predialysis stage. They found that 67% of patients with AVF and 71% of patients 
with AVG commenced dialysis in the two year follow up period, however only half of 
these patients started dialysis via a functioning AVF/ AVG. Catheter dependence was more 
common in patients receiving predialysis AVF than AVG (46.0% vs. 28.5%; P<0.001) 
(Lee et al. 2015). The rate of decline in renal function needs to be balanced against life 
expectancy and quality of life. Conservative care and palliation should always be 
considered as a treatment option in older patients (Combs & Davison, 2015). 
 
An individualised approach to vascular access is essential (Moist et al. 2012). Perhaps 
more than any other patient cohort, the heterogeneity that exists amongst life expectancy 
and functional status in the elderly, highlights the need for tailored decision-making 
(Cherukuri et al. 2016). For example, a fistula may be most appropriate for an elderly 
patient with minimal co-morbidity who is seen in the pre-dialysis clinic with anticipated 
dialysis start six months in the future, whilst an AVG (or TCVC) may be more appropriate 
in an elderly patient with multiple comorbidities and life expectancy <2 years (Moist et al. 
2010). 
 
There has been considerable debate in recent literature around the issue of whether AVF or 
AVG should be favoured in the elderly (Moist et al. 2012; Tordoir et al. 2015; Allon & 
Lok, 2010). Certainly, the initial operative procedure to create an AVF is simpler, 
associated with a shorter hospital stay and minimal morbidity (Swindlehurst et al. 2011). 
Despite poorer maturation rates, many elderly patients do still benefit from receiving 
dialysis via an AVF. In the UK more patients >60 years than <60 years start dialysis via an 
AVF (UK Renal Registry, 2016) (though this is likely to be the result of a slower rate of 
decline in function, rather than better AVF outcomes per se). And it must be remembered 
that the infective complications of TCVCs are most marked in the elderly and co-morbid. 
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Most European clinicians would still favour trying to create an AVF in a co-morbid 75 
year old rather than seeking alternative access (van der Veer et al. 2015).  
 
Conversely, elderly patients are likely to have a short life expectancy and unpredictable 
start to dialysis, factors that may favour the use of an AVG over AVF. A recent large 
observational study has demonstrated comparable survival from AVF and AVG in patients 
aged over 67 years (DeSilva et al. 2013). Survival was found to be comparable for all 
access types (including TCVC) in patients >80 years old. Likewise, Tamura and colleagues 
(2011) estimated the remaining lifetime absolute risk reduction in vascular access 
bacteraemia attributable to the use of preferred versus non-preferred access e.g. AVF vs. 
AVG and AVG vs. TCVC for patients with different life expectancies. AVF conferred a 
very modest risk reduction over AVG especially in the elderly e.g. in patients >85 years 
with life expectancy in the 25th percentile, more than 200 AVF would be required to 
prevent one episode of graft related bacteraemia. Similarly, whilst the number of AVGs 
required to prevent an episode of catheter-related bacteraemia was much less, the relative 
benefit of AVG versus TCVC also declines with age and life expectancy (Cherukuri et al. 
2016). Accounting for primary failures, the cumulative patency of AVG and AVF are 
comparable for the first 18 months (Xue et al. 2003; Astor et al. 2005; Lee et al. 2007), 
therefore many authors now advocate AVG in elderly patients with a life expectancy less 
than 2 years to avoid the need for a TCVC (Allon & Lok, 2010; Lok, 2007; Moist et al. 
2012). 
 
Autologous AVF take longer to mature in the elderly (Viedma et al. 2005; Ravani et al. 
2013b) with delayed maturation having the inadvertent consequence of prolonged catheter 
use. DeSilva and colleagues (2013) found that nearly half of elderly patients who had 
planned to start dialysis via an AVF ended up starting with a TCVC, compared to only 
25% of patients who had planned start via an AVG. Given that infective complications of 
line use are more significant in frail, elderly patients (Thomson et al. 2007), Moist and 
colleagues (2012, pp.647) reflect that: 
 
‘the need for prolonged catheter use during AVF maturation may be considered 
harm if the patient will not live long enough to reap the benefits’ 
 
With the survival benefits of autologous access deferred, many now question the benefit of 
AVF in those with a short life expectancy instead advocating a policy of “watch and wait” 
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to see if dialysis is actually going to be required and then consider AVG as an alternative 
to AVF as first line vascular access (Drew & Lok, 2014; Tordoir et al. 2015).  
 
1.8.3.  An individualised approach  
 
Recent literature (and clinical practice) reflects a gradual shift away from “Fistula First” 
towards a “patient first” approach to vascular access (Moist et al. 2012). There is 
increasing recognition of the need for an individualised approach, rather than a disease-
based model of vascular access provision (Cherukuri et al. 2016; O’Hare et al. 2010; 
Bowling & O’Hare, 2012). The relative advantages and disadvantages of various access 
types are well documented at a population level, however the benefits and harms will also 
vary between individuals as a function of their need for dialysis and life expectancy 
(Cherukuri et al. 2016). Moist and colleagues (2014, pp.645) highlight that: 
 
‘Quality improvement initiatives in end-stage kidney disease care advocate for 
quality benchmarks, but fail to identify patients who may not benefit from 
‘standard of care’ applicable to a ‘standard patient’’ 
 
1.9. SO WHAT IS “BEST PRACTICE” FOR VASCULAR ACCESS?  
 
An inherent tension exists between best practice guidelines and the optimal care of an 
individual patient (Drew & Lok, 2014). Benchmarking and targets can fail to meet the 
unique needs of a specific individual. The “standard of care” can only be applied to a 
standardised patient and fails to take into account the significant heterogeneity within the 
ESRD population. A fistula primacy at all costs approach will inevitably lead to 
inadvertent surgical fatigue and prolonged catheter dependence (Lok, 2007). As such there 
are calls for the Fistula First Breakthrough Initiative target of 65% of patients with AVF to 
be revised to achieving 65% of patients with functioning AVF (Lok, 2007). 
Patient-centred care must therefore be considered “best practice” for vascular access 
provision (Drew & Lok, 2014). A “one size fits all” approach is not effective (Lok, 2007). 
Personalised and bespoke vascular access planning is required to meet the individual’s 
needs (Drew & Lok, 2014). It is essential that the focus is placed on the patient, not the 
access and that a “package of care”, rather than a single intervention, is delivered (Lok et 
al. 2012). Lee and Allon (2012, pp.6) highlight that:  
‘clinicians should exercise their clinical judgement, experience and interpretation of 
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the literature….(rather than following) mindlessly rigid guidelines’ .  
 
The aim is to achieve the right access, for the right patient, at the right time (Lok & Foley, 
2013). 
A number of authors have developed predictive models in an attempt to inform clinical 
practice and determine which patients should have autologous access placed (Lok et al. 
2006; Drew & Lok, 2014; Lee & Allon, 2012).  
In their Risk Equation Determining Unsuccessful Cannulation Events and Failure to 
Maturation  (REDUCE-FTM I) study, Lok and colleagues (2006) evaluated patient 
characteristics associated with AVF failure to mature, developing and validating a 
predictive scoring system. Age ≥ 65years, peripheral vascular disease, coronary artery 
disease and non-White ethic origin were identified as risk factors for FTM and a score (-3 
to +3) assigned according to the presence or absence of each. This score is then used to 
predict a risk category of FTM, from which the authors extrapolate clinical advice for 
access planning. For example, a 40 year-old white male with no other risk factors confers a 
score of 0 and low risk (<25%) of FTM, so the authors advise clinical assessment ± pre-
operative vein mapping and AVF creation. Conversely, a 70 year-old AfroCaribbean man 
with coronary heart disease scores 7.5 and is classified as very high risk (>70%) of FTM. 
The authors recommend consideration of another form of permanent access e.g. graft.  
This model of Lok and colleagues (2006) has been heavily criticised in the literature 
(Beathard 2015; Lilly et al. 2012). In their study utilising a large US-administrative 
dataset, Lilly and colleagues (2012) failed to demonstrate the same risk stratification for 
FTM as did Lok, highlighting the importance of validating any predictive scoring system 
within the local population. Others criticise the inflexibility of such models and protocols. 
Beathard (2015) warns against excluding patients for autologous access creation based on 
the prescriptive instruction derived from demographic risk stratification alone, without 
surgical and radiological assessment of the vessels. It is crucial that any risk stratification 
scores for AVF maturation are exercised only as a guideline to inform practice rather than 
as a substitute to clinical judgment (Lee & Allon, 2012). 
Latterly there has been recognition of the importance of assessing the needs of the whole 
patient rather than just the likelihood of attaining a functioning vascular access. Several 
authors have devised a decision tree to inform clinicians on the choice between AVF or 
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AVG (Allon & Robbin, 2002; Lee et al. 2005; Drew & Lok, 2014). The likelihood of 
fistula success is balanced against the perceived benefit to the patient of AVF creation and 
a recommendation made as to whether it is worth attempting autologous access or whether 
the patient would be better off with an AVG. Lee and colleagues (2012) propose a model 
that takes into account time on dialysis, predicted life expectancy and whether or not the 
patient has had prior failed attempts at AVF creation (Figure 1.18). Based on the likelihood 
of successful maturation, the authors then advise AVF or AVG as the most appropriate 
access for the individual patient (Lee & Allon, 2012). Drew and Lok (2014) recently 
proposed a similar, but somewhat simpler, model (Figure 1.19) derived from three 
fundamental questions: Is the patient on haemodialysis? What is the likelihood of long-
term survival? And does the patient’s age, co-morbidities etc. make them a good candidate 
for AVF creation? Their model favours AVG over AVF for all but the optimal fistula 
candidate and advocates adopting a watch-and wait approach to pre-dialysis patients with 
poor life expectancy is an attempt to avoid unnecessary surgeries in these patients. Whilst, 
individualised care must take precedent over any predictive modelling (Lok & Foley, 
2013) and no patient should be deprived the opportunity for autologous access based on 
predictive modeling alone (Beathard, 2015), models such as those of Drew and Lok (2014) 
highlight an increasing trend towards patient-centred rather than access-focussed care 
(Drew & Lok, 2014; Lok & Foley, 2013; Allon & Robbin, 2002). 
 
 
Figure 1.18: Algorithm to assist in the most appropriate choice of vascular access for 
an individual patient. The protocol requires nephrologist and access surgeon to consider 
three important clinical factors: timing of access surgery relative to initiation of dialysis; 
life-expectancy and prior failed access attempts. This information is used to determine the 
likelihood of fistula maturation and therefore the most appropriate access for the patient: 
fistula (F) or graft (G). Reproduced with permission from John Wiley and Sons Ltd. (Lee 
& Allon, 2012). 
 
 88 
 
 
Figure 1.19: Flow diagram outlining a strategy for choosing the optimal vascular 
access for an individual patient. Reproduced with permission from Lippincott, Williams 
& Wilkins (Drew & Lok, 2014). 
 
The provision of individualised patient-focussed care necessitates input from an extended 
multidisciplinary team. It is vitally important that every member of the team is aware of 
the bigger picture and is focussed on a achieving a ‘lifelong ultilisation strategy’ (Lok & 
Davidson, 2012, pp.532) for vascular access. This forward-thinking begins in pre-dialysis 
education with vessel preservation and TCVC avoidance to prevent central vein stenosis 
and surgical fatigue in the future, and ends with a dialysis exit strategy e.g. transplantation, 
which must be the ultimate aim wherever possible. It is the success of the strategy rather 
than a single vascular access procedure which should be the goal of the vascular access 
service (Drew & Lok, 2014). Co-operation between healthcare professionals and an 
integration of the various elements of vascular access care is essential to ensure than there 
is unity between the ‘prescribers of care (nephrologists), providers of care (access 
surgeons) and providers of cure (transplant surgeons)’(Kingsmore, 2016). 
 
1.10. RATIONALE 
 
Vascular access is the ‘key modifiable risk factor’ (National Kidney Care Vascular Access 
Report, 2012, pp.6) for mortality in patients on HD. Despite this, it remains a ‘Cinderella’ 
speciality (Konner, 1999, pp.2094) and is often overlooked in service development and 
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provision of care for patients with ESRD. Good quality research into vascular access is 
also limited. Fewer than 3,000 articles have been published in the past 15 years and, of 
these, only 59 studies were randomised controlled trials (RCTs) (Kian & Asif, 2010). 
 
Despite the relative successes of strategies such as “Fistula First” and the best practice 
target in England and Wales, and the simultaneous improvement in rates of prevalent 
autologous access, there has been no associated improvement in incident vascular access 
rates (Fistula First Breakthrough Initiative, 2013; Sharif & Baboolal, 2011; Department of 
Health, 2010; Pisoni et al. 2015; Ethier et al. 2008).The importance “getting it right from 
the start” cannot be overemphasised (Lok, 2007). 
Patients who start dialysis via a line are more likely to stay on a line (Weber et al. 2009; 
UK Renal Registry, 2016). Data from the UK Renal Registry (2014) indicate that 59.8% of 
patients starting on a TCVC remain dialysing via a TCVC at 3 months. Similar figures 
from the National Kidney Care Vascular Access Report (2012) suggest that this figure 
could be as high as 90% (Table 1.6). DOPPS data indicate that >40% will remain with 
their TCVC for more than a year (Ethier et al. 2008; Moist et al. 2012). The presence of a 
CVC at the time of dialysis commencing is associated with poorer AVF maturation 
(Brunori et al. 2005). Similarly, although underpowered for the secondary end-point, 
Weber and colleagues (2009) demonstrated a trend towards improved patency in AVF 
created when the patient was pre-dialysis. Patient refusal of AVF is also higher in those 
who had previously experienced dialysis via a line (Nica et al. 2013). The legacy of poor 
access planning and inappropriate line usage in the early days of HD follows a patient for 
life. Central venous stenosis can occur with just a few days of line exposure and has 
significant impact on both positioning and longevity of future vascular access (Agarwal et 
al. 2007; Moist et al. 2012; Jackson et al. 2014). Finally, mortality amongst dialysis 
patients is highest in the first year after starting HD (UK Renal Registry, 2016; USRDS, 
2014). Catheter-related infection (which peaks between 3 and 6 months after starting 
dialysis) is the principle cause of death (Ravani et al. 2013a; Thomson et al. 2010; Collins 
et al. 2009). The risk of early sepsis episodes is higher in patients with delayed autologous 
access creation (>4 months after starting HD), independant of catheter use (Oliver et al. 
2004). Likewise, in their study of 510,000 patients, Malas and colleagues (2015) found that 
patients commencing dialysis via an AVF had a 35% lower mortality than those starting 
via a TCVC (even accounting for confounding factors). Optimisation of incident vascular 
access is therefore vital, both to improve early patient survival, but also to reduce long-
term morbidity and the exhaustion of access options for the future.  
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Table 1.6:  Comparison of vascular access at first dialysis and vascular access at 3 
months after commencing haemodialysis. Reproduced with permission from the Health 
and Social Care Information Centre. (National Kidney Care Vascular Access Report, 
2012). 
 
Access at 3 months 
 
Access 
at first 
dialysis 
 
 
AVF 
 
AVG 
 
TCVC 
 
NTCVC 
 
PD 
catheter 
 
Death 
within 
3 
months 
 
 
Transplant 
 
No 
data 
 
Total 
AVF 748 1 27 3 2 28 3 29 841 
AVG  13 2  1    16 
TCVC 76 5 595 1 30 55 6 41 809 
NTCVC 34 5 246 19 19 43 2 44 412 
PD 
catheter 
4  4 1 148 4 5 2 168 
No data   4   2  5 11 
 
Total 
 
862 
 
24 
 
878 
 
24 
 
200 
 
132 
 
16 
 
121 
 
2257 
 
 
Within this thesis, I will focus on incident patients and evaluate methods for improving 
vascular access within the incident patient cohort. I will take a multifaceted approach 
focusing on five main themes: 
1. Line complications and central vein stenosis: avoiding problems for the future. 
2. Predicting maturation: is the incident patient different? 
3. Promoting maturation: are there strategies to optimise maturation? 
4. Right access, right patient: how do you provide individualised, patient-centred 
care? 
5. ‘Crashlanders’: how do you manage patients who present without prior warning? 
The emphasis of this work is directed towards finding pragmatic, patient-focussed 
solutions to clinically relevant problems. 
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TUNNELLED CENTRAL VENOUS CATHETERS (TCVCs): THE 
EXTENT OF THE PROBLEM 
 
2.1. INTRODUCTION  
 
It is widely accepted that AVFs are the optimal method of achieving vascular access for 
haemodialysis for most patients, with fewer complications and lower mortality than 
TCVCs (UK Renal Registry, 2016.; McGee & Gould, 2009). As previously discussed, the 
use of TCVCs is associated with a six-fold increased risk of systemic sepsis and three 
times increased risk of all cause mortality compared to AVF, in addition to the long-term 
morbidity from central vein stenosis (Thomson et al. 2007; Bray et al. 2012). Given that 
the complications of vascular access account for 20% of all hospital admissions and one-
third of in-patient bed usage for patients with ESRD (USRDS, 2007), AVFs are also a 
more cost-effective means of providing haemodialysis (Leermakers et al. 2013). For these 
reasons the National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
Clinical Practice Guidelines for Vascular Access (NKF-KDOQI, 2006) in the USA and 
The Renal Association (2011) in the UK advise that AVF should be the access modality of 
choice wherever possible. 
 
The Fistula First Breakthrough Initiative has been very effective at improving AVF usage 
in the United States (Massoud et al. 2006).The financially incentivized, multifaceted 
approach to encouraging optimal vascular access has resulted in a steady, incremental 
increase in the use of AVF (from 32.2% in 2003 to 60.4% in 2012) (Lynch et al. 2011a). 
The target of 66% of prevalent haemodialysis patients dialysing via an AVF is fast 
approaching.  
In the UK, the Renal Association has suggested even more optimistic goals, advocating 
that 85% of prevalent and 65% of incident haemodialysis patients should be dialysing via 
an AVF (Fluck & Kumwenda, 2011). Recently the controversial best practice tariff in 
England and Wales has rekindled the vascular access debate and drive for definitive access 
this side of the Atlantic. The aim of Payment by Results (PbR) is to provide a rules-based 
framework that financially rewards efficiency and best practice (Sharif & Baboolal, 2011). 
Best practice tariffs were calculated based on 85% of prevalent haemodialysis occurring 
via an AVF or AVG by 2013/2014 (Department of Health, 2010). Healthcare trusts are 
financially recompensed for achieving these targets. Obviously this has heightened the 
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drive to achieve definitive vascular access, but many units have struggled to meet such 
stringent goals.  
An increasingly elderly and comorbid dialysis population has led some to consider whether 
AVFs are in fact the best option for all patients. The peak age of prevalent haemodialysis 
patients in England and Wales is now 70-79 years, with the number of extreme elderly 
patients (>85 years old) on haemodialysis doubling in the past 5 years (UK Renal Registry, 
2014). Life expectancy and quality of life may influence the optimal choice of vascular 
access (Latos, 2002). The Fistula First Breakthrough Initiative states that AVFs should be 
attempted first in all “suitable” dialysis patients. (Massoud et al. 2006) However, defining 
those suitable, or perhaps more importantly those unsuitable, for AVF is often difficult. It 
is important that national targets do not compromise individualised care and patient-
centred vascular access solutions.  
In 2010, despite national targets, only 75% of prevalent patients and 42% of incident 
patients were dialysing via autologous access (Scottish Renal Registry, 2013). Locally in 
the West of Scotland, prevalent AVF usage rates were even lower with significant 
variation between units (63-75%) (Scottish Renal Registry, 2013). We sought to embark 
on a multifaceted Quality Improvement (QI) project, of which the research studies 
described in this thesis were an integral part.  
The study outlined in this chapter reflects the initial “fact-finding” element of the QI 
project, in which we attempted to characterise the scale of the problem, the causes of 
TCVC usage and to assess the impact of our first intervention (a surgically aggressive 
approach to definitive access creation).  
 
2.2. METHODOLOGY  
 
Approval for the study was obtained from the Clinical Effectiveness Department at the 
Western Infirmary, Glasgow. Formal ethics committee approval was not required for this 
service improvement project.  
 
In November 2010, the Scottish Electronic Renal Patient Record (SERPR) was 
interrogated for all prevalent haemodialysis patients in the West of Scotland (n=636). 
SERPR is a computerised patient record system that allows prospective collection of data 
on all aspects of renal patients’ illness (including dialysis status, dialysis parameters, 
vascular access, blood results). It can be searched as a database of audit purposes. The 
 93 
volume of TCVC usage, reasons for line use and complications arising from TCVCs were 
recorded. Data pertaining to previous AVF and failed attempts at AVF creation were also 
obtained.  
All patients dialysing via a TCVC were subsequently visited on haemodialysis by a 
clinician experienced in vascular access. Options for creation of definitive access in the 
form of AVF or AVG were explored. Over the subsequent year, aggressive operative 
attempts were made to achieve definitive vascular access in all patients who were fit and 
had a suitable anatomical option.  
Patients were then visited 1 year later (November 2011) with re-evaluation of all prevalent 
haemodialysis patients (n=634). TCVC usage and reasons for this were again recorded. 
The fate of those patients dialysing via a TCVC in 2010 and all incident patients was 
evaluated.  
Statistical analysis was undertaken using SPSS Statistics for Windows Version 19.0 (IBM 
Corp., Armonk, NY, USA). Continuous data are presented as mean (standard deviation 
(SD)) and categorical data are presented as median (interquartile range (IQR)). Otherwise 
results are presented as a percentage of the total population. Chi-squared test and paired 
sample t-test were used to compare outcomes between the two years. P-value <0.05 was 
significant.  
 
2.3. RESULTS 
 
2.3.1.  Baseline demographics 
 
The total number of patients on haemodialysis in the West of Scotland was similar in 2010 
(n=636) and 2011 (n=634), with 267 new incident patients, 92 renal transplants and 177 
deaths. There was no significant difference in the overall number of patients dialysing via a 
TCVC in 2010 (pre-intervention) compared to 2011 (post-intervention) (30.3% (n=193) vs. 
31.7% (n=201) respectively; P=0.56). There was, however, a substantial flux and attrition 
of patients dialysing via a TCVC so that the majority of those on TCVC in 2011 were not 
those on TCVC in 2010 (Figure 2.1). Of the 267 incident patients, 125 (46.8%) began 
haemodialysis via an AVF; 108 patients (40.4%) commenced dialysis via a TCVC and 34 
patients (12.7%) began haemodialysis via a temporary line.  
 
 
 94 
 
Figure 2.1: Fate of patients dialysing via a TCVC between 2010 and 2011 and reasons 
for TCVC usage in 2011 
 
Table 2.1 highlights the demographics of the patients dialysing via TCVCs. The majority 
of patients were dialysing via internal jugular lines (Table 2.2). There was no significant 
difference in the mean number of previous TCVCs or AVF attempts per patient between 
years 2010 and 2011. However, following aggressive attempts at trying to achieve 
definitive vascular access, there were fewer patients dialysing via a TCVC who had never 
had an attempt at AVF creation (21.2% vs. 13.9%; P=0.02) (Table 2.3).  
 
Table 2.1: Demographics of patients dialysing via a TCVC in 2010 and 2011. Results 
are presented as mean (SD) unless otherwise stated. 
 2010 2011 
Age (years) 65.5 (6.5) 62.3 (6.3) 
Sex (percentage male) 48% 46% 
Time on haemodialysis (years) 5.7 (3.4) 5.1 (5.4) 
Number of previous TCVCs 3.06 (range: 1-15) 2.95 (range: 1-13) 
Number of previous AVF attempts 1.9 (0.7) 2.2 (0.6) 
Percentage of patients with at least 3 previous AVF 
attempts 
23.3% 27.9% 
Percentage of patients with no previous AVF attempts 21.2% 13.9% 
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Table 2.2: Site of tunnelled central venous catheter. 
 2010 2011 
Internal jugular 92.7% (n=197) 95.0% (n=192) 
Subclavian 3.1% (n=6) 2.0% (n=4) 
Femoral 3.1% (n=6) 1.5% (n=3) 
Translumbar 1.0% (n=2) 1.5% (n=3) 
 
Table 2.3: Reasons for TCVC use in 2010 (pre-intervention) and 2011 (post-
intervention). Following the intervention more patients had a decision made not to attempt 
further definitive vascular access either due to comorbidities or exhaustion of anatomical 
options. Groups were compared using a paired-sample t-test.  
 
 2010 2011 P-value 
Permanent TCVC 
Unfit 
Non anatomical option 
Patient choice 
 
28.2% 
9.8% 
11.4% 
 
32.8% 
19.4% 
7.9% 
 
0.08 
<0.001 
0.13 
Awaiting new AVF creation/ maturation 
Awaiting maturation 
Awaiting surgery to create AVF 
 
8.8% 
12.6% 
 
5.4% 
14.4% 
 
0.05 
0.45 
Awaiting imaging/ review 12.6% 9.5% 0.23 
Awaiting intervention for problematic AVF 7.8% 9.9% 0.35 
Awaiting transplantation 1.0% 0.6% 0.06 
Lost to follow-up 9.8% -  
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2010 2011
Lost to follow-up
Awaiting transplantation
Problematic AVF - awaiting
imaging/ intervention
Awaiting further attempt at
AVF creation (previous failed)
Awaiting attempt at first AVF
creation
Permanent TCVC
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2.3.2.  Complications of TCVCs 
Culture-proven Staph.aureus bacteremia rate during the period November 2010 to 
November 2011 was 1.6 per 1,000 catheter days; 32 patients (16.6%) required their TCVC 
removed for infection within the year. One patient died from line sepsis. 13 patients (6.7%) 
required TCVC replaced for occlusive problems or poor flow in the period 2010-2011. A 
further 12 patients (6.2%) had difficulties with poor flows in their line which were 
managed conservatively. 24 patients (12.4%) had previously had >5 TCVCs replaced for 
complications and 24 patients (12.4%) had evidence of symptomatic or previously 
symptomatic central vein stenosis.  
 
2.3.3. Indications for TCVC use  
 
Table 2.3 outlines the reasons for TCVC use at the time of the initial clinical review in 
November 2010. 25.6% (n=49) of patients were deemed unfit for any further definitive 
access options; one-third of patients (n=64) were awaiting imaging or operative 
intervention and 10.5% (n=20) of patients did not wish AVF creation. A further 9.8% 
(n=19) of patients were found to be dialysing via a TCVC for no reason other than they 
appeared to have been lost to follow-up and plans for definitive access not made.  
Following the initial review, a plan for vascular access was created in each patient. A 
decision was made to keep the TCVC in 51.8% of patients (n=99). 7.8% (n=15) required 
imaging and/or intervention (either surgical or angiographic) for a problematic fistula. No 
patient was suitable for or willing to consider a switch to peritoneal dialysis (11.4% (n=22) 
had previously failed peritoneal dialysis). All other patients were at various stages of work-
up for surgery (25.3% (n=49) were awaiting preoperative imaging; 2.1% (n=4) were 
awaiting clinical review; 12.4% (n=24) were on the waiting list for surgery).  
 
2.3.4.  Outcomes following aggressive intervention for definitive access  
 
A year later, following aggressive attempts to achieve definitive access, the fate of the 
original TCVC patients is outlined in Figure 2.2. Of the 193 patients dialysing via a TCVC 
in November 2010, 37% (n=71) had died by November 2011. An active decision had been 
made for 22% (n=43) to remain on a long-term TCVC; 20% (n=39) had undergone 
successful AVF creation; 1% (n=2) were dialysing via an AVG and 2% (n=4) had received 
a renal transplant. A total of 34 patients (17.6%) were still trying to achieve definitive 
access 1 year on.  
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Figure 2.2: Outcome of those patients who were dialysing via a TCVC in November 
2010 (first audit cycle) at the time of the second audit cycle. 
 
Seventy-seven patients (39.9%) had 91 attempts made at creating definitive access during 
the follow-up period. 50.6% (n=39) of patients had successful AVF created at the first 
attempt (two were subsequently transplanted) and 2.6% (n=2) had an AVF successfully 
secured at the second attempt. In this patient group the success of AVF creation declined 
with the number of previous attempts at AVF creation and the length of time a patient had 
been on haemodialysis (Table 2.4). 44.2% (n=34) of patients had significant difficulties or 
complications following attempted AVF creation. A total of eight patients (10.4%) 
required ligation of a functioning AVF (two for venous swelling secondary to central vein 
stenosis; four for steal; two with calciphylaxis at the operative site). Five patients (6.5%) 
died within 28 days of surgery to create AVF. Two patients successfully had AVF created 
but have subsequently had stenotic complications and were again dialysing via TCVC 
awaiting reintervention. A total of 17 patients (22.1%) had undergone imaging and failed 
attempts at AVF creation in the subsequent year and continued to await further attempts at 
definitive surgery. 9 patients (11.7%) with bilateral CVS had attempts at achieving lower 
limb access via a thigh graft.  
All patients had a documented “vascular access plan” at the time of the second clinical 
review. Reasons for TCVC use differed in 2011 (following the intervention) compared to 
2010 (Table 2.3): 61.9% of patients (n=125) had an active decision made to continue 
dialysis via a TCVC at the time of second review (November 2011). A total of 40.1% 
37%
22%
20%
1%
2%
18%
Died
Remains on TCVC
Got AVF
Got AVG
Transplanted
Still trying to obtain
definitive access
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(n=81) had a new decision to dialyse via a permanent TCVC after imaging confirmed no 
suitable anatomical option for definitive vascular access or the patient had additional 
unsuccessful attempts at AVF creation. 21.8% (n=44) remained on a TCVC following the 
initial review. 15.8% (n=32) of patients were still trying to achieve definitive access 1 year 
on. A total of 7.9% of the patients (n=16) required TCVC insertion due to new problems 
(stenosis, occlusion etc.) that developed with their AVF and 13.9% of patients (n=28) were 
incident dialysis patients who commenced haemodialysis without definitive access and 
were dialysing via TCVC until AVF creation or maturation. Following aggressive 
intervention, significantly more patients had an active decision made to dialyse via a 
permanent TCVC either due to comorbidities or exhaustion of native options (19.4% 
vs.9.8%; P<0.001). There was no significant difference in the number of patients awaiting 
surgery or intervention either for first AVF, after multiple unsuccessful attempts, or for 
problematic AVF (Table 2.4).  
Table 2.4: Success of subsequent AVF creation in patients dialysing via TCVC who 
have had previous attempts at AVF creation. 
 Total number of 
attempts at definitive 
access creation 
Percentage of patients 
with successful AVF 
creation 
P-value 
Number of previous attempts at 
AVF creation 
0 
1 
2 
3 
4 
>4 
Total 
                                                                                       
 
16 
13 
24 
15 
15 
8 
91 
 
 
81.2% (n=13) 
69.2% (n=9) 
66.7% (n=16) 
6.7% (n=1) 
13.3% (n=2) 
0% (n=0) 
45.1% (n=41) 
 
 
 
 
 
 
 
 
 
<0.001 
Length of time on 
haemodialysis 
<1 year 
1-2 years 
2-5 years 
5-10 years 
>10 years 
Total 
     
                                                                 
20 
6 
24 
29 
12 
91 
 
80.0% (n=16) 
66.7% (n=4) 
50.0% (n=12) 
17.2% (n=5) 
33.3% (n=4) 
45.1% (n=41) 
 
 
 
 
 
 
 
0.02 
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2.3.5. Incident patients  
 
During the same time period, 142 incident patients commenced haemodialysis via a central 
venous catheter (CVC) (108 TCVC; 34 temporary). 82 of these patients (57.7%) had 
attempted AVF creation prior to commencing haemodialysis via a TCVC; 30 patients 
(21.1%) were deemed unsuitable for definitive vascular access attempts and 30 patients 
(21.1%) were not referred for access creation prior to starting haemodialysis. A total of 
50% of these (n=15) were “crashlanders”. 18.3% (n=26) had late referral for vascular 
access creation (within 6 weeks of the need to commence haemodialysis) and therefore did 
not yet have a mature AVF. A total of 38 patients (26.7%) had AVF created more than 6 
weeks prior to starting haemodialysis that were inadequate to sustain dialysis and a further 
18 patients (12.7%) had AVF which had adequately matured but subsequent thrombosis 
had gone unrecognised until the need to commence dialysis, also necessitating TCVC 
insertion.  
 
2.4. DISCUSSION 
 
Aggressive surgical attempts to achieve definitive access in prevalent patients resulted in 
20% of patients previously dialysing via a TCVC having successful AVF creation. Due to 
the high turnover of patients and persistent difficulties in achieving AVF for incident 
patients, there was no reduction in the absolute number of TCVCs required one year after 
the initial intervention. Perhaps more importantly, as a result of active management, all 
patients obtained a formal “vascular access plan”. Aggressive intervention certainly 
benefited some patients but this was offset against high background mortality and 
significant morbidity and complication rates among others in this relatively high-risk 
patient group.  
 
The study represents a local service improvement initiative and, as such, results may not be 
generalisable to other units. However, our practice is comparable to that observed in other 
units in UK and the problems highlighted in this study are those encountered within the 
“real world” of vascular access. Furthermore, with the recent implementation of a PbR 
strategy in England and Wales, the findings are timely to illustrate the difficulties (central 
vein stenosis, lack of native vessels and comorbid patients) that clinicians are likely to 
encounter in trying to achieve inflexible targets in a complex patient group of long-term 
prevalent haemodialysis patients.  
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This study highlights the importance of a “personal vascular access solution” and targetted 
“vascular access plans”. Some patients derived significant benefit from aggressive attempts 
at AVF creation. 20% of prevalent patients who were dialysing via a TCVC had a 
functioning AVF after 1 year, including several patients who had been on haemodialysis 
for over 10 years. Others did not obtain similar benefit with a high complication rate and 
poor functional patency derived from access procedures performed in complex patients 
who had multiple previous access attempts. Following several additional failed attempts at 
AVF creation, a number of these patients had an active decision to continue dialysis via a 
TCVC documented in their “vascular access plan”. The vascular access plans were 
individualised, taking into account comorbidities, life expectancy, anatomical options and 
patient preference. Failure to achieve a functional AVF does not always reflect poor care, 
just as it is not always appropriate to assume that autologous access is the measure of good 
quality care. Additionally, maintaining a high proportion of such complex patients on AVF 
may become increasingly challenging (Mendelssohn et al. 2006; Thomson, 2009). AVF 
will inevitably suffer complications including stenosis and thrombosis. CVCs are likely to 
remain an essential stop-gap measure from time to time in patients with problematic 
vascular access. It is important to recognise that patients’ “vascular access plans” are not a 
once-off, all-or-nothing decision, rather they will evolve, require fluidity and will need 
regular revision.  
Unique complex vascular access problems occur in patients with bilateral central vein 
stenosis. The prevalence of bilateral central vein stenosis in our patient group was 
significant (11.7%) and higher than in other similar series (Antoniou et al. 2009). A 
recognised complication of long-term TCVC use, bilateral central vein stenosis makes it 
difficult to achieve upper limb venous access (Agarwal et al. 2007). Attempts at upper 
limb AVF creation in patients with unrecognised central vein stenosis were associated with 
venous swelling of the limb necessitating abandonment of the AVF in this study. Thigh 
grafts were attempted in a number of patients and provided good quality dialysis with 
avoidance of TCVCs in patients who had few other access options. A number of patients 
with bilateral central vein stenosis had significant comorbidities precluding them from 
general anesthetic and thigh graft creation however. As such they were subsequently 
recorded as having no further anatomical options for definitive access.  
Just over half of patients in whom AVF was attempted had a functioning fistula after one 
year. The other half had significant difficulties either with complications of the AVF or 
with multiple unsuccessful attempts at achieving fistula maturation. 25% continue to have 
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ongoing attempts at definitive access creation beyond 1 year after the initial intervention, 
demonstrating the high failure rate of AVF in this population. These findings are consistent 
with data from the Dialysis Outcomes and Practice Patterns Study (DOPPS), which found 
that the risk of AVF failure was increased in patients with prior CVC (OR1.8) (Rayner et 
al. 2004). Our findings also support those of Lawrence et al. (2002), confirming a law of 
diminishing returns with each subsequent vascular access attempt (81.2% functional 
patency for first AVF vs. 13.3% functional patency in patients who have had four previous 
attempts at AVF creation). Repeated admissions for unsuccessful AVF attempts and 
significant morbidity associated with definitive access attempts in this complex patient 
group justify the pragmatic approach taken during the second clinical review, with an 
increase the number of patients with a “vascular access plan” to remain on TCVC due to 
lack of anatomical options after several further unsuccessful attempts at achieving 
definitive access.  
The number of haemodialysis patients in Scotland over the age of 75 years has doubled in 
the past 10 years (Scottish Renal Registry, 2015). Similarly, in the USA, the average age of 
a patient commencing haemodialysis is now 63 years (20 years older than 15 years ago) 
(USRDS, 2014). As previously described, definitive vascular access creation in an 
increasingly elderly, comorbid population presents unique challenges. In this study over 
one-third of patients who were dialysing via a TCVC at the time of initial review were 
dead within a year, illustrating the importance of considering life expectancy in the 
decision-making process for vascular access. There is a high mortality in extremely elderly 
haemodialysis patients, with a mean survival of only 386 days in patients over 80 years old 
(Vachharajani et al. 2011). This illustrates the futility of blindly creating an AVF in every 
octogenarian. Patency and success rates of AVF in older patients should also be considered 
when planning vascular access. Many authors have not shown any significant difference in 
AVF outcome in elderly dialysis patients (even at the extremes of age) and would argue 
that age, in isolation, should not be a contraindication to AVF creation (Morsy et al. 2011; 
Lok et al. 2005). However, the combination of advancing age and other comorbidities, 
including diabetes and PVD, is likely to be associated with poor AVF maturation (Lok et 
al. 2006). This risk of poor AVF maturation in patients with diabetes and PVD requires to 
be offset against an increased number of catheter-related bacteremia in comorbid patients 
(Thomson et al. 2007).  
Both the Fistula First Breakthrough Initiative and PbR (Massoud et al. 2006; Department 
of Health, 2010) focus on minimising prevalent TCVC usage. However, this study has 
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highlighted the difficulties associated with a “one size fits all” approach to obtaining 
definitive vascular access in this population. Universal targets at the expense of 
individualised care may compromise outcomes in this complex patient group. It is vital 
that national targets and PbR do not jeopardise personal solutions. Conversely, incident 
patients would provide an appropriate target group, in whom definitive access is likely to 
be easier to create (Rayner et al. 2004) and prevention of TCVC-related complications, for 
example, central vein stenosis, would minimise the number of patients with complex, end- 
stage vascular access and no anatomical options for AVF creation in the future (Agarwal et 
al. 2007). During the time period of this study, only 46.8% of incident patients in the West 
of Scotland commenced haemodialysis via an AVF. It is essential that government 
initiatives to minimise prevalent TCVC usage do not occur at the expense of incident 
patients.  
In conclusion, this study clearly demonstrates the need for accurate data collection and 
highlights the role that research can play in QI projects. It has illustrated that prevalent 
haemodialysis patients, previously dialysing via a long-term TCVC, are a high-risk and 
challenging group in whom to obtain vascular access. They have high background 
mortality and definitive vascular access is both difficult to achieve and associated with 
significant morbidity. Targetting resources towards the simpler incident patients, with 
higher likelihood of success, may provide better return and avoid patients with complex 
vascular access needs in the future. Furthermore, the study serves as a root-cause analysis 
to identify the main reasons for TCVC use in our practice and highlight areas requiring 
additional work both for service improvement and future research: the difficulties 
associated with non-maturation and associated consequential TCVC use; the need to 
identify patients in whom attempts at AVF creation may be futile and alternative vascular 
access may be more appropriate; and the importance of an individualised approach to 
vascular access. These are areas that have subsequently been targetted for development 
both in our clinical practice and research. They provide the basis for the main questions 
and themes of this thesis. 
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THE BURDEN OF CENTRAL VEIN STENOSIS AND “END STAGE” 
VASCULAR ACCESS 
 
3.1. INTRODUCTION 
 
Vascular access dysfunction is the leading cause of healthcare expenditure and second 
most common cause for mortality in patients on haemodialysis (Fluck & Kumwenda, 
2011). Choice of vascular access modality is strongly associated with survival on 
haemodialysis (Malas et al. 2015). TCVCs are associated with greater all cause mortality, 
increased risk of systemic bacteraemia and long-term morbidity as a result of central 
venous stenosis (CVS) compared to alterative forms of vascular access (Thomson et al. 
2010; Bray et al. 2012). Whilst infection and Staph.aureus bacteraemia rates are very 
tightly audited and regulated adverse outcomes, CVS is rarely considered as a marker of 
quality of care. 
 
Central vein stenosis is a delayed complication of TCVC insertion (Agarwal, 2013; NKF-
KDOQI, 2000), with a published incidence ranging from 25 to 40% amongst patients who 
are dialysing (or have dialysed) via a TCVC (Suroweic et al. 2004; Quinn et al. 2003).  It 
can cause debilitating symptoms of upper limb and facial swelling, vascular access 
dysfunction and, once advanced, life-threatening loss of vascular access (Dammers et al. 
2003a; NKF-KDOQI, 2006). Little is understood about the pathogenesis of CVS 
(Dammers et al. 2003a), however our own recent work suggests that prolonged duration of 
line use is a risk factor for CVS and there is a negative correlation with line infection. In 
this study, either CVS and/or line sepsis was found to be an inevitable consequence of 
every TCVC not removed for another reason (Aitken et al. 2015b). Treatment strategies 
are suboptimal, and affected patients suffer with frequent hospitalisation and deterioration 
in quality of life.  
Notwithstanding the well-recognised complications associated with their usage, TCVCs 
remain fundamental in delivering HD to patients with no other functioning vascular access 
(Thomson et al. 2010; Aitken et al. 2014a; Schwab, 1999). They can be inserted quickly 
and easily to permit immediate access for HD, making them the default, stock choice for 
incident dialysis patients without a working AVF. Despite aggressive attempts to minimise 
usage, nearly 50% of incident patients and 25% of prevalent patients in Scotland continue 
to dialyse via a TCVC (Scottish Renal Registry, 2015). In the USA, nearly 80% of patients 
still commence haemodialysis via a line (Lok & Foley, 2013). However, the choice (or 
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necessity) for TCVC in incident dialysis patients can have significant negative long-term 
repercussions. 
 
The clinical manifestations of CVS (vascular access dysfunction and/or limb swelling) are 
well recognised and the healthcare burden of CVS experienced by clinicians and patients is 
subjectively high, however the true cost to both patients and healthcare services has not 
been defined. The natural history and optimal treatment strategy of CVS is not known. 
Furthermore, due to the temporal separation between line insertion and CVS, there is often 
lack of awareness and accountability for the complication and it is rarely factored into the 
clinical and economic arguments driving high rates of provision of autologous vascular 
access.  
 
Central vein stenosis is notoriously difficult to treat (Dammers et al. 2003a). Management 
presents two, often dichotomised, challenges: to both preserve vascular access and reduce 
symptoms. Attempts at autologous vascular access creation or rescue on the side affected 
with the CVS are doomed to fail without robust management of the stenosis itself, and 
patients have frequently already exhausted multiple alternative potential vascular access 
sites (Dammers et al. 2003a). There is no well-defined universal treatment algorithm for 
maintaining vascular access in this context (Lumsden et al. 1997). Symptomatic relief and 
maintenance of any autologous AVF is the optimum outcome of intervention for CVS. 
Endovascular intervention, by either angioplasty or stent insertion, has become the 
mainstay of treatment, providing a method that can potentially relieve symptoms and 
preserve access (Suroweic et al. 2014). Current data suggests that primary 12 month 
patency of angioplasty ranges from 23-63% (Suroweic et al. 2014; Quinn et al. 2003; 
Dammers et al. 2003b) and 31 to 91% for endovascular stenting (Suroweic et al. 2004; 
Dammers et al. 2003b; Quinn et al. 2003; Kovalik et al. 1994; Günther et al. 1989). When 
endovascular treatment fails to preserve existing autologous access, subsequent steps for 
further access provision must be taken. In patients with unilateral CVS, this normally 
involves creation of contralateral AVF or AVG.  
 
Patients with bilateral central vein occlusion provide a uniquely challenging patient group 
for the vascular access surgeon as they have no upper limb options for vascular access 
(either native or prosthetic) (Ayarragaray, 2003). In severe cases it can lead to absolute 
loss of vascular access for dialysis. The true incidence of complete access failure is 
unknown, however most clinicians responsible for caring for patients with ESRD will 
recall the occasional patient who dies from loss of vascular access.   
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Case reports of exotic, last-resort procedures for end-stage vascular access are found 
throughout the vascular literature (Zanow et al. 2005; Zamani et al. 2012; Hamish et al. 
2006). Considerable time and resources may be invested in heroic attempts at providing 
vascular access. Such attempts are costly and often only provide a short-lived solution 
(Yevzlin, 2008). 
 
Many patients with bilateral central vein occlusion can be managed with a combination of 
a relatively limited number of second line access options. These treatment options include 
tunnelled catheters (femoral (Falk, 2007) and translumbar (Power et al. 2010)), HeRO 
grafts (Glickman, 2011),  lower limb access (native long saphenous vein loop (Pierre-Paul 
et al. 2004; Gilbert & Gibbs, 2011) or prosthetic (Cull et al. 2004; Chemla et al. 2005)), 
peritoneal dialysis (Chemla et al. 2005; Kumbar & Besarab, 2013) and renal 
transplantation. The infection and occlusion rates of these second line access procedures 
(particularly those in the lower limb) are recognised to be higher than autologous upper 
limb fistulae (Cull et al. 2004) however they can provide effective access for 
haemodialysis, either in isolation or in combination with another modality, in patients with 
limited alternative options. There are no comparative data on which procedure offers the 
best options for long-term haemodialysis in these patients. Ranking of these options could 
provide a decision-making framework for intervention, generally leading to a “personal 
vascular access solution” on an individual patient basis (Aitken et al. 2014a).  
 
The aims of this study were two fold: firstly to describe the burden of central vein stenosis, 
both to the patient (in terms of vascular access provision, hospitalisation and quality of 
life) and to the healthcare system (with associated costs of treating CVS and maintaining 
vascular access); and secondly to compare outcomes of the various treatment modalities 
(femoral tunnelled catheters, translumbar catheters, native long saphenous vein thigh 
loops, prosthetic thigh grafts, peritoneal dialysis and renal transplantation in patients with 
bilateral central vein occlusion. By demonstrating the significant affliction caused by 
ESVA, the importance of ‘getting it right from the start’ (Lok et al. 2013, pp.812) with 
TCVC avoidance in incident patients is highlighted.   
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3.2.  METHODOLOGY 
 
3.2.1.  Study design and participants 
 
The Vascular Access Service at the Western Infirmary, Glasgow serves a haemodialysis 
population of 700 patients in the West of Scotland, with approximately 170 incident 
patients commencing HD each year. Patients with symptomatic central vein stenosis 
(defined as CVS causing disabling limb or facial swelling, AVF dysfunction or loss of 
vascular access) were identified via a weekly Multidisciplinary Team (MDT) vascular 
access meeting attended by renal surgeons, interventional radiologists and nephrologists.  
All patients with problematic vascular access were referred to the surgical team via this 
MDT. A prospectively maintained database of patients with symptomatic central vein 
stenosis was created.  
 
This was an exploratory study with the aim of comprehensively characterising and 
describing the central vein stenosis population in the West of Scotland: natural history, risk 
factors, impact on the patient and the healthcare system etc. For this reason, several 
different patient cohorts were evaluated: 
 
1. All patients with symptomatic CVS referred to the Vascular Access MDT between 
1st January 2011 and 31st December 2014 (4 years). This patient cohort was 
followed up until 1st September 2016 
2. A subgroup of these patients deemed to have “end stage” vascular access (ESVA), 
defined as bilateral central venous stenosis/occlusion diagnosed as symptoms 
and/or access failure with no further options for upper limb access plus 
angiographic evidence of stenosis or occlusion which was no longer amenable to 
radiologic intervention. Recruitment occurred over the same time period outline 
above. 
3. A subgroup of patients with ESVA considered eligible for renal transplantation. 
(This population is described in greater detail below). 
4. 500 consecutive patients undergoing TCVC insertion between 1st January 2008 and 
22nd October 2011. Follow-up on this patient population ended on 31st December 
2014. 
 
Approval for the study was obtained from the Greater Glasgow and Clyde Clinical 
Effectiveness Department. Formal ethics committee approval was not required for this 
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evaluation of existing clinical practice.  
3.2.2.  Data collection 
 
The main prospective CVS database was maintained by two researchers (EA, AJ), Data 
entry was cross-checked to ensure accuracy. Basic patient demographic data were recorded 
weekly following the MDT, including age, sex, comorbidities, smoking status, medication 
history, vascular access status and central venous catheterisation history. Presenting 
clinical problems were also documented. The location of lesions was determined by central 
vein angiography. Patients were categorised into unilateral CVS and those with bilateral or 
superior vena cava stenosis. Patients with ESVA were considered separately. Prospective 
data were recorded on: treatment strategies (described below); treatment outcomes 
including access patency (primary, secondary and primary-assisted patency); 
complications (stenosis, occlusion, infection); re-interventions and hospitalisation 
episodes. Vascular access status (i.e. AVF, AVG, TCVC, PD, renal transplant) was 
recorded at 6 monthly intervals from diagnosis.  
 
Primary assisted patency was defined as the time from access creation to thrombosis  (or 
occlusion in the case of catheters). Secondary patency was defined as the time from access 
creation to access occlusion or loss (including any salvage procedures). “Loss of patency” 
has also been used to describe graft loss in the case of transplantation to permit comparison 
between cohorts. 
 
Quality of life was also recorded. This was determined from self-reported EQ-5D (Szende 
et al. 2007; Brazier et al. 2004) questionnaires recorded at the time of diagnosis of CVS 
and 6 and 12 months post-diagnosis. 
 
Additionally, data was retrospectively collected on 500 consecutive patients undergoing 
TCVC insertion. The Scottish Electronic Renal Patient Record (SERPR) was interrogated 
to obtain data on basic patient demographics, the date of each catheter insertion and 
number of preceding/ subsequent TCVCs. The number and date of culture-proven catheter- 
related blood stream infection (CRBSI) and CVS were recorded. Culture-proven catheter-
related bacteraemia was defined as the presence of positive blood cultures associated with 
a systemic inflammatory response (e.g. pyrexia, raised white cell count (WCC) or C-
reactive protein (CRP)) in the absence of clinical or radiological signs of a non-catheter-
related source.  Local exit site infections in the absence of systemic bacteraemia were 
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excluded. This approach is in keeping with the definition of CRBSI commonly used in the 
literature and consistent with that used in routine clinical practice (Thomson et al. 2010). 
Where patients were found to have developed CRBSI, the date of first positive blood 
culture was entered as the event date and time to event subsequently calculated. All 
TCVCs were removed following culture-proven CRBSI. For the purposes of this cohort, 
CVS was defined as typical symptoms (including limb swelling and access dysfunction or 
failure) along with radiographic evidence of central vein stenosis or occlusion. The date of 
diagnostic venography was used to calculate time to event. Patients in this cohort were 
followed prospectively to completion of the study or death. 
 
3.2.3.  Treatment strategies 
Treatment strategies were selected based on the consensus of the multi-disciplinary team, 
adhering to the concept of a “personal vascular access solution” (i.e. the vascular access/ 
dialysis modality most likely to provide long-term successful RRT) and a philosophy of 
ranking autologous vascular access first, prosthetic vascular access second, and TCVC 
third. PD and transplantation were considered if appropriate. With failure of treatment, 
patients were again discussed at the MDT meeting, and a further treatment strategy agreed 
and implemented.  
 
The procedures described below reflect standard practice within our institution: 
 
3.2.3.1. Angioplasty and/or stenting to maintain autologous access 
 
Theses procedures were mainly performed on an out-patient basis with few requiring 
hospital admission. Procedures were performed under local anaesthesia with or without 
intravenous sedation as required. 
 
Balloon angioplasty was considered the treatment of choice, with stenting only employed 
if there was immediate elastic recoil following angioplasty, or of the stenosis recurred 
within the first three months. 
 
Ultrasound-guided puncture of the basilic or brachial vein was performed and a 7-10F 
vascular sheath placed. Angiographic assessment of the central veins was performed. The 
length and diameter of the stenosis measured and the balloon/ stent size selected to over-
estimate the vessel size by 10-20% in order to prevent migration. The stenosis was then 
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crossed with a standard hydrophilic guidewire. The hydrophillic wire was then exchanged 
for a stiffer non-hydrophilic 0.035mm guidewire and the stricture dilated with a balloon 
catheter placed over the stiff guidewire. The vein is dilated to the diameter of the 
subclavian or brachiocephalic vein immediately proximal to the stenosis. Generally 
balloon diameters between 10 and 20mm were required. If a balloon diameter >20mm was 
required a larger sheath was first inserted.  
 
In the event that stenting was required, a standard Wallstent (Boston Scientific, Boston, 
MA, USA) or Viabahn (W.L. Gore Associates, Flagstaff, AZ) was used. The stent was 
oversized by 10-20% compared to the normal vessel to prevent migration. Balloon 
angioplasty of the stent was employed after deployment.  
 
3.2.3.2. Prosthetic thigh grafts 
 
In this study, mid-thigh loop grafts were performed under general anaesthesia. An 8-10cm 
diagonal incision was placed on the medial aspect of the right thigh at the anterior border 
of the sartorius muscle. The sub-sartorial femoral vein and superficial femoral artery were 
exposed and controlled. A separate small incision was made laterally to permit tunnelling 
of the graft. Both standard and early cannulation PTFE grafts were used at the discretion of 
the operating surgeon. An arteriotomy and venotomy were made on the superficial femoral 
artery and femoral vein respectively. End-to side anastomoses were performed with or 
without Miller cuffs. Vancomycin was routinely used as antibiotic prophylaxis. 
 
3.2.3.3. Native long saphenous vein thigh loops 
 
Under general anaesthesia, and again after vancomycin antibiotic prophylaxis, the long 
saphenous vein was mobilised through a series of incisions in the leg and divided distally. 
The common femoral artery was mobilised and controlled. A longitudinal arteriotomy was 
performed. The vein was brought through a subcutaneous loop tunnel and then an end-to-
side anastomosis of long saphenous vein to common femoral artery was performed. 
 
3.2.3.4. Tunnelled femoral catheters 
 
Catheters were inserted under local anaesthesia with ultrasound-guidance. A short 
subcutaneous tunnel was created. The common femoral vein was cannulated with the 
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micropuncture needle and a Seldinger technique used to insert a 16F Split AshCath® 
(MedComp, Harleysville, PA, USA) catheter.  
 
Our standard catheter care protocol was employed throughout the observation period. This 
demanded complete sterile precautions during catheter insertion and upon manipulation of 
the hub. Following catheter hub manipulation, the skin surrounding the insertion site was 
soaked with chlorhexidine solution prior to a sterile dressing being applied. An 
interdialytic lock with heparin 5,000iU/ml to the internal volume of the catheter was 
employed. 
 
3.2.3.5. Tunnelled translumbar catheters 
 
Catheters were inserted into the inferior vena cava (IVC) under local anaesthesia and 
moderate sedation with fluoroscopic guidance. The common femoral vein was punctured 
to permit guidewire insertion as a fluoroscopic target. A micropuncture needle was then 
used to gain access to the IVC and a Seldinger technique used to insert a 14F Translumbar 
AshSplitCath® (MedComp, Harleysville, PA, USA). The exit site was tunnelled across the 
lumbar region.  
 
3.2.3.6. Peritoneal dialysis 
 
Under general anaesthesia a 5-7cm mini-laparotomy was performed and a 15F Curl Cath®  
(Covidien, Dublin, Ireland) peritoneal dialysis catheter was inserted into the peritoneum. 
The laparotomy wound was closed and use of the catheter delayed for 7-10 days. 
Intravenous antibiotic prophylaxis was given. 
 
3.2.3.7. Haemodialysis reliable outflow (HeRO) device 
 
The HeRO device (Hemosphere Inc., Minneapolis, MN, USA) is a standard 6mm ePTFE 
graft attached to a 5mm nitinol-reinforced silicon outflow component. The outflow 
component was inserted under radiographic screening by an interventional radiologist in a 
similar fashion to a standard TCVC. The tip of the outflow component was placed in the 
right atrium and position confirmed radiologically. The inflow component/ graft was 
routinely replaced with Gore®ACUSEAL (W.L. Gore Associates, Flagstaff, AZ, USA) 
6mm graft to permit early cannulation. This was anastomosed end-to side to the brachial 
artery and tunnelled in the standard fashion to a separate incision at the deltopectoral 
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groove. The two components are then brought together at this counter incision with a 
titanium connector as is described by Katzman and colleagues (2009). 
 
 3.2.3.8. Priority allocation of renal transplants from donation after circulatory death 
(DCD) donors 
 
In the United Kingdom, cadaveric kidneys are allocated for transplantation according to 
the National Health Service Blood and Transplant (NHS-BT) Deceased Donor Organ 
Allocation Policy (Kidney Advisory Group, 2016). This complex matching algorithm 
attempts to provide equity of access to renal transplantation by prioritising based on factors 
such as waiting time, HLA-match, blood group and age difference.  The median waiting 
time for a deceased donor kidney transplant is 3 years via this system (Hudson & Curnow, 
2013). 
 
Locally we recognised that there was a small cohort of patients with precarious vascular 
access whose lives were threatened by potential access loss and were likely to require 
transplantation more quickly than could be provided via the NHS-BT Deceased Donor 
Organ Allocation Policy. A strategy was devised within our unit for prioritise allocation of 
certain cadaveric kidneys to patients with failing vascular access. We describe our early 
(four year) experience with this approach. 
 
Cadaveric kidneys donated after circulatory death (DCD) in the UK were, at the time of 
this study, allocated locally. Individual transplant units could allocate these kidneys to 
recipients based on local policies. Generally units choose to allocate such kidneys similarly 
to donation after brain death (DBD) kidneys, based on the national matching scheme. 
However within our unit it was agreed that patients with ESVA would be given priority to 
receive DCD kidneys if blood group compatible and cytotoxic (CDC) cross-match 
negative. Such patients were offered the first suitable available kidney. The full details of 
this strategy are described in more detail below. 
 
3.2.4.  Data analysis 
 
Patient demographics, presenting symptoms and risk factors for CVS were evaluated. 
Thereafter, the aim of data analysis was four-fold. Firstly to define and describe a 
“standard” CVS patient pathway; secondly to outline the success of individual treatment 
strategies for CVS; thirdly to describe the personal burden in terms of quality of life, 
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hospitalisation etc. for patients living with CVS; and finally to describe the financial cost 
of CVS. The success of individual access modalities (prosthetic thigh grafts, native long 
saphenous vein thigh loops, tunnelled femoral catheters, tunnelled translumbar catheters, 
peritoneal dialysis). in patients with ESVA was considered separately, as was the role of 
expedited renal transplantation. 
 
3.2.5.  Statistical analysis 
 
Statistical analysis was undertaken using SPSS Statistics for Windows Version 19.0 (IBM 
Corp., Armonk, NY, USA). Continuous data is presented as mean and standard deviation 
(SD). Categorical data is presented as median and interquartile range (IQR) or as a 
percentage of the total population. Event rates are presented per 1,000 dialysis days. 
Primary, primary-assisted and secondary patency rates at 3, 6 and 12 months for each RRT 
modality/access are provided. Vascular access/ RRT modality was recorded as a 
percentage of the total population at 6 monthly intervals from the time of diagnosis. 
Parametric testing with student’s t-test and non-parametric testing with Mann-Whitney U-
test were used in the assessment of continuous variables, while catergorical variables were 
assessed using Pearson chi-squared test. Kaplan Meier survival analysis was used to 
compare patencies for the various access modalities (log-rank). Finally, multivariate 
analysis of all patients undergoing TCVC insertion was performed using a Cox-
proportional hazards model with stepwise conditional entry to test for independent risk 
factors for the development of central vein stenosis. Linearity and normal distribution of 
the relationship between TCVC insertion and the occurrence of CVS were evaluated and 
confirmed. Variables with  P<0.1 on univariate analysis were considered for entry to 
multivariate analysis. P<0.05 on multivariate analysis was considered significant.  
 
Healthcare costs were estimated from hospital practice and unit costs were taken from 
Personal Social Service Research Unit (PSSRU5) figures, NHS Reference Costs, 2013-
2014) and published literature (Curtis, 2012; Hockenhull et al. 2008; Department of 
Health, 2015). All costs are quoted in pounds Sterling (£).  Healthcare costs in each of the 
first three years following diagnosis were calculated, both for the individual patient and the 
overall population of patients with CVS treated locally. Healthcare costs were combined 
with EQ-5D data to calculate the cost per quality adjusted life year (cost per QALY) in 
patients with quality of life data available, using the National Institute of Clinical 
Excellence (2014) framework. The cost-per QALY represented the cost of the treatment 
philosophy, rather than a specific intervention. 
 113 
3.2.6.  Expedited renal transplantation 
 
The West of Scotland Renal Transplant Unit, based at the Western Infirmary, Glasgow, 
serves a population of approximately 2.6 million people. There are approximately 230 
patients active on the renal transplant waiting list. 152 renal transplants were performed at 
our institution last year (April 2015-March 2016) (NHS Blood and Transplant, 2016). 
 
On 1st January 2011, our centre implemented a strategy of “expedited renal 
transplantation” for patients with ESVA. At the time, a policy of local allocation of all 
DCD kidneys existed within the UK. This permitted individual transplant centres to choose 
‘the most appropriate means of allocating [DCD] kidneys to patients on their lists’  
(Kidney Advisory Group, 2014a, pp.1) and determine locally which patient received the 
offer of a DCD kidney outwith the national matching algorithm. (Since then the policy has 
been revised so that one of the two DCD kidneys is retained locally and the other offered 
regionally for donors aged 5-50 years old) (Kidney Advisory Group, 2016).  
 
It was agreed that patients with failing vascular access should be prioritised above all 
others to receive DCD kidneys from donors ≥ 50 years old or with other adverse 
prognostic features (e.g. prolonged cold ischaemic time (CIT) or poor perfusion) or tier E 
DBD kidneys retained at the local centre after failure to find another named recipient (as 
advised by NHS-BT)). ESVA was defined as bilateral central venous occlusion, failed or 
contraindication to peritoneal dialysis and survival deemed by the MDT to be <1 year on 
haemodialysis as a result of predicted access failure.  
 
The clinical team of nephrologists and vascular access surgeons identified potentially 
eligible patients. All patients were discussed at our monthly Renal Transplant MDT 
Meeting comprised of nephrologists, transplant surgeons, vascular access surgeons, 
dialysis and transplant nurses and transplant coordinators and a consensus decision was 
reached as to whether the patient fulfilled the criteria to be listed for priority/ expedited 
transplantation. If deemed suitable, the patient was approached and the concept of the 
priority waiting list explained to them. If agreeable, the patient’s name was added to a 
“priority transplant” waiting list held by the Histocompatibility and Immunogenetics 
Department responsible for tissue typing and crossmatching. The clinical team identified 
suitable donors and a crossmatch was performed for any blood group compatible 
donor/recipient pair.  
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Prior to implementation of the strategy, it was discussed locally at the Multidisciplinary 
Team Meeting and all satellite and feeder units were written to advising them of the 
allocation policy and rationale. Stakeholders were encouraged to respond and unanimous 
agreement regarding the policy was reached prior to its implementation. Nephrologists in 
feeding units were also encouraged to identify and bring to MDT any patient that they 
thought might be eligible or benefit from the new allocation strategy. 
 
Basic demographic data was collected for both donor and recipient e.g. age, sex, cause of 
renal failure, vascular access history, waiting time, cRF (calculated reactive frequency), 
type of donor, cause of death. Additional data on specific aspects of the transplant, for 
example immunology (mismatch, match score, match points, immunosuppression) and 
technical/ anatomical challenges and difficulties was also collected. The match score is a 
hypothetical score calculated by NHS-BT based on recipient HLA-type and blood group (it 
reflects the number of patients out of a standard cohort of 10,000 patients who are blood 
group identical, HLA-compatible and 000 or favourably [100, 010, 110] matched). Match 
points convert the match score into a points score for the matching algorithm based on ease 
of transplantation (Kidney Advisory Group, 2016).  A standard post-Symphony 
immunosuppressive strategy (Ekberg et al. 2007) with tacrolimus, mycophenolate and 
prednisolone was employed for all patients. Basiliximab (20mg day 0, day 4) was the 
standard induction agent. Anti-thymocyte globulin (ATG) induction (2mg/kg day 0, day 4) 
was considered for patients deemed to be of higher immunological risk (cRF >90% and/or 
pre-formed donor specific antibody (DSA)) in the absence of contraindication. Outcome 
measures include delayed graft function (DGF), biopsy-proven acute rejection (BPAR), 
primary non-function, 1-year graft and patient survival, estimated glomerular filtration rate 
(eGFR) at 6 and 12 months, in-patient bed days and number of admissions. Additionally a 
“chance of transplant” at 1, 2, 3, 4 and 5 years was calculated from the NHS-BT Chance of 
Transplant Calculator (NHS Blood and Transplant, 2014). This online calculator uses 
patient age, ethnicity, blood group and immunological profile to predict the likelihood of 
receiving a cadaveric kidney transplant through the national matching algorithm. 
 
Patients with ESVA receiving a priority allocated kidney were compared to (where 
appropriate) one of: the entire cohort of patients receiving a renal transplant at our 
institution over the same time period (n=452) (1st January 2011-31st December 2014); 
patients with ESVA transplanted via the national matching algorithm over the same time 
period (n=6); or an age and sex-matched control cohort (n=18). All patients were followed 
up for 1 year post-transplant. 
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Results for this patient cohort are presented as either mean (SD), median (IQR) or as a 
percentage of the total population. Continuous data were compared using either student’s t-
test or one-way analysis of variance (ANOVA). Categorical data were compared using chi-
squared or Fischer’s exact text. P<0.05 is considered statistically significant. 
 
3.3.  RESULTS 
 
3.3.1.  Patient demographics 
 
155 of the 1,192 patients on haemodialysis in the West of Scotland between 1st January 
2011 and 31st December 2014 were identified as having symptomatic CVS, giving a period 
prevalence of 13.0%. Mean patient age was 59.0 years (range: 17-93) (Table 3.1). Most 
patients had multiple preceding TCVCs (median 3; IQR 2,6), however there was one 
patient who developed symptomatic CVS after only 4 days with a single left internal 
jugular non-dialysis CVC 12 years previously.  
Table 3.1: Patient demographics of the central vein stenosis population. Results are 
presented as mean (SD) or percentage of total. ††Vasculitides include vasculitis, systemic 
lupus erythematosus (SLE)/ scleroderma and Henoch-Schönlein purpura (HSP) 
 
Characteristic 
 
Value 
Age (years) 
 
59.02 (15.72) 
Male 
 
56.1% 
Cause of Renal Failure 
Glomerulonephritis 
APKD 
Unknown 
Pyelonephritis 
Hypertensive disease 
Diabetic nephropathy 
IgA nephropathy 
Renovascular disease 
Vasculitides†† 
Unknown 
Other 
 
                                
11.2% 
8.0% 
21.0% 
5.4% 
5.2% 
19.0% 
6.4% 
6.8% 
3.2% 
21.0% 
12.0% 
Diabetes mellitus 
 
31.8%  
Cardiac event 
 
 49.6%  
Length of time on haemodialysis (days) 
 
1712.41 (77.457) 
Number of previous lines 
1 
2-4 
5-7 
8-10 
11+ 
 
32.8% 
45.2% 
14.2% 
4.4% 
3.4%  
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60% (n=93) of patients had unilateral stenosis, with 62% of these being left sided. 40% 
(n=62) of patients had bilateral or caval stenosis/occlusion. In patients with unilateral CVS 
41% affected the subclavian vein; 9% affected the subclavian/ brachiocephalic junction; 
35% affected the brachiocephalic vein and 15% affected the brachiocephalic/ caval 
junction. In patients with bilateral CVS 12% had lesions in both subclavian veins; 20% had 
lesions in both brachiocephalic veins; 32% had a lesion in the superior vena cava and 36% 
had lesions at multiple sites. 
 
The predominant clinical presentation was of vascular access loss rather than limb or facial 
swelling. Isolated facial or arm swelling only occurred in 8% of patients (n=12).  36% of 
patients (n=59) presented with loss of autologous vascular access and a further 32% (n=50) 
presented with a dysfunctional AVF in isolation. A further 32% (n=50) presented with 
both access loss/ dysfunction and arm/facial swelling. 
 
3.3.2.  Risk factors for central vein stenosis 
 
23.6% of TCVCs (n=118) inserted between 1st January 2008 and 22nd October 2011 
resulted in the development of CVS (median follow-up: 1,967 ± 567 days). Central vein 
stenosis was an inevitable consequence of any TCVC not removed for alternative reason 
e.g. bacteraemia or alternative access. Table 3.2 outlines risk factors for the development 
of CVS.  Number of line days (OR 1.02, p=0.003), age (OR 1.04, p=0.04) and culture-
proven line infection (OR 0.59, p=0.014) were all independently associated with CVS on 
multivariate analysis. (Table 3.3). 
 
3.3.3.  The patient pathway and access status 
 
Patients experienced frequent intervention and hospitalisation beginning soon after the 
time of diagnosis and increasing exponentially over the subsequent three years. Table 3.4 
describes interventions and hospitalisations and their associated healthcare costs during the 
first 3 years after diagnosis. A high number of TCVC insertions are required despite 
concurrent attempts to maintain vascular access through central vein angioplasty and 
creation of alternative vascular access.  
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Table 3.2: Risk factors for central vein stenosis. †Early infection is culture-proven 
bacteraemia within 90 days of line insertion. ††Vasculitides include vasculitis, systemic 
lupus erythematosus (SLE)/ scleroderma and Henoch-Schönlein purpura (HSP). * <0.001 
comparing vasculitides in isolation. 
 
Risk Factor Central Vein 
Stenosis 
 
No central vein 
stenosis 
P 
value 
Age (years) 
 
54.8 (1.3) 61.9 (1.2) 0.001 
Male  
 
51.6% 48.9% NS 
Cause of Renal Failure 
Glomerulonephritis 
APKD 
Unknown 
Pyelonephritis 
Hypertensive disease 
Diabetic nephropathy 
IgA nephropathy 
Renovascular disease 
Vasculitides†† 
Unknown 
Other 
 
 
17.9% (n=10) 
20.0% (n=8) 
15.2% (n=16) 
18.5% (n=5) 
19.2% (n=5) 
20.8% (n=20) 
18.7% (n=6) 
17.6% (n=6) 
75% (n=12)* 
15.2% (n=16) 
23.3% (n=14) 
 
82.1% (n=46) 
80.0% (n=32) 
84.8% (n=89) 
81.5% (n=22) 
80.8% (n=21) 
79.2% (n=76) 
82.3% (n=24) 
82.4% (n=28) 
25.0% (n=4) 
84.8% (n=89) 
76.7% (n=46) 
 
NS 
Diabetes mellitus 
 
30.5%  (n=36) 24.1% (n=92) 0.17 
Cardiac event 
 
47.5% (n=56) 50.0% (n=191) NS 
Mean number of lines 
 
5.4 (2.3) 2.9(1.7) <0.001 
Number of line days 
 
1488.7(135.2) 1268.4 (103.4) <0.001 
Length of time on HD (days) 
 
2313.7 (189.6) 1677.75(129.2)* <0.001 
Culture-proven bacteraemia rate 
 
2.6 (1.4) 2.35 (0.5) NS 
Early infection† 
 
22.8% 5.9% <0.001 
   
Table 3.3: Logistic regression analysis for risk factors of central vein stenosis. 
 
 B 
 
SEM P-value Odds ratio (95% CI) 
Age 
 
0.21 0.007 0.003 1.02 (1.00, 1.03) 
Length of time on 
haemodialysis 
 
0.00 0.00 0.26 1.04 (1.04,1.04) 
Number of line days 
 
0.00 0.00 0.04 1.04 (1.04,1.04) 
Culture proven infection 
 
-0.56 0.23 0.014 0.59 (0.37,0.93) 
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Table 3.4: Number of interventions per patient per annum and estimated cost per 
patient and overall to the local service. Costs estimates reflect both the costs of the 
interventions and additional bed days. *  Healthcare costs were estimated from hospital 
practice and unit costs were taken from Personal Social Service Research Unit (PSSRU5) 
figures, NHS Reference Costs, 2013-2014 and published literature (Curtis, 2012; 
Hockenhull et al. 2008; Department of Health, 2015).  
Intervention Year 1 
(n=155) 
Year 2 
(n=102) 
Year 3 
(n=93) 
Cost per 
procedure* 
Total Per 
Patient 
Total Per 
Patient 
Total Per 
Patient 
TCVC 208 1.34 105 1.13 70 1.2 £614 
Angioplasty 93 0.59 48 0.51 30 0.51 £2 882 
Angiogram  27 0.18 19 0.2 19 0.32 £2 389 
Central Venous 
Stent 
13 0.08 0 0 1 0.02 £3 829 
AVF 
Creation/Ligation 
56 0.36 14 0.15 0 0 £1 368 
Endovascular 
Declot 
45 0.28 30 0.32 0 0 £2 769 
Surgical Declot 30 0.09 0 0 0 0 £1 368 
Thigh/Arm Graft 30 0.19 22 0.24 18 0.29 £1 998 
Peritoneal 
Dialysis Catheter 
3 0.02 1 0.02 1 0.02 £1 366 
Translumbar 
Line 
3 0.02 13 0.13 19 0.3 £720 
Additional bed 
days 
1391.6 8.9 741.8 8.0 681.9 12.5 £1 865 
Total Costs (£) 3.6m 22k 1.8m 19k 1.6m 27k  
  
Patients required frequent intervention, with a mean of 3.87 interventions per patient in the 
first year of diagnosis. Frequent hospitalisation also featured, with patients accruing 
between 8 and 12 bed days per year per patient in addition to those required for specific 
interventions. For those with bilateral central vein stenosis, the requirement of intervention 
and hospitalisation was significantly higher. Patients with unilateral central vein stenosis 
utilised a mean 6.2 (2.3) bed days per annum in the first year after diagnoses; 3.2 (3.4) in 
the second year; and 6.9 (2.3) in the third year. Patients with bilateral central vein stenosis 
utilised 11.3 (3.4) bed days per annum. This was consistent across all of the first three 
years after diagnosis. In the first year following diagnosis patients with unilateral CVS had 
a mean of 2.9 (1.6) interventions/ year to maintain vascular access; in the second year this 
reduced to 1.2 (0.9) interventions per year. There were no interventions in the unilateral 
cohort in the third year after diagnosis. In the bilateral CVS cohort, the number of 
interventions/ year was: 4.0 (1.9), 3.2(1.5), 3.9 (2.3) for years 1,2 and 3 respectively. 
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The primary vascular access for haemodialysis changed as time passed following the 
diagnosis of CVS (Figure 3.1). 12 months following diagnosis, 29% (n=45) of the patents 
were dialysising via their AVF and 54% (n=81) were dialysing via TCVC. Conversely by 
5 years following diagnosis, only 13% (n=20) of patients were using an AVF and 24% 
(n=37) were using a femoral line for dialysis. The majority of the cohort was utilising/ had 
utilised one or more complex forms of vascular access. 17% (n=26) of patients had died by 
5-year follow-up and a further 18% (n=28) were transplanted. 
 
 
Figure 3.1: Vascular access/ RRT modality utilised by patients with CVS at 6 
monthly intervals following diagnosis. 
 
 
3.3.4.  Economic cost of central vein stenosis 
 
The crude costs for managing patients with CVS are outlined in Table 3.4. The average 
annual cost/ patient to treat CVS in this cohort was £27 000 in year 3 of diagnosis. 
Bilateral CVS incurs significant more annual cost than unilateral stenosis, escalating on an 
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annual basis as maintaining vascular access becomes more problematic (£22 500, £24 000 
and £28 000 for bilateral in year 1, 2 and 3 respectively compared to £17 500, £8 000 and 
£15 500 for unilateral). 
 
3.3.5.  Personal cost of central vein stenosis 
 
Quality of life data was collected on 120 patients with CVS (77.4%). 1 year follow-up data 
was collected on all patients who completed initial EQ-5D questionnaires.  
 
Median EQ-5D quality of life scores at baseline were as follows: mobility 2 (IQR 2,4), 
self-care 2 (IQR 1,3), usual activities 2 (IQR 2,4), anxiety/ depression 2 (IQR 2,4), pain 3 
(IQR 2,5). There was a significant increase in two domains of the EQ-5D score at 1 year:  
anxiety/ depression 4 (IQR 3,5) (P<0.01) and usual activities 3 (IQR 3,4) (P<0.01). There 
was no significant difference in the other three domains of the EQ-5D score after 1 year. 
 
For ease of analysis, the EQ-5D score was also used to calculate a mean QoL score at 0, 6 
and 12 months. These were 0.557, 0.484 and 0.448 respectively. (By comparison, patients 
established on haemodialysis generally have EQ5D/L scores between 0.6 and 0.7 in the 
first year of diagnosis (Manns et al. 2003))  
 
The cost-per-QALY of maintaining vascular access in the first year of diagnosis of central 
vein stenosis equates to £42 308.  
 
3.3.6.  Outcomes in patients with bilateral central venous occlusion and end-stage 
vascular access 
 
Sixty-two patients had evidence of bilateral CVS with loss of upper limb access at some 
point during the follow-up period. These patients were considered to have “end stage” 
vascular access and have been evaluated separately from the overall cohort. These patients 
reflect 40% of the overall CVS population and 5.2% of the entire dialysis population. 
 
155 procedures for RRT access were performed on the 67 patients with ESVA during a 
four-year follow-up period, including 62 tunnelled femoral catheters in 36 patients and 25 
prosthetic thigh grafts in 21 patients (Table 3.5). Table 3.6 outlines the basic demographics 
for each group. All but two of these patients had undergone previous attempts to salvage 
upper limb access with cutting balloon angioplasty ± stenting of the central veins. 
Access modality Total 
number of 
procedures 
Total number of 
patients receiving 
this access modality 
Number of patients 
receiving access 
modality as first access 
Number of patients 
receiving access modality 
as second access 
Number of patients 
receiving access modality as 
third access 
Number of patients 
receiving access modality 
as fourth access 
Tunnelled femoral 
catheter 
62 36 29 6 1  
Tunnelled 
translumbar 
catheter 
25 23 14 9   
Long saphenous 
vein loop 
15 13 9 3 1  
HeRO 6 6 0 2 4 0 
Prosthetic thigh 
graft 
25 21 10 6 2 4 
Peritoneal dialysis 8 8 0 2 3 3 
Renal transplant 18 18 0 5 8 5 
 
Table 3.5: Numbers of procedures to achieve access for RRT performed on patients with end stage vascular access.  
 
 Tunnelled 
femoral 
catheter (n=36) 
Translumbar 
catheter 
(n=23) 
Long saphenous 
vein loop 
(n=13) 
HeRO 
(n=6) 
Prosthetic 
thigh graft 
(n=21) 
Peritoneal 
dialysis 
(n=8) 
Renal 
transplant 
(n=18) 
P-value 
Age (years) 65.5 (6.5) 62.3 (6.3) 53.4 (7.9) 49.6 (6.5) 58.7 (8.7) 62.3 (6.7) 44.6 (9.3) 0.04 
Sex (percentage male) 50% 52.2% 53.8% 50% 47.6% 50% 44.4% 0.87 
Time on haemodialysis (years) 5.7 (3.1) 4.8 (3.2) 6.5 (4.6) 5.8 (6.8) 4.9 (2.8) 5.1 (3.2) 12.3 (5.6) <0.01 
Number of previous TCVCs (subclavian/ internal 
jugular)* 
3 (1,8) 3 (1,6) 4 (2,7) 5 (3,7) 3 (2,5) 2 (1,4) 4 (2,10) 0.53 
Number of previous upper limb AVF attempts* 2 (1,3) 2 (1,3) 3 (2,4) 3 (1,4) 3 (1,4) 3 (1,4) 3 (1,4) 0.65 
Percentage of patients with at least 3 previous 
upper limb AVF attempts 
16.7% 17.4% 23.1% 45.3% 28.1% 25% 36.3% <0.01 
Number of previous attempts at complex 
procedures for end-stage vascular access** 
2 (1,5) 3 (1,5) 3 (1,6) 2 (1,4) 2 (1,4) 3 (1,6) 3 (2,6) 0.67 
 
Table 3.6: Demographics of patients with end stage vascular access. Results presented as mean (SD) unless otherwise stated. * Number of previous 
upper limb AVF attempts and previous TCVCs is presented as median (IQR/ range); **Complex procedures for end-stage vascular access are those 
outlined in this paper (long saphenous vein loops, mid-thigh prosthetic grafts; femoral vein catheters; translumbar lines; HeRO).
The ultimate choice of access modality was made by the multidisciplinary vascular access 
team after discussion between patient, nephrologist, vascular access surgeon and 
interventional radiologist, taking into account patient choice, co-morbidities, and 
anatomical/ technical factors. Most patients tried more than one of the access modalities 
during the follow-up period (41 patients (67.2%) tried two and 10 patients (16.4%) tried 
three). 16 patients (26.2%) were unfit for thigh grafts and 42 patients (68.9%) were unfit 
for consideration of transplantation due to co-morbidities. 3 patients (4.9%) had 
contraindications to peritoneal dialysis (previous abdominal surgery or severe peritonitis). 
Mean follow-up time was 1,202 ±120 days per patient. Long-term secondary patency of 
each access/ RRT modality option is illustrated in Figure 3.2. Overall no access modality 
was superior to another (P=0.57) at 12 month follow-up, however the analysis is limited by 
lack of follow-up beyond two years for patients in the HeRO groups. Native long 
saphenous vein (LSV) loops had better secondary patency at 900 days (76.9%) than 
prosthetic thigh grafts (49.2%) or tunnelled femoral catheters (35.8%) (p<0.01), however 
there was a rapid decline in long saphenous vein loop patency beyond 900 days. 
 
 
Number at risk 0 days 200 days 400 days 600 days 800 days 1000 days 
Tunnelled femoral vein 
catheter 
62 17 4 3 3 3 
Tunnelled translumbar catheter 25 14 12 8 4 3 
Prosthetic thigh graft 25 8 5 2 2 2 
Native long saphenous vein 
loop 
17 9 7 4 4 4 
HeRO 6 4 4 0 0 0 
Renal transplant 18 14 11 9 8 6 
Peritoneal dialysis 8 7 6 4 4 2 
 
Figure 3.2:Kaplan Meier survival curve outlining long-term patency/ durability of 
each of the access modalities. There was no difference in the long-term secondary 
patency with any of the access modalities (P=0.57). 
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Primary, primary-assisted and secondary patency rates at 3, 6 and 12 months for each of 
the modalities are shown in Table 3.7. Tunnelled catheters had acceptable 3 month primary 
and secondary patency rates, however this was poorer in the long-term. Whilst short-term 
primary patency rates of thigh grafts were poorer, secondary patency of both prosthetic 
thigh grafts and native long saphenous vein grafts were better (41.7% and 77.8% 
respectively). The HeRO device had a 1-year primary, primary assisted and secondary 
patency rate of 66%. 
 
Infective complications are outlined in Table 3.8. Culture proven bacteraemia rate was 
highest in patients with tunnelled femoral catheters (1.8 per 1,000 catheter days) and 
peritoneal dialysis (2.0 per 1,000 dialysis days) in this patient population. There was no 
culture proven bacteraemia in patients with native long saphenous vein loops, however two 
patients did develop local infections at needling sites. Similarly the culture proven 
bacteraemia rate from prosthetic thigh loop grafts was 1.6 per 1,000 dialysis days, however 
5 of 25 grafts (20%) also developed local infection without systemic sepsis. 
 
Patients with femoral tunnelled central venous catheters (7.2 per patient/ year) and 
prosthetic thigh grafts (6.5 per patient/ year) required significantly more additional hospital 
days as a result of access (or transplant) related complications than the other access 
modalities (P<0.05). 12 patients died during the follow-up period, none as a result of loss 
of vascular access (3 cardiac events, 3 complications of peripheral vascular disease, 2 chest 
sepsis, 2 line sepsis, 1 diabetic hypoglycaemia, 1 pulmonary thromboembolism). 
 
3.3.7.  Expedited renal transplantation 
 
24 of the 62 patients (38.7%) with ESVA were deemed to be eligible and fit for renal 
transplantation by their referring nephrologist. After discussion at the Renal 
Transplantation MDT meeting, 22 patients were deemed suitable for the “urgent” waiting 
list. 18 patients (81.8%) were transplanted during the follow-up period (9 patients (50%) 
via the “urgent” waiting list, 6 patients (33%) via the national waiting list and 3 patients 
(16.7%) received expedited live donor transplants). Two patients were removed from the 
waiting list as they became unfit for transplantation and two patients remain actively 
awaiting an “urgent” renal transplant (Figure 3.3). 
 Tunnelled femoral 
catheter 
 
Translumbar 
catheter 
Long saphenous 
vein loop 
Prosthetic thigh 
graft 
HeRO Peritoneal  
Dialysis 
Renal 
transplant 
Primary patency 
3 months 
6 months 
12 months 
 
 
75.4% 
48.1% 
24% 
 
88% 
65% 
50% 
 
87.5% 
60% 
44.4% 
 
64% 
38% 
23.5% 
 
83.3% 
66.6% 
66.6% 
 
62.5% 
62.5% 
50% 
 
72.7% 
72.7% 
72.7% 
Primary assisted patency 
3 months 
6 months 
12 months 
 
 
75.4% 
60% 
28% 
 
88% 
65% 
50% 
 
87.5% 
80% 
56.5% 
 
64% 
38% 
23.5% 
 
83.3% 
66.6% 
66.6% 
 
62.5% 
62.5% 
50% 
 
72.7% 
72.7% 
72.7% 
Secondary patency 
3 months 
6 months 
12 months 
 
 
75.4% 
60% 
28% 
 
88% 
65% 
50% 
 
87.5% 
80% 
77.8% 
 
72% 
52.4% 
41.7% 
 
83.3% 
66.6% 
66.6% 
 
62.5% 
62.5% 
50% 
 
72.7% 
72.7% 
72.7% 
 
Table 3.7: Primary, primary assisted and secondary patency of each of access modalities at 3, 6 and 12 months in patients with end-stage 
vascular access 
 
 Tunnelled 
femoral catheter 
Translumbar 
catheter 
Long saphenous 
vein loop 
Prosthetic 
thigh graft 
HeRO Peritoneal 
dialysis 
Priority renal 
transplant 
P-value 
Culture proven bacteraemia rate 
(per 1,000 dialysis days) 
1.8 0.6 0 1.6 0 2.0 0.1 <0.05 
Additional bed days due to access 
related complications (per 
patient/year) 
7.2 2.6 3.2 6.5 3.2 4.3 3.3 <0.05 
 
Table 3.8: Access related complications in patients with end stage vascular access. Culture proven bacteraemia rate per 1,000 dialysis (or transplant) 
days and additional bed days (per patient/year) as a result of access related complications. 
  
 
 
Figure 3.3: Flow diagram describing fate of patients considered for “urgent” renal 
transplant waiting list. 24 patients were considered and 22 deemed suitable for listing. 2 
patients were subsequently removed from the waiting list as they became unfit. 18 patients 
were transplanted (9 via the “urgent” list, 6 via the national waiting list and 3 expedited 
live donor transplants (*one paired pool)). 2 patients remain active on the “urgent’ renal 
transplant waiting list. 
 
 
3.3.7.1. Demographics of ESVA patients considered for “urgent” transplantation 
 
Table 3.9 outlines the characteristics of each patient with ESVA undergoing 
transplantation. Each patient was unique in the anatomical, technical and immunological 
challenges that they posed. These are described in the table.
Identified by nephrology team and considered at MDT (n=24)
Medically unfit for transplantation (n=2)Suitable for wait listing for "urgent" renal transplantation (n=22)
Removed from waiting list as became unfit (n=2)Remained fit for transplantation (n=20)
Remain active on "urgent" waiting list (n=2)Expedited live donor transplantation (n=3)*Cadaveric transplantation via national waiting list (n=6)Transplanted via "urgent" waiting list (n=9)
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EXPEDITED TRANSPLANTS 
 
Recipient 
age (years) 
Recipient 
sex 
Current 
vascular 
access 
Vascular access 
history 
Donor 
type 
Donor 
age 
(years) 
Donor 
sex 
cRF Previous 
transplant 
Additional 
immunological 
comments 
Additional 
technical 
comments 
eGFR at 1 year 
(ml/min/1.73m2) 
Complications 
37 Male Femoral 
TCVC 
4 upper limb AVF; 2 
leg vein loops; 3 
lower limb AVGs; 
failed PD; 25 
TCVCs 
DBD 64 Female 100% 1 Positive B-cell 
CDC crossmatch; 
DSA at time of 
transplant, 
cumulative MFI 
28,000; ATG 
induction 
 13.3 Poor graft function; 
pulmonary thromboembolism 
and death 13 months post-
transplant (unable to obtain 
any vascular access to permit 
thrombolysis) 
45 Female Femoral 
TCVC 
3 upper limb AVF; 1 
leg vein loop; 1 
lower limb AVG; 14 
TCVCs; unsuitable 
for PD 
DCD 25 Male 95% 1 Weak DSA at 
time of transplant 
(MFI 1700); 
multiple 
mismatches with 
previous 
transplant; 
basiliximab 
induction 
Donor AKI 
(creatinine 
approx. 300 
at time of 
transplant) 
47  
42 Female Femoral 
TCVC 
3 upper limb AVF; 6 
TCVCs 
DCD 41 Female 22% 2 Basiliximab 
induction 
Long CIT (20 
hours); poor 
perfusion; 
previously 
turned down 
by several 
other units 
80.2  
54 Female Thigh AVG 
with ruptured 
pseudo-
aneurysm 
2 upper limb AVF; 
failed PD; 8 
TCVCs; 1 thigh 
AVG with ruptured 
pseudo-aneurysm on 
day of transplant 
DCD 39 Female 48% 0 Basiliximab 
induction 
Long CIT 
(16.5 hours) 
71  
57 Male Thigh AVG 18 TCVCs; 1 upper 
limb AVF; 
unsuitable for PD 
DCD 
(dual) 
66 Male 0% 0 Basiliximab 
induction 
Donor 
hypertension 
(3 agents), 
diabetes and 
CKD; dual 
transplant 
54 Transplant renal artery 
stenosis; thigh graft ligated 
post-transplant for steal. 
46 Female LSV loop  12 TCVCs, 3 upper 
limb AVF, 2 LSV 
loops, failed PD 
DCD 50 Female 99% 1 Basiliximab 
induction 
3 arteries 57.6  
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62 Female Thigh AVG 26 TCVCs, 3 upper 
limb AVF; APKD; 
unsuitable for PD 
DCD 60 Male 58% 0 Weak DSA at 
time of transplant 
(MFI 1300). ATG 
induction 
 NA Complicated by PRES and 
sepsis; CNI withdrawn, then 
got ABMR. Graft loss and 
death 5months post-
transplant 
30 Female Thigh AVG 
(recently 
revised for 
pseudo-
aneurysm) 
6 TCVCs, no native 
upper limb options 
(1 failed AVF); 1 
LSV loop; 1 thigh 
AVG (revised x2) 
DCD 55 Female 97% 1 Multiple weak 
DSA at time of 
transplant (total 
MFI 8000). ATG 
induction 
 73.7  
44 Male Thigh AVG 
(infected at 
time of 
transplant) 
15 TCVCs, 4 upper 
limb AVF, Failed 
PD 
DCD 62 Female 8% 0 Basiliximab 
induction 
 48.2 Infected thigh graft removed 
at time of transplant 
END-STAGE VASCULAR ACCESS PATIENTS TRANSPLANTED VIA NATIONAL MATCHING ALGORITHM 
 
42 Male Thigh AVG 16 TCVC, 3 upper 
limb AVF, LSV 
loop; thigh AVG; 
failed PD 
DBD 
(dual) 
3.5 Male 99% 1 No pre-formed 
DSA. ATG 
induction 
En-bloc 
transplant of 
paediatric 
kidneys; 
donor IVC 
and aorta to 
recipient 
external iliac 
vessels 
103.2 Thigh graft (ipsilateral) 
ligated intra-operatively to 
improve perfusion to 
transplant kidneys 
46 Male Subclavian 
TCVC 
(inserted after 
angioplasty) 
 
25 TCVC, 5 upper 
limb AVF, PPM, 
failed PD 
DBD 70 Female 91% 0 (previous 
heart 
transplant) 
No pre-formed 
DSA. ATG 
induction 
 28 Re-explored x3 for post-op 
bleeding (heparinized) 
54 Male Temporary 
femoral line 
3 upper limb AVF; 3 
thigh AVGs, 32 
TCVCs; failed PD 
DBD 71 Female 96% 1 Multiple pre-
formed weak DSA 
(cumulative MFI 
10000); historic 
positive B-cell 
flow crossmatch; 
ATG induction 
Iliac vessels 
completely 
occluded; 
donor renal 
artery and 
vein to 
recipient 
aorta and IVC 
 
NA Venous thrombosis; re-
explored day 3; graft loss and 
graft nephrectomy day 7 
40 Male BCF draining 
to collaterals 
2 upper limb AVF; 
thigh graft; 
subclavian to iliac 
graft 
DBD 66 Female 98% 0 Multiple pre-
formed DSA 
(cumulative MFI 
7300). ATG 
induction 
 
 NA Primary non-function; 
presumed ABMR; 
calciphylaxis and access loss; 
died 4 months post-transplant 
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44 Male LSV loop 4 upper limb AVF; 
24 TCVCs; 2 LSV 
loop; 2 thigh AVG 
DBD 64 Male 100% 1 No pre-formed 
DSA. 000 
mismatch. 
Basiliximab 
induction 
 24  
55 Female Femoral 
TCVC 
14 TCVCs, 2 upper 
limb AVF 
DCD 67 Female 40% 0 Weak DSA (MFI 
1000) 
 NA Wound infection and 
breakdown; Gram negative 
sepsis; immunosuppression 
stopped; ABMR; persistent 
life-threatening sepsis; graft 
nephrectomy after 1 month; 
died from sepsis 2 months 
after transplant 
ESVA PATIENTS HAVING LIVE DONOR TRANSPLANT 
 
25 Female BCF draining 
via collaterals 
2 upper limb 
AVF; failed PD 
LD 
(related) 
23 Male 98% 2 No pre-formed 
DSA. 000 
mismatch. 
Basiliximab 
induction 
 125.6  
41 Female Temporary 
femoral line 
2 upper limb 
AVF; 2 thigh 
AVGs 
LD 
(unrelated) 
45 Male 0% 0 Basiliximab 
induction 
Kidney 
transplanted 
onto iliac 
over femoral 
line as 
contralateral 
side not 
patent 
19 Graft loss after 15 months; 
ABMR secondary to non-
compliance 
39 Femoral  Subclavian 
(post-
angioplasty) 
32 TCVCs; 4 
upper limb 
AVF; failed PD 
LD (paired 
pool) 
52 Female 99% 1 No pre-formed 
DSA. Previous 
PTLD; 
basiliximab 
induction 
 36.7  
 
Table 3.9: Descriptive data summarising demographics and transplant details of all patients with ESVA. DBD= donation after brain death; DCD= 
donation after cardiac death; LD= live donor; PD= peritoneal dialysis; TCVC= tunnelled central venous catheter; AVF= arteriovenous fistula; AVG= 
arteriovenous graft; BCF=brachiocephalic fistula; LSV= long saphenous vein; IVC= inferior vena cava; PTLD= post-transplant lymphoproliferative 
disorder; PPM= permanent pacemaker; APKD= adult polycystic kidney disease; CKD= chronic kidney disease; ABMR= antibody mediated rejection; 
ATG= anti-thymocyte globulin; DSA= donor specific antibody; MFI= mean fluorescence intensity
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The mean age of patients with ESVA undergoing renal transplantation was comparable to 
that of the general transplant population (44.6 ±9.3 years vs. 48.8 ±12.9 years; P=0.65). 
There was also no significant difference in wait time prior to transplantation between 
patients with ESVA and the overall transplant cohort (1305.4 ± 925.5 days vs. 1168.2 
±675.4 days; P=0.15) (Table 3.10). Immunologically patients with ESVA were also more 
complex to transplant than the overall transplant cohort. 11 patients (61.1%) with ESVA 
had a cRF (calculated reactive frequency) >90%. Mean cRF and match score in the ESVA 
cohort and overall transplant population were 96% (IQR; 40%, 99%) vs. 32% (IQR: 24%, 
83%) and 12 (IQR 0,41) vs. 132 (IQR 67, 237); P<0.001 respectively. Patients with ESVA 
had been on dialysis for longer than the overall transplant cohort (12.3 ±5.6 vs. 3.7 ± 1.2 
years; P<0.001). 11 of the 18 patients (61.1%) were receiving a second or subsequent 
transplant and most were dialysing via either a TCVC or AVG at the time of 
transplantation (Table 3.10). 
 
Table 3.10: Basic demographics of patients with ESVA undergoing renal 
transplantation compared to a control group of all patients undergoing renal 
transplantation at our institution over the same time period. There was no significant 
difference in age or gender, however patients with ESVA were more likely to be dialysing 
via a TCVC or AVG rather than AVF and were also more highly sensitised and more 
difficult to transplant. Results are reported as either mean (SD) or median (IQR). AVF= 
arteriovenous fistula; AVG= arteriovenous graft; TCVC= tunnelled central venous 
catheter; cRF= calculated reaction frequency, match score= a hypothetical score calculated 
based on recipient HLA-type and blood group (it reflects the number of patients out of a 
standard cohort of 10,000 patients who are blood group identical, HLA-compatible and 
000 of favourably [100, 010, 110] matched); match points= converts the match score into a 
points score for the matching algorithm based on ease of transplantation.  
 Patients with ESVA 
undergoing renal 
transplant 
All renal transplants (n=452) P-value 
Age (years) 44.6 (9.3) 48.8 (12.9) N.S. 
Sex (%age male) 44.4% (n=8) 47.1% (n=213) 0.13 
Vascular access 
AVF 
AVG 
TCVC 
Temporary line 
 
22.2% (n=4) 
38.9% (n=7) 
33.3% (n=6) 
5.5% (n=1) 
 
74.1% (n=335) 
1.1% (n=5) 
24.8% (n=112) 
- 
 
 
 
 
<0.01 
cRF (%age) 96% (IQR 40%,99%) 32% (IQR 24%, 83%) 0.02 
Waiting time (days) 1305.4 (925.5) 1168.2 (675.4) 0.15 
Total time since first 
commencing dialysis 
(years) 
12.3 (5.6) 3.7 (1.2) <0.001 
Match score 12 (IQR 0,41) 132 (IQR 67,237) <0.001 
Match points 
Easy (1-3) 
Moderate (4-7) 
Difficult (8-10) 
 
22.2% (n=4) 
27.8% (n=5) 
50% (n=9) 
 
39.8% (n=180) 
44.7% (n=202) 
15.5% (n=70) 
 
 
 
<0.001 
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3.3.7.2. Outcomes of renal transplantation in patients with ESVA 
 
Patients with ESVA were more likely to experience delayed graft function (DGF) post-
transplant than the general population (44.4% vs. 24.7%; P<0.001). Primary non-function 
was also more common (11.1% vs. 1.1%; P<0.001) (Table 3.11). Not unsurprisingly, given 
the higher immunological risk that these patients pose, biopsy-proven acute rejection 
(BPAR) was also more common in the first year post-transplant (27.8% vs. 8.4%; 
P<0.001). Five patients with ESVA had BPAR on indication biopsy. One patient had been 
non-compliant with medication, three patients developed BPAR after immunosuppression 
was reduced or withdrawn as a result of other complications and one patient developed 
BPAR whilst on adequate immunosuppression (cell-mediated which responded well to 
intravenous methylprednisolone). One-year graft survival was lower in patients with 
ESVA (77.8% vs. 92.0%; P<0.001); however in those with a functioning graft at 1-year 
eGFR was comparable to that of the overall transplant population (62.0 ±13.4 vs. 58.4 
±20.9 ml/min/1.73m2; P=0.54) (Table 3.11). 1-year patient survival in the ESVA cohort 
undergoing transplantation was lower than in the overall transplant cohort (83.3% vs. 
95.1%; p<0.001) however this was higher than in the cohort of ESVA patients (n=45) 
during the same time period that did not get transplanted (P<0.01). In this cohort, one-year 
survival (from time of identification as having ESVA) was 68.9%, with one dying as a 
result of loss of access and inability to dialyse and the others dying from co-morbidities 
and complications of end-stage renal disease. 
 
Table 3.11: Outcomes of transplantation in patients with ESVA compared to the 
overall transplant cohort demonstrating higher rates of DGF, BPAR and primary 
non-function amongst patients with ESVA. One-year graft and patient survival was 
also lower, however in those patients with ESVA who had a functioning graft at 1 
year, the eGFR was comparable to that of the overall transplant population.   
 Patients with ESVA 
undergoing renal transplant 
All renal transplants P-value 
DGF (%age) 44.4% (n=8) 24.7% (n=112) <0.001 
BPAR in first year post-
transplant (%age) 
27.8% (n=5) 8.4% (n=38) <0.001 
Primary non-function (%age) 11.1% (n=2) 1.1% (n=5) 0.01 
eGFR at 6 months 
(ml/min/1.73m2) 
63.4 (14.5) 61.2 (15.4) N.S. 
eGFR at 12 months 
(ml/min/1.73m2) 
62.0 (13.4) 58.4 (20.9) N.S. 
1 year graft survival (%age) 77.8% (n=14) 92.0% (n=416) <0.001 
1 year patient survival 
(%age) 
83.3% (n=15) 95.1% (n=430) <0.001 
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3.3.7.3. Characteristics and outcomes of patients with ESVA receiving an expedited 
cadaveric renal transplant 
 
There was no significant difference in donor or recipient age between patients with ESVA 
receiving a transplant via the expedited list or national matching algorithm (46.3 ± 10.0 vs. 
46.8 ± 6.3 years; P=0.54 and 51.3 ± 14.2 vs. 56.9 ± 26.3; P=0.11 respectively) (Table 
3.12). All kidneys came from extended criteria donors in both cohorts. 88.9% (n=8) of the 
expedited transplants came from donation after cardiac death (DCD) donors, whilst most 
of those allocated from the national matching algorithm were donation after brain death 
(DBD) donors (83.3% [n=5]). There was also no significant difference in waiting time 
between patients with ESVA transplanted via the expedited list and national matching 
algorithm (1254.3 ±754.8 vs. 1403.4 ±403.4 days; P=0.26). 
 
There was no significant difference in the eGFR obtained at 12 months from kidneys 
allocated via the expedited list and those allocated via the national algorithm to patients 
with ESVA (65.8 ±23.2 vs. 56.9 ±26.3 ml/min/1.73m2; P=0.16). DGF was less common in 
patients transplanted via the expedited list (33% [n=3] vs. 100% [n=6]; P<0.001). There 
was no significant difference in 1-year patient survival (88.9% [n=8] vs. 66.7% [n=4]; 
P=0.09), however 1-year graft survival was better in the expedited transplant cohort than 
those transplanted via the national algorithm (88.9% [n=8] vs. 50% [n=3]; P=0.04) (Table 
3.12). 
 
3.3.7.4. Impact of transplantation of patients with ESVA on resource utilisation 
 
Table 3.13 compares the number of hospital admissions, bed days and interventions 
performed in patients with ESVA during the year prior to a following renal transplantation. 
Overall there were fewer hospital admissions following transplantation (6.5 ±1.6 vs. 2.4 
±2.7 days/ patient/ year; P<0.01) and patients spent less time hospitalised in the year after 
transplant than in the year before (21.3 ±12.3 vs. 11.6 ± 0.7 days/patient/year; P=0.02). 
This latter observation would be even more marked were it not heavily influenced by three 
patients who had very complicated and torrid post-operative courses with in-patient stays 
>3 months. Notably the mean length of hospital stay for the entire transplant population 
was 11.2 ± 3.2days/ patient in the first year post-transplant (P=0.72).  
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Table 3.12: Comparison of transplants carried out in patients with ESVA (expedited 
cadaveric; those allocated via national matching algorithm; and live donor). 
Recipient characteristics were comparable. Graft outcomes are at least comparable 
and may be better in the expedited cadaveric cohort than in those transplanted via 
the national matching algorithm. Results are reported as either mean (SD) or median 
(IQR). DBD= donation after brain death; DCD= donation after cardiac death; cRF= 
calculated reaction frequency, match score= a hypothetical score calculated based on 
recipient HLA-type and blood group (it reflects the number of patients out of a standard 
cohort of 10,000 patients who are blood group identical, HLA-compatible and 000 of 
favourably [100, 010, 110] matched); match points= converts the match score into a points 
score for the matching algorithm based on ease of transplantation. The level of match 
reflects the HLA-mismatch (Level 1: 000, Level 210, 010, 110, 200 or 210; Level 3: 020, 
120, 220, 001, 201, 011, 111 or 211; Level 4: 021, 121, 002, 102, 202, 012, 112, 212, 022, 
122 or 222). DGF= delayed graft function; eGFR= estimated glomerular filtration rate. 
 
 Patients with ESVA 
undergoing 
expedited renal 
transplant 
(n=9) 
Patients with ESVA 
receiving cadaveric 
transplant via 
national matching 
algorithm (n=6) 
Patients with 
ESVA having 
live donor 
transplant 
(n=3) 
 
P-value* 
Recipient Age 
(years) 
46.3 (10.0) 46.8 (6.3) 35 (8.7) N.S. 
cRF (%age) 58% (IQR 22%,99%) 97% (IQR 91%,99%) 90% (IQR 
0%,99%) 
N.S. 
Waiting time 
(days) 
1254.3 (754.8) 1403.4(634.6) 342.6 (267.5) N.S 
Match score 0 (IQR 10,33) 12 (IQR 2,16) 266 (IQR 1,320) N.S. 
Level of mismatch 
Level 1 
Level 2 
Level 3 
Level 4 
 
11.1% 
- 
66.7% 
22.2% 
 
33.3% 
- 
33.3% 
33.3% 
 
33.3%  
- 
66.7% 
- 
 
N.S 
Donor age (years) 51.3 (14.2) 56.9 (26.3) 40 (15.1) 0.11 
Type of donor 
(%age) 
DBD 
DCD 
 
 
11.1% (n=1) 
88.9% (n=8) 
 
 
83.3% (n=5) 
16.7% (n=1) 
 
 
NA 
 
 
<0.001 
Extended criteria 
donor (%age) 
100% (n=9) 100% (n=6) NA N.S. 
DGF (%age) 33.3% (n=3) 100% (n=6) 33% (n=1) <0.001 
eGFR at 12 
months 
(ml/min/1.73m2) 
65.8 (23.2) 56.9 (26.3) 58.5 (47.3) 0.16 
1 year graft 
survival (%age) 
88.9% (n=8) 50% (n=3) 100% (n=3) 0.05 
1 year patient 
survival (%age) 
88.9% (n=8) 66.7% (n=4) 100% (n=3) 0.09   
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Table 3.13: A comparison between the number of bed days and hospital admissions in 
patients with ESVA in the year prior to and the year following transplantation. 
Results are presented as mean (SD) and are expressed per patient per year.* Interventions 
include any surgical procedure e.g. transplant or vascular access procedure, interventional 
radiology procedure e.g. angiography or nephrostomy or other invasive procedure e.g. line 
insertion performed on the patient.  
 In the year prior to 
transplantation 
In the year following 
transplantation 
P-value 
Number of hospital 
admissions (per patient/yr) 
6.5 (1.6) 2.4 (3.7) <0.01 
Number of unplanned 
hospital admissions (per 
patient/yr) 
4.9 (1.9) 1.4 (3.2) <0.01 
Number of bed days (per 
patient/yr) 
21.3 (12.3) 11.6 (13.6) 0.02 
Number of interventions* 
(per patient/ yr) 
5.4 (4.3) 1.6 (0.7) <0.01 
 
 
Fewer interventional procedures were also performed in the year post transplantation (5.4 
± 4.3 vs. 1.6 ± 0.7 procedures per patient/ year). Pre-transplant the procedures primarily 
related to vascular access including 37 TCVCs, 52 angioplasties or declotting procedures 
and 32 access creations. Post-transplant procedures also primarily related to complications 
of vascular access including ligation/ removal of access for infection, steal or rupture 
(n=7), TCVC insertion (n=4) and also one patient who required nephrostomy insertion. 
 
A total of 39 cross-match tests have been performed to permit 9 expedited transplants (4.33 
cross matches per transplant). 
 
3.3.7.5. Chance of transplant in patients with end-stage vascular access 
 
Compared to an age and sex matched cohort (n=18), patients with ESVA had a higher cRF, 
poorer match score, longer wait time and more previous transplants (Table 3.14). As a 
result, their chance of transplantation is significantly lower. The age and sex-matched 
cohort has a 50% chance of transplant after 3.7 years according to the NHS Blood and 
Transplant Chance of Transplant Calculator (NHS Blood and Transplant, 2014), whilst 12 
of the 18 patients (66.7%) in the ESVA had a 50% chance of transplant >5 years. The 
ESVA cohort had a 4%, 10%, 20%, 32% and 43% chance of transplant at 1, 2, 3, 4 and 5 
years respectively (Figure 3.4).  
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Table 3.14: Comparison of patients with ESVA undergoing renal transplantation 
(n=18) and an age and sex-matched cohort of other patients undergoing renal 
transplantation (n=18). Patients with ESVA had a higher cRF, longer wait time and 
poorer match score. Results are presented as a mean (SD), median (IQR) or percentage of 
total. cRF= calculated reaction frequency, match score= a hypothetical score calculated 
based on recipient HLA-type and blood group (it reflects the number of patients out of a 
standard cohort of 10,000 patients who are blood group identical, HLA-compatible and 
000 of favourably [100, 010, 110] matched); match points= converts the match score into a 
points score for the matching algorithm based on ease of transplantation.  
 Patients with ESVA 
undergoing renal 
transplant (n=18) 
 
Age and sex matched cohort 
(n=18) 
P-value 
cRF (%age) 96% (IQR 40%,99%) 21% (IQR 12%, 85%) <0.01 
Waiting time (days) 1305.4 (925.5) 1032.4 (457.4) <0.01 
Total time since first 
commencing dialysis 
(years) 
12.3 (5.6) 3.2 (1.3) <0.001 
Match score 12 (IQR 0,41) 167 (IQR 79,312) <0.001 
Number of previous 
transplants 
0 
1 
2 
3 
 
 
 
38.9% (n=7) 
50% (n=9) 
5.6% (n=1) 
5.6% (n=1) 
 
 
 
94.4% (n=17) 
5.6% (n=1) 
 
 
 
 
 
 
<0.01  
  
Figure 3.4: Chance of transplant at 1, 2, 3. 4 and 5 years post wait-listing in patients 
with ESVA (black) compared to an age and sex-matched cohort (gray). Error bars 
show 1 SD 
0%10%
20%30%
40%50%
60%70%
80%90%
100%
1yr 2yr 3yr 4yr 5yr
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3.3.7.6. Patients with ESVA still untransplanted despite expedited transplant list 
 
After 5 years of the expedited transplant list, two patients remain untransplanted. Both 
have been on the expedited waiting list for the entire 5 years with total waiting times of 
3657 and 1954 days respectively. Both patients have a cRF of 100% (even after removing 
weak unacceptable [MFI<3000]) and match scores of 1. Each has been considered for over 
20 potential “priority” blood group compatible kidneys but no cross-match performed due 
to high levels of unacceptable antibodies. Figure 3.5 outlines the antibody profile of one of 
these two patients, highlighting the difficulties of transplantation in this cohort. 
 
 
  
Figure 3.5: Antibody profile of one of the two patients with ESVA in whom it has not 
been possible to find a kidney for transplantation via the expedited waiting list. Even 
after removing all acceptable mismatches (MFI <3000), he still has a cRF of 100% 
and match score of 1. He has high levels of pre-formed antibodies to most HLA class I 
(top) and almost all HLA class II except self (-DR4, -DQ4, -DP3, -DP4) (bottom). With 
thanks to Dr Ann-Margaret Little. 
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3.3.7.7. Impact of the expedited list on the rest of the transplant population 
 
All patients who were ranked top of the local matching algorithm on the day that the 
kidney was allocated to an ESVA patient via the expedited waiting list were transplanted 
within one year and all bar one were transplanted within 6 months. The mean waiting time 
from the day of the potential offer to transplantation was 128.2 ± 97.5 days. During this 
time one patient had an arteriovenous fistula that failed and required admission for TCVC 
and new AVF creation. Otherwise no patient suffered any obvious adverse consequence of 
additional waiting time and no additional hospital admissions were incurred. 
 
3.4. DISCUSSION  
  
3.4.1. The burden of central vein stenosis 
 
Although central vein stenosis is a well recognised phenomenon in individual patients, the 
collective extent and impact on the overall patient cohort and the subsequent healthcare 
costs has been underappreciated. This study has utilised a comprehensive electronic 
database of all procedures and complications to allow, for the first time, the true impact of 
CVS on the RRT population to be analysed. We have shown that CVS is common, costly 
and has a dramatic adverse impact on quality of life (QoL). These data, in addition to the 
widely recognised risks of infection, allow a risk to be estimated from the consequences of 
using TCVC in both the short and long-term. 
 
There is a clear causative relationship between central vein stenosis and TCVC use in both 
this study and others (Lumsden et al. 1997) supported by histopathological evidence 
demonstrating stenosis formation after even short periods of central venous catheterisation 
(Agarwal, 2013).  
 
In this cohort of patients, the prevalance of clinically significant CVS was 13%. Other 
studies that report a higher prevalence included patients with incidental findings on 
angiography (Agarwal et al. 2007; Suroweic et al. 2004).  A critical new observation in 
this patient cohort is the description that the principal presenting complaint in CVS is 
vascular access dysfunction rather than isolated limb or facial swelling. Preservation of the 
original vascular access was just 16% by 3 years, highlighting that the fate of dysfunctional 
access should be a key primary outcome when reporting on intervention for CVS. 
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CVS patients demonstrated objective evidence of deterioration in QoL. The quality of life 
outcome is limited by incomplete data collection. Only three-quarters of the cohort 
completed QoL questionnaires. The demographics of this subgroup were, however, similar 
to the overall CVS cohort. This is the first published QoL data for patients with CVS. 
Previous studies have shown that quality of life on HD with a functioning fistula is 
comparable to with TCVC (Manns et al. 2003). Although direct comparisons cannot be 
drawn, this reinforces the assertion that the psychosocial impact of CVS carries negative 
effects for the patient beyond the frequency of procedures and hospitalisation. 
 
CVS also carries a significant economic and financial burden. The healthcare costs of 
repeated and frequent intervention rapidly accumulates. This does not appear to be as a 
result of the failure of any one of our treatment strategies. Angioplasty (Dammers et al. 
2003a; Kovalik et al. 1994),  TCVC (Agarwal, 2013) and AVG (Harish & Allon, 2011) 
outcomes were largely in keeping with those published in specific series. Clinical 
performance met accepted standards. The crude cost of looking after 97 patients in the first 
year of diagnosis was £2.1 million. This equated to a cost per QALY of £42 307.69. In the 
UK, the National Institute of Clinical Excellence (NICE), generally only consider funding 
treatments with a cost per QALY of less than £20 000, extended to £30 000 under certain 
circumstances (NICE, 2014). While this costing does not represent one specific treatment, 
it does represent a treatment philosophy that is representative of that which is provided by 
most clinicians managing patients with CVS. As a total cost to the NHS, if a prevalence of 
13% nationwide is assumed amongst the 20 000 patients on HD in the UK, nationally this 
could amount to a spend of £57 million per annum. This reflects the delayed price that both 
patients and healthcare systems are paying for the early convenience of commencing 
dialysis with a line. Better systems of planning and initiating dialysis at diagnosis of end 
stage renal failure are required to protect patients from this significant delayed 
complication. 
 
CVS presents two major challenges: prevention and “cure”. This study demonstrates the 
burden of care incurred in the pursuit of a “cure” for CVS and indirectly highlights the 
importance of prevention. Contemporary practice has inherited a generation of HD patients 
who have been exposed to a practice whereby central vein catheterisation was performed 
more liberally than it is today, following the drive for “Fistula First” and timely creation of 
autologous access (Vassalotti et al. 2012). Prevention of CVS should be considered a 
clinical priority. Timely referral, education and an integrated structure for referral and 
access creation is essential to optimise the rates of autologous vascular access in incident 
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HD patients (Hughes et al. 2013). Emergency peritoneal dialysis is an under-explored 
potential alternative (Ilbaca-Avendano et al. 2008) . The development of prosthetic early 
cannulation arteriovenous grafts (ecAVGs), which can be used within 24 hours of 
insertion, may provide a viable alternative to TCVCs in patients who need to commence 
HD but who do not yet have a functioning vascular access (Tozzi et al. 2014b). Perhaps 
even revisiting old technologies such as the Scribner shunt (Quinton et al. 1962) for 
emergency dialysis may allow for safe anaesthesia prior to insertion of a more durable 
access. 
 
3.4.2. End stage vascular access: outcomes of differing treatment modalities 
 
Contrary to other published series, we report good short and longer term patencies of 
native long saphenous vein loop grafts in patients with bilateral central venous occlusion 
.The 900 day primary assisted patency rate of 76.9% is favourable compared to 66% at 2 
years and 40% at 3 years presented by other institutions (May et al. 1980), however long-
term patency is unlikely to rival that of femoral vein transposition (56% at 9 years) 
obtained by some authors (Hazinedaroğlu et al. 2004) . We believe that this is a result of 
careful patient selection, pre-operative ultrasound imaging to confirm suitability of the 
vessels and aggressive surgical and radiological re-intervention for stenotic and thrombotic 
complications. We advocate that long saphenous vein loops be considered as an excellent 
lower limb autologous option for all end-stage access patients who are fit enough and are 
likely to require vascular access for haemodialysis for more than 6 months. 
 
Lower limb prosthetic thigh grafts have been used with variable success in patients with 
ESVA. Both primary and secondary patency rates were lower than native long saphenous 
vein loops and comparable to other published series. Cull et al. (2004) report 2-year 
primary and secondary functional patency rates for prosthetic lower limb grafts of 19% and 
54% respectively. There was a high culture-proven bacteraemia rate from prosthetic thigh 
grafts in the high-risk patient group with bilateral central vein stenosis, which was 
comparable to that of TCVCs (Harish & Allon, 2011). Furthermore, infected haematomas 
proved problematic in many cases (Aitken et al. 2014a). Nevertheless, novel ecAVGs may 
be beneficial in patients who require immediate vascular access for haemodialysis and 
cannot wait for a native vein loop to mature, with superior patency rates than tunnelled 
femoral catheters. 
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Bacteramia rates associated with tunnelled catheters were relatively low in the end-stage 
access cohort (1.8 per 1,000 catheter days and 0.6 per 1,000 catheter days for tunnelled 
femoral and translumbar catheters respectively) compared to standard rates for all-comers 
on HD. Local culture-proven bacteraemia rate of tunnelled central venous catheters is 1.6 
per 1,000 catheter days for all patients on haemodialysis (Thomson et al. 2010). Power and 
colleagues (2010) report exit site infection rates of 2.02 per 1,000 catheter days and culture 
proven bacteraemia rates of 0.8 per 1,000 catheter days for translumbar catheters. For 
tunnelled femoral lines, Falk (2007) quotes a bacteraemia rate of 6.3 per 1,000 catheter 
days. We postulate that the low infection rates seen in our cohort, even with higher risk 
femoral catheters, may be due to heightened vigilance for infection control procedures in 
patients deemed to have precarious vascular access with protection of the “last access 
option”. 
 
There were a small number of patients (n=6) who had a HeRO in this cohort. All had a 
Gore®ACUSEAL graft (W.L. Gore Associates, Flagstaff, AZ, USA) attached to permit 
immediate cannulation. Follow-up in this patient cohort is limited, as the device only 
became available in the UK in 2013, however primary, primary assisted and secondary 
patency at 12 months was 66%. Unlike other modalities in this series, multiple 
interventions within the first year were not required to maintain patency of the HeRO 
device. Our results are at least comparable with those observed in other series. Nassar and 
colleagues (2014) report 1-year primary and secondary patency rates of 34.8% and 67.6% 
respectively. Similarly, Katzman et al. (2009) report a secondary patency rate of 72.2% at 
mean follow-up 8.6 months. 
 
No patient died as a result of loss of vascular access and there was no requirement of 
exotic, “last resort” procedures within this patient group. This highlights that it is possible 
to maintain the majority of patients with bilateral central venous occlusion and ESVA on 
RRT with a relatively limited number of secondary vascular access procedures and renal 
transplantation where appropriate. Most patients needed to utilise more than one access 
modality, illustrating the burden of bilateral central vein stenosis on both the patient and 
healthcare services. Additionally, this demonstrates the importance of individualised 
vascular access care, which needs regular review and revision. 
 
This study is limited by its retrospective, observational nature and relatively short follow-
up. The choice of access procedure performed in each patient often reflects clinician 
preference and, as such introduces an inherent and indefinable selection bias. It therefore 
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cannot be used to determine the superiority of any treatment option for bilateral central 
venous occlusion .Nevertheless, intervention outcomes appeared ‘satisfactory’ in all 
modalities for providing dialysis. Furthermore, large randomised studies in this population 
would be very difficult to conduct due to the relative rarity of the condition and very 
heterogeneous population. Observational data perhaps better reflects the complexities that 
these patients face in the real world, switching between treatment modalities to achieve a 
“personal solution”. 
 
As the life-expectancy of patients on haemodialysis improves (Scottish Renal Registry, 
2015), the number of patients with complex vascular access needs will increase. This study 
demonstrates that it is possible to maintain patients with ESVA on RRT, often via a 
combination of modalities including renal transplantation, however the morbidity 
associated with bilateral central vein stenosis is considerable. Prevention of central venous 
stenosis by catheter avoidance is essential to minimise the number of patients with 
complex vascular access needs in the future. 
 
3.4.3.  Expedited renal transplantation in patients with failing vascular access 
 
Almost every clinician involved in the care of patients with ESRD will recall a handful of 
patients who have died as a result of vascular access loss. Despite this, there are virtually 
no reports in the academic literature of the phenomenon and there is no consensus 
agreement about how best to manage patients with failing vascular access. Many countries’ 
transplant allocation algorithms pay lip service to “medically urgent” patients (Canadian 
Council of Organ Donation and Transplantation, 2007), however these strategies are often 
ad hoc and the number of patients who benefit (or who might be eligible to benefit but 
have not been considered) is unknown. To our knowledge, this is the first description of 
outcomes from renal transplantation in a system based on clinical need. We describe 
acceptable outcomes from transplantation in this cohort, with comparable 1-year post-
transplant eGFR in patients with failing vascular access, those with failing access who 
were prioritised for transplantation and. the overall transplant cohort at our centre. We also 
demonstrate a reduction in morbidity following transplantation in patients with failing 
vascular access (fewer hospital admissions and fewer bed days), with minimal negative 
impact on our global transplant population. 
 
As we have already described, patients with ESVA consume a vast amount of healthcare 
resources.  On average, in the year prior to transplantation they had 6.5 ± 1.6 hospital 
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admissions and utilised 21.3 ± 12.3 bed days per patient, almost solely as a result of 
access-related complications. Repeated interventions to preserve or restore vascular access 
were shown to cost £27 000 per patient/ year, often with more than one access modality 
required to provide ongoing vascular access. 12-month primary patency of most access 
modalities was less than 50% in this patient cohort. Additionally, the plethora of vascular 
access complications result in considerable morbidity and have a negative impact on QoL 
Expedited transplantation appears to offer an escape from this cycle of problematic and 
failing vascular access.  
 
Transplantation can prove challenging, both anatomically and immunologically in patients 
with failing vascular access. The median cRF in this patient cohort was 96%. Patients were 
often receiving a second or subsequent transplant. Nearly half the patients had pre-formed 
DSAs and one-third required ATG induction therapy. Not unsurprisingly therefore, rates of 
BPAR were higher in this patient cohort. Additionally, these patients proved technically 
complex to transplant. A number had been anuric for many years, with mean time on 
dialysis prior to transplantation approximately 12 years. As a result, the bladder was often 
chronically shrunken and atrophic and arteries heavily calcified. Often the venous anatomy 
was even more challenging. Several patients had occluded iliac veins, necessitating 
transplantation onto the inferior vena cava. In one case, the only vascular access was an 
ipsilateral femoral line, which remained positioned in the iliac veins while the transplant 
was performed. Another patient with an ipsilateral thigh graft had it ligated in the early 
post-operative period in an attempt to improve graft perfusion. The intricacies of 
transplantation in this difficult patient group require an intimate knowledge of both donor 
and recipient to ensure that the right kidney is given to the right patient at the right time 
e.g. the 57 year-old Asian gentleman dialysing via a rather precarious thigh graft, in whom 
a decision was made to perform a dual-kidney transplant from a 67 year old, hypertensive, 
diabetic donor with CKD 3 and proteinuria (kidneys which had previously been rejected by 
several other transplant centres due to concerns regarding primary non-function) because it 
was felt that the chances of him receiving a better offer prior to his vascular access failing 
was slim. Additionally, given these complexities, a recognition and acceptance of a 
possible stormy perioperative period is required and allowances should be made for 
potentially longer hospital stays and higher readmission rates than the over transplant 
cohort (though still substantially lower than within the same cohort on dialysis).   
 
The concept of medical urgency is inherent in most countries’ renal transplant matching 
algorithms (Canadian Council for Organ Donation and Transplantation, 2007; Baran, 
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2006) however only the EuroTransplant zone has an explicit “high urgent” list within their 
Kidney Allocation System (ET-KAS) (Eurotransplant, 2014) The exact criteria for listing 
as “high urgent” differ between the Netherlands and Germany, however both countries will 
list “medically urgent” patients for priority organ allocation above all other adult 
recipients. In South Africa, patients get allocated additional “points” within the standard 
matching algorithm for conditions such as failing vascular access necessitating accelerated 
transplantation (Muller, 2013). Other countries, including Australia and New Zealand, the 
United States and Canada (The Transplantation Society of Australia & Zealand, 2014; 
Organ Procurement and Transplantation Network, 2015) have no such formalised policy. 
This was also the case in the United Kingdom until last year, when the Kidney Advisory 
Group produced a policy advocating prioritisation for patients ‘whose vascular access has 
“run out”’(Kidney Advisory Group, 2014b, pp.1). Patients can now be referred to a 
National Appeals Panel and, if deemed appropriate, will be placed top of the national 
matching run. A priori requirements for consideration are failed peritoneal dialysis and 
consideration at a vascular access multidisciplinary meeting. The exact criteria for vascular 
access failure however are poorly defined. A number of suggestions are provided within 
the document ranging from failed internal jugular catheterisation to dialysis via a 
transhepatic line. No consideration is given within the guidelines for more aggressive and 
novel attempts to salvage autologous or definitive access such as the HeRO (Katzman et al. 
2009; Shakarchi et al. 2015c) or lower limb access (Antoniou et al. 2009),  despite patients 
using such forms of vascular access often being in similarly dire need of transplantation to 
those using tunnelled lines. In our cohort of patients only one-third was actually dialysing 
via a TCVC despite the clinical team considering them to be at imminent risk of access 
loss. This is likely the result of an aggressive vascular access service (Aitken & 
Kingsmore, 2012a; Aitken et al. 2014a) at our centre, and does not reflect the fact that 
these patients are at any lesser need of transplantation than those dialysing via a 
transhepatic line. We fully recognise and understand the difficulties faced by the authors of 
the Kidney Advisory Group (KAG) guidelines (2014b) in defining the patient cohort with 
“failing vascular access”. Even locally, within our cohort of patients, there is great 
heterogeneity and it is problematic outlining the exact patient population who should be 
considered for such an intervention. However we would argue that, particularly given the 
uniqueness and individual idiosyncrasies of these patients, a national strategy for their 
management cannot best serve their needs. Unlike the prioritisation for liver 
transplantation, where it is possible to clearly define indications for “super-urgent” 
transplantation based on clinical need (Liver Advisory Group, 2014) e.g. fulminant liver 
failure due to paracetamol poisoning with coagulopathy or refractory acidosis, 
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characterising access failure and predicting the trajectory or mortality risk in a meaningful 
way is very difficult. We would advocate that a local approach to organ allocation for these 
patients permits the complexities of each case to be considered on their own merits and 
allows flexibility to be built into the system. Our local criteria to consider a patient with 
failing access were intentionally loose to allow adaptation to facilitate transplantation of 
patients who were considered to be in desperate need of a transplant. Our selection criteria 
included patients with bilateral central venous stenosis and loss of upper limb access, 
however the role of a multidisciplinary team who knew the patient intimately cannot be 
over-emphasised. Additionally, as highlighted in the KAG policy document (Kidney 
Advisory Group, 2014b), different units have different strategies to vascular access 
provision. In order to ensure equity, it is essential that priority transplantation does not 
serve as a solution to poor access planning or management. Local allocation would prevent 
unit differences in access provision affecting this. Furthermore, the loose definitions and 
soft symptoms of access failure could lead to exaggeration of a patient’s condition in an 
attempt to allow them to be listed for “urgent” transplantation. Again, local allocation of 
organs to patients known personally to those deciding on listing would prevent any 
“gaming” either intentional or otherwise. 
 
Transplantation is a specialty founded on ethical principles. Currently matching algorithms 
attempt to ensure distributive justice of a limited resource (Paul et al. 2004), and any 
proposed change in organ allocation must be transparent and maintain equity of allocation 
and access. The concept of equity is not always  synonymous to equality (Davis, 2006). 
We believe that our strategy of prioritising based on clinical need maintains distributive 
justice, whilst facilitating a life-saving intervention in those who require it urgently without 
negatively impacting on the rest of the transplant population. Furthermore, given that in the 
majority of cases, patients with failing access are young and (apart from their failing 
vascular access) often don’t have the significant co-morbidities of many other patients with 
ESRD, a functioning graft is likely to be sustained for many years. We have demonstrated 
good graft outcomes in this patient cohort with similar 1-year eGFR to the overall 
transplant cohort, and would argue that this strategy also ensures best use of the organs and 
fulfills the principle of utility (Davis, 2006). 
 
This study involves only a small cohort of patients who were transplanted and, like the 
description of other RRT/ access modalities, is limited by short-term follow-up only. 
However for most patients with failing vascular access, one-year post-transplant survival 
seems an appropriate end-point as, without transplantation, many will not survive even this 
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short time. It has proven difficult to quantify the true success or failure of our strategy of 
expedited renal transplantation as an appropriate comparator group is difficult to define. 
The overall transplant population is an inappropriate comparator as the intended outcomes, 
goals and aims of transplantation in this cohort are principally in optimising graft and 
patient survival and longevity, where as in patients with failing access, the priority and 
objective of transplantation is primary function and short-term survival. Conversely, 
comparing patients with failing access who received an expedited transplant to those with 
failing access who were not transplanted (only 31% of the patients with ESVA were 
eligible for transplantation) is also inappropriate, because often there was another reason 
e.g. comorbidity why these patients were not transplanted, which could confound results. 
For this reason, wherever possible (and despite small numbers) we have attempted to 
compare patients with failing access transplanted via the expedited list to those patients 
with failing access transplanted via the National Matching algorithm, because we believe 
that this is the most representative comparator group.  
 
The current study is UK centric and its direct generalisability beyond patients transplanted 
via the NHS-BT Deceased Donor Organ Allocation Policy (Kidney Advisory Group, 
2016) is difficult to quantify. Furthermore, the implications and impact of the new Kidney 
Advisory Group recommendations for regional sharing of DCD kidneys (Kidney Advisory 
Group 2014a) (rather than the local sharing of DCD kidneys within Scotland between the 
transplant centres in Glasgow and Edinburgh, which permitted early crossmatching and 
short cold ischaemic times) on our system remain to be elucidated. Our study does 
however highlight the problems faced by patients with failing access in a quantifiable 
manner and, for the first time, describes an attempt at a “real-world” clinical solution to 
this difficult issue. We believe that the numbers and problems described in this patient 
group are representative of those seen to transplant centres elsewhere in the UK and that 
this “hard data”, lacking in many other descriptions of failing vascular access, could be 
instrumental in informing national policy. 
 
In summary, we have described a unique local strategy for managing patients with failing 
vascular access by renal transplantation within the constraints of a national matching 
algorithm that doesn’t account for clinical need. The medical urgency of transplantation 
and high mortality without transplantation in patients with ESVA has been highlighted. We 
believe our strategy, working within the NHS-BT Deceased Donor Organ Allocation 
policy but allowing local discretion of organ allocation for certain higher risk kidneys to 
specific recipients in dire clinical need, provides the best option for management of these 
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complex patients. We welcome the Kidney Advisory Group’s appeals policy for priority 
kidney allocation due to shortage of vascular access (Kidney Advisory Group, 2014b) in 
highlighting the plight of these patients, but would caution against a national “urgent” 
waiting list for kidneys. A national list fails to consider the individuality that each unique 
patient with failing access has within a very heterogeneous patient cohort. The personal 
complexities (anatomical, immunological and psychosocial) can only be fully understood 
by the group of clinicians directly involved in the patient’s care.  For this reason, we 
advocate local discretion in organ allocation for the management of these rare patients. Our 
results have demonstrated that it is possible to achieve this in an equitable fashion within 
the constraints of the current utilitarian national allocation policy without adversely 
impacting on the rest of the transplant waiting list. 
 
3.4.4.  Summary 
 
This chapter highlights the significant personal and economic burden of central vein 
stenosis. Effective treatment options are limited and associated with considerable 
morbidty. Ultimately, without an “exit strategy”, complete vascular access failure with an 
inability to dialyse may occur. It is clearly evident that prevention is very much preferred 
over attempts at cure. Improving autologous vascular access rates and minimising TCVC 
use in incident haemodialysis patients is therefore vital.  
The legacy of bad vascular access decision-making in the early period remains with the 
patient throughout their life on dialysis. CVS may occur with only 12 days exposure to 
CVC. Similarly, catheter-related bacteraemia is highest in the early days after commencing 
on dialysis with a median time from TCVC insertion to first bacteraemic episode only 54 
days (Thomson et al. 2010). Only 11% of patients commencing dialysis via a TCVC are 
using an AVF after 3 months (UK Renal Registry, 2014), and more than 60% of 
“crashlanders” still have their TCVC after 6 months (National Kidney Care Vascular 
Access Report, 2012). Given that prolonged catheter dependence is associated with 
increased long-term complications including bacteraemia and CVS, the work presented in 
this chapter clearly demonstrates the importance of getting it right from the outset. Starting 
HD via a TCVC should be considered a treatment failure, with CVS perhaps the strongest 
argument for the “Fistula First, Line Last” mantra. 
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PREDICTING FISTULA MATURATION IN INCIDENT DIALYSIS 
PATIENTS: THE INFLUENCE OF URAEMIA 
 
4.1. INTRODUCTION 
 
Arteriovenous fistulae (AVF) are the dialysis access modality of choice for patients with 
end stage renal disease (ESRD) (UK Renal Registry, 2016; NKF-KDOQI, 2010). They are 
associated with lower risks of systemic sepsis, infective and all-cause mortality (Thomson 
et al. 2007; Bray et al. 2012). For this reason both the UK Renal Association and the 
Fistula First Initiative in the United States have set targets that two-thirds of incident 
haemodialysis patients should commence dialysis via an AVF (Renal Association, 2011; 
Massoud et al. 2006). 
 
There is little evidence however regarding the optimal timing of vascular access creation in 
incident HD patients. Broad consensus exists that timely surgical referral for access 
creation is important, however clinical practice guidelines are largely opinion-based and 
vary widely. Furthermore, the exact timing of dialysis initiation for an individual patient 
can be unpredictable (O’Hare et al. 2007). The UK Renal Association (2011) advocates 
that referral for vascular access should occur when the patient enters CKD stage 4 taking 
into account co-morbidities, rate of decline in renal function and the surgical pathway. 
Similarly, the Canadian Society of Nephrology guidelines recommend that a patient be 
referred with ‘creatinine clearance <15-20ml/min or serum creatinine 3.4-5.6mg/dl (300-
500µmol/l) depending on the size and weight of the patient’ (Jindal et al. 2006, pp.S7). In 
contrast, the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines (2006, 
pp.S260) provide a timeframe for referral  ‘at least six months before the anticipated need 
for dialysis’.  
 
One of the major problems in vascular access planning is the unpredictability of successful 
maturation. Initial patency rates vary from 60-80% (Lazarides et al. 2007; Dixon et al. 
2002) and one recent multicentre study found that 60% of AVFs were not suitable for 
cannulation 4-5 months after creation (Dember et al. 2008). Various risk factors for early 
AVF failure have been identified including advancing age (Feldman et al. 2003), female 
gender (Lok et al. 2006) and diabetes (Huijbregts et al. 2008).  
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Several authors have speculated that the timing of access creation itself may influence 
AVF outcome. Data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) 
indicates that patients are less likely to start HD via an AVF if there was a longer time 
from referral to surgical evaluation or longer time from creation to first cannulation (Ethier 
et al. 2008). The presence of a central venous catheter at the time of commencing dialysis 
has also been shown to be associated with poor AVF maturation (Brunori et al. 2005). 
Similarly, Weber and colleagues (2009) demonstrated a trend towards improved patency in 
AVF created when the patient was pre-dialysis, but the study was underpowered to 
formally assess this secondary outcome measure. 
 
Associations between the uraemia which occurs in CKD, altered immune response (Vaziri 
et al. 2012) and deranged vascular biology (Juncos et al. 2011; Croatt et al. 2011) are well 
recognised. It may be, therefore, that the uraemic state of patients with ESRD influences 
AVF outcomes.  In a rat model of AVF maturation, Langer and colleagues (2011) found 
inferior vessel dilatation and an exacerbation of neointimal hyperplasia in uraemic animals. 
These factors may need to be taken into account when planning and timing AVF creation. 
 
The aim of this study was to evaluate the hypothesis that uraemia drives vascular smooth 
muscle (VSM) cell proliferation and impairs AVF maturation. Early fistula failure rates (6 
weeks) were compared between pre-dialysis patients and those already on haemodialysis 
for different eGFR and serum urea at time of AVF creation and (in those patients who had 
already commenced HD) between patients who dialysed on the same day as surgery and 
those who dialysed on the day prior to surgery.  
 
4.2. METHODOLOGY 
 
4.2.1.  Study design and participants 
 
Retrospective analysis of a prospectively collected database of all simple arteriovenous 
fistulae created in our tertiary referral vascular access centre during a three-year period 
(January 2010-December 2012) was performed. The database was derived from the 
Scottish Electronic Renal Patient Record. Patients were excluded if they were switching 
from peritoneal dialysis to HD or if they had a failing transplant.  Patients undergoing 
brachiobasilic AVF creation were also excluded, so the study population only included 
brachiocephalic (BCF) and radiocephalic (RCF) fistulae. 
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Approval was obtained from the West of Scotland Research Ethics Committee Number 1. 
Research was conducted in accordance with the Declaration of Helsinki. Written informed 
consent was not required unless additional blood samples were taken for a sub-study (not 
presented).  
 
4.2.2.  Data collection 
 
Demographic details (age, sex, number of previous fistulae), operative details (site of 
AVF, type of anaesthetic) and details regarding dialysis status and renal function (dialysis 
modality, estimated glomerular filtration rate (eGFR) and serum urea in patients who were 
pre-dialysis (Pre-D) at the time of AVF creation and whether or not the patient had pre-
operative haemodialysis on the day of surgery in patients who were already dialysis 
dependant (HD) were recorded. A measurement of serum urea and eGFR were obtained 
within 2 weeks prior to surgery. eGFR was calculated using the Modification of Diet in 
Renal Disease 4-variable (MDRD-4) formula. 
 
4.2.3.  Outcome measures 
 
The primary outcome variable was clinical patency at 6 weeks. Clinical patency was 
defined as an AVF with thrill and bruit and adequate maturation to permit needle 
cannulation if required as assessed by Vascular Access Specialist Nurses. Secondary 
outcomes were functional patency (defined as the ability of the AVF to sustain six 
consecutive dialysis sessions with two needles in those patients who required 
haemodialysis), clinical patency at time of hospital discharge (defined as the presence of 
thrill or bruit) and date of loss of clinical patency. 
 
4.2.4.  Statistical analysis 
 
Statistical analysis was performed using the SPSS Statistics for Windows Version 19.0 
(IBM Corp., Armonk, NY, USA). Patients were stratified according to site of AVF. 
Dialysis status (HD or pre-D), eGFR, serum urea and whether or not the patient dialysed 
pre-operatively were evaluated to determine if they affected early AVF failure. Results are 
presented as a mean ± SEM or percentage of the total population. Continuous data were 
compared using a Mann Whitney U-test and categorical data compared using chi-squared 
test. Kaplan Meier survival curves were used to assess long-term patency. These were 
compared using a log-rank method. P<0.05 is considered significant.  
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4.3.  RESULTS 
 
A total of 705 AVF were created during the three-year period. 12 (1.7%) were excluded as 
the patient had a failing transplant and 23 (3.3%) were excluded as the patient was on 
peritoneal dialysis at the time of AVF creation.  102 patients undergoing BBF formation 
were also excluded, leaving 569 AVF for analysis (287 RCF, 282 BCF). Of these, 216 
(38.0%) were created in patients already on haemodialysis and 353 (62.0%) were created 
in pre-D patients. Table 4.1 outlines the patient demographics and operative details.  
 
Table 4.1: Basic demographics of the 705 patients undergoing AVF creation. Results 
are presented as mean ± SEM or percentage of total for the entire population and by 
dialysis status at the time of AVF creation. *P-values compare pre-D and HD populations. 
 
 Total population 
 
Pre-D (n=353) HD (n=216) P-value* 
Age (years) 60.5±0.9 
 
62.3±1.2 59.1±1.9 <0.05 
Sex (%age male) 56.2% (n=320) 
 
52.4% (n=185) 62.5% (n=135) <0.001 
Previous 
attempted AVF? 
 
31.8% (n=181) 17.8% (n=63) 54.6% (n=118) <0.001 
Anaesthesia 
Local 
Regional  
General 
 
24.1% (n=137) 
50.3% (n=286) 
25.7% (n=146) 
 
 
30.0% (n=106) 
49.0% (n=173) 
21.0% (n=74) 
 
14.4% (n=31) 
52.3% (n=113) 
33.3% (n=72) 
 
<0.001 
Site of AVF 
RCF 
BCF 
 
50.4% (n=287) 
49.6% (n=282) 
 
 
53.3% (n=188) 
46.7% (n=165) 
 
45.8% (n=99) 
54.2% (n=117) 
 
N.S. 
 
There was no significant difference in the primary outcome (loss of clinical patency at 6 
weeks) of either RCF or BCF depending on dialysis status (pre-D RCF 31.4% (n=188) vs. 
HD RCF 29.3% (n=99), P=0.34; pre-D BCF 22.4% (n=165) vs. HD BCF 25.9% (n=116), 
P=0.43). There was no significant difference in either patency on discharge or functional 
patency between pre-D and HD groups (Table 4.2).  
 
There was no difference in mean eGFR between those patients with early AVF failure 
(loss of clinical patency at 6 weeks) and those without (11.2 ± 0.2ml/min/1.73m2  vs. 11.6 
± 0.4 ml/min/1.73m2 ; P=0.47). Uraemia was strongly associated with loss of clinical 
patency at 6 weeks. Mean serum urea in pre-D patients with early AVF failure was 35.0 ± 
0.7mg/dl compared to 26.6 ± 0.3mg/dl in those with patent AVF at 6 weeks (P<0.001). 
Similarly, in patients already established on HD, loss of clinical patency at 6 weeks was 
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more likely to occur in patients who dialysed the day prior to surgery for AVF creation 
compared to those who dialysed on the same day as AVF creation (32.9% vs. 17.7%; 
P=0.005) (Table 4.3). 
 
Table 4.2: Comparison of AVF outcomes of RCF and BCF created in patients who 
were pre-D and those on HD at the time of AVF creation. *Functional patency was 
defined as the ability of an AVF to sustain HD for 6 consecutive sessions with two needles 
at any time during the follow-up period. AVF that failed to achieve initial patency on 
discharge and AVF that never required needling (i.e. the patient remained pre-D or was 
transplanted prior to ever using the AVF) were excluded from this analysis. 
 
 Radiocephalic P-value Brachiocephalic P-value 
Pre-D HD Pre-D HD 
Primary outcome 
Clinical patency at 6 
weeks 
 
69.6% 
(n=130) 
 
71.7% 
(n=71) 
 
0.34 
 
77.6% 
(n=128) 
 
74.1% 
(n=86) 
 
0.43 
Secondary outcomes 
Patency on discharge 
 
 
Functional patency* 
 
90.4% 
(n=170) 
 
80.3% 
(n=98) 
 
 
91.9% 
(n=91) 
 
80.2% 
(n=65) 
 
0.76 
 
 
0.87 
 
89.1% 
(n=147) 
 
84.1% 
(n=122) 
 
90.5% 
(n=105) 
 
81.7% 
(n=85) 
 
0.72 
 
 
0.79 
 
Table 4.3: Effect of eGFR, uraemia, and pre-operative haemodialysis on early AVF 
failure (loss of clinical patency at 6 weeks). *For patients who are pre-D; **For patients 
who are already dialysis dependant at time of AVF creation.   
 Clinical patency at 
6 weeks 
Failure to achieve 
clinical patency at 6 
weeks 
 
P-value 
eGFR (ml/min/1.73m2 )* 
 
11.6±0.4 11.2±0.2 0.47 
Serum urea (mg/dl)* 
 
26.6±0.3 35.0±0.7 <0.001 
Pre-operative HD** 
Percentage of patients having pre-
operative HD 
 
Percentage of patients not having 
pre-operative HD 
 
 
82.3% 
 
 
67.1% 
 
17.7% 
 
 
32.9% 
 
0.005 
 
Long-term clinical patency of RCF was better in patients with lower serum urea when the 
AVF was created (P=0.01; Figure 4.1b). This association between uraemia and AVF 
failure was not seen in BCF (P=0.78; Figure 4.1d). Similarly there was no association 
between eGFR and long term RCF (P=0.38; Figure 4.1a) and BCF (P=0.61; Figure 4.1c) 
patency. 
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Figure 4.1: Kaplan Meier survival curves comparing long term AVF clinical patency 
stratified by eGFR(<10 ml/min/1.73m2; 10-15 ml/min/1.73m2; >15 ml/min/1.73m2) 
and serum urea (<30mg/dl; 30-40mg/dl; >40mg/dl) in patients who were pre-D at the 
time of AVF creation. A. There was no difference in long-term RCF patency with 
different eGFR (P=0.38). B. Long-term patency of RCF was better in patients with 
lower serum urea at the time of AVF creation (P=0.01). C. There was no difference in 
long-term BCF patency with different eGFR (P=0.61). D. There was no difference in 
long-term BCF patency depending on serum urea at time of AVF creation (P=0.79). 
 
4.4. DISCUSSION 
 
No difference was found in the primary outcome, patency at 6 weeks, between pre-D and 
HD patients for either BCF or RCF. This novel finding is in conflict with the results of 
Rayner and colleagues (2003), who concluded that dialysis via a TCVC at the time of 
access creation was associated with early access failure. Similarly, Weber and colleagues 
(2009) achieved excellent “real world” outcomes in their cohort of patients who had AVF 
created prior to starting HD compared their cohort of patients who had AVF creation 
delayed until after commencing HD, with 81% vs. 44% of patients using an AVF at 6 
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months. It should be noted however that the criteria for referral for access creation in this 
study was an eGFR ≤25ml/min, whilst the mean eGFR at time of AVF creation in our 
study was 11ml/min. 
 
This is the first clinical study to evaluate the relationship between renal function and AVF 
outcome. We found no association between eGFR at the time of access creation and either 
short or long-term patency. However increasing serum urea was associated with worse 
clinical patency at 6 weeks and poorer long-term outcomes from RCF. Similarly, in those 
patients who had already commenced HD at the time of access creation, dialysis on the 
same day as surgery was associated with better early patency rates. These findings are 
consistent with our cell signalling experiments. It is hypothesied that the VSM cell 
proliferation and neointimal hyperplasia which occur at the site of endothelial injury and 
surgical trauma when the AVF is created are exacerbated by the pro-mitogenic effect of 
uraemic serum and are deleterious to early fistula maturation (Aitken et al. 2014d; 
MacCaskill et al. 2015). 
 
The factors affecting AVF maturation are multifactorial including vascular anatomy 
(Papachristou & Vazquez-Padron, 2012) and haemodynamics (Krishnamoothy et al. 2008; 
Krishnamoothy et al. 2012), vessel quality (Konner et al. 2013) and immune and 
biochemical properties (Juncos et al. 2011; Croatt et al. 2010). Fistulae require adequate 
arterial inflow and venous outflow to permit maturation. Inflow may be compromised by 
technical failure at the anastomosis or a poor quality arterial tree. Outflow may be impaired 
by anatomical or technical “kinking” of the vessels or altered vascular biology leading to 
VSM cell proliferation, neointimal hyperplasia and venous outflow stenosis. Uraemia 
alters vascular biology, physiology and biochemistry (Vazari et al. 2012; Juncos et al. 
2011; Croatt et al. 2010) and may contribute to both inflow and outflow difficulties.  
 
Both arterial stiffness and vascular calcification are increased in uraemic patients. In 
particular, calcification of the media is unique to ESRD and may impair AVF maturation 
by limiting arterial inflow (O’Neill & Lomashvili, 2010).  Atherosclerosis is accelerated in 
patients with CKD with increased cardiovascular mortality (Linder et al. 1974) and 
increased intima-medial thickness in both coronary and carotid arteries (Schwarz et al. 
2000; Ojo et al. 2002). An increased intima-medial thickness is seen in the radial artery of 
uraemic patients and is associated with poor arterial inflow and failure of maturation in 
RCF (Ku et al. 2006). Most studies of CKD-mediated vasculopathy focus on the arterial 
system, however it’s likely that the detrimental effects of uraemia also affect the venous 
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system in a similar manner (Rothuizen et al. 2013). Arterial calcification is well known to 
impair an artery’s ability to distend upon high flow stimulation (Guerin et al. 2000). Lee 
and colleagues (2012) have recently demonstrated extensive calcification within the intima 
and media of venous segments harvested at the time of vascular access surgery which, 
similar to in the arterial setting, may result in reduced venous compliance and inhibition of 
the outward remodelling of the venous outflow required for AVF maturation.  
 
VSM cell proliferation and neointimal hyperplasia occur at the sites of vessel injury, for 
example the surgical anastomosis, leading to perianastomotic stenosis (Roy-Chaudhury et 
al. 2007). Uraemia has previously been shown to promote neointimal hyperplasia, inhibit 
vascular repair and promote stenosis in a rodent fistula model (Langer et al. 2011). 
Additionally endothelial progenitor cells (EPCs), which contribute to vessel repair and 
neovascularisation, have reduced ability to migrate in uraemic serum (Herbig, 2004). Work 
conducted at our institution has isolated human VSM cells and exposed them to 
hyperuraemic serum and compared proliferation and the associated pro-mitogenic 
signalling (MacCaskill et al. 2015). Our observations support the notion that hyperuraemic 
serum contains pro-growth factors which upregulate VSM cell proliferation and neointimal 
hyperplasia leading to early AVF failure. This process may occur de novo at the site of 
surgical injury or may be an exacerbation of existing neointimal hyperplasia of the outflow 
vein, which is known to predate AVF creation in patients with CKD (Moist et al. 2012). 
The clinical consequences are likely to be most marked in small vessels, as evidenced by 
the poorer long-term outcomes of RCF and not BCF created in uraemic patients. 
 
As with many in ESRD, this study is limited by a heterogeneous patient population. 
Multiple potential confounding variables exist. In particular, our assertion that the 
improved AVF outcomes in patients who dialyse on the same day as AVF creation reflects 
reduction in serum urea may be erroneous. There are many potential confounding 
variables, including the administration of systemic heparin and optimisation of 
cardiovascular function, which could improve AVF outcomes in patients having HD on the 
same day as surgery. Secondly, our primary endpoint of clinical patency at six weeks is 
vulnerable to observer bias with different clinicians interpreting patency differently. We 
chose this pragmatic endpoint which does not include cannulation in an attempt to permit 
comparison between pre-D and HD patients. By using experienced Vascular Access Nurse 
Specialists to assess patency we have attempted to maintain standardisation and perform a 
clinically relevant assessment of outcome. 
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Our results indicate that uraemia (independent of dialysis status or eGFR) is a risk factor 
for early AVF failure. This has significant clinical implications regarding the timing of 
referral for AVF creation. Whilst most authors favour early referral (Jindal et al. 2006; 
Hiremath et al. 2011), a recent sensitivity analysis actually suggests comparable life 
expectancy and improved quality of life for patients with CKD stage 4 when a watchful 
waiting approach to access creation is adopted (Wasse et al, 2012). We would support 
creation of AVF in all incident patients prior to starting HD. Our results indicate that, in 
order to optimise maturation rates, even earlier referral prior to development of significant 
uraemic symptoms may be required. Secondly, for a number of years it had been local 
practice to expedite access creation in patients with rapidly declining renal function and 
progression to end-stage disease (Aitken et al, 2012a). The results of this study have 
prompted a change in that practice, given the poor AVF outcomes in uraemic patients. It 
may be that there is a subset of patients who are imminently requiring haemodialysis who 
would benefit for commencement of HD via a TCVC, physiological and biochemical 
optimisation and then AVF creation. Finally, the beneficial effect of same day 
haemodialysis has significant service provision and logistical implications if it is to be 
implemented for every patient. 
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A RANDOMISED CONTROLLED TRIAL OF INTERRUPTED 
VERSUS CONTINUOUS SUTURING TECHNIQUES FOR 
RADIOCEPHALIC FISTULAE 
 
5.1. INTRODUCTION 
 
As previously discussed, AVF are the haemodialysis access modality of choice for patients 
with ESRD (Vascular Access Working Group, 2006; National Kidney Care Vascular 
Access Report, 2012.). However, the Achilles’ heel of native fistulae is poor early patency 
(Riella & Roy-Chaudhury, 2013). This limits greatly the universal use of AVF. Until 
recently few interventions have been proposed to help improve early patency. The next 
two chapters will focus on this issue: one looking at operative technique and one 
examining anaesthetic technique in an attempt to improve early fistula outcomes. 
 
Approximately one-third of AVF fail at an early stage (Golledge et al. 1999; Nguyen et al. 
2007). Early failures of RCF, made from the small, distal vessels at the wrist, are 
particularly common. Primary patency for RCF remains between 50-65% (Nguyen et al. 
2007; Rooijens et al. 2004; Golledge et al. 1999). Numerous reasons for early failure and 
“failure to mature” have been postulated, including abnormal anastomotic haemodynamics, 
venous diameter, intimal hyperplasia and scarring/stenosis and inadequate arterial inflow 
(Lin et al. 2005; Hofstra et al. 1995). Technical factors will also invariably affect early 
AVF patency rates (Konner, 2002). The influence of operative technique is likely to be 
most marked for the challenging small wrist vessels and microsurgical anastomoses using 
magnification with operating loupes required for RCF (Lin et al. 2005; Konner, 2002; 
Mozaffar et al. 2013). 
 
A number of different operative modifications, including side-to-side anastomoses (Hong 
et al. 2013; Moini et al. 2009), vein cuffs (Lemson et al. 2000) and variations in the 
anastomotic angle (Rajabi Jagahrgh et al. 2013), have been proposed in an attempt to 
improve flow dynamics and minimise early AVF failure. All use conventional continuous 
suturing techniques and none have proven particularly successful. Other clinical fields, 
including free-flap transfer (Griffin & Thornton, 2005), coronary artery bypass grafts 
(Gerdisch et al. 2003) and hepatic artery reconstruction (Starzl et al. 1985; Tzeng et al. 
2010), and small animal models (Schlechter & Guyuron, 1994; Chen et al. 2001) utilise 
interrupted suturing techniques (or modifications of interrupted suturing techniques with 
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interrupted sutures for at least part of the anastomosis) for microsurgical anastomoses 
(with either operating microscope or surgical loupes) with excellent results. Theoretical 
benefits include improved anastomotic compliance and reduced puckering and luminal 
narrowing (Lin et al. 2005; Griffin & Thornton, 2005) . 
 
In this study it was hypothesised that, akin to other microsurgical anastomoses, the small 
vessels of radiocephalic fistulae may benefit from interrupted suturing techniques. Our aim 
was to compare early patency rates of RCF created with interrupted versus continuous 
suturing techniques. 
 
5.2.  METHODOLOGY 
 
5.2.1.  Study design and participants 
 
Patients were recruited from the regional Vascular Access Centre at the Western Infirmary, 
Glasgow between August 2012 and January 2014. All adults patients (over the age of 18 
years) who were having RCF created were eligible to participate. Patients were excluded if 
they were unable or unwilling to provide consent; if they had previous ipsilateral attempts 
at AVF creation; if the radial artery was <1.8mm or cephalic vein at the wrist <2mm on 
pre-operative ultrasound (without tourniquet). 
 
Ethical approval for this trial was granted by the West of Scotland Research Ethics 
Committee Number 4 and research has been carried out in accordance with the Declaration 
of Helsinki. All participants provided written informed consent. The trial was registered 
prospectively with the ClinicalTrials.gov database (NCT01704313).  
 
5.2.2.  Randomisation 
 
Patients were randomised in a 1:1 fashion to either interrupted or continuous suturing 
technique. The randomisation sequence was generated using a web-based random 
sequence generator and sequentially numbered, opaque, sealed envelopes were produced 
by a colleague independent of the research team. 
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5.2.3.  Recruitment 
 
Patients were approached pre-operatively by a member of the research team. If willing to 
participate, they were assigned a study number and sealed envelope. The sealed envelope 
was opened by the operating surgeon in theatre immediately pre-operatively. The operating 
surgeons were independent of the research team. 
 
Both patient and research team were blinded to the allocation. Concealment was 
maintained until all patients had reached the primary end point. 
 
5.2.4.  Operative technique 
 
The procedures were performed by a total of eight experienced consultant vascular access 
surgeons (or senior trainees under consultant supervision).  All surgeons had experience of 
performing anastomoses with both interrupted and continuous suturing techniques 
however, prior to the study, all but one would routinely use a continuous suturing 
technique for creation of RCF. 
 
Anaesthetic was provided with either supraclavicular block or local injection. All surgeons 
used operating loupes with x8 magnification. Standard approach to the vessels and 
arteriotomy was performed. The anastomoses were performed with 6.0 or 7.0 Prolene® 
(Ethicon, Sommerville, NJ, USA) as was surgeon preference. For the continuous suturing 
technique, a stay suture was inserted at the toe of the vein and then a single suture run 
around the entirety of the anastomosis starting from the heel (Figure 5.1). The interrupted 
suturing technique also required a stay suture. Then three single interrupted sutures were 
placed at the heel of the anastomosis and tied before a continuous suture used to complete 
the remainder of the anastomosis (Figure 5.1 and 5.2).  
 
5.2.5.  Outcome measures 
 
The primary end point was primary patency at 6 weeks (assessed by a blinded observer for 
the presence of thrill and bruit). Secondary end points were immediate patency, functional 
patency (assessed clinically and by ultrasound) at six-weeks, patency at time of discharge 
from hospital and presence of anastomotic stenosis.  
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Figure 5.1: Illustration of continuous and interrupted suturing techniques. Continuous 
suturing technique (top): a single suture length is used to perform the entire anastomosis. 
Interrupted suturing technique (bottom): the interrupted sutures were inserted first into the 
heel of the anastomosis (bottom left). These were then tied down (bottom middle) before 
another suture was used to run around the rest of the anastomosis (bottom right). Diagram 
courtesy of Jessica Thompson, Dundee University Medical School. 
 
 
 
Figure 5.2: Photographs of the interrupted suturing technique. Top left: interrupted 
sutures at the heel of the anastomosis. Top right: Interrupted sutures at the heel of the 
anastomosis tied down. Bottom left: Continuous sutures were used to complete the 
anastomosis. Bottom right: Blood flow restored with dilatation of the anastomosis. 
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Primary patency at 6 weeks was assessed by blinded members of the research team. This 
was defined clinically as the presence of thrill and bruit confirmed by two members of the 
research team. Immediate patency and patency at time of discharge were also assessed 
clinically (presence of thrill and bruit) by the research team. Functional patency at six 
weeks was assessed by the research team both clinically (deemed suitable for cannulation 
by experienced dialysis nurse) and by ultrasound (>6mm diameter, <6mm from skin 
surface, flow rate >600ml/min) (Vascular Access Working Group, 2006; Tessitore et al. 
2011) . All ultrasound measurements were obtained in triplicate by a single skilled-
operator and an average obtained. Anastomotic stenosis was defined as a clinically relevant 
ultrasound-detected stenosis with access flow (Qa) <650ml/min (Tessitore et al. 2011) or 
peak systolic velocity ratio (SVR) ≥ 3:1 (Grogan et al. 2005) and failure to mature. 
Complications including need for re-exploration, bleeding and wound infection were also 
recorded. 
 
5.2.6.  Sample size calculation 
 
A priori power calculation determined that a total of 78 patients (39 in each arm) would be 
required to detect an improvement in primary patency at 6 weeks from 50% to 80% with 
80% power and significance 0.05. Due to the short follow-up period, it was not anticipated 
that there would be any drop-outs. However, due to organisational issues, concerns that 
patients may be randomised and then surgery not proceed were overcome by replacing any 
subject withdrawn from the study following randomisation with another subject. 
 
5.2.7.  Statistical analysis 
 
Results were analysed using GraphPad Prism™ 6 (San Diego, CA, USA). Data were tested 
for normality. Assuming normal distribution, a student’s t-test (2-tailed) was used to 
compare continuous data and Fischer’s exact test used to compare categorical data. P<0.05 
was significant. Results are presented as mean (SD) and median (IQR) if not normally 
distributed or as a percentage of the total population. 
 
5.3.  RESULTS 
 
93 patients were considered for participation in the study. 3 were excluded (1 unable to 
provide informed consent; 2 declined participation). 90 patients were randomised. 78 
patients completed the study protocol (36 continuous sutures; 42 interrupted sutures). 8 
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patients had surgery cancelled due to organisational issues and 3 for medical reasons (1 
developed chest pain and 2 had uncontrolled hypertension) after randomisation and 1 
patient had a protocol breach with the surgeon deciding to create a brachiocephalic fistula 
despite meeting the criteria for radiocephalic fistula and having been randomised. All 78 
patients completed the study and follow-up period. The CONSORT diagram (Schulz et al. 
2010) is shown in Figure 5.3. 
 
 
 
Figure 5.3: Trial flow and CONSORT diagram of assignment to interrupted or 
continuous suturing technique. 
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Mean patient age was 58.9 (13.3) years; 67.9% (n=53) male. Table 5.1 outlines basic 
patient demographics, co-morbidities and medications at the time of fistula creation. 
Generally the groups were comparable for age and sex. More patients in the interrupted 
cohort had peripheral vascular disease and atrial fibrillation, while more patients in the 
continuous cohort had adult polycystic kidney disease (APKD) as their cause of renal 
failure. There was no significant difference between the groups with regards dialysis 
status, anaesthetic technique or operating surgeon.  
 
Table 5.1: Baseline characteristics of patients in the BPB and LA cohorts. Results are 
presented as mean (SD) or as a percentage of the total unless otherwise stated. * Median 
(IQR). 
 
 Continuous Interrupted 
Age (years) 57.7 (15.2) 60.0 (12.9) 
Sex (%age male) 69% (n=25) 67% (n=28) 
Cause of renal failure 
Diabetic nephropathy 
APKD 
Glomerulonephritis 
Reflux nephropathy 
Hypertensive nephropathy 
IgA nephropathy 
Other 
Unknown 
 
25% (n=9) 
22% (n=8) 
6% (n=2) 
8% (n=3) 
3% (n=1) 
3% (n=1) 
14% (n=5) 
19% (n=7) 
 
21% (n=9) 
2% (n=1) 
14% (n=6) 
4% (n=2) 
7% (n=3) 
19% (n=8) 
24% (n=10) 
7% (n=3) 
Comorbidities 
Diabetes 
Hypertension 
Atrial fibrillation 
PVD 
IHD 
 
36% (n=13) 
28% (n=10) 
14% (n=5) 
0% (n=0) 
17% (n=6) 
 
31% (n=13) 
43% (n=18) 
5% (n=2) 
9% (n=4) 
19% (n=8) 
Medications 
Antihypertensives (number)* 
Beta-blocker 
Aspirin 
Clopidogrel 
Warfarin 
Statin 
 
2(1,3) 
53% (n=19) 
28% (n=10) 
14% (n=5) 
3% (n=1) 
39% (n=14) 
 
2(1,4) 
57% (n=24) 
17% (n=7) 
12% (n=5) 
12% (n=5) 
43% (n=18) 
Dialysis status 
Pre-dialysis 
Haemodialysis 
Peritoneal dialysis 
Failing transplant 
 
53% (n=19) 
44% (n=16) 
 
3% (n=1) 
 
57% (n=24) 
38% (n=16) 
2% (n=1) 
2% (n=1) 
Surgeon 
1 
2 
3 
4 
5 
6 
Others 
 
14% (n=5) 
19% (n=7) 
6% (n=2) 
8% (n=3) 
17% (n=6) 
11% (n=4) 
25% (n=9) 
 
31% (n=13) 
19% (n=8) 
7% (n=3) 
9% (n=4) 
5% (n=2) 
7% (n=3) 
21% (n=9) 
Anaesthetic technique 
Local anaesthetic 
Supraclavicular block 
General anaesthetic 
 
56% (n=20) 
41% (n=15) 
3% (n=1) 
 
52% (n=22) 
36% (n=15) 
12% (n=5) 
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Pre-operative vessel diameters and radial artery blood flow were comparable between the 
two cohorts with mean radial artery diameter 2.16 (0.27) mm in the continuous cohort and 
2.14 (0.24) mm in the interrupted cohort (P=0.71) and mean cephalic vein diameters 2.59 
(0.61) mm in the continuous cohort and 2.41 (0.43) mm in the interrupted cohort (P=0.14) 
(Table 5.2). Mean pre-operative radial artery blood flow was also comparable between the 
two cohorts (44.3 (13.2) vs. 43.7 (12.9) ml/min; P=0.76) (Table 5.2). 
 
Table 5.2: Pre-operative mean radial artery and cephalic vein diameters and radial 
artery blood flow. Results are presented as mean (SD). 
 
  
Continuous 
 
Interrupted 
 
P-value 
 
Radial artery (mm) 
 
2.16 (0.27) 
 
2.14 (0.24) 
 
0.71 
 
Cephalic vein (mm) 
 
2.59 (0.61) 
 
2.31 (0.430 
 
0.14 
 
Blood flow in radial artery 
(mL/min) 
 
44.3 (13.2) 
 
43.7 (12.9) 
 
0.76 
 
Primary patency at 6 weeks was higher in the interrupted suturing technique group (71.4% 
vs. 47.2%; P=0.01). Immediate patency was also higher in the interrupted suturing 
technique group (92.9% vs. 66.6%; P<0.001). There was no significant difference in 
functional patency at 6 weeks (52.4% vs. 36.1%; P=0.18) (Table 5.3). 
 
Table 5.3: Comparison of patency rates between RCF created with interrupted and 
continuous suturing techniques. Results are presented as a percentage of the total (n). 
 
  
Continuous 
 
Interrupted 
 
P-value 
 
Patency at 6 weeks 
 
47% (n=17) 
 
71% (n=32) 
 
0.01 
 
Functional patency at 6 weeks 
 
36% (n=13) 
 
52% (n=22) 
 
0.18 
 
Immediate patency 
 
67% (n=24) 
 
93% (n=39) 
 
<0.01 
 
Thrill on discharge 
 
53% (n=19) 
 
83% (n=35) 
 
<0.01 
 
Bruit on discharge 
 
56% (n=20) 
 
88% (n=37) 
 
<0.01 
 
Three patients developed an anastomotic stenosis. All were in the interrupted suturing 
technique group. One patient in the continuous suturing cohort developed evidence of a 
venous outflow stenosis (5cm above the anastomosis) during the follow-up period. One 
patient from the interrupted suturing technique cohort required re-exploration and ligation 
for bleeding from the suture line day 3 post-operatively. 3 patients in the continuous 
suturing technique arm were re-explored immediately due to absence of thrill and bruit. 
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Patency was restored in one of the three. 8 patients required surgical revision after 
assessment at 6 weeks due to inadequate maturation and lack of functional patency (3 
anastomotic stenosis (all in the interrupted arm); 2 superficialisation; 3 ligation of 
collaterals). The venous outflow stenosis was successfully treated with angioplasty. 
 
5.4.  DISCUSSION 
 
These results demonstrate superiority of an interrupted suturing technique for the creation 
of radiocephalic fistulae with improved early (6 week) primary patency rates compared to 
continuous techniques (71.4% vs. 47.2%; P=0.01). There was no significant difference in 
functional patency at 6 weeks (52.4% vs. 36.1%; P=0.18). This is the first clinical study to 
demonstrate benefit of a specific suturing technique in arteriovenous fistulae creation. 
 
Latterly there has been increasing interest in involved and technically advanced vascular 
access procedures for patients with complex vascular access needs e.g. central venous 
stenosis (Agarwal et al. 2007) . Such procedures are time consuming, costly, associated 
with significant morbidity and generally have poor outcomes (Bakken et al. 2007). 
Similarly many targets and tariffs focus on optimising prevalent vascular access in long-
term haemodialysis patients (Lok, 2007). Conversely, optimising native AVF usage in 
incident patients, new to haemodialysis is simpler, more cost-effective and may prevent to 
complex “end-stage” vascular access cases for the future. Local root cause analysis 
(presented in Chapter 2) has determined that one of the principal reasons for incident 
patients commencing haemodialysis via a TCVC is failure of the initial AVF to mature 
(Aitken et al. 2014a). Patients who start haemodialysis via a TCVC are more likely to 
continue with a long-term TCVC (with patient choice and loss of future access options 
being sited as potential causes) (Hughes et al. 2013), therefore optimising early AVF 
patency and incident vascular access is essential to minimise TCVC usage. This study has 
demonstrated that simple modifications to the anastomotic suturing technique can improve 
early patency. 
 
Interrupted suturing techniques are well-established and used routinely in clinical practice 
for many microsurgical anastomoses in plastic surgery and maxillofacial surgery (Griffin 
& Thornton, 2005) . However much of the evidence derives from small animal models.  
Schelchter and Guyuron (1994) demonstrated a reduced rate of anastomotic stenosis with 
interrupted suturing techniques in their rabbit femoral artery model. Similarly, Tozzi and 
colleagues (2002) demonstrated increased anastomotic luminal diameter with interrupted 
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suturing in their bovine model of internal mammary artery grafting and Gerdisch et al. 
(2003) showed improved anastomotic compliance, reduced pulsatility indices and 
increased diastolic and peak flow through the vessels in their porcine model of coronary 
artery bypass grafting.  The ability of the anastomosis to expand between the interrupted 
sutures (rather than tightening and puckering as occurs with continuous techniques) 
permits distension of the anastomosis (Lin et al. 2005).This is particularly important in the 
vessels of RCF, which are often sub-2mm (Konner, 2002; Laskar et al. 1988). 
Additionally, improved anastomotic compliance and reduced compliance mismatch have 
been found by other authors to improve haemodynamics and are believed to reduce 
perianastomotic neointimal hyperplasia (Lin et al. 2005; Clark et al. 1976; Smith et al. 
2012). Notably however, Joos and colleagues (1990) failed to demonstrate any histological 
differences at the anastomosis of rodent femoral vein 3 weeks following anastomosis with 
interrupted and continuous microsuturing techniques. Ongoing work at an English 
university evaluating the relationship between anastomotic compliance and histological 
changes at AVF anastomoses in humans, may better clarify this in the future (Smith et al. 
2012). 
 
Several clinical studies have demonstrated benefit of interrupted suturing techniques (or 
modifications of the interrupted suturing technique) for hepatic artery reconstruction in 
liver transplantation (Starzl et al. 1985) and coronary artery bypass grafting (Loop et al. 
2009). Other authors have shown no difference in patency in animal models (Chen et al. 
2001; Lee et al. 1982). The sole previous clinical study of suturing technique for RCF, 
showed no benefit of interrupted over continuous suturing technique (Laskar et al. 1988). 
Their patient numbers however were small (only 20 patients in each arm) and follow-up 
was over 3 years, potentially missing the important differences in early patency related to 
the anastomotic technique and risking confounding factors, not least neointimal 
hyperplasia and venous outflow stenosis at sites of needle injury (Roy-Chaudhury et al. 
2003). Studies of side-to side anastomoses in both RCF and BCF are small and 
retrospective. Nevertheless they have indicated that, despite the obvious improved flow 
volume across the anastomosis, AVF patency is not improved compared to simple end-to-
side anastomoses (Hong et al. 2013; Moini et al. 2009).  Zeebregts and colleagues (2004) 
demonstrated improved patency and fewer anastomotic stenoses in AVF created with 
interrupted titanium clips over continuous sutures. They cite superior haemodynamics and 
improved healing pattern with the interrupted clipping technique as an explanation. In our 
cohort, the incidence of anastomotic stenosis was actually higher in the interrupted 
technique arm. Three patients in the interrupted suturing technique arm had an anastomotic 
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stenosis. All three went on the have successful surgical revision of the AVF, ultimately 
resulting in functionally patent AVF. It is hypothesised that the patients in the interrupted 
technique arm of the study who developed an anastomotic stenosis may be akin those in 
the continuous technique arm who had an early thrombosis, but they retained patency 
(albeit with an anastomotic stenosis) perhaps due to improved haemodynamic properties of 
the anastomosis.  
 
One of the criticisms of the interrupted suturing technique is that it is more time consuming 
(Chen et al. 2001) . Our interrupted technique is similar to the “combined interrupted-
continuous” technique described by Lykoudis and colleagues (2008), utilising interrupted 
sutures around the heel of the anastomosis and then continuous sutures for the rest. Other 
authors who report an “interrupted” suture technique commonly use modifications of this 
with partial interrupted and partial continuous sutures (Starzl et al. 1985; Tzeng et al. 
2010). In this way, it takes no longer than a standard continuous anastomosis to perform. 
 
Additionally, there is a theoretical risk that interrupted sutures could bleed more from the 
gaps between suture lines. Chen and colleagues (2001) found a significantly increased 
bleeding time and blood loss from interrupted suture lines in their rabbit femoral artery 
model. Alternatively it could be argued that the improved anastomotic compliance of the 
interrupted anastomosis actually improves contraction and may reduce the risk of bleeding( 
(Lin et al. 2005).  In our cohort, the single bleeding complication was in the interrupted 
suturing technique arm. Bleeding from the anastomosis was identified when the patient 
underwent re-exploration 3 days post-operatively and the fistula required ligated. The 
exact bleeding point could not be identified. It is postulated that this bleed was a sporadic 
event, however no clear conclusions can be drawn from this as the study was inadequately 
powered to detect complications.  
 
The primary end point for this study was primary patency at 6 weeks as assessed by two 
independent blinded members of the research team (an experienced clinician and a senior 
dialysis nurse). An early end point was chosen to minimise the multiple confounding 
factors (e.g. cannulation technique, outflow stenosis etc.) that are inherent to evaluating 
vascular access. A clinically relevant end point for the study was essential. Ideally primary 
functional patency evaluated by ability to sustain dialysis would have been chosen as the 
end point. However, due to the large number of patients who were pre-dialysis at the time 
of AVF creation, this was not feasible. It is acknowledged that clinician assessment could 
be open to observer bias, however both observers were blinded and there was 100% 
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agreement between independent assessors for both patency and functional patency, 
indicating good validity and reproducibility. Furthermore, confirmation of patency by 
defined ultrasonographic criteria provides a second quantitative measurement of 
functionality. 
 
As with any operative technique, both the interrupted and continuous suturing techniques 
in this study are susceptible to surgeon bias. Nearly half of the AVF created in this study 
were formed by only two surgeons. One routinely performed RCF using interrupted 
technique, the other routinely used a continuous technique. There was no significant 
difference in the relative proportions of interrupted and continuous technique AVF created 
by any surgeon and the study was underpowered to evaluate outcomes by individual 
surgeon. However it is recognised that the technical abilities and preferences of individual 
surgeons could skew results. 
 
In conclusion, this is a single-centre randomised controlled trial comparing interrupted to 
continuous suturing techniques for creation of the radiocephalic AVF anastomosis. 
Superiority of the interrupted suturing technique with improvement in the primary outcome 
(patency at six weeks) has been demonstrated. On this basis, it is advocated that an 
interrupted suturing technique be adopted for all radiocephalic fistulae.  
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A RANDOMISED CONTROLLED TRIAL COMPARING LOCAL 
VERSUS REGIONAL ANAESTHESIA IN ARTERIOVENOUS 
FISTULA CREATION 
 
6.1.  INTRODUCTION 
 
As discussed in the previous chapter, one of the major shortcomings of autologous AVF is 
their high early failure rate. 
 
Different anaesthetic techniques can influence both pre-operative arterial and venous 
diameters and early blood flow within the fistula, factors which are known to affect AVF 
maturation (Dember et al. 2008; Lin et al. 2005; Hofstra et al. 1995). Regional anaesthetic 
techniques can directly influence venous diameter as well as intra- and post-operative 
blood flow (Wong et al. 2011). However, there is no conclusive evidence that any 
particular anaesthetic technique can significantly influence either early patency or long-
term AVF outcome. 
 
General anaesthesia, regional anaesthesia and local anaesthetic (LA) infiltration are all 
acceptable anaesthetic techniques for AVF creation. Whilst general anaesthesia increases 
intra-operative vasodilatation, it is associated with increased cardiorespiratory 
complications in ESRD patients (Howell et al. 1998). Regional anaesthesia, such as a 
brachial plexus block (BPB), involves targetted injection of LA to specifically “block” the 
motor and sensory nerves that supply the operative site, avoiding the need for general 
anaesthesia. Both local and regional anaesthesia avoid the risks associated with general 
anaesthesia, but only regional anaesthesia produces an associated sympathetic nerve block. 
This sympathetic blockade increases venous diameter and arterial flow both intra-
operatively and in the early post-operative period (Shemesh et al. 2006; Mouquet et al. 
1989). Maintenance of adequate blood flow through the fistula in the perioperative period 
may prevent thrombosis and early fistula failure and can assist in maturation (Mouquet et 
al. 1989). Additionally, arterial and venous spasm has been demonstrated to be more 
common with local infiltration than regional (or general) anaesthesia (Konner, 1999).  
Several small, single-centre observational cohort studies have previously demonstrated 
that, compared to local infiltration, a BPB results in better immediate AVF patency rates 
(Shemesh et al. 2006; Zaliunate et al. 2011) and also improved surgical ability to identify 
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the optimal site for intervention (Glover et al. 2007). To date however there is no evidence 
that any short-term benefits of regional anaesthesia can influence medium- or long-term 
AVF patency. There are only two small, randomised trials in the literature comparing BPB 
and LA. One detected increased AVF flow rates for up to 8 weeks in patients who received 
a BPB compared to local infiltration, but with no difference in primary patency 
(Laskowski et al. 2007). The other demonstrated increased vessel diameters in the BPB 
cohort (Renaud et al. 2015).   
It was hypothesised that immediate and medium-term AVF patency could be improved by 
using regional anaesthesia (BPB) compared to local anaesthesia. We aimed to conduct a 
randomised controlled trial to answer the question: Does regional anaesthesia, compared to 
local infiltration, improve medium-term AVF patency (3 months)? 
 
6.2.  METHODOLOGY 
 
6.2.1.  Study design and participants 
 
This prospective randomised controlled trial recruited patients from three University 
teaching hospitals in Glasgow (Stobhill Ambulatory Care Hospital, Western Infirmary and 
Queen Elizabeth University Hospital) between February 2013 and October 2015. All 
adults patients (over the age of 18 years) who were having primary RCF or BCF fistulae 
created were eligible to participate. Patients were excluded if they were unable or 
unwilling to provide consent, if they had previous ipsilateral attempts at AVF creation, if 
the radial or brachial artery was <1.8mm or cephalic vein was <2mm at the wrist or <3mm 
at the elbow on pre-operative ultrasound (without tourniquet). Patients with allergy to local 
anaesthesia, coagulopathy, infection at anaesthetic or surgical site, significant peripheral 
neuropathy or neurological disorder affecting the upper limb or known ipsilateral central 
vein stenosis (even if treated) were also excluded. 
 
Ethical approval for this trial was granted by the West of Scotland Research Ethics 
Committee 5 (12/WS/0199) and research was carried out in accordance with the 
Declaration of Helsinki and adhered to the standards of ICH Good Clinical Practice. All 
participants provided written, informed consent. The protocol was published prior to the 
initiation of recruitment (Macfarlane et al. 2013). 
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6.2.2. Randomisation 
 
Patients were randomised in a 1:1 fashion to either BPB or LA anaesthetic technique. The 
randomisation sequence (in blocks of 8) was generated using a web-based computer 
random sequence generator. Sequentially numbered, opaque, sealed envelopes were 
produced by a colleague independent of the research team. 
 
6.2.3. Recruitment 
 
Patients were approached pre-operatively by a member of the research team. Pre-operative 
ultrasound was performed to ensure suitable vessels for AVF creation. If suitable and 
willing to participate, they were assigned a study number and sealed envelope. The sealed 
envelope was opened by the anaesthetist immediately pre-operatively. Due to the nature of 
the intervention, it was not possible to blind, patient, surgeon, anaesthetist or study team 
involved at the time of surgery, however the Vascular Access Nurse Specialist who 
assessed the primary end point was independent and blinded to the randomisation. 
 
6.2.4.  Operative technique 
 
The procedures were performed by a total of nine experienced consultant vascular access 
surgeons (or senior trainees under consultant supervision).  No formal operative technique 
was stipulated within the study protocol in order to permit individual surgeons to react to 
variations in anatomy that might be encountered intra-operatively. Nevertheless, surgeons 
largely followed a standard operating technique. All surgeons used operating loupes with 
x8 magnification and microinstruments. A standard approach to the vessels was performed 
with transverse incision at, or just below, the elbow crease for BCF and longitudinal 
incision at the wrist for RCF. The cephalic vein (or median cubital vein if suitable at the 
elbow) were dissected and skeletalised for a short length proximally. Visible branches 
were ligated and divided. The vein was then divided, spatulated and flushed with 
heparinised saline. The artery was then dissected and controlled with bulldog clamps. At 
the elbow, a true BCF was created in every case rather than proximal RCF. The decision to 
utilise median cubital, perforating branch or true outflow cephalic vein was left to the 
surgeon’s discretion. Similarly the surgeon’s discretion was utilised to determine the size 
of the arteriotomy performed based on risks and benefits for the individual patient (e.g. 
vessel quality, risk of steal etc.) Generally arteriotomies on the brachial artery were 
between 3-5mm in length with radial artery arteriotomies made slightly larger (7-10mm). 
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An end-to-side anastomosis of vein to artery was then performed with continuous 6.0 
(elbow) or 7.0 (wrist) Prolene® (Ethicon, Sommerville, NJ, USA). Most procedures were 
performed as day case surgery. 
 
6.2.5.  Anaesthetic techniques 
 
Two consultant anaesthetists skilled in BPB (or senior trainees under consultant 
supervision) performed all of the BPBs in this study. Patients in the BPB group all 
received an ultrasound guided BPB. The supraclavicular approach was chosen unless there 
was a contraindication, in which case an axillary block was undertaken. A 1:1 mixture of 
0.5% L-bupivacaine and 1.5% lignocaine with epinephrine (1 in 200,000) was injected up 
to a maximum volume of 40 mL (Soares et al. 2007). Maximum dose limits of 2 mg/kg for 
bupivacaine and 7 mg/kg for lignocaine with epinephrine were observed. The time taken to 
perform the block and any technical problems during block insertion (intravascular 
puncture, paraesthesia) were recorded. Measurements of the sensory block of the 
musculocutaneous, median, radial and ulnar nerves were recorded every five minutes by a 
non-blinded observer using a previously validated 3-point scale using a cold test: 0 = no 
block, 1 = analgesia (can feel touch but not cold) and 2 = anaesthesia (patient cannot feel 
touch). Motor block of the musculocutaneous, median, radial and ulnar nerves was graded 
as either 0 = no block, 1 = paresis, 2 = paralysis (Rodriguez et al. 2004). Measurements 
were continued until either the sensory block was adequate in the operative area 
distribution or a maximum of 20 minutes had elapsed at which point the block was 
supplemented by targetted axillary or midhumeral supplementation as appropriate using 
ultrasound. If a BPB block failed despite supplementation, LA infiltration was used. This 
was recorded as a failed block. If additional analgesia or conversion to general anaesthesia 
was required, this was regarded as a failed block.  
 
Patients in the LA infiltration group received infiltration of local anaesthetic into the 
surgical site by the operating surgeon under sterile conditions using a combination of 0.5% 
L-bupivacaine and 1% lignocaine injected subcutaneously immediately prior to the 
commencement of surgery. Maximum dose limits of 2 mg/kg for bupivacaine and 3 mg/kg 
for lignocaine were observed, recognising that these are additive.  
 
 
 
 171 
6.2.6.  Duplex ultrasound 
 
Pre-operative vein mapping and Doppler ultrasound assessment of the upper limb arterial 
tree was performed on all patients prior to the administration of anaesthesia by a member 
of the study team experienced in ultrasound assessment of peripheral vessels. 
Measurement of the cephalic vein diameter 2cm above the wrist and at the elbow and of 
the basilic vein of the elbow were recorded in triplicate. Radial and brachial artery 
diameters and brachial artery blood flow was also recorded in triplicate. Similar 
assessment of the vasculature was performed following administration of anaesthesia, 
immediately pre-operatively and at 3-month follow-up. At the 3-month follow-up visit the 
diameter of the outflow cephalic vein was measured at 5, 10 and 15cm intervals above the 
anastomosis. 
 
6.2.7.  Outcome Measures 
 
The primary end point was primary patency at 3 months. Secondary end points were 
immediate patency (at time of discharge from hospital), functional patency (assessed 
clinically and by ultrasound) at 3 months and the change in brachial artery blood flow and 
diameter and cephalic vein diameter immediately following administration of anaesthesia 
and after 3 months. Additionally the need for additional administration of local 
anaesthesia, pain scores and patient satisfaction scores were also evaluated. Operative and 
anaesthetic complications were recorded.  
 
Primary patency at 3 months was assessed by a Vascular Access Nurse Specialist, blinded 
to the mode of anaesthesia. Primary patency was defined clinically as the presence of a 
thrill or bruit in the absence of any additional intervention to re-establish function. 
Immediate post-operative patency (patency at time of discharge from hospital) was also 
assessed clinically (presence of thrill and/or bruit) by the research team. Functional 
patency at 3 months was assessed by the research team both clinically (used for dialysis or, 
in pre-dialysis patients, deemed suitable for cannulation by the Vascular Access Nurse 
Specialist) and by ultrasound (>6mm diameter, <6mm from skin surface, flow rate 
>600ml/min) (NKF-KDOQI, 2006; Vascular Access Working Group, 2006). All 
ultrasound measurements were obtained in triplicate by a member of the research team pre-
anaesthetic, immediately following anaesthesia and at 3 months follow-up as described 
previously. Pain scores were recorded on a Numeric Pain Rating Scale (0 (no pain) to 10 
(worst pain ever)) immediately after and one hour following the procedure. Patient 
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satisfaction scores were recorded prior to discharge on a Numeric Pain Rating Scale (0 
(very dissatisfied) to 10 (highly satisfied)).  
 
6.2.8.  Sample size calculation 
 
A priori power calculation determined that a total of 126 patients (63 in each arm) would 
be required to detect an improvement in primary patency at 3 months from 65% to 85% in 
patients having AVF creation under BPB with 80% power and significance 0.05, allowing 
for 10% loss to follow-up or mortality. The 65% primary patency rate at 3 months is 
representative of maturation rates for AVF described elsewhere in the literature (Dember et 
al. 2008). We anticipated that an increase in primary patency at 3 months from 65 to 85% 
was a conservative estimate given local observational data had previously demonstrated 
AVF patency of 93% in patients having BPB compared to 52% in those having AVF 
creation under LA (Zaliunate et al. 2011). 
 
6.2.9.  Statistical analysis 
 
Results were analysed using SPSS Statistics for Windows Version 22.0 (IBM Corp., 
Armonk, NY). Data were tested for normality. Assuming normal distribution, a student’s t-
test (2-tailed) was used to compare continuous data and chi-squared or Fischer’s exact test 
used to compare categorical data. Mann-Whitney U-tests were used for non-normally 
distributed data. P<0.05 was significant. Results are presented as mean (95% CI ±SD) or as 
median (IQR) if not normally distributed, or as a percentage of the total population and 
odds ratio (OR). Missing data was limited and assumed to be missing at random. If a data 
point was missing, this case was removed from analysis of the specific variable of interest. 
Data has been analysed on an intention-to-treat basis. 
 
The trial was registered prospectively with the ClinicalTrials.gov database 
(NCT01706354). 
 
6.3.  RESULTS 
 
163 patients were considered for participation. 37 were excluded and 126 patients were 
randomised. 125 patients completed the study protocol (63 LA; 62 BPB). 1 patient had a 
protocol breach having been randomised prior to vein mapping ultrasound at which point 
no suitable vessel was found for RCF/BCF creation. This patient was followed-up on an 
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intention-to-treat basis. All 126 patients completed the study and follow-up period. The 
CONSORT diagram is shown in Figure 6.1 (Schulz et al. 2010). 
 
 
 
 
 
                        
 
 
 
Figure 6.1: Trial flow and CONSORT diagram of assignment to local or regional 
anaesthesia. 
 
 
The groups were comparable for age, sex, co-morbidities, medications and renal 
replacement modality (Table 6.1). There was no significant difference between the groups 
with regards operating surgeon or site of AVF.  
 
 
Assessed for eligibility (n=163) 
Excluded  (n=37) 
i Failed to meet inclusion 
criteria (n=24) ((no suitable 
vessels (14), on warfarin (10)) 
i Declined to participate (n=12) 
i Unable to provide informed 
consent  (n=1) 
 
Analysed (n=63)  
Lost to follow-up (n=0)  
Discontinued intervention (n=0) 
Allocated to BPB (n=63) 
i Received allocated intervention (n=62) 
i Did not receive allocated intervention 
(n=1)          
(protocol breach- randomised prior to vessel 
assessment then found to have no suitable 
vessels) 
Lost to follow-up (n=0)  
Discontinued intervention 
(n=0) 
Allocated to LA (n=63) 
i Received allocated intervention 
(n=63)  
Analysed (n=63) 
  
Allocation 
Analysis 
Follow-Up 
Enrolment 
Randomised  
(n=126) 
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Table 6.1: Baseline characteristics of patients in the BPB and LA cohorts. Data are 
presented as n (%) or mean ± SD unless otherwise stated. *median (IQR)  
 
 
 Overall patient 
population (n=126) 
BPB 
(n=63) 
LA 
(n=63) 
Age (years) 60.8+/-14.8 59.5+/-15.3 62.1+/-14.3 
Sex (% male) 79 (62.7%) 40 (63.5%) 39 (61.9%) 
Primary renal disease 
Diabetes 
Multisystem 
Interstitial 
Glomerulonephritis 
Unknown 
 
21 (16.7%) 
16 (12.7%) 
41 (32.5%) 
24 (19.0%) 
24 (19.0%) 
 
10 (15.9%) 
9 (14.3%) 
16 (25.4%) 
15 (23.8%) 
13 (20.6%) 
 
11 (17.5%) 
7 (11.1%) 
25 (39.7%) 
9 (14.2%) 
11 (17.5%) 
Co-morbidities 
Diabetes 
IHD 
CVA 
Hypertension 
Obesity (BMI <30) 
 
34 (27.0%) 
48 (38.1%) 
9 (7.1%) 
93 (73.8%) 
41 (32.5%) 
 
17 (27.0%) 
22 (34.9%) 
3 (4.8%) 
40 (68.3%) 
22 (34.9%) 
 
17 (27.0%) 
26 (41.2%) 
6 (9.5%) 
53 (84.1%) 
19 (30.2%) 
Medications 
Antihypertensives (number)* 
Aspirin 
Clopidogrel 
Statin 
 
2 (1,4) 
85 (67.4%) 
29 (23.0%) 
73 (57.9%) 
 
2 (1,4) 
42 (66.7%) 
13 (20.6%) 
38 (60.3%) 
 
2 (1,4) 
43 (68.3%) 
16 (25.4%) 
35 (55.6%) 
RRT modality at time of 
randomisation 
HD 
Pre-dialysis 
 
 
63 (50%) 
63 (50%) 
 
 
30 (47.6%) 
33 (52.4%) 
 
 
33 (52.4%) 
30 (47.6%) 
Site of AVF 
RCF 
BCF 
 
51 (40.5%) 
75 (59.5%) 
 
26 (41.2%) 
37 (58.7%) 
 
25 (39.7%) 
38 (60.3%) 
Surgeon 
1 
2 
3 
4 
5 
Others 
 
35 (27.8%) 
23 (18.3%) 
16 (12.7%) 
16 (12.7%) 
14 (11.1%) 
22 (17.4%) 
 
16 (25.4%) 
13 (20.6%) 
8 (12.7%) 
8 (12.7%) 
8 (12.7%) 
10 (15.9%) 
 
19 (30.2%) 
10 (15.9%) 
8 (12.7%) 
8 (12.7%) 
6 (9.5%) 
12 (19.0%) 
Anaesthetist 
1 
2 
  
36 (57.1%) 
27(42.9%) 
 
 
 
51 patients (40.5%) had RCF creation, with the remainder having BCF creation. Mean 
brachial artery flow was 30.7±13.1mL/min (95% CI: 28.4%, 33.0%) (n=124). There was 
no difference in pre-operative brachial artery blood flow in patients who had AVF creation 
under BPB compared to LA (31.3 ± 14.1mL/min (95% CI: 30.5, 35.1) vs. 30.1 ± 
12.1mL/min (95% CI: 27.0, 31.4); P=0.61). In patients undergoing RCF creation, mean 
pre-operative radial artery diameter was 2.1 ± 0.29mm (95% CI: 1.99, 2.21) and cephalic 
vein (wrist) was 2.28 ± 0.49mm (95% CI: 2.15, 2.41). In BCF, mean brachial artery 
diameter was 3.05 ± 0.57mm (95% CI: 3.01, 3.09) and cephalic vein (elbow) was 3.23 ± 
0.75mm (95% CI: 3.1, 3.35). There was no significant intraobserver variability in the 
measurement of brachial artery/ cephalic vein diameter or brachial artery blood flow 
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(Appendix 3). There were no significant differences in any of these parameters between 
BPB and LA cohorts (Table 6.2). 
 
Table 6.2: Pre-operative vessel diameters and brachial artery blood flow. All 
measurements have been obtained in triplicate. Mean (95% CI) are presented.  
 
 Overall patient 
population  
BPB 
 
LA 
 
P-
value 
BA blood flow (mL/min) (n=124) 30.7  
(28.4, 33.0) 
31.3  
(30.5, 35.1) 
30.1 
(27.0, 31.4) 
0·61 
RCF (n=51) 
Radial artery diameter (mm) 
 
 
Cephalic vein (wrist) diameter (mm) 
 
2.10  
(1.99, 2.21) 
 
2.28  
(2.15, 2.41) 
 
2.11  
(2.0, 2.21) 
 
2.21  
(2.13, 2.29) 
 
2.08  
(1.99, 2.17) 
 
2.32  
(2.24, 2.4) 
 
0.79 
 
 
0.82 
BCF (n=75) 
Brachial artery diameter (mm) 
 
 
Cephalic vein (elbow) diameter (mm) 
 
3.05  
(3.01, 3.09) 
 
3.23  
(3.10, 3.33) 
 
3.09  
(3.04, 3.14) 
 
3.30  
(3.12, 3.48) 
 
3.02  
(3.0, 3.04) 
 
3.16 
(3.05, 3.25) 
 
0.75 
 
 
0.31 
 
Primary patency at 3 months was higher in patients having their AVF created under BPB 
than LA (84.1%  (73.0%, 91.3%) vs. 61.9% (49.5%, 72.3%); P=0.005; OR 2.1). This 
difference was observed for both RCF and BCF but the effect size appeared to be greater 
in RCF (76.9% (64.6%, 87.4%) vs. 48.0% (34.8%, 61.5%); P=0.03; OR 3.6). Immediate 
patency was also better in patients having BPB (92.6% (82.3%, 97.0%) vs. 73.0% (60.9%, 
81.4%); P=0.005; OR 4.6). There was 100% concordance for functional patency at 3 
months when assessed clinically and by ultrasound. There was no significant difference in 
functional patency at 3 months overall (41.3% (30.0%, 53.6%) vs. 27.0% (17.5%, 39.1%); 
P=0.09; OR 7.3), however a difference in favour of BPB was observed in RCF (73.1% 
(60.3%, 84.2%) vs. 40.0% (27.6%, 53.8%); P=0.02; OR 4.1) (Table 6.3). 
 
Patients in the BPB group experienced significant increase in both arterial and venous 
diameters following administration of anaesthesia. A similar change was not observed in 
the LA patient cohort (Table 6.4). An increase in brachial artery blood flow was also 
observed in the BPB cohort that was not seen in the LA group, when comparing 
immediately prior to and immediately following administration of anaesthesia (+45mL/min 
(95% CI: 16, 74) vs. +1mL/min (95% CI: -6, 8)); P<0.001). At 3 months follow-up, there 
was no significant difference between the groups in the diameter of the outflow vein at 5, 
10 or 15cm above the anastomosis in mature fistulae. There were more patients in the BPB 
cohort with brachial artery flows >250mL/min at 3 months follow-up (68.3% (56.0%, 
78.5%) vs. 42.9% (31.4%, 55.1%); P=0.01; OR 2.9). 
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Table 6.3: Patency rates of AVF in BPB and LA cohorts (immediate*, 3-month 
primary and 3-month functional). Numbers presented are total number of patients 
(percentage [95% CI]).* Immediate patency is patency at time of discharge from hospital.  
 Overall patient 
population (n=126) 
BPB 
(n=63) 
LA 
(n=63) 
P-
value 
ALL AVF 
Immediate patency* 
 
Primary patency at 3 months 
 
Functional patency at 3 months 
 
104 (82.5%) 
[74.9%, 88.2%] 
92 (73.0%) 
[64.6%, 80.3%] 
44 (34.9%) 
[27.1%, 43.6%] 
 
58 (92.1%) 
[82.3%, 97.0%] 
53 (84.1%) 
[73.0%,91.3%] 
26 (41.3%) 
[30.0%, 53.6%] 
 
46 (73.0%) 
[46.2%, 64.9%] 
39 (61.9%) 
[49.5%,72.3%] 
18 (28.6%) 
[18.8%, 40.7%] 
 
0.005 
 
0.005 
 
0.15 
RCF 
Immediate patency* 
 
Primary patency at 3 months 
 
Functional patency at 3 months 
 
38 (74.5%) 
[62.5%, 85.8%] 
32 (62.7%) 
[50.1%, 75.9%] 
29 (56.9%) 
[44.2%,70.6%] 
 
23 (88.5%) 
[76.9%, 98.9%] 
20 (76.9%) 
[64.6%, 87.4%] 
19 (73.1%) 
[56.2%, 88.8%] 
 
15 (60.0%) 
[40.7%, 77.6%] 
12 (48.0%) 
[34.8%, 61.5%] 
10 (40.0%) 
[23.4%, 59.3%] 
 
0.02 
 
0.03 
 
0.02 
BCF 
Immediate patency* 
 
Primary patency at 3 months 
 
Functional patency at 3 months 
 
66 (88.0%) 
[77.2%, 92.9%] 
60 (80.0%) 
[66.4%,85.0%] 
15 (20.0%)  
[11.9%, 29.5%] 
 
35 (94.6%) 
[78.5%,98.0%] 
33 (89.1%) 
[72.2%,94.7%] 
7 (18.9%) 
[8.9%, 33.7%] 
 
31 (81.5%) 
[66.2%, 91.1%] 
27 (62.7%) 
[55.1%, 73.2%] 
8 (21.1%) 
[10.8%, 36.6%] 
 
0.08 
 
0.05 
 
0.95  
 
Table 6.4: Change in vessel diameters before and immediately following 
administration of anaesthesia. Results are presented as median (95% CI). Δ change 
(post-anaeasthetic minus pre-anaesthetic). 
 
 BPB LA P-value 
Δ Cephalic vein 
(wrist) diameter (mm) 
(n=87) 
0.1 (-0.03, 0.5) -0.5 (-1.7, 3.2) 0.37 
Δ Cephalic vein 
(elbow) diameter 
(mm) (n=124) 
0.5 (0.2, 1.2) 0.1 (-0.1, 0.2) 0.006 
Δ Basilic vein (elbow) 
diameter (mm) 
(n=121) 
0.5 (0.2, 1.4) 0.1 (-0.4, 1.3) 0.09 
Δ Radial artery 
diameter (mm) 
(n=124) 
0.1 (0, 0.4) 0 (-2.4, 4.7) 0.01 
Δ Brachial artery 
diameter (mm) 
(n=124) 
1.6 (0.5, 2.6) 0.2 (-0.4, 0.3) <0.0001 
Δ Brachial artery 
blood flow (mL/min) 
(n=120) 
45 (13,75) 1 (-10, 9) <0.001 
 
 
Patients in the BPB cohort had mean volume of 23.7±4.0mL of 0.5% L-bupivacaine + 
1.5% lignocaine with adrenaline (1 in 200,000), whilst a mean volume of 14.7 ± 5.0mL of 
0.5% L-bupivacaine + 1% lignocaine was infiltrated in the LA cohort. The time taken to 
administer anaesthesia was significantly longer in the BPB cohort (17.0±-5.7 (95% CI: 
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12.5, 21.5) vs. 3.4 ± 2.5min (95% CI: 2.3, 4.5) ; P<0.0001). No patient developed any 
anaesthetic complications. Both cohorts of patients achieved excellent anaesthesia, with all 
patients reporting pain scores of 0 both during and 1 hour following completion of surgery. 
Significantly fewer patients in the BPB cohort required additional local anaesthetic 
supplementation (3.2% (1.2%, 7.5%) vs. 14.3% (8.5%, 21.2%); P<0.001). For the two 
patients in the BPB who required additional anaesthesia, one responded to targetted 
supplementation with an axillary block and one had a failed block necessitating local 
anaesthetic field infiltration. No patient required conversion to general anaesthesia. 
 
Four patients had a change in operative plan following administration of BPB. Initial 
decision to create a BCF was modified to RCF as the diameter of the cephalic vein at the 
wrist increased following BPB. There was no difference in the duration of surgery between 
BPB and LA cohorts (62.1 ± 11.8 (95% CI: 55.4, 68.8) vs. 62.8 ± 12.2min (95% CI: 57.5, 
68.1); P=0.77). One patient in the BPB developed a superficial wound infection and three 
patients in the LA cohort developed clinically significant steal necessitating operative 
intervention. No patient in the BPB cohort developed steal. Patient satisfaction scores were 
higher in the BPB cohort (9.8 ± 0.6 (95% CI: 9.7, 9.9) vs. 9.4 ± 1.0 (95% CI: 9.2, 9.6); 
P=0.02). 
 
6.4. DISCUSSION 
 
These results demonstrate superiority of BPB for the creation of AVF, with improved early 
(3 month) primary patency rates compared to LA (84.1%  (73.0%, 91.3%) vs. 61.9% 
(49.5%, 72.3%); P=0.005; OR 2.1). This difference was associated with immediate and 
significant increases in both vessel diameter and brachial artery blood flow following 
administration of BPB. Patient satisfaction was high in both groups, but superior in the 
BPB group. This is the first randomised controlled trial to demonstrate benefit of a BPB on 
medium-term AVF patency and one of the few studies in which anaesthetic technique 
influences surgical outcome. 
 
These findings are consistent with other recent studies which demonstrate an improvement 
in arterial blood flow and vasodilatation with regional anaesthesia (Sahin et al. 2011; 
Meena et al. 2015; Howell et al. 1998; Lo et al. 2010). The effect size of this difference 
appeared to be greater in distal RCF with small vessels. The biological plausibility of these 
observations is supported by the observed changes in the haemodynamics of the vascular 
tree. Dilatation of both artery and vein makes the anastomosis technically less challenging 
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(particularly in very small vessels) whilst improved arterial inflow (Lin et al. 2005; Wong, 
2006), increased venous compliance (Lin et al. 2005) and reduced pulsatility index 
(Hofstra et al. 1995) promote blood flow through the AVF immediately after creation and 
reduce early thrombosis within the first hours to days. Once laminar “fistula-type” blood 
flow has been established, the rate of thrombosis appears similar between the two cohorts. 
Like other authors who found improved blood flow at 8 weeks with BPB compared to LA 
(Sahin et al. 2011), we observed that more patients in the BPB cohort had good blood flow 
via the AVF at 3 months  (brachial artery blood flow >250mL/min). This is perhaps simply 
as there were more patent AVF in the BPB group, rather than any lasting effect of the BPB 
per se.  
 
The benefits of BPB compared to LA in promoting AVF maturation appeared to occur 
early, with the difference in patency between the two cohorts manifesting immediately (at 
time of hospital discharge) but persisting until at least 3 months. Similarly the benefits 
were more marked in achieving a patent fistula rather than in obtaining functional patency 
with a fistula capable of sustaining dialysis. This discrepancy was most marked in the 
BCF, which achieved 80% primary patency at 3 months but only 20% functional patency. 
These functional patency rates fall below those observed in other retrospective series 
(Wilmink et al. 2016). The explanation for this is likely to be multifactorial. Balloon 
assisted-maturation is not performed at our institution and none of the AVF in this study 
had received any procedure to promote functional maturation by 3 months follow-up. It is 
anticipated that with future interventions, subsequent functional patency rates will 
improve. Secondly, the it is well recognised that advancing age, coronary artery disease 
and peripheral vascular disease are associated with inadequate maturation (Lok et al. 2006; 
Masengu et al. 2015). The patients in this cohort had significant co-morbidities. Finally 
over one-third of patients had a BMI >30, which is likely to necessitate superficialisation 
to achieve functional patency. 
 
A further benefit of regional anaesthesia is that, as demonstrated elsewhere, the operative 
plan in this study was modified in several cases due to the vasodilatation from BPB, and 
more distal AVF were created (Reynolds et al. 2011). Indeed, in one study of patients 
deemed not to have any suitable vessels for autologous access, one-third of patients listed 
for arteriovenous graft insertion successfully underwent AVF creation following BPB 
(Schenk, 2010). 
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The administration of the BPB is operator-dependent and it is well recognised that failure 
rate of BPB is higher if the operator is inexperienced (Sandhu et al. 2006). In this study, 
only two consultant anaesthetists, experienced in ultrasound-guided BPB, performed the 
procedure to minimise inter-operator variability. There were no complications and only 
one block failure which was a combination of poor ultrasound views and patient 
discomfort during the nerve block leading to a decision to change to LA which would be 
quicker for the patient. Complications of supraclavicular blocks such as pneumothorax can 
occur, and adequate training is necessary to undertake these blocks (Soares et al. 2007). 
Nevertheless with the advent of ultrasound guidance this block is now commonly used for 
upper limb surgery (Perlas et al. 2009). It may be that other approaches to the brachial 
plexus confer the same benefit as all approaches result in sympathetic blockade but this 
cannot be inferred with certainty from the data presented here. 
 
BPB took significantly longer than LA to perform (17.0 vs. 3.4 minutes; P<0.0001) and 
necessitated the presence of a skilled anaesthetist, which is not the case for LA. Performing 
regional anaesthesia and surgery in parallel rather than sequentially can help improve 
efficiency and minimise operative delays between patients (Chiazapis et al. 2014). Whilst 
an analysis of cost was outwith the scope of this work, any additional costs associated with 
employing an anaesthetist to perform BPB could potentially be offset against the cost 
savings of improved AVF maturation, reduction in need for second and subsequent 
surgeries and the complications of TCVC use. 
 
The high early thrombosis rate of AVF observed in recent randomised controlled trials 
(Dember et al. 2008; Irish et al. 2017) coupled with an increasingly elderly, co-morbid 
population, have seen a growing body of opinion advocating alternatives to autologous 
vascular access in recent years (Tozzi et al. 2014a; Glickman, 2016). Furthermore, political 
pressure (such as the tariff imposed by the government in England and Wales) focuses on 
optimising prevalent, rather than incident, vascular access (Lok, 2007). Many of these 
prevalent patients have complex vascular access needs such as multiple failed AVF, 
prolonged TCVC use and central venous stenosis (Agarwal et al. 2007). Obtaining 
vascular access in such patients is time consuming, costly, associated with significant 
morbidity and generally has poor outcomes (Bakken et al. 2007). Conversely, this study 
has focussed on simple RCF and BCF creation, principally in incident patients with no 
previous vascular access. We have demonstrated that in this patient group it is possible to 
achieve good outcomes from autologous vascular access and that a relatively simple 
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modification to the anaesthetic technique (BPB) can improve immediate and longer term 
patency.  
In summary, this randomised controlled trial compared BPB to LA for AVF creation and 
demonstrated superiority of BPB, with significant improvement in the primary outcome of 
patency at 3 months. Based on these findings, consideration should be given to utilising 
BPB for all AVF creation. 
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EARLY CANNULATION GRAFTS: OUR EARLY EXPERIENCE 
WITH GORE® ACUSEAL AND MODIFICATION OF A TECHNIQUE 
7.1.  INTRODUCTION 
The merits of a fistula primacy at all costs approach to vascular access have been 
challenged in recent years (Lok, 2007; Lok & Davidson, 2012; Allon & Robbin, 2002). 
Age, co-morbidity and likely survival time on dialysis need to be balanced against the 
likely success or failure of a vascular access in order to choose the optimal access for the 
individual patient. Suboptimal AVF maturation rates and changing demographics of the 
dialysis population (Rayner et al. 2003) have led to a swing from a “Fistula First” to 
“Catheter Last” approach to vascular access planning (Lok, 2007; Tonnessen & Money, 
2005). As a result, arteriovenous grafts are again gaining popularity as a choice for 
vascular access. 
 
Universal usage of autologous AVF is hindered by a 6-8 week maturation period from 
creation to first cannulation (Donnelly & Marticorena, 2012) and 30%-50% early failure 
rate (Saucy et al. 2010; Rodriguez et al. 2000; Dember et al. 2008). Unfortunately, due to a 
combination of late referral, primary access failure and acute presentation of renal failure, 
40%-50% of incident patients do not have a functioning AVF when they commence HD 
(Scottish Renal Registry, 2015). Current practice necessitates TCVC for these patients 
until definitive vascular access can be secured. Given that patients who began HD via a 
TCVC are more likely to remain with TCVC (Hughes et al. 2013), optimising incident 
vascular access is vitally important. 
Arteriovenous grafts (AVGs) provide an intermediate option between AVF and TCVC, 
permitting earlier cannulation than AVF but lower bacteraemia rates than TCVC (0.6 per 
1,000 catheter days) (Taylor et al. 2002). The recent development of early cannulation 
arteriovenous grafts (ecAVG), which permit needling within 24 hours of insertion, now 
means that grafts may be considered as an alternative to TCVCs in patients requiring 
immediate access for haemodialysis, in addition to their role in patients with no native 
vessels. 
 
The Gore®ACUSEAL vascular access graft is one such ecAVG. The tri-layer construction 
comprises of an inner layer of heparinsied expanded polytetrafluoroethylene (ePTFE), 
outer layer of standard ePTFE graft and a central elastomeric layer. This central layer gives 
the graft its unique “low bleed” properties and permits early cannulation, reducing the time 
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to achieve haemostasis significantly compared to standard PTFE (Glickman, 2016). 
Cannulation within 24 hours of insertion is possible. 
 
To date, there is little published in the literature on the use of the Gore®ACUSEAL  
vascular access graft. Tozzi and colleagues (2014a) report 12-month primary patency rates 
of 68% in their case series. In their multicentre study published last year Glickman and 
colleagues (2015) found a 79% 1-year cumulative patency rate. They observed 15 
infections in their series of 138 patients. 
 
In this chapter the initial experience with the Gore®ACUSEAL early cannulation graft in 
our unit is described. The initial problems and complications are highlighted along with 
our attempts to modify practice and technique to improve outcomes. A descriptive 
commentary of our experiential learning is provided. 
 
7.2.  METHODOLOGY 
 
7.2.1.  Initial experience with Gore®ACUSEAL  
 
A single-centre early experience of Gore®ACUSEAL at the Department of Renal Surgery, 
Western Infirmary, Glasgow is described. As previously described, this is a large-tertiary 
referral vascular access centre in the West of Scotland, serving approximately 700 
prevalent haemodialysis patients. There are approximately 170 incident patients annually. 
Around 400 vascular access procedures are performed each year (including approximately 
100 for complex access). AVG usage at initiation of this study was <1%. 40-50% of 
incident patients commenced HD via a TCVC/temporary catheter.  
All adult patients who had Gore®ACUSEAL ecAVG inserted over a 3-year period 
(between July 2010 and July 2013) were included for analysis (‘early’ cohort). Data were 
prospectively collected on indications for ecAVG, timing and success of initial 
cannulation, complications (including culture-proven bacteremia, other graft infection, 
thrombosis, stenosis and haematoma) and patency rates. Both local and systemic infections 
were recorded.  Stenosis was defined as a 50% reduction in luminal diameter on ultrasound 
or angiography in the presence of typical symptoms.  
Additionally, there was interest in the concept of vascular access providing a “personal 
cure.” For example, ecAVG may function as a ‘bridge’ to transplantation or AVF 
maturation in some patients, whilst in others they may provide a salvage procedure for 
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end-stage vascular access. Data on the ultimate intention of the ecAVG were also recorded 
to determine if the patients achieved their “personal vascular access solution.”  
Bacteremia rates are presented per 1,000 dialysis days. Primary and secondary patency 
rates were determined from life tables. Other complication rates are presented as a 
percentage of the total population.  
 
7.2.2.  Changing practice to improve outcomes 
 
It was perceived that the ‘early’ patient cohort treated with Gore®ACUSEAL experienced 
a relatively high rate of complications (described below), which the clinical team was 
determined to address and minimise.   
 
A number of modifications to both operative and perioperative care were made, along with 
development of a more structured service for the management of complications 
(particularly thrombosis). This experiential learning and the adaptations made to practice 
are described. 
 
Like any other novel technique, education and dissemination of lessons learned is critical. 
Several education sessions for dialysis nurses and vascular access surgeons were run 
during the implementation phase for the ecAVG. The rationale for and execution of these 
courses is described along with an evaluation of the impact that they made, in line with 
Kirkpartick’s model of change (Kirkpatrick, 1996) (Appendix 1). 
 
7.2.3.   Re-evaluation of Gore®ACUSEAL outcomes 
 
Over the six-months subsequent to recruitment of the initial patient cohort (July-December 
2013) modifications in operative technique and perioperative care were gradually 
implemented. An expansion of the ecAVG practice was also observed, with 49 patients 
having Gore®ACUSEAL inserted over this time period (‘later’ cohort). Data were 
prospectively collected on complications (including culture-proven bacteremia, local graft 
infection, thrombosis, venous stenosis, pseudoaneurysm, steal, wound complications and 
haematoma). Outcomes from this second cohort of patients were compared to the ‘early’ 
cohort. 
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7.3.  RESULTS 
 
7.3.1.  ‘Early’ experience with Gore®ACUSEAL 
 
A total of 37 Gore®ACUSEAL were placed in 37 patients. Median follow-up was 17 
months. Table 7.1 outlines basic patient demographics of the ‘early’ cohort.  
 
Table 7.1: Basic demographics of the ‘early’ patient cohort of Gore®ACUSEAL. 
Results are presented as percentage of total population (n) unless otherwise stated. 
Median age (years) 
 
42 (range: 21-72) 
Sex (percentage male) 
 
54.1% (n=20) 
Mean time on dialysis (years) 
 
3.2 (range: 0-10.2) 
Median number of previous autologous AVF 
attempts 
 
2 (range: 0-6) 
Ethnicity 
White British 
Chinese 
 
 
(94.6% (n=35) 
5.4% (n=2) 
Co-morbidities 
Hypertension 
Diabetes 
Coronary heart disease 
Cerebrovascular disease 
Peripheral vascular disease 
Smoking 
 
 
97.3% (n=36) 
40.5% (n=15) 
32.4% (n=12) 
21.6% (n=8) 
21.6% (n=8) 
35.1% (n=13) 
 
Mean BMI (kg/m2) 
 
31.2 (range: 22.3-42.5) 
 
The indications for ecAVG were as follows: “crashlander” to HD 13.5% (n=5) (three to 
AVF maturation, one had no native options, one as a bridge to transplantation); revision of 
existing AVF to permit immediate use 8.1% (n=3); bridge to transplantation 21.6% (n=8) 
(in three cases the patient had recurrent line sepsis and the ecAVG provided a sepsis-free 
window for live donor transplantation); removal of infected line 24.3% (n=9); no native 
options 67.6% (n=25) (including 17 patients with bilateral central vein stenosis).  
A total of 11 upper limb AVGs (2 forearm loops, 3 interposition grafts of existing AVF, 2 
brachial artery to basilic vein, 6 brachial artery to axillary vein); 24 mid- thigh loop grafts 
and two complex procedures in patients with end-stage vascular access (axillary artery to 
common femoral vein and common iliac vein to contralateral femoral artery) were 
performed. All grafts were at least 25 cm in length. 36 AVGs (97.3%) were successfully 
cannulated. Mean time to first cannulation was 30.4 ± 23.4 hours (range: 2-192).  
There was one perioperative death after thigh graft insertion (postoperative day 1) from 
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myocardial infarction in an elderly gentleman with a history of ischaemic heart disease. 
There was one postoperative haematoma, which did not require re-exploration and one 
significant wound infection and dehiscence following upper limb graft. Long-term 
complications are outlined in Table 7.2. Venous outflow stenosis was common (29.7%) 
particularly in upper limb grafts. All but two of the stenoses were initially treated with 
angioplasty with limited benefit; four subsequently went on to have surgical revision. A 
total of 4 of 15 cases (26.7%) of thrombosis were treated with percutaneous 
thrombectomy, the others (73.3%) underwent surgical thrombectomy. The systemic 
bacteremia rate was 0.2 per 1,000 access days. However, 16.2% (n=6) developed local 
infection around the AVG at the site of haematoma, necessitating AVG removal in four 
cases. Local haematomas and pseudoaneurysms often related to poor needling technique 
with inadequate needle site rotation (Figure 7.1).  
Table 7.2: Complications of ecAVG in the ‘early’ cohort. Data are presented as n (%) or 
mean ± SD unless otherwise stated.  
Complication Percentage affected Percentage resulting in failure 
of AVG 
 
Stenosis 
Venous outflow 
Inflow 
 
 
14 (37.8%) 
11 (29.7%) 
 
12 (32.4%) 
10 (27.0%) 
Thrombosis 
 
15 (40.5%) 13 (35.1%) 
Haematoma 
Uncomplicated 
Associated local infection 
 
 
2 (5.4%) 
6 (16.2%) 
 
- 
4 (10.8%) 
Systemic bacteraemia 
 
2 (5.4%) 2 (5.4%) 
Pseudoaneurysm 
 
3 (8.1%) 3 (8.3%) 
Graft breakdown 
 
1 (2.7%) 1 (2.7%) 
Steal syndrome 
 
1 (2.7%) 1 (2.7%) 
Wound infection/ dehiscence 
 
1 (2.7%) - 
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Figure 7.1: Explant ecAVG removed for extensive haematoma and bleeding. The 
front wall of the graft was found to have almost completely disintegrated from 
repeated area cannulation. 
 
 
Primary and secondary patency rates at 3, 6 and 12 months were 64.9%, 48.6%, 32.4% and 
70.2%, 59.4%, 40.5%, respectively (Table 7.3). These rates were comparable for upper 
arm grafts (72.7%, 45.5%, 27.2% and 72.7%, 55.5%, 45.5%) and lower limb grafts 
(58.3%, 50%, 37.5% and 66.6%, 58.3%, 33.3%).  
Table 7.3: Primary and secondary patency rates of ecAVG in the ‘early cohort’ at 3, 
6, 12 and 24 months  
 
  
Number at 
risk 
 
Number 
failed 
 
Timed out/ 
not yet 
reached 
follow-up 
 
 
Effective 
sample size 
 
Interval 
patency 
 
Cumulative 
patency 
 
Primary patency 
3 months 
6 months 
12 months 
24 months 
 
 
32 
20 
10 
2 
 
8 
6 
4 
2 
 
4 
4 
4 
0 
 
30 
18 
8 
2 
 
75.0% 
70.0% 
60.0% 
0% 
 
64.9% 
48.6% 
32.4% 
0% 
 
Secondary patency 
3 months 
6 months 
12 months 
24 months 
 
 
32 
22 
14 
3 
 
6 
4 
7 
2 
 
4 
4 
4 
0 
 
30 
20 
12 
3 
 
81.2% 
81.8% 
50.0% 
33.3% 
 
70.2% 
59.4% 
40.5% 
35.7% 
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A total of 24 patients (64.9%) had prior TCVC. 17 patients (45.9%) had either TCVC or 
temporary line in situ at the time of ecAVG insertion. These were removed following first 
successful cannulation. All patients who had ecAVG inserted following an episode of line 
sepsis were 48 hours “plastic free” to ecAVG insertion. No patient with line sepsis went on 
to have infection of their graft.  
In 26 of 37 patients (70.2%) the ecAVG provided a “personal vascular access solution” 
(Table 7.4); 35.1% of ecAVGs remain in use for HD (n=13), 1 patient died with a 
functioning ecAVG and 29.7% of patients successfully used their ecAVG as a bridge to 
either AVF maturation (n=3) or transplantation (n=8) with avoidance of TCVC.  
Table 7.4: Ultimate intention of ecAVG highlighting the proportion of patients 
achieving a “personal vascular access solution” 
Ultimate intention of ecAVG Number of patients Number achieving a “personal 
vascular access solution” 
 
Permanent vascular access for HD 
(inc. patients with bilateral CVS) 
 
25 (30) 15 (60%) 
(one death with functioning ecAVG) 
Bridge to transplantation 
(inc. patients with bilateral CVS) 
 
9 (7) 8 (86.9%) 
Bridge to AVF maturation 
 
3 3 (100%) 
 
7.3.2.  Changing operative technique to improve outcomes 
7.3.2.1. Tunnelling 
 
Many of the complications in the ‘early’ cohort of ecAVG related to difficulties with 
cannulation, in particular failure to adequately rotate needle sites, cluster/ area cannulation 
and “missed cannulations” leading to haematoma  (21.8%) and pseudoaneurysm (8.1%) 
formation. Anecdotal evidence and verbal feedback from nursing staff was that the graft 
was often tunnelled too deep and that there was not enough length of superficial graft to 
permit adequate needle site rotation. The operative technique was subsequently modified 
in an attempt to provide a longer more superficial tunnel. 
 
After exposure of the vessels the graft is tunnelled using a standard Kelly-Wick type 
curved tunneller. A long, looping tunnel has been adopted to assist in cannulation. For 
example, in an upper limb brachioaxillary graft, the tunnel will extend down the forearm in 
a loop before running back up the arm to drain into the axillary vein. This configuration 
has been found to provide the dialysis nurses with a long superficial segment of graft for 
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cannulation, permitting needle site rotation over a large area, thereby reducing the chance 
of “one site-itis” and pseudoaneurysm formation. Similarly in the leg, the mid-thigh loop 
of the ‘early’ cohort was modified to a D-shaped configuration with the arterial 
anastomosis to the common femoral artery at the groin and the venous anastomosis to the 
sub-sartorial femoral vein, leaving a long superficial segment of AVG suitable for 
cannulation on the lateral aspect of the thigh. 
 
In the early cohort, wound breakdown commonly occurred at the site of tunnel relieving 
incisions, leading to areas of exposed graft (2.7%). The technique was adapted to off-set 
relieving incisions from the main tunnel to reduce the risk of infection and exposure of the 
graft (Figure 7.2). 
 
 
 
Figure 7.2: Photograph demonstrating the subcutaneous tunnel of a thigh graft. The 
tunnel extends out over the lateral aspect of the thigh to permit a long superficial segment 
of graft suitable for cannulation and relieving incision placed distant to the tunnel. 
 
7.3.2.2. Arterial anastomosis 
 
The Gore®ACUSEAL graft has a fixed 6mm internal diameter (Glickman, 2016), 
necessitating a 6mm arteriotomy (routinely made with an aortic punch) and end-to-side 
anastomosis of the graft onto the inflow artery is performed using 5.0 Prolene® (Ethicon, 
Sommerville, NJ, USA). A large arteriotomy predisposes to steal syndrome. In diabetics 
and women with small vessels who are at high-risk of steal, the technique has been 
modified to reduce the size of the anastomosis. Firstly the distal open end of the graft is 
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oversewn using 5.0 Prolene®. A small 3-4mm arteriotomy is then made in the side of the 
graft just proximal to the oversewn free end and a similar sized arteriotomy made in the 
native artery. A side-to-side (functional end-to side) anastomosis is then made of the graft 
onto the artery, again using 5.0 Prolene®  (Figure 7.3). Alternatively, a long upper limb 
axillo-axillary loop may be performed to proximalise the graft inflow and avoid 
anastomosing onto a small brachial artery. 
 
Figure 7.3: Diagrams illustrating the configuration of a small side-to-side arterial 
anastomosis to minimise steal. Left: The end of the graft was oversewn and a small 
(4mm) hole punched in the side of the graft to create the anastomosis. Right: Side-to-side 
anastomosis of graft (top) to artery (bottom). 
 
7.3.2.3. Venous anastomosis 
 
The early cohort of patients had a standard venous anastomosis where the graft was 
spatulated and then anastomosed end-to-side onto the venous outflow. Particularly in the 
upper limb, we observed high rates of venous stenosis and thrombosis. We have 
subsequently employed the technique described by Eric Chemla (St.George’s Hospital, 
London) to perform the venous anastomosis (Chemla, 2014), with a reduction in venous 
outflow stenosis from 30% to 18% in the first 12 months after adoption.  
 
A long 4cm venotomy is performed and the graft spatulated using sharp scissors to create a 
long 4cm “mouth” before performing the end-to-side venous anastomosis with 5.0 
Prolene® (Figure 7.4). By lengthening the area of graft used for the anastomosis, the graft 
is “softened” and less distortion of the native vein is seen. It is hypothesised that the longer 
!
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anastomosis improves the flow dynamics of the graft outflow and stops the outflow vein 
being kinked and drawn up into the graft.  
 
It was hypothesised that the high incidence of venous stenosis observed in the initial 
patient cohort may, in part, be due to initmal injury occurring when the outflow vein was 
clamped. Latterly, the technique of the Tozzi and colleagues (2014a) has been adopted, 
utilising a Foley catheter to control the venous outflow, with subsequent reduction in 
venous outflow stenosis. 
 
7.3.2.4. Wound Closure 
 
It is our opinion that meticulous wound closure is vital to reduce post-operative 
complications. Careful haemostasis is essential to avoid early post-operative haematoma 
which, in the initial cohort, subsequently became infected over two-thirds of cases. The 
gentamycin-impregnanted collagen, Colatamp™ (Tribute Pharmaceuticals, Milton, 
Ontario, Canada) is routinely placed around both anastomoses and in the subcutaneous 
tissue beneath the relieving incisions for the tunnel in an attempt to reduce early graft 
infection. The wound is then closed in layers with 2.0 Vicryl® (Ethicon, Sommerville, NJ, 
USA) for the subcutaneous tissue and 3.0 subcuticular Biosyn™ (Covidien, Dublin, 
Ireland) for the skin. 
 
7.3.3.  Optimising perioperative care to improve outcomes 
7.3.3.1. Prophylactic antibiotics and skin preparation 
 
Local infection was one of the most common complications observed in the ‘early’ 
Gore®ACUSEAL cohort affecting 16.2% of patients. 5.4% developed systemic infection. 
 
1g of intravenous vancomycin is administered at induction of anaesthesia as antibiotic 
prophylaxis for skin commensals. Pre-operatively the skin is prepared with chlorhexidine 
2% and then covered using Ioban™ (3M Healthcare, Bracknell, UK) iodine-impregnated 
operative site dressing.  
 
Prophylactic antibiotics are continued for 2 weeks following implantation of the 
Gore®ACUSEAL graft. 1g of vancomycin is administered intravenously three times per 
week on haemodialysis. If the patient is vancomycin allergic, intravenous teicoplanin is 
administered instead. 
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Figure 7.4: Creation of the venous anastomosis. Top The Foley catheter is placed 
proximally to provide control of the outflow. A 4cm venotomy is created. Middle. The end 
of the graft is spatulated and a parachute technique is used for the “heel” of the 
anastomosis using 5.0 Prolene®. Bottom: The completed anastomosis. 
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7.3.3.2. Anticoagulation 
 
Over 40% of patients in the initial ecAVG cohort experienced thrombosis of their graft. 
The evidence for antiplatelets and anticoagulation to prevent graft thrombosis is limited, 
but the literature would suggest a moderate benefit in the use of an anti-platelet agent 
(Osborn et al. 2008).All patients are now commenced on oral clopidogrel 75mg o.d. for 
graft patency at the time of graft insertion. In the event of unexplained graft thrombosis 
(i.e. without underlying stenosis) full anticoagulation with warfarin  (INR: 2-3) is 
employed after patency is restored. Latterly, in light of the findings of Lok and colleagues 
(2012), fish oil 1g QDS is also administered (although, given the findings of this trial were 
not published until after the protocol for our ecAVG RCT had been written, we did not 
implement this practice locally until 2016).  
 
7.3.4.  Modifying practice to treat complications 
7.3.4.1. Stenosis, thrombosis and declotting the Gore®ACUSEAL graft 
 
Venous stenosis occurred in between one-third and a half of all ecAVG in the early series, 
leading to thrombosis in the vast majority. A strategy for rapid thrombectomy is required 
to avoid TCVC insertion in such cases.  
 
Our unit has developed a strategy of same day thrombectomy with simultaneous 
angioplasty of any outflow stenosis in the event of graft thrombosis. A combined 
procedure between the vascular surgeon and interventional radiologist is performed under 
local anesthetic. A small 2-3cm surgical incision is made over the graft and proximal and 
distal control obtained with sloops. A small transverse arteriotomy is made in the graft and 
the graft trawled proximally and distally with a 3 French Fogarty® catheter. The 
Gore®ACUSEAL graft is easy to declot in this fashion as the inner layer of PTFE is 
heparin bonded (Glickman, 2016). Upon restoration of flow, an angiogram is then 
performed and angioplasty ± stenting undertaken in the standard fashion. The arteriotomy 
in the graft is closed with 5.0 Prolene® at the end of the procedure and the patient 
systemically anticoagulated. The graft can be cannulated for dialysis immediately 
following the procedure, but care must be taken to needle distant from the arteriotomy site. 
By utilising an open thrombectomy technique, the declotting procedure takes only 5-10 
minutes, whilst still allowing a subsequent radiological procedure to definitively treat the 
outflow stenosis at the same sitting. The entire procedure takes less than 30 minutes and 
has successfully restored patency in 92% of grafts. 
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7.3.4.2. Steal syndrome  
 
The fixed outflow and high access flows (>600mL/min) occurring immediately after 
insertion of an arteriovenous graft mean that patients with AVGs are particularly at risk of 
steal syndrome and distal hypoperfusion (Al-Shakarchi & Inston, 2015a). Despite 
modifying the technique for the arterial anastomosis (as described above) to minimise the 
risk of steal, it still occurred in 10% of patients. In most cases it was mild and could be 
managed conservatively, however if severe, the graft can be occluded with simple firm 
digital pressure for 15-20 minutes to obstruct the flow of blood through the graft and cause 
it to clot. This has proven successful in three patients with symptoms of steal syndrome 
who no longer required their AVG. Firm external digital pressure alone was sufficient to 
occlude the graft permanently without complication and avoided the need for further 
surgery in these patients. 
 
7.3.4.3. Exposed graft 
 
A few cases skin breakdown leaving a short segment of exposed graft were observed in the 
early patient cohort. These patients were elderly or obese with fragile, vulnerable skin. The 
breakdown occurred at the site of the tunnel relieving incision (Figure 7.5). In each case, 
the graft continued to function without difficultly. We simply covered the area of exposed 
graft with a non-adherent Inadine® (Systagenics, Skipton, UK) dressing and continued to 
dialyse needling the graft distant to the exposed site. In all but one case the wounds closed 
by secondary intention after a few weeks. 
 
Figure 7.5: Exposed segment of graft at a relieving incision. This elderly lady had very 
thin, fragile skin. 
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7.3.4.4. Pseudoaneurysm and graft breakdown/ rupture 
 
Pseudoaneurysms are a well-recognised complication of arteriovenous grafts (Sgroi et al. 
2013).  In the early cohort of Gore®ACUSEAL grafts, 3 of 37 patients (8%) developed a 
pseudoaneurysm. Repeated cannulation of the same area of graft (“one site-itis”) damages 
the integrity of the wall of the graft and prevents it from self-sealing, leading to 
pseudoaneurysm formation. Explanted grafts from such patients were been found to have 
multiple puncture sites coalescing into larger holes in the graft (Figure 7.1). In the majority 
of cases pseudoaneurysm formation was attributed to poor needling technique. Dialysis 
nurse education sessions (outlined in detail below) focussed on the importance of needle 
site rotation and use of sharp, small gauge needles. In line with the manufacturer’s 
guidance (W.L.Gore Associates, n.d.), cannulation with 17G sharp needles throughout the 
lifespan of the graft with needle site rotation of approximately 1cm with each cannulation 
was advocated.  Firm pressure should be applied at needle sites for 10-15 minutes after 
removal of the needles to prevent local haematoma formation. Low flow rates of 200-
250mL/min for the first two weeks after insertion to minimise damage to the venous 
anastomosis that may occur with higher flows is also advised. This cannulation technique 
was taught in the education sessions, following which no further complications with 
pseudoaneurysm formation were observed in the subsequent 49 graft implantations. 
 
7.3.4.5. Graft infection 
 
Despite preventative measures (meticulous haemostasis and antibiotic prophylaxis) graft 
infection still occurs. Like other authors (Harish & Allon, 2011), two peaks in the 
incidence of graft infection were observed in our cohort: early post-operatively and 
delayed (Figure 1.12). All but one (87.5%) of the infected haematomas occurred within 
two months of graft insertion and were either associated with post-operative haematoma 
(42.9%) or cannulation (57.1%). They all presented with erythema, pain and swelling at 
the graft site with minimal systemic upset. In the majority of cases, these were successfully 
managed conservatively with intravenous antibiotics without necessitating graft explant. 
Conversely, the graft infections that occurred later (>3months) were all associated with 
systemic signs of sepsis (pyrexia, tachycardia etc.) and normally demanded removal of the 
graft. It is believed that, at least in part, these later graft infections relate to poor 
cannulation technique, failure to adhere to strict aseptic technique and the introduction of 
skin commensals into the bloodstream resulting in systemic infection. Investment in 
education of dialysis nurses to re-itterate the importance of strict asepsis when cannulating 
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the graft and also the importance of pressure after removal of needles from the graft to 
minimise haematoma (that can then become secondarily infected), coincides with a 
significant reduction in the number of graft infections. Local infection rates fell following 
the education sessions from 22% to 4%. Whilst it is impossible to attribute the reduction in 
infection rates observed entirely to the education sessions and scrupulous cannulation 
technique, the temporal association implies a relationship. A coincidental reduction in 
haematoma associated with cannulation from 24% to 4% was also observed, adding 
plausibility to this assertion. 
 
7.3.5. The ecAVG courses 
 
Education sessions were originally instigated locally for dialysis nurses in response to a 
perceived need (high rate of cannulation-related complications). The initial intention had 
been to run a single course for a small core group of nursing staff (who could then 
disseminate the information back to individual dialysis units) in an attempt to optimise and 
standardise practice ahead of commencing the RCT (Chapter 9).  However, the initial 
session was very well received and the course was expanded and developed allowing 
surgeons and dialysis nurses from around Europe to attend the latest iteration. 
 
A two-day interactive, multi-disciplinary course was run at the Clinical Anatomy Skills 
Centre, University of Glasgow. The course was funded by industry (W.L. Gore Associates) 
but run by clinicians, with no industry involvement in the content. The focus was on 
discussing broad-themes of early cannulation grafts and strategies for line avoidance, 
rather than promotion of any particular graft. Multi-modal teaching methods were 
employed with hands-on small group sessions, in addition to more didactic lecturing styles 
and group discussion (Appendix 2). The emphasis was on strategies to solve “real-life” 
clinical problems. A faculty of five senior clinicians from various disciplines (vascular 
access surgeon, interventional radiologist, nephrologist, vascular access nurse) were 
supported by six “junior faculty” to assist in the running of the course. Parallel sessions 
were run for vascular access surgeons and dialysis nurses with cross-over and overlap as 
appropriate to permit multidisciplinary discussion between the different groups of 
professionals around common themes and how dialysis practice might affect surgical 
outcomes and vice versa (For example, the idea for a longer arm loop to facilitate better 
needle site rotation came from this forum). The second day of the course for the surgeons 
comprised of hands-on experience of insertion of early cannulation grafts using fresh-
frozen cadavers. Delegates had the opportunity to perform upper limb (brachio-axillary 
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and forearm loop) and lower limb (femoro-femoral grafts). The session was supported by 
personalised advice and appraisal of surgical technique, along with tips and technical 
points from experienced vascular access surgeons. Following this dialysis nurses then had 
the opportunity to practice cannulating the newly inserted grafts in the cadavers. 
 
30 surgeons, 3 nephrologists, 2 interventional radiologists and 56 vascular access nurses 
from around the UK attended the latter two courses. All participants reported that the 
course improved their knowledge and ability to think critically about the subject matter. 
Common themes identified in the post-course questionnaire (Appendix 1) were in support 
of the “multidisciplinary nature” of the course and the ethos of “team work” that it 
promoted. 
 
Most of the nurses attending the course had a good knowledge of cannulation techniques 
and the particulars of graft cannulation prior to the course with 100% knowing of the need 
to apply pressure for 10-15 minutes after needle removal and 93% to use small gauge 
needles. This increased to 100% following the course. Fewer nurses were aware of the 
anatomy of grafts prior to the course, with only 45% understanding the configuration of a 
brachioaxillary graft and 78% being able to identify the venous outflow. At the end of the 
course, all nurses could accurately describe the anatomy of the graft and identify the 
venous outflow. Qualitative data from the free-text responses suggests that many nurses 
felt that a better understanding of the anatomy and operative procedure made them more 
confident in cannulation (Table 7.5). 
 
Table 7.5: Responses of nursing staff in the post-course evaluation questionnaire. 
 
“Cannulation will be much easier now that I can visualise the graft in 3D” 
“It was great to see the DVD of how the graft is tunnelled. I now understand why the 
patients are sometimes bruised and sore.” 
“It was nice to see what the graft actually looked like because it will help with 
cannulation” 
“I now know why I was having all the problems. My needle kept hitting the side of 
the graft. It was only once I could look at it in the cadaver that I could realise it” 
“I’ll be able to explain the procedure to my patients now” 
“It’s just given me better confidence in cannulation” 
 
The course appeared to influence the subsequent behaviour and practice of participants. 
Prior to the course only 50% of nursing staff had any prior experience cannulating 
ecAVGs and 60% of surgeons had ever inserted one. Three months following the course 
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78% of nurses reported having cannulated an ecAVG, with 65% indicating they did so on a 
regular basis. 94% of surgeons inserted an ecAVG in the three months following the 
course, with a total of 35 successful graft procedures performed by course delegates. 
 
With regards outcomes, it has already been highlighted that there was a significant 
reduction in cannulation related complications locally in the 6 months following the course 
(an observation which, at least in part, is likely attributable to the education of dialysis 
nursing staff). A five-fold reduction in cannulation-related haematoma and local infection 
was observed and no new pseudoaneurysms occurred in the six-months following the 
course. 
 
7.3.6.  Re-evaluation of Gore®ACUSEAL outcomes 
 
A total of 49 Gore®ACUSEAL grafts were inserted locally in the six-months between July 
and December 2013 (following implementation of the modifications to technique and 
practice described above). A significant reduction in the incidence of local infection (4% 
vs. 22%; P=0.01) and haematoma (24% vs. 4%; P=0.01) was observed. There were no 
pseudoaneurysms in the latter cohort. Rates of thrombosis and venous stenosis were also 
lower, though this difference was not statistically significant (Table 7.6). 
 
Figure 7.6: A comparison of the complications observed in the ‘early’ and ‘later’ 
cohorts of ecAVG. 
 
 Graft outcomes in 
‘early’ cohort (n=37) 
Graft outcomes in 
‘later’ cohort (n=49) 
  P-value 
Thrombosis 41% (n=15) 31% (n=15)   0.23 
Venous Stenosis 30% (n=11) 20% (n=10)   0.25 
Systemic infection 5% (n=2) -   0.09 
Local infection 22% (n=8) 4% (n=2)   0.01 
Haematoma 24% (n=9) 4% (n=2)   0.01 
Pseudoaneurysm 8% (n=3) -   0.02 
Steal 3% (n=1) 10% (n=5)   0.14 
Wound breakdown 3% (n=1) 4% (n=2)   N.S 
Cardiovascular 
complications 
3% (n=1) 4% (n=2)   N.S 
 
 
 198 
7.4. DISCUSSION  
 
Our early experience with Gore®ACUSEAL ecAVG was encouraging. The six-month 
secondary patency of 60% is comparable to other published series of standard PFTE 
(patency rates 40%-80% described) (Schild et al. 2007; Glickman et al. 2001). Perhaps of 
greater importance than long-term ecAVG patency was the provision of a “personal 
vascular access solution.” Although the concept of “tailoring” vascular access to the 
individual is extensively described in the literature (Lok et al. 2005; Lok, 2007), this was 
the first study to highlight its practical application in clinical practice. In the early patient 
cohort, 26 of 37 patients (70.2%) achieved a “personal vascular access solution” from their 
ecAVG with the role of Gore®ACUSEAL in TCVC avoidance, as a bridge to transplant or 
alternative vascular access, clearly demonstrated.  
Both primary and secondary patency rates at 12 months (32% and 40% respectively) in our 
early cohort of patients were lower then those described elsewhere in the literature on 
Gore®ACUSEAL. Tozzi and colleagues (2014a) report 12-month primary and secondary 
patencies of 68% and 93%. While, in their multicentre study, Glickman et al. (2015) report 
a secondary patency of 78% at 1-year. We believe that these discrepancies observed are the 
result of differences in case mix, with our early patient cohort reflecting the extremes of a 
dialysis population. Many of the patients treated with Gore®ACUSEAL in the ‘early’ 
cohort had been waiting for many years for a solution to their precarious vascular access. 
Nearly half had bilateral central vein stenosis and two-thirds of the procedures were lower 
limb grafts. Conversely, the grafts in the study of Glickman and colleagues provided 
‘upper limb vascular access in patients not suitable for arteriovenous fistulae’ (2015, 
pp.465) and Tozzi et al. placed upper limb grafts in 90% of patients who were ‘poor 
candidates for autologous access’ (2014, pp.386). 
The mean age of patients in our early cohort was 42 years. This is substantially younger 
than the average age of the dialysis population as a whole and also lower than in other 
published series of Gore®ACUSEAL (Maytham et al. 2015; Tozzi et al. 2014b; Glickman 
et al. 2015). This may potentially explain the low infection and complication rates 
observed. However, we believe that the relatively young chronological age of the patient 
cohort in this study does not reflect their biological age as they form some of the most 
complex, comorbid dialysis patients, having often accrued many years on HD resulting in 
end-stage vascular access.  
Lower limb grafts are traditionally associated with high rates of infection (Harish & Allon, 
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2011). However, in our early cohort of patients, the systemic bacteremia rate of 0.2 per 
1,000 dialysis days is lower than in other AVG studies and comparable to that of AVF, 
despite nearly two-thirds of patients having a lower limb graft placed (Taylor et al. 2002; 
Thomson et al. 2007). Local infection rates fell further following modification of operative 
technique and education of our dialysis nursing staff. We believe that careful patient 
selection, strict asepsis during surgery and cannulation, the use of Colatamp™, 
prophylactic antibiotics and the choice of mid-thigh loop grafts in the majority of patients 
explains this (Scott et al. 2006; Bagul et al. 2015).  
This study and the subsequent modifications to technique that ensued highlight the 
importance of experiential learning. Despite the benefits of ecAVG observed in the initial 
cohort, it was perceived that outcomes were suboptimal and could be improved. The 
operative, perioperative and cannulation techniques evolved gradually, through trial and 
error in response to problems encountered. As such, no individual intervention can be 
credited with the improvements in graft outcome observed within the latter cohort.  
Nevertheless, several of the practical lessons learned for our experiences warrant 
discussion. Firstly, patient selection is vitally important. Often patients requiring AVGs are 
frail with small vessels and have exhausted their alternative options. Many have been on 
HD for many years and have extensive vascular calcification. For these reasons careful 
assessment of cardiac fitness and the vascular tree is essential preoperatively to minimise 
ischaemic complications. Secondly good needling technique is vital. The haematomas and 
pseudoaneurysms observed in our ‘early’ cohort of patients are not unique. In fact, in 
almost every case series of ecAVG, the authors highlight the importance of cannulation 
technique and nursing education (Tozzi et al. 2014b; Berard et al. 2015; Al-Shakarchi & 
Inston, 2015b). Certainly the learning curve for ecAVGs applies equally to cannulation as 
operative technique.  
The description of our graft course and its role as an intervention to improve outcome is 
the first such description of an educational intervention in vascular access. The success of 
the intervention was evaluated according the Kirkpartick’s four-level model for learning 
evaluation (Kirkpatrick, 1996). To this end, we have demonstrated that the “reaction” to 
the courses was universally positive and that the nurses “knowledge” of the anatomy of 
AVGs improved significantly following the course. Both nurses and surgeons “behaviour” 
changed after the course with more nurses regularly cannulating grafts and all but one 
surgeon implementing their knowledge and inserting a graft in the three months following 
the course. Finally, whilst the improved graft “outcomes” and the lower complication rate 
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observed in the ‘later’ patient cohort cannot be directly attributed to attendance at the graft 
course, the temporal association makes a contributory influence likely. 
In both patient cohorts, we describe a heterogeneous patient group with a variety of 
requirements from the ecAVG, including TCVC- free bridge to transplantation or AVF 
maturation and end-stage vascular access with no further autologous options. The variety 
of patients (and indications) that we have treated reflects the versatility of the 
Gore®ACUSEAL graft. It provides a useful option in a multifaceted approach to achieving 
a personal vascular access cure. Perhaps in the future, the traditional “Fistula First” idiom 
will require modification to “Line Last” in light of the unique role which ecAVGs can 
provide (Vassalotti et al. 2012). It may be that, temporally at least, a “Graft First” approach 
followed by AVF is favored for many patients.  
In conclusion, our initial experience with the Gore®ACUSEAL graft proved encouraging 
with bacteremia rates comparable to native AVF. The fact that ecAVGs permitted 
cannulation within 24 hours of insertion meant that line avoidance was potentially 
achievable in the majority of patients. Nearly three-quarters of patients in the initial cohort 
achieved a definitive “personal vascular access solution”. With modification of technique 
and education it was possible to further reduce the rates of venous stenosis and local 
haematoma and pseudoaneurysm formation. We had taken ecAVGs from a novel concept 
utilised in a few selected patients to become a mainstream treatment option. The scene was 
set and the technique optimised to permit progress into further studies and ultimately a 
randomised controlled trial. 
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ARE EARLY CANNULATION ARTERIOVENOUS GRAFTS A 
VIABLE ALTERNATIVE TO TUNNELLED CENTRAL VENOUS 
CATHETERS: AN OBSERVATIONAL “VIRTUAL STUDY” AND 
BUDGET IMPACT ANALYSIS 
 
8.1. INTRODUCTION 
As previously discussed, AVF are the vascular access of choice for patients requiring 
haemodialysis. TCVCs are used only as an option of necessity (Fluck & Kumwenda, 
2011).  In practice however, AVF usage is  limited by delays in operative planning, 
maturation time (necessitating AVF creation 3-4 months before the anticipated date of 
dialysis commencement) and a failure to mature rate approaching 60% in some 
randomised trials (Dember et al. 2008; Irish et al. 2017). If dialysis is required before the 
AVF is functionally mature, an alternative access modality (generally TCVC) is required 
(Rodriguez et al. 2000). 
Dialysis via a TCVC confers significantly higher risk of infection, mortality and central 
venous stenosis than dialysis via an AVF. Recently, a Scottish study of 2666 patients 
revealed a 2-3 fold increased risk in all-cause mortality and a 7-fold increase in death from 
septicaemia with the use of TCVCs (Bray et al. 2012). The complications of vascular 
access are responsible for over 20% of hospitalisations in patients on HD and account for 
one third of all in-patient renal bed usage (Rayner et al. 2003; Thomson et al. 2010; 
Feldman et al. 1993). It therefore follows that a strategy of TCVC avoidance is likely to 
have significant benefits both for individual patients and healthcare providers.  
Arteriovenous grafts (AVGs) provide an alternative means of vascular access. 
Traditionally AVGs have been used only when all other native venous options have been 
exhausted. However, the recent development of early cannulation AVGs (ecAVGs) now 
allows grafts to be considered as an alternative to TCVC in patients requiring vascular 
access imminently (Tozzi et al. 2014a; Aitken et al. 2014b). As previously discussed, the 
benefits and limitations of an AVG lie somewhere between those of a TCVC and an AVF: 
they require significantly greater initial outlay in surgical expertise, time, and material cost 
(Leermakers et al. 2013), but have rates of infection and complication rates lower than a 
TCVC (Thomson et al. 2007). Culture-proven bacteraemia rates for TCVCs are 1·77 per 
1,000 catheter days compared to 0·6 per 1,000 dialysis days for an AVG and 0·3 per 1,000 
dialysis days for an AVF (Taylor et al. 2002; Thomson et al. 2007). Primary patency rates 
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for AVGs range from 40-60% at 1 year (Fernstrom et al. 2007). However, with aggressive 
management of thrombosis, secondary patency rates of as high as 90% at 1 year can be 
achieved (Akoh, 2009). 
30-35% of patients needing to start haemodialysis are referred for access creation less than 
90 days prior to the date that they require to commence dialysis, leaving insufficient time 
for planning, surgery and maturation of an AVF (National Kidney Care Vascular Access 
Report, 2012.; Ethier et al. 2008). In the UK only 40% of patients commence 
haemodialysis via an AVF (UK Renal Registry, 2014). ecAVGs may have a role in these 
incident patients, in whom there has not been sufficient time to create and mature an AVF 
and avoid the need for TCVC in this population of “crashlanders” . (We do not advocate 
the long-term use of ecAVGs in patients in whom it would be possible to create an AVF, 
rather the ecAVG would provide temporary vascular access until the native option had 
matured adequately).  
With this in mind, we proposed a “virtual study” to answer the question of whether 
(outwith the confines of an idealized, protected trial) ecAVGs could be a better real-world 
alternative to TCVC in patients requiring imminent haemodialysis. The study aimed to 
answer the following questions: 
1. Is it an acceptable alternative for patients to have an ecAVG rather than a TCVC? 
2. Are urgent ecAVGs a practical alternative in the population presenting with an 
immediate need for vascular access in a regional centre with limited resources? 
3. What are the individual and service costs through the current pathways using 
TCVC and can these be reduced using ecAVGs? 
We additionally estimated the potential budget impact to the centre of adopting ecAVGs 
for clinically suitable patients while they awaited a functioning AVF.  
The “virtual study” is a novel concept not previously described in the literature, permitting 
a “real-world” observational study of current practice and comparing it to a hypothetical 
model of an alternative treatment strategy based on best available evidence and data 
collected “real-time” about the feasibility of any change in practice. It can be used to 
inform cost calculations, future research and the clinical implementation of any subsequent 
practice change. It may be useful in situations, such as the one proposed, where the 
implementation of any strategy involving ecAVGs as an alternative to TCVCs would 
necessitate a paradigm shift in nephrology thinking and service provision.  
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The results of our “virtual study” and the associated health economic cost-consequence 
analysis are presented. 
8.2.  METHODOLOGY 
8.2.1.  Study design and setting 
A prospective observational cohort study of current standard practice (TCVCs) with a 
hypothetical comparator group (ecAVGs) and associated budget impact analysis was 
performed. Data was collected from the Department of Renal Surgery, Western Infirmary, 
Glasgow.  
Formal approval from the Research Ethics Committee was not required for this 
observational study of standard practice. Approval for data collection was obtained from 
the hospital Clinical Effectiveness Department. 
8.2.2.  Recruitment and participants 
This was an inclusive study. All patients having TCVC inserted over a 6-month period 
between December 2012 and June 2013 were included for analysis. It was anticipated that 
this time period would permit recruitment of a representative proportion of our dialysis 
population. All referrals for TCVC insertion were managed by a dedicated Vascular 
Access Coordinator who identified patients and highlighted them to the research team on 
the day of referral. 
8.2.3.  Data collection 
Basic patient demographic data (including age, sex, cause of renal failure, duration on 
haemodialysis, indications for TCVC insertion) were obtained from the Scottish Electronic 
Renal Patient Record (SERPR). Prior to TCVC insertion all patients were approached by a 
member of the research team and the features of ecAVG explained. Patients were informed 
of the risks of infection and central vein stenosis of TCVC. ecAVG were proposed as an 
alternative with lower infection rates than TCVC. It was explained that ecAVG would 
necessitate an additional operative procedure with potential risks of steal and thrombosis 
described. It was explained to those patients for whom ecAVG was not intended to be the 
definitive management strategy, that further AVF creation was still needed. Their views 
and opinions regarding whether or not they would accept ecAVG in place of the TCVC, if 
the option were available to them, were explored.  These same questions were asked to the 
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patients after 6 months follow-up also to assess if their opinion had changed. Ultrasound 
vein mapping was performed to determine the optimal placement of ecAVG and AVF. It 
was assumed that ultimate aim was to achieve autologous AVF wherever possible, with 
TCVC with and ecAVG used only as an interim measure. Patients were deemed 
anatomically suitable for ecAVG if they had an artery measuring >2.5mm diameter and 
suitable venous landing site. If no upper limb option was suitable, leg grafts were 
considered in patients fit for general anaesthesia. Patients who had previously had access 
ligated for steal or who had monophasic arterial flow were excluded from upper limb 
ecAVG. Finally the practicalities of ecAVG were considered: Was the patient fit for 
surgery? Did they have significant hyperkalaemia or pulmonary oedema necessitating 
temporary access for haemodialysis prior to ecAVG? Was there an operating theatre 
available that could be used to permit ecAVG insertion and AVF creation? What delays 
might be involved in this process? What was the patient’s definitive vascular access and 
how might this be best expedited?  Although no ecAVGs were implanted, the answers to 
these questions allowed us to assess patient suitability and waiting time in a hypothetical 
scenario.  
 
8.2.4.  Follow-up 
All patients were followed-up for 6 months. Treatment delays and complications of 
TCVCs (wait time for TCVC insertion, bed days required as a result of vascular access 
complications, culture-proven bacteraemia, suspected bacteraemia, antibiotic usage, line 
thrombosis, urokinase infusions, new TCVCs/ temporary lines/ AVF other line 
complications) were recorded. Data were also recorded on AVF creation, maturation and 
suitability for cannulation for dialysis, along with what form of vascular access was used 
for haemodialysis at 6 month follow-up. Data was collected prospectively, so there were 
no missing data points and no patients were lost to follow-up. Patients who died had death 
recorded and data collated prior to death was retained for analysis. 
8.2.5.  Statistical analysis 
Patient demographics and complication rates for patients having TCVC insertion are 
presented as mean ± SD or as a percentage of the total patient population (n=79). Data on 
the practicalities and acceptability of ecAVG are presented similarly.  
This data was then used to create a model for “standard” practice of TCVC insertion, 
including treatment delays and complications. A similar model for ecAVGs was also 
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created using data obtained from the real-time study (acceptability derived from patient 
questionnaires, theatre availability and anatomically feasibility from clinical ultrasounds) 
and previously published rates of graft infection and thrombosis (Taylor et al. 2002; Akoh 
2009). These models permitted a comparison of the “real-world” current practice of TCVC 
insertion until definitive autologous access could be created and a hypothetical model of 
ecAVGs used until the AVF was mature. It must be emphasised that the ultimate aim for 
every patients was to achieve autologous vascular access if possible. Both TCVCs and 
ecAVGs were considered a “bridge” to this definitive access wherever possible. 
A budget impact model was used to estimate the total costs to the hospital of the two 
treatment strategies over a 6-month time period. These strategies are illustrated in Figure 
8.1a and Figure 8.1b. Figure 8.1b reflects the current treatment pathway, where patients 
primarily use TCVCs as temporary vascular access while awaiting definitive AVF 
formation and maturation. Figure 8.1a represents the proposed strategy with ecAVGs 
replace TCVCs where possible. To reflect real-world practice, patient suitability and 
acceptability for ecAVG and AVF taken from the “virtual study” was incorporated into the 
analysis. Clinical inputs including referral delays for treatment, complications and repeat 
procedures were derived directly from the observational data, internal audits and published 
literature. We assumed that the re-intervention and infection rates of ecAVG were 
equivalent to conventional AVGs (58% secondary patency rate at 6 months (Schild et al. 
2007; Akoh 2009)). Access-related bacteraemia rates for TCVCs were derived from the 
“virtual study” data and from the published literature for AVGs and AVFs (Taylor et al. 
2002) (Table 8.1). The model includes costs for all initial procedures and re-interventions, 
in additional to treatment costs for complications including thrombosis and infection. The 
costs of individual procedures are listed in Table 8.2. Resource use was based on hospital 
practice and unit costs were taken from Personal Social Service Research Unit (PSSRU5) 
figures, NHS Reference Costs 2011-2012 and published literature (Curtis, 2012; 
Hockenhull et al. 2008; Department of Health, 2013). All costs are quoted in pounds 
Sterling (£).  A sensitivity analysis was conducted to consider varying rates for TCVC 
bacteraemia, referral days for TCVC insertion, and the percentage of patients using the 
ecAVG as their definitive access option. 
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Figure 8.1a (above): Proposed novel treatment strategy for patients requiring urgent 
vascular access for haemodialysis (ecAVG). Figure 8.1b (below): Current treatment 
algorithm for patients requiring urgent vascular access for haemodialysis (TCVC). 
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Table 8.1: Vascular access associated bacteraemia rates 
 
Vascular access Bacteraemia rate (per 1,000 dialysis 
days) 
Source 
TCVC 1.4 Observed rates 
AVF 0.3 Taylor et al. 2002  
AVG 0.6 Taylor et al. 2002  
 
Table 8.2: Baseline costs for interventions in health economic model. All costs are 
quoted in pounds Sterling (£). 
 
Intervention 
Cost per 
event (£) Source 
Temporary Line 
Insertion £209.0 
 
Staff cost per hour: Curtis, 2012  
Consumables: NHS Greater Glasgow and Clyde purchasing contract 
TCVC Insertion £524.7 
 
Staff cost per hour: Curtis, 2012  
Consumables: NHS Greater Glasgow and Clyde purchasing contract 
TCVC Removal £32.6 
 
Staff cost per hour: Curtis, 2012  
Consumables: NHS Greater Glasgow and Clyde purchasing contract 
AVF creation- 1st 
attempt £1 072.0 
 
Staff cost per hour: Curtis, 2012  
Consumables: NHS Greater Glasgow and Clyde purchasing contract 
Cost of bed days: Authors’ estimate 
AVF creation- 2nd 
attempt £1 381.0 
 
Staff cost per hour: Curtis, 2012  
Consumables: NHS Greater Glasgow and Clyde purchasing contract 
Cost of bed days: Authors’ estimate 
Combined ecAVG 
and AVF 
implantation £1 982.0 
 
Staff cost per hour: Curtis, 2012  
Consumables: NHS Greater Glasgow and Clyde purchasing contract 
Cost of bed days: Authors’ estimate 
Device cost of ecAVG (Acuseal): W.L. Gore Associates 
ecAVG 
implantation £1 768.7 
 
Staff cost per hour: Curtis, 2012  
Consumables: NHS Greater Glasgow and Clyde purchasing contract 
Cost of bed days: Authors’ estimate 
Device cost of ecAVG (Acuseal): W.L. Gore Associates 
Ultrasound £56.0 
 
NHS Reference Costs 2011-2012 
Fistuloplasty – 
Radiological £1 957.0 
 
NHS Reference Costs 2011-2012 
Thrombectomy – 
Radiological £1 957.0 NHS Reference Costs 2011-2012 
Thrombectomy – 
Surgical £3 451.0 
 
NHS Reference Costs 2011-2012 
Sepsis episode 
treatment £9 148.0 Hockenhull et al. 2008  
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8.3.  RESULTS 
8.3.1.  Patient demographics 
79 patients were assessed prior to TCVC insertion (mean age: 62.8 ± 13.1 years; 51.4% 
male) requiring 101 TCVCs and 40 temporary lines over 6 months.  Table 8.3 outlines 
basic patient demographics. Reasons for TCVC usage were as follows: problems with 
existing AVF (22.7%), problems with existing TCVC (48.5%) and need to commence HD 
without functioning AVF (28.7%) (Figure 8.2).  
 
Table 8.3: Demographics of patients having TCVC inserted. Results reflect a mean ± SD 
or as a percentage and number of the total population unless otherwise stated 
 
Age (years) 62.4 ±12.7 
Sex (percentage male) 65.8% (n=52) 
Cause of renal failure 
Diabetes 
Hypertension 
Glomerulonephritis 
Interstitial nephritis 
Other 
 
35.4% (n=28) 
15.2% (n=12) 
12.7% (n=10) 
21.5% (n=17) 
15.1% (n=12) 
Time on haemodialysis (years) 3.8 ±2.3 
Number of previous TCVCs (median) 4 (range: 0-21) 
Co-morbidities 
Hypertension 
Previous myocardial infarction 
Previous cerebrovascular event 
Diabetes 
COPD 
 
75.9% (n=60) 
27.8%% (n=22) 
12.7% (n=10) 
44.3% (n=35) 
30.4% (n=24) 
 
8.3.2.  Delays and complications associated with TCVCs 
 
Patients had a median delay of 7 days in hospital for TCVC implantation (range: 0-27). 35 
had discharged delayed solely due to delays in TCVC insertion (median time: 6 days).  
34.7% of TCVCs (n=35) had significant complications (including 17 episodes of culture 
proven bacteraemia and 13 flow-related problems) during the 6-month follow-up period.  
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Figure 8.2: Indications for TCVC insertion. The majority of patients requiring TCVC 
insertion were already on haemodialysis (most having problems with an existing TCVC with a 
smaller number having problems with an AVF). 28.7% of patients needing TCVC were incident 
haemodialysis patients (who were either referred late for vascular access creation or “crashlanded” 
onto dialysis. 
 
Table 8.4: Complications of TCVCs. Results are presented as absolute number observed and 
(where relevant) number per patient per year. 
 
 Number of episodes (total) Number of episodes (per 
patient/ year) 
Complication 
Culture-proven line sepsis 
Suspected or proven line sepsis 
Poor flows 
Cracked line 
Accidental removal  
 
17 (all lines replaced) 
19 (all lines replaced) 
13 (5 new lines) 
1 (replaced) 
3 (all replaced) 
 
1.4 per 1,000 cathter days 
1.6 per 1,000 catheter days 
Bed days 357 days 11.9 days/ patient/ year 
Intervention 
IV vancomycin 
Urokinase infusion 
New TCVC 
Temporary line 
 
198 doses (15 patients) 
56 infusions (11 patients) 
28 lines 
5 lines 
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8.3.3.  Definitive vascular access 
 
56 AVF access creation procedures were performed during the first 6 months after TCVC 
insertion. Median time from referral to actual AVF procedure was 79 days and 57 days 
thereafter for AVF maturation (until first successful cannulation). 7 patients (8.8%) died 
during the follow-up period and were removed from the analysis at the time of their death. 
1 death was the result of proven line sepsis. 31 patients successfully dialysed through their 
AVF at some point during the first 6 months, but many failed early, and only 16 patients 
had a functioning AVF capable of giving sustained dialysis at 6 month follow-up.  
 
8.3.4.  Acceptability and practicality of an alternative ecAVG strategy 
 
ecAVG were a clinically suitable alternative to TCVC in 66 of the 79 patients (83.5%). 64 
patients (81%) would have been suitable for a strategy of ecAVG and AVF. A total of 13 
patients were not clinically suitable for ecAVG for the following reasons: acute illness 
which would have precluded ecAVG (n=5); chronically too frail or unfit for ecAVG 
(n=11). 12 (11.8%) would have required temporary access to permit HD for hyperkalaemia 
or fluid overload prior to ecAVG insertion.  
 
53 patients would have accepted ecAVG as an alternative to TCVC. 13 patients declined 
ecAVG (the majority also declined an AVF) at initial and 6 months interviews, however 
these were different sets of patients. This meant that 81% of patients were anatomically 
suitable for an ecAVG ± AVF, and 72% of these patients would have accepted this as a 
treatment option (Figure 8.1a). Table 8.5 outlines the acceptability of ecAVGs to patients 
at outset and at 6-month follow-up.  
 
In all but two cases, the emergency CEPOD theatre was available within 4 hours. In these 
two cases a theatre slot would have been available within 24 hours and there would have 
been no need for additional temporary access. 
 
21.2% of ecAVG would have been sited in the forearm, 69.7% in the upper arm and 9.1% 
in the thigh. ecAVG would have been the final definitive access option in 23.4%.  
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Table 8.5: Reasons for ecAVG refusal at initial interview and after 6 month follow-
up. 13 of 66 patients (19.7%) declined ecAVG at each time point, however, these were not the 
same 13 patients and opinions were affected by experience with TCVC. Patients who had TCVC 
for a short period of time with rapid AVF maturation felt that ecAVG may have been unnecessary, 
while patients who initially would not have wished ecAVG but then experienced complications of 
TCVC usage, subsequently wished for ecAVG instead. 
 
Initial interview 6 month interview 
Reason for declining ecAVG Number of 
patients 
(n=13) 
Reason for declining ecAVG Number of 
patients 
(n=13) 
Did not want either AVF or AVG 
x Previous failed attempts 
x Prior AVF rupture 
x Cosmesis 
x Convenience of TCVC 
 
10 
5 
1 
2 
2 
Did not want either AVF or AVG 
x Previous failed attempts 
x Prior AVF rupture 
x Cosmesis 
x Convenience of TCVC 
 
8 
4 
1 
2 
1 
Did not want ecAVG 1 Did not want ecAVG 1 
Concerned renal failure not 
permenant 
2 Concerned renal failure not 
permanent 
- 
  Wishes to switch to PD 1 
  Happy with new AVF and would 
not have wished ecAVG 
2 
  Multiple failed access attempts 1 
 
8.3.5.  Budget impact analysis 
 
Over a 6-month period, total treatment costs per patient were £5 882 in the TCVC strategy 
and £4 954 in the ecAVG strategy, delivering potential savings of £927 per patient in the 
ecAVG arm. Although ecAVGs had higher procedure and re-intervention costs reflecting 
longer procedure time and device costs (£3 014 vs. £1 836), these were offset by 
significant reductions in septicaemia treatment costs (£1 322 vs. £2 176) and in-patient 
waiting time bed costs (£619 vs. £1 870) (Table 8.6). 
 
Table 8.6: Health economic analysis highlighting relative intervention and 
complication costs of standard practice (TCVCs) and the novel strategy (ecAVG). All 
costs are quoted in pounds Sterling (£). 
 
 TCVC+AVF 
(A) 
ecAVG+AVF 
(B) 
Difference 
(A-B) 
Initial Procedure Costs per Patient 857 1 372 -515 
Re-intervention Costs per Patient 978 1 641 -663 
Bed Day Costs per Patient (Represent referral delay 
while waiting for TCVC implant) 
1 870 619 
 
1 251 
Sepsis Treatment Costs per Patient 2 176 1 322 854 
Total Cost 5 882 4 954 927 
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Figures 8.3, 8.4 and 8.5 are graphical models demonstrating how the overall cost savings 
(or otherwise) of an ecAVG strategy may change if various factors in the model (TCVC 
bacteraemia rate, delay for TCVC insertion or proportion of patients using ecAVG as their 
definitive access option) changed. For example, the observed bacteraemia rate for TCVCs 
was 1.4 per 1,000 catheter days. At this rate, the estimated cost savings of an ecAVG 
strategy are £927 per patient at 6 months follow-up. Figure 8.3 illustrates that if the TCVC-
associated bacteraemia rate were to reduce to 1.0 per 1,000 catheter days, ecAVGs would 
continue to derive a lesser cost saving of £548 per patient. Similarly Figure 8.4 
demonstrates a lesser cost saving of £228 per patient if the delay waiting for TCVC 
insertion reduced for 7 to 3 days, while Figure 8.5 demonstrates greater cost savings with 
the ecAVG strategy if the proportion of patients using ecAVG as their definitive access 
option were to increase. 
 
 
Figure 8.3: Graphical model reflecting varying cost savings if bacteraemia rate 
amongst TCVC patients were to change. For example, the observed bacteraemia rate for 
TCVCs was 1.4 per 1,000 catheter days. At this rate, the estimated cost savings of an ecAVG 
strategy are £927. If the TCVC-associated bacteraemia rate were to reduce to 1.0 per 1,000 catheter 
days, ecAVGs would continue to derive a lesser cost saving of £548. All costs are in pounds 
Sterling (£). 
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Figure 8.4: Graphical model reflecting varying cost savings if delays associated with 
TCVC insertion were to change. For example, the observed delay for TCVC insertion was 7 
days. At this rate, the estimated cost savings of an ecAVG strategy are £927. If the delay for TCVC 
insertion were to reduce to 3 days, ecAVGs would continue to derive a lesser cost saving of £228. 
All costs are in pounds Sterling (£). 
 
 
 
Figure 8.5: Graphical model reflecting varying cost savings if the percentage of 
patients using ecAVGs are their definitive access option were to change. For example, 
the observed proportion of patients using ecAVGs as their definitive option was 21%. At this rate, 
the estimated cost savings of an ecAVG strategy are £927. If this proportion were to increase to 
40%, estimated cost savings would be higher at £953. All costs are in pounds Sterling (£). 
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8.4.  DISCUSSION 
 
This study demonstrates that ecAVGs may provide a viable alternative to TCVCs in 
patients requiring urgent vascular access for haemodialysis. It has been demonstrated that 
ecAVGs are acceptable to patients and practical to insert within the confines of our busy 
NHS practice. Moreover, when offset against delays and complications (particularly 
infective) associated with the current TCVC usage, ecAVG have been shown to deliver 
cost-savings of nearly £1 000 at 6 months over TCVCs. 
 
A strategy of line avoidance is the holy grail of vascular access. Both short-term risks of 
infection and long-term risks of central venous stenosis associated with TCVC usage are 
associated with access loss, morbidity and mortality for patients on haemodialysis (Bray et 
al. 2012; Thomson et al. 2007; Agarwal et al. 2007). Despite concerted efforts to decrease 
TCVC usage, it has not been possible to reduce prevalent TCVC usage below 30-35% in 
most units (Massoud et al. 2006; Lynch et al. 2011a). With “Fistula First” in the United 
States and governmental tariffs in the England and Wales, there are now financial 
incentives to minimise TCVC usage (Lynch et al. 2011a; Sharif & Baboolal, 2011; NHS 
Information Centre, 2014). This study demonstrates that there may be cost savings to be 
derived simply from the policy of TCVC replacement with ecAVG itself. 
 
Clinically, early cannulation grafts have been used for a number of years, however 
published literature on their use, and indications for their use, is sparse (Tozzi et al. 2014a; 
Berard et al. 2015). In most cases they continue to be used in situations analogous to 
conventional AVGs, where there are no alternative autologous options. Our, recently 
published, observational data (described in Chapter 7) demonstrates the successful use of 
ecAVGs as a “bridge” to autologous AVF maturation or transplantation in selected patients 
(Aitken et al. 2014b). However, this is the first study to propose the use of ecAVG as an 
alternative to TCVCs for the entire dialysis population. Such a change would necessitate a 
paradigm shift in current nephrology thinking and resource allocation. 
 
The approach adopted in this study is one of autologous primacy, with both ecAVG and 
TCVC used, wherever possible, only as a stop-gap until native AVF maturation. We 
advocate this approach because of the well-recognised lower infection and better long-term 
patency rates provided by native AVF (Bray et al. 2012; Thomson et al. 2007). It should be 
noted however that only 16 patients had autologous access at 6-month follow-up. This 
seems low and, given the 30-35% primary failure rate quoted in most studies of de novo 
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AVF (Rayner et al. 2004; Dember et al. 2008) could be seen to limit the generalisability of 
or results. However we believe this observation is representative of “real-world” practice 
and is probably comparable to other studies trying to achieve vascular access in prevalent 
patients (Rayner et al. 2004; Aitken et al. 2014c). The recent DAC multicentre study found 
that more than 60% of AVFs were not suitable for cannulation at 4- 5months (Dember et 
al. 2008). Furthermore dialysis via a TCVC is recognised as a risk factor for early AVF 
failure (Rayner et al. 2004) with Weber and colleagues (2009) achieving 81% primary 
patency in patients who had AVF created prior to commencing dialysis, compared to only 
44% patients in patients who had AVF created after commencing on haemodialysis. This 
highlights that the concept of short-term TCVC for only 6-8 weeks to permit AVF 
maturation, may be flawed and a slightly more robust, albeit temporary, vascular access 
may have benefits.  
 
This work utilises the novel concept of a “virtual study” to compare “real-world” 
prospective data collected on standard practice  (the TCVC cohort) to an innovative, but as 
yet unproven, hypothetical new treatment strategy arm (ecAVG). It allows real-time 
assessment of the practicality, feasibility and acceptability of the proposed new 
management strategy and can inform a health economic analysis. The model can be 
adapted to permit cost-analyses for business cases prior to implementation of a new 
treatment plan or, in our case, has been used to inform cost calculations for a future 
randomised controlled trial. The real-time data collection in the standard practice cohort, 
allows very accurate figures, often lacking from other health economic analyses, and 
modeling that allows manipulation of variables such as bacteraemia rates and waiting time 
for TCVC provides generalisability to other centres, which may have differing baseline 
rates for these factors. 
 
The “virtual study” model uses real-life data to inform cost-analysis in the TCVC arm, 
however data in the ecAVG arm is extrapolated from the literature. Data collected from 
this “virtual study” was subsequently used to inform the randomised controlled trial  
(RCT) comparing TCVC vs. ecAVGs described in Chapter 9. We propose that similar 
studies could be used to support the conduct of other RCTs (either to demonstrate potential 
cost savings to sponsors, or to assist in grant applications). This study has informed the 
power calculation for our subsequent trial, which is unique in the fact that it could be 
manipulated and modelled to take into account changes in practice that might occur over 
time or between units. The “virtual study” can also inform potential recruitment to 
subsequent RCTs by assessing acceptability of the novel intervention and likely refusal 
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rates or eligibility criteria for future studies. This is particularly relevant in trials of 
heterogeneous patient groups, such as those on dialysis, where strict inclusion criteria may 
necessitate large number of patients to be screened to determine eligibility. For example, a 
recent New England Journal of Medicine study evaluating tissue plasminogen activator 
(tPA) in dialysis catheter malfunction, failed to recruit the intended 380 participants 
despite screening nearly 2,500 patients (Hemmelgarn et al. 2011). The “virtual study” 
allowed us to assess likely uptake to a RCT prior to beginning recruitment. Finally, the 
results from our “virtual study” were used to support the application for conducting a RCT 
to our NHS trust sponsor, indicating that the study will, at a minimum, be cost-neutral to 
the hospital. This allowed our research to progress without the need to seek additional 
funding. In an era where research costs can often be prohibitive and charitable funding is 
limited, demonstrating potential cost-savings achievable from conducting the research 
itself has proven very valuable in this case.  
 
In conclusion, the “virtual study” is a novel research methodology that can be used to 
compare current standard practice to an alternative management strategy and model 
potential outcomes. We have used it to demonstrate that ecAVGs could provide a practical, 
acceptable and cost-effective alternative to TCVCs in patients requiring urgent vascular 
access for haemodialysis. 
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A RANDOMISED CONTROLLED TRIAL AND COST-
EFFECTIVENESS ANALYSIS OF EARLY CANNULATIONS 
GRAFTS VS. TUNNELLED CENTRAL VENOUS CATHETERS IN 
PATIENTS REQUIRING URGENT VASCULAR ACCESS FOR 
HAEMODIALYSIS 
 
9.1. INTRODUCTION 
 
On the back of the “virtual study” described in the previous chapter, a formal randomised 
controlled trial comparing ecAVGs to TCVCs in patients requiring urgent vascular access 
for HD was proposed. We hypothesised that ecAVG would result in a lower bacteraemia 
rate than TCVCs and could potentially deliver cost-savings. 
The timing of the randomised controlled trial was salient, in that it followed five years 
ofdeveloping experience with the Gore®ACUSEAL ecAVG. The technical lessons learned 
from evaluating our observational data (described in Chapter 7 of this thesis) were 
employed throughout the study period. 
Data from the “virtual study” suggested that a strategy of ecAVG as opposed to TCVCs 
could deliver cost-savings of nearly £1,000 at 6 months (Aitken et al. 2016). This 
demonstration of potential clinical cost-savings permitted engagement with our hospital’s 
Research and Development Department. After discussion, the randomised trial was 
allowed to commence without additional funding due to the potential financial benefits that 
the research could have for the clinical service. 
The randomised trial subsequently described was therefore performed based on the same 
rationale previously described for the “virtual study” (Chapter 8). It also represents a 
culmination of the clinical experience gained and is the actualisation of an ethos cultivated 
through the virtual study. 
9.2. METHODOLOGY 
9.2.1.  Study design and participants 
This prospective single-centre randomised controlled trial was performed in the 
Department of Renal Surgery, Western Infirmary, Glasgow. The trial protocol was 
published prior to the trial commencing (Aitken et al. 2015c). It was an inclusive study. All 
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patients aged 18 years or older with established renal failure who required urgent vascular 
access for HD (i.e. needed to dialyse within 48 hours for referral) were eligible to 
participate. Patients were excluded if they had a recent myocardial infarction (< 4 weeks), 
active systemic sepsis, no anatomically suitable vessels for ecAVG based on pre-operative 
imaging, anticipated life expectancy < 3months, existing AVF thought likely to be useable 
within 2 weeks, if they lacked capacity to provide informed consent, or declined 
participation in the study.  
The study protocol was reviewed and approved by the West of Scotland Research Ethics 
Committee 4 (13/WS/0187). All trial procedures followed were in concordance with the 
Declaration of Helsinki, 1975 (revised 2000). All participants provided written informed 
consent. A Trial Steering Committee was convened prior to the start of the study and 
annually to evaluate data and safety. All serious adverse events, defined as death or life-
threatening sepsis, were reported to the research ethics committee. 
9.2.2.  Randomisation 
Patients were randomly assigned (1:1) by a computer-generated randomisation sequence 
and sealed envelopes to receive either TCVC ± AVF or ecAVG ± AVF. Due to the nature 
of the treatment and any subsequent interventions, it was not possible to mask the 
allocation of treatment to patient, surgeon or study investigator. 
9.2.3.  Recruitment 
Patients were identified at time of referral to the Vascular Access Coordinator for urgent 
insertion of TCVC. All eligible patients were then approached by a member of the research 
team, the study discussed and, if agreeable, pre-operative imaging undertaken. 
9.2.4.  Procedures 
9.2.4.1.    Pre-operative planning 
All patients underwent Duplex ultrasound of both arms (and legs where no suitable upper 
limb option was determined). Both the venous and arterial tree was assessed and a pre-
operative plan made to site both ecAVG and native AVF (if possible). A minimum arterial 
cross-sectional diameter of 2mm was deemed necessary to sustain either AVF or ecAVG. 
Venous diameters of 2mm at the wrist and 3mm at the elbow were considered suitable for 
AVF (or forearm loop graft). A patent basilic/ axillary artery measuring at least 3mm was 
deemed necessary to site the venous outflow of an ecAVG. Care was taken in the choice of 
anatomical site for the ecAVG in order to preserve all possible sites for future autologous 
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access, with the site of native AVF favoured distally in the non-dominant arm. ecAVG was 
placed to accommodate optimal AVF placement. For example, a native left radiocephalic 
fistula and right brachioaxillary graft was favoured in a left-handed patient with good 
native vessels and no previous vascular access; whilst revision of an existing occluded left 
brachiocephalic fistula using an interposition ecAVG and contralateral elbow AVF would 
be considered in an elderly patient with poor vessels and occluded existing AVF.  
9.2.4.2.    TCVC ± AVF 
The TCVC ± AVF strategy reflected standard practice at our institution with TCVC 
insertion performed either by a radiologist or nurse specialising in TCVC insertion. A 
single dose of intravenous vancomycin was administered prior to line replacement. 
Tunnelled Ash Split® (Medcomp, Harleysville, PA, USA) 14Fr double-lumen 
polyurethane haemodialysis catheters were inserted with 280mm (left) or 320mm (right) 
catheters inserted via a Seldinger technique under image guidance. A standard catheter 
care protocol was employed throughout the study period. This demanded complete sterile 
precautions during insertion and manipulation with an assistant or non-touch technique to 
manipulating the hub of the catheter. Full aseptic technique was used to commence and 
disconnect from dialysis. The catheter hubs were wrapped with 70% isopropyl alcohol 
wipes to maintain asepsis and permit no touch initiation/ discontinuation of dialysis. At the 
end of dialysis, chlorhexidine cleansing of the skin was performed prior to application of a 
new sterile dressing and an interdialytic lock with TauroHep500™ (TauroPharm GmbH, 
Waldbűttelbrunn, Germany) was utilised.  
First haemodialysiswas performed by trained nursing staff within the In Patient Renal 
Unit.Subsequent dialysis sessions were performed at regional outpatient dialysis units in 
the West of Scotland. 
9.2.4.3.  ecAVG ± AVF 
Patients randomised to receive ecAVG ± AVF underwent anaesthetic assessment and 
surgery within 24 hours of randomisation wherever possible. Prophylactic vancomycin 1g 
intravenously (or teicoplanin if the patient was vancomycin allergic) was given 
preoperatively. All ecAVG implantations were performed by a single operating surgeon 
under either supraclavicular block or general anaesthetic.  
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The operative technique is summarised below, but employed all of the modifications 
described in Chapter 7. Alcoholic betadine was used for cleaning the skin and an Ioban™ 
skin covering (3M Healthcare, Bracknell, UK) applied to maintain strict asepsis. The 
vessels were exposed and controlled in a standard fashion. The Gore®ACUSEAL graft 
(W.L. Gore Associates, Flagstaff, AZ, USA) was then tunnelled in the subcutaneous fat 
using standard Kelly-Wick tunnellers. A 4-cm longitudinal venotomy was performed and 
the graft spatulated at the venous end in an attempt to minimise venous stenosis. A 4-6mm 
arteriotomy was made to accommodate the graft. Arterial and venous anastomoses were 
performed using continuous 5.0 Prolene. Colatamp™ (Tribute Pharmaceuticals, Milton, 
Ontario, Canada) was inserted prior to wound closure to minimise the risk of infection. 
Drains were not routinely used. 
First cannulation of the ecAVG was performed by trained dialysis nursing staff in the 
InPatient Renal Unit. The timing of cannulation was determined by clinical need with no 
minimum period post-surgery. Sharp needles (17G), low flows (200 to 250mL/min) and 
minimal heparin were used for first cannulation. Full aseptic technique was employed for 
cannulation and direct pressure applied at the needle sites for at least 10 minutes after the 
needles were removed. These same techniques were used for the first 2 weeks of 
cannulation. Thereafter, higher flow rates were permitted if necessary to achieve adequate 
dialysis clearance. Patients were discharged after at least two successful cannulations of 
the ecAVG. Maintenance dialysis was performed at Outpatient Dialysis Units in the West 
of Scotland.   
All patients completed one-week of intravenous vancomycin post-operatively. Heparin, 
warfarin and anti-platelet agents were administered at the discretion of the operating 
surgeon. All patients who re-presented with thrombotic complications were anti-
coagulated with warfarin  unless contraindicated. All ecAVGs underwent surveillance 
ultrasound and angiography at 3 months and at 3 monthly intervals thereafter. Any stenosis 
(on either imaging modality) in the context of access dysfunction was considered clinically 
significant, prompting angioplasty±stenting (for recurrent lesions). In the event of 
thrombosis aggressive attempts at declotting were made by a combined surgical and 
radiological approach. 
9.2.4.4.  Autologous AVF 
Patients in both treatment arms also underwent creation of an autologous AVF (if this was 
anatomically possible). In the ecAVG cohort, this was performed at the same time as 
 221 
ecAVG if possible, otherwise every effort was made to provide the patient with 
opportunity of AVF creation on the next available theatre list (within 1-2 weeks). The 
ecAVG/TCVC was utilised for haemodialysis until the AVF was mature enough to 
cannulate. The decision to perform first cannulation of the AVF was taken by the clinical 
team (normally ~6 weeks after creation) following clinical assessment by the Vascular 
Access Co-ordinator. 
Once established on dialysis via an AVF the fate of a redundant ecAVG was decided after 
discussion between the patient and surgical team. In the majority of cases it was left in situ 
but on occasion was removed or ligated if required/wished. TCVCs were removed by the 
surgical team after six successful AVF cannulations as is standard practice.  
9.2.5.    Follow-up 
Patients were reviewed on day 1, day 7 and at 3 and 6 months. Additionally data on access-
related complications were recorded prospectively at each dialysis session. In addition to 
demographics and operative details, data were collected on perioperative complications, 
date of first access use, treatment delays, requirement for antibiotics and/or urokinase 
infusions, access complications (bacteraemia, local infection, thrombosis, stenosis, poor 
flows) and re-interventions (new access creation/ insertion, thrombectomy, angioplasty). 
Quality of life data were collected at time of entry to the study and 6-month follow-up.  
9.2.6.  Outcome measures 
The primary outcome measure was culture-proven bacteraemia at 6 months, defined 
according to the Centre for Disease Control (CDC) as laboratory confirmed positive 
peripheral blood cultures in association with clinical symptoms of access infection or 
failure to identify infection at a secondary site (Centre for Disease Control, 2015).  
Secondary outcomes were local infection, thrombosis, stenosis, re-interventions (including 
thrombectomy, antibiotics and urokinase locks), additional vascular accesses, quality of 
life, whether or not the access provided a “personal vascular access solution”(Aitken et al. 
2014a), length of inpatient hospital stay, and death at 6 months. Local infection was also 
defined according to CDC definitions as proven (laboratory confirmed positive cultures 
from local swabs) or suspected (clinical signs and symptoms but no positive culture) 
(Centre for Disease Control, 2015). Thrombosis was defined clinically as the absence of 
thrill or bruit from a graft and inability to dialyse via it, or the inability to dialyse via, flush, 
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or aspirate from a TCVC. Health-related quality of life (HR-QoL) was evaluated using the 
EuroQoL-5D (EQ-5D) questionnaire (Szende et al. 2007). 
 
9.2.7.  Sample size calculation 
A reduced incidence of systemic bacteraemia in the ecAVG ± AVF group was postulated. 
Using previously published bacteraemia rates for TCVCs and ecAVG in our own 
institution (Thomson et al. 2010; Aitken et al. 2014b), it was calculated that 53 patients 
would be needed in each group to provide 80% power to detect a reduction in the 
incidence of systemic bacteraemia from 24% to 5% at six months follow-up with α level 
0·05. In order to account for attrition/ loss to follow-up of 10%, we aimed to recruit 118 
patients (n=59 per arm). 
9.2.8.  Statistical analysis 
All analysis was performed on an intention-to treat basis. Any patient randomised but who 
withdrew from the study prior to the procedure was replaced by another patient but 
continued to be followed-up on an intention-to-treat basis. Normal distribution of data was 
confirmed by limited skewness and kurtosis. Results for continuous variables are reported 
as mean (± standard deviation [SD]) or median (interquartile range [IQR]). Access-related 
bacteraemia rates are presented both as a proportion of the total population (and risk ratio) 
and as a rate per 1,000 access days. Having confirmed normal distribution, treatment 
groups were compared using t-tests for continuous variables and χ2 tests for categorical 
variables. 
 
Additionally, a cost-effectiveness analysis was performed to compare the average total 
treatment costs within each arm. Average costs per patient were derived from direct 
resource utilization data along with the unit costs for each procedure.  Unit costs were 
obtained from 2013-2014 NHS Reference Costs, Scottish Health Service Costs 2014-2015 
and Personal Social Services Research Unit: Unit Costs of Health and Social Care 2015 
(Department of Health, 2015; Curtis, 2015). All costs e.g. bed days, material costs of 
ecAVG/ TCVC or antibiotics were derived directly from those observed in the study. An 
intention-to-treat analysis was conducted with the perspective of the provider.  Results 
summarise the average cumulative total costs per patient from trial initiation to 6-months 
of patient follow-up. 
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This trial was registered with the International Standard Randomised Controlled Trial 
Number (ISRCTN 80588541). 
 
9.3.  RESULTS 
 
Between December 5, 2013 and February 5, 2015, 121 patients were randomly assigned to 
ecAVG ±AVF group (n=60) or TCVC ±AVF group (n=61). 13 patients (10·7%) died 
during the follow-up period. No other patient was lost to follow-up (Figure 9.1).  
 
Table 9.1 shows baseline characteristics of randomised patients. 31·4% of patients (n=38) 
commenced dialysis for the first time (of whom 39·4% (n=15) were “crashlanders” i.e. 
known to a nephrologist of <90 days prior to starting dialysis). The remainder of patients 
had previously been on renal replacement therapy via another modality or vascular access 
which had failed (Table 9.2). AVF was the ultimate intended vascular access in 62·0% of 
patients (n=75), with the intention of long-term AVG in 33·1% (n=40). A total of 52 AVF 
in 34 patients were also made during the follow-up period. 
 
There was a significantly higher culture-proven bacteraemia rate in the TCVC ±AVF 
cohort (0·97 per 1 000 catheter days) compared to the ecAVG ±AVF cohort (0·19 per 
1,000 access days) with 16.4% of patients (n=10) developing culture-proven bacteraemia 
during the first 6 months in the TCVC ±AVF arm compared to 3·3% (n=2) in the ecAVG 
±AVF arm (risk ratio 0·2 95% CI 0·12, 0·56; P=0·02). Mortality was also higher in the 
TCVC ±AVF cohort with (16·4% [n=10] vs. 5% [n=3](risk ratio 0·3 95% CI 0·08, 0·45; 
P=0·04)). No patient died as a result of access-related complications (including access-
related sepsis). One patient died from a perioperative myocardial infarction (MI) in the 
ecAVG ±AVF arm. 
 
Median waiting time for TCVC insertion was 6 days (range: 1-21 days). Median waiting 
time for ecAVG insertion was 14 hours (range: 1- 168 hours) (P<0·001). Twice as many 
patients in the TCVC ±AVF cohort required a bridging temporary line than in the ecAVG 
±AVF cohort (49·2% [n=30] vs. 25·0% [n=15]; P=0·006). Median length of hospital stay 
for vascular access (including associated delays) was 4 (IQR 2,7) days in the ecAVG 
±AVF cohort and 7 (IQR 3,13) days in the TCVC ±AVF cohort (P<0·0001). Four patients 
in the ecAVG arm had perioperative complications: MI (n=2); venous hypertension and 
limb swelling (n=1); pseudoaneurysm (n=1).  Four patients had failed attempts at TCVC 
insertion and one had initial attempts at insertion abandoned due to flash pulmonary 
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oedema. Sites of ecAVG were as follows: upper arm (brachioaxillary) (n=33); forearm 
(brachial artery to basilic vein forearm loop) (n=2); lower limb (superficial femoral artery 
to subsartorial femoral vein) (n=10); interposition (inserted into previous fistula at site of 
aneurysm excision etc.) (n=8). Median time to first graft cannulation was 22 hours (range: 
30 minutes- 130 hours). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
Figure 9.1 Trial flow and CONSORT diagram of assignment to ecAVG or TCVC 
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Analysed (n=60)  
Lost to follow-up (n=3) (Death (3)) 
Discontinued intervention (n=0) 
Allocated to ecAVG (n=60) 
i Received allocated intervention (n=53) 
i Did not receive allocated intervention (n=7)          
(withdrew consent prior to surgery (2), recovery of 
renal function prior to surgery (1), cancelled by 
anaesthetist (2), no suitable vessels found intra-
operatively (2)) 
Lost to follow-up (n=10) (Dead (10)) 
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Allocated to TCVC (n=61) 
i Received allocated intervention (n=61)  
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Table 9.1: Baseline characteristics of patients randomised to ecAVG or TCVC. Data 
are presented as n (%) or mean ± SD unless otherwise stated.  
 
 Overall patient 
population 
(n=121) 
 
AVG 
(n=60) 
TCVC 
(n=61) 
Age (years) 57·8+/-15·6 54·5+/-15·3 60·9+/-15·5 
 
Sex (% male) 66 (54·5%) 32 (53·3%) 34 (57·4%) 
 
Primary renal disease 
Diabetes 
Multisystem 
Interstitial 
Glomerulonephritis 
Unknown 
 
30 (24.·%) 
17 (14·0%) 
28 (23·1%) 
26 (21·5%) 
20 (16.1%) 
 
19 (31·1%) 
4 (6·6%) 
15 (24·6%) 
12 (19·7%) 
20 (18·0%) 
 
11 (18·3%) 
13 (21·7%) 
13 (21·7%) 
14 (23·3%) 
9 (15·0%) 
 
Co-morbidities 
Diabetes 
IHD 
CVA 
Hypertension 
Obesity 
 
39 (32·2%) 
25 (20·7%) 
20 (16·5%) 
43 (35·5%) 
19 (15·7%) 
 
 
22 (36·7%) 
13 (21·7%) 
10 (16·7%) 
20 (33·3%) 
10 (16·7%) 
 
 
17 (27·9%) 
12 (19·7%) 
10 (16·4%) 
23 (37·7%) 
9 (14·8%) 
 
Access modality at 
time of randomization 
Failing transplant 
HD 
PD 
Pre-dialysis 
 
 
5 (4·1%) 
67 (55·3%) 
7 (5·8%) 
42 (34·7%) 
 
 
3 (5·0%) 
38 (63·3%) 
3 (5·0%) 
16 (26·7%) 
 
 
2 (3·4%) 
29 (48·3%) 
4 (6·7%) 
26 (43·3%) 
 
Time on dialysis 
(median, IQR) 
 
3·4 (2·5, 5·2) 
 
3·4 (3·2, 6·8) 
 
3·2 (1·8, 6·2) 
 
Previous vascular 
access (median, range) 
AVF 
TCVC 
 
 
2 (range:0-6) 
1 (range: 0-43) 
 
 
2 (range: 0-6) 
2 (range: 0-43) 
 
 
1 (range: 0-6) 
0 (range: 0-25) 
Access modality at 
time of randomization 
AVF 
AVG 
PD 
Pre-D/ failing transplant 
TCVC 
 
 
29 (24·0%) 
8 (6·6%) 
6 (5·0%) 
47 (38·8%) 
30 (24·8%) 
 
 
18 (30·0%) 
7 (11·7%) 
3 (5·0%) 
19 (31·1%) 
13 (21·7%) 
 
 
11 (18·0%) 
1 (1·6%) 
3 (4·9%) 
28 (45·9%) 
17 (27·7%) 
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Table 9.2: Indications for requiring “urgent” vascular access. Data are presented as n 
(%).   
Indication for needing access 
 
Number (%) 
Acute-on-chronic renal failure 
Late presentation 
Problems with AVF maturation 
Rapid progression to end-stage 
 
 
14 (11·6%) 
5 (4·1%) 
4 (3·3%) 
Failed transplant 
 
6 (5·0%) 
Problematic AVF/ AVG 
Aneurysm/ rupture 
Thrombosis 
Infection 
 
 
17 (14·0%) 
28 (23·1%) 
1 (0·8%) 
Problematic TCVC 
Thrombosis 
Infection 
 
 
13 (10·7%) 
12 (9·9%) 
Failed PD 
 
6 (5·0%) 
Crashlander  
 
15 (12·4%) 
 
Access complications and their implications are outlined in Table 9.3. 34 episodes of graft 
thrombosis were observed in 16 patients (26·7%). Patients in the TCVC ±AVF arm spent 
an average of 4·7 days/ patient in hospital for access-related complications compared to 
2·7 days/ patient in the ecAVG ±AVF arm (P<0·001). The total number of hospital days 
were reduced in the ecAVG ±AVF cohort in the 6 months following graft insertion 
compared to the 6 months prior to ecAVG insertion (4 days (IQR 3,7) vs. 8 days (IQR 
4,12); P=0·02). A similar trend was not seen in the TCVC ±AVF cohort (10 days (IQR 
8,14) vs. 8 days (IQR4,10)). Initial HR-QoL scores were comparable at entry to the study 
(total EQ-5D: 67 ± 12 vs. 67 ± 14; P=0·89). However at 6-month follow-up, patients in the 
ecAVG ±AVF cohort had better HR-QoL scores (74 ± 18 vs. 63 ± 16; P=0·001).  
 
At six-month follow-up only 23·3% (n=14) of patients in the ecAVG ±AVF arm and 
16·4% (n=10) of patients in the TCVC ±AVF arm were dialysing via autologous AVF. 34 
patients were still awaiting further attempts at achieving autologous access at the end of 6-
month follow-up. In the ecAVG ±AVF cohort 50% (n=30) were still using their ecAVG. 
In the TCVC ±AVF arm 52·5% (n=32) of patients were still dialysing via a TCVC. The 
ecAVG was deemed to be a “personal vascular access solution” (i.e. it was still being used 
for access, had served as a “bridge” to AVF maturation or transplantation or was the 
vascular access at time of death) in 73·3% of patients (n=44). 68·9% (n=42) in the TCVC 
±AVF arm could consider the initial TCVC to be their “personal solution”. 
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Table 9.3: Other vascular access complications and the implications of these 
including interventions and need for alternate vascular access.  Data are presented as 
number of episodes per patient in 6 months (n). * All of these complications resulted in access loss 
unless otherwise stated. ** Of the 36 episodes of stenosis requiring intervention 26 were venous, 7 
arterial, 1 cephalic arch and 2 central veins. @ One patient required urgent graft ligation for steal 
syndrome. The other cases were clinically relative mild and did not require urgent intervention. 
Three further grafts were ligated but this was after alternative access in the form of AVF had been 
established. 
 
 
Complication 
 
Episodes per patient in 6 months (n) 
TCVC ARM 
 
Infection 
Systemic proven 
Systemic suspected 
Access removed 
Additional hospital days 
Days with antibiotic treatment 
 
0·16 (n=10) 
0·07 (n=4) 
0·26 (n=15) 
2·49 (n=152) 
3·16 (n=193) 
Thrombosis/ inadequate flow* 
Urokinase 
0·15 (n=9) 
0.27 (n=17) 
Line displaced* 0·07 (n=4) 
Additional vascular access 
AVF  
Tenckhoff catheter 
AVG 
Temporary line 
TCVC 
 
0·38 (n=23) 
0·03 (n=2) 
0·08 (n=5) 
0·16 (n=10) 
0·32 (n=32) 
AVG ARM 
 
Infection 
Systemic proven 
Local proven 
Local suspected 
Access removed 
Additional hospital days 
Days with antibiotic treatment 
 
0·03 (n=2) 
0·1 (n=6) 
0·03 (n=2) 
0·05 (n=3) 
0·7 (n=42) 
3·37 (n=160) 
Thrombosis/ stenosis** 
Thrombosis 
Stenosis 
Surgical thrombectomy 
Surgical revision 
Angioplasty 
Stent 
Revision with additional graft (inc HeRO) 
 
0·57 (n=34) 
0·6 (n=36) 
0·52 (n=31) 
0·12 (n=7) 
0·5 (n=30) 
0·12 (n=7) 
0·03 (n=2) 
Graft erosion* 0·03 (n=2) 
Steal syndrome*@ 0·08 (n=5) (4 grafts were ligated) 
Wound dehiscence 0·02 (n=1) 
Pseudoaneurysm (re-exploration) 0·02 (n=1) 
Additional vascular access 
AVF  
Tenckhoff catheter 
AVG 
Temporary line 
TCVC 
 
0·48 (n=29) 
0·02 (n=1) 
0·03 (n=2) 
0·12 (n=7) 
0·27 (n=16) 
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In the ecAVG ±AVF arm, 32 patients (52.1%) had AVF planned as their definitive 
vascular access at the start of the study. 8 of these AVF (25%) thrombosed immediately, 6 
were deemed unsuitable to ever provide dialysis and 4 required an additional procedure to 
try to achieve functional patency. Of the 14 patients with failed AVF, 9 had a second 
attempt at AVF creation during the study follow-up. Only 14 patients (23.3%) were using 
their AVF at 6 months. With regards to relative placement of ecAVG and AVF in patients 
having both created (n=32), 15 were deemed to have a radiocephalic fistula option, 14 a 
brachiocephalic option and 3 only had a mid forearm or lower limb autologous option at 
the time of graft placement. 21 patients had placement of a contralateral brachioaxillary 
graft, 8 had an interposition graft (into an otherwise defunct fistula), two had forearm loops 
and one a leg graft. In both the patients with forearm loops, the ecAVG was utilised to 
mature an outflow cephalic or basilic vein, which was subsequently used to create an 
autologous fistula, suitable for immediate cannulation. No autologous access option was 
lost as a result of the ecAVG, even in the 10 patients whose grafts thrombosed. 
 
There was no significant difference in overall costs per patient at 6-months in the ecAVG 
±AVF compared to TCVC ±AVF arm (£11 393 vs £9 692, P=0.24).  Infection-related 
costs made up the largest proportion of costs in the TCVC ±AVF arm and were 
significantly higher than infection costs incurred in the ecAVG ±AVF arm (£2 011 vs. 
£453, P=0.02). Re-interventions made up the largest proportion of costs in the ecAVG 
±AVF arm (average £1 042 re-intervention costs per patient) (Table 9.4). 
 
A comparison between the findings of the “virtual study” (Chapter 7) and the randomised 
controlled trial has demonstrated that the overall cost savings of AVGs were greater in the 
RCT than in the “virtual study” (-£1,702 vs. -£927). The estimated costs of TCVC, TCVC 
infection and bed days as a result of TCVC complications were lower in the “virtual study” 
than in reality in the RCT. Similarly, bed day utilisation and procedural costs (especially 
re-intervention costs) were higher in the AVG in the RCT compared to the estimated costs 
of the “virtual study” (Table 9.5). 
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Table 9.4: Average costs per patient at six-months follow-up by treatment group. All 
costs are calculated in 2014-2015 pounds Sterling. *The other costs category refers to peritoneal 
dialysis catheter insertions and transplants.   
 
  
AVG TCVC 
Difference 
(AVG-
TCVC) P value 
N 60 61     
AVG procedure costs £2 432 £212 £2 220 <0.001 
AVF procedure costs £426 £465 -£40 0.7 
TCVC costs £390 £1 824 -£1 434 <0.001 
Temporary line costs £62     £121 -£60 0.003 
Index TCVC bed days £244 £4 222 -£3 978 <0.001 
Infection costs £453 £2 011 -£1 558 0.02 
AVG or AVF intervention costs £1 042 £85 £957 <0.001 
Bed day costs    £3 781 £1 965 £1 816 0.004 
Other costs*     £862 £487 £375 0.52 
Average total costs per patient at 180 days £9 692 £11 393 -£1 702 0.24 
 
 
Table 9.5: A comparison between findings of the “virtual study” and the RCT 
 Virtual study 
Difference (AVG-
TCVC) 
Randomised 
controlled trial 
Difference (AVG-
TCVC) 
RCT-virtual study 
AVG procedure costs 
 
£764 £2 200 £1 463 
AVF procedure costs 
 
£25 -£40 -£65 
TCVC costs 
 
-£265 -£1 434 -£1 169 
Temporary line costs 
 
-£9 -£60 -£51 
Index TCVC bed days 
 
-£972 -£3 978 -£3 006 
Infection costs 
 
-£854 -£1 558 -£704 
AVG or AVF 
intervention costs 
 
£663 £957 £294 
Bed days 
 
-£279 £1 816 £2,095 
Other additional costs 
 
£0 £375 £375 
Average total costs 
per patient at 180 
days 
-£927 £-1 702 -£775 
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9.4. DISCUSSION 
The study has demonstrated that the incidence of culture-proven bacteraemia in patients 
requiring “urgent” vascular access for HD was higher in those dialysing via a TCVC than 
those using an ecAVG. There was also a higher mortality rate observed in the TCVC±AVF 
cohort. ecAVGs were found to be cost-neutral with the initial outlays and costs of re-
intervention offset against lower costs conferred from the treatment of sepsis and treatment 
delays.  
This is the first randomised controlled trial comparing TCVCs to AVGs, however there is a 
significant quantity of observational data supporting the findings of this study. The higher 
mortality rate in patients dialysing via TCVCs is well described (Bray et al. 2012; Malas et 
al. 2015; Thomson et al. 2007). The survival difference between the access modalities 
emerges early in the life of the vascular access and is only in part attributable to infectious 
deaths (Bray et al. 2012; Thomson et al. 2010). Recent retrospective data collected from 
over half a million patients via the US Renal Data System indicates that cardiovascular and 
all-cause mortality are higher in patients dialysing via TCVC (Malas et al. 2015). In our 
study, whilst no patient died as a result of access-related bacteraemia, a clear difference in 
mortality rates was observed as early as six-month after insertion of the vascular access.  
Similarly, many large observational cohort studies concur with our finding of a higher 
culture-proven bacteraemia rate in TCVCs than AVGs. Three-fold higher rates of 
bacteraemia are commonly reported for TCVC than AVG (Taylor et al. 2002; Thomson et 
al. 2007). Data from these population-based studies is inherently vulnerable to selection 
bias with frailer, sicker patients more likely to dialyse via a line (Thomson et al. 2010). 
Additionally it can be difficult to compare infection rates between populations, and there 
are few observational studies comparing bacteremia rates between access modalities within 
the same population (Thomson et al. 2010). The magnitude of difference observed in the 
cohort studies is however similar to that observed in our series, adding validity to our 
results. It should be acknowledged that most of the reported bacteraemia rates for AVGs 
relate to traditional poly-tetrafluoroethylene (PTFE) grafts and not ecAVGs. Previously 
published small case-series of ecAVGs report slightly lower culture-proven bacteraemia 
rates of 0·2-0·3 per 1,000 access days (Aitken et al. 2014b; Glickman et al. 2015; Chiang 
et al. 2014). The rate of culture-proven bacteraemia observed in this study was also lower 
than previously published in both ecAVG ±AVF and TCVC ±AVF cohorts. We attribute 
this to good practice, with strict infection control measures employed both at the time of 
access insertion and for graft cannulation/ catheter care.  
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Most importantly, this study reflects real-world practice with an inclusive recruitment 
strategy. We have demonstrated the role that ecAVGs can play in an unselected cohort of 
patients requiring “urgent” vascular access for HD, making the findings of this study both 
clinically applicable and generalisable to a wide variety of patients. Conversely however, 
the population is very heterogeneous. It may be that there are specific subgroups of 
patients more or less likely to benefit from ecAVG/ TCVC. The study was underpowered 
for any subgroup analysis. One such subgroup of interest is the “crashlanders”. It had been 
anticipated that this would be a study principally of “crashlanders”, however in actuality 
less than one-third of patients were new-starts onto dialysis. De novo dialysis patients pose 
unique challenges. The National Kidney Foundation Vascular Access Report (2012) found 
that 60% of “crashlanders” still had their TCVC six months after commencing dialysis and 
AVF maturation rates are poorer in patients already on HD via a TCVC (Weber et al. 
2009; Brunori et al. 2005), supporting the adage “start with a line, stay on a line”. It is 
essential to optimise the initial vascular access as legacy of bad access decision-making 
may have lifelong implications for patients. For these reasons we hypothesise that the 
beneficial effects of the ecAVG may be even more marked in the cohort of “crashlanders” 
but this study was not powered to demonstrate this.  
We observed a high rate of autologous fistula failure, with 2.2 attempts at AVF creation for 
every successfully matured AVF. This high failure rate is not significantly different from 
that observed in other randomised trials. Dember and colleagues (2008) found that 60% of 
AVF remained unsuitable for use five months after creation and reflects the difficulties 
creating autologous access in a contemporaneous dialysis patient cohort. These patients 
run the risk of surgical fatigue with second and subsequent AVF having lower success 
rates, longterm line use leading to central vein stenosis, and ultimate patient refusal of 
further perceived futile attempts at vascular access (Aitken et al. 2014a; Nica et al. 2013). 
Although the high thrombosis rate of AVG is well recognised (Akoh, 2009; Schild et al. 
2007), there is good observational data to suggest that the cumulative patency rates of 
AVGs are at least comparable to AVF up to two years accounting for the high early 
primary failure of AVF (Lok, 2007; Allon & Lok, 2010). Whilst, we do not advocate 
choosing an AVG over a native AVF, such factors need to be considered in choosing the 
correct access for the correct patient, particularly if the patient’s life expectancy is short. 
Prior to embarking on the study, the authors had concerns that ecAVG would risk 
compromising future sites for upper limb autologous access, particularly given the whole 
premise of the work was to view vascular access planning as a lifetime journey (initially 
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inspired by trying to minimise autologous options lost as a result of central vein stenosis 
from inappropriate TCVC use). In reality however, we did not find this to be the case. Of 
the 32 patients having both ecAVG and AVF made, one had lower limb ecAVG and 8 had 
interposition grafts into already defunct AVF, so no potential autologous option was 
compromised. In two cases, a forearm loop ecAVG was actually used to mature the 
outflow vein for subsequent successful AVF creation. We therefore, despite our initial 
concerns, have been relatively reassured that, in this study, ecAVG placement has not 
compromised any future options for autologous access placement. 
More than a study of ecAVGs versus TCVCs per se, this study is considered a 
comparsison of strategies and approaches to vascular access provision. A change in 
practice has been evaluated, with a move away from TCVC as default to an ethos that 
considers alternative options to permit line avoidance. Such a change in practice requires a 
concerted, team-based approach to minimise inertia in the system, as evidenced by the fact 
that, with effort, ecAVG could be inserted within 14 hours of referral compared to a 6 days 
wait-time for TCVC (acknowledging that this may lead to bias with fewer temporary lines 
inserted in the ecAVG ±AVF cohort). We adopted an ethos of native primary (with 
preservation of the best autologous option) and future access planning. No patient had an 
access placed (either TCVC or ecAVG) without considering what their “exit strategy” 
from that access was (i.e. a long-term plan). Such a change in approach to vascular access 
requires a greater integration in care. We observed a shift in service demands away from 
interventional radiology, who traditionally placed TCVCs in all of these patients, towards 
surgery, with a greater ownership of complications by the surgical service for patients 
within the ecAVG ±AVF cohort. A policy of ecAVG insertion requires flexibility in 
operative planning and commitment to provide a 24/7 graft thrombectomy service in order 
to achieve a line-minimisation culture. Significant education of nephrology and nursing 
colleagues is also required to ensure correct cannulation technique and minimise graft 
complications. Furthermore, it must also be acknowledged (as we have observed moving 
forward adopting the findings of this study into clinical practice), that adoption of such a 
monumental strategy in vascular access provision on a large scale requires significant 
redistribution of resources (both manpower and monetary) to reflect the additional 
pressures placed on the surgical service. 
Locally, the timing of the randomised controlled trial was critical. The protocol and 
implementation built on five years of exponential experience with ecAVGs and the lessons 
learned from this e.g. a long venous anastomosis to reduce outflow stenosis and the 
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importance of education and graft care to minimise infective complications and 
pseudoaneurysm formation (as described in Chapter 7). Furthermore, the “virtual study” 
(Chapter 8) provided a financial incentive to consider an alternative to the status quo. 
Perhaps most importantly however, the study came at a time when the mind-set of 
clinicians within the unit was beginning to change. The study was certainly driven by a 
small number of committed “early adopters”(Rogers, 1962), but was generally received 
positively by clinicians and dialysis nurses who recognised difficulties with current 
standard practice and were keen to engage with any research that might lead to an 
alternative. This attitude certainly aided in recruitment. Additionally, the RCT itself has 
actually guided and shaped clinical practice moving forward. Rather than the paradigm 
shift previously described and anticipated, we have observed a mission creep (Anon., 
2016), with ecAVG slowly becoming our local standard of care for patients requiring 
vascular access urgently. There has been significant stakeholder engagement at a clinical 
level, with nephrologists now referring directly to the surgical service for ecAVG rather 
than TCVC. Currently however, this ad hoc approach remains sporadic and under-
resourced. Large-scale implementation of this practice will require significant 
redistribution of resources and funding. As described, an access practice with a large 
number of ecAVG requires a commitment and provision to deal with the complications, 
especially thrombosis, expectantly. This requires investment in surgical services to provide 
adequate flexible theatre time and manpower without detracting from an elective service, 
which should still maintain an ethos of fistula primacy. In summary, this study highlights 
how research that answers an important clinical question, can be rapidly disseminated into 
a clinical environment. Moreover, the simply conducting the study, appears to have 
improved clinical outcomes with a reduction in overall Staph.aureus bacteraemia rates 
from 1.75 per 1,000 catheter days in September 2011 to 0.45 per 1,000 catheter days in 
September 2015 (P. Thomson, personal communication), a observation that, at least in 
part, can be attributed to an overall shift in the prevalent vascular access modality from 
TCVC to AVG.  
In conclusion, this study demonstrates that a strategy of ecAVG ±AVF for patients 
requiring urgent vascular access for haemodialysis reduces culture-proven bacteraemia rate 
and mortality at 6-months compared to TCVC ±AVF. The implementation of these 
findings into clinical practice will necessitate a paradigm shift in thinking towards vascular 
access, and supports a culture of “Fistula First” rather than “Line Last”. Successful 
vascular access provision requires a team-based approach that incorporates close 
integration between the prescription of care by nephrologists and the provision of care by 
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surgeons and interventional radiologists, within the wider context of provision of cure 
through renal transplantation. The successful delivery of this philosophy can help patients 
receive a more optimally tailored, “personalised vascular access solution”. 
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CONCLUSION 
 
10.1.  CONCLUSIONS 
 
Vascular access is the ‘key modifiable risk factor’ (National Kidney Care Vascular Access 
Report, 2012, pp.6) for mortality in patients on HD. Despite this, it remains 
underrepresented in the nephrology literature with fewer than 60 randomised controlled 
trials published in the worldwide literature prior to initiation of this thesis (Kian & Asif, 
2010; Inston & Jones, 2014). A niche audience, heterogeneous patient population and 
multiple non-standard outcome measures often hinder publication of studies of vascular 
access in high impact journals (Lok & Oliver, 2003).  The relative dearth of existing 
evidence presented a blank canvas and unique opportunity for the work presented in this 
thesis however. 
 
Contrary to the previous precedent, research in vascular access actually lends itself very 
well to randomised controlled trials (Inston & Jones, 2014). A high early AVF failure rate 
(30-40%) (Dember et al. 2008) means that it is possible to adequately power a study for an 
end-point of immediate thrombosis with fewer than 100 patients. The overwhelming 
importance of early maturation on long-term outcomes necessitates only short follow-up 
period to achieve clinically relevant results. It is possible to instigate RCTs of 
interventions, devices and operative technique that are not subject to the same especially 
stringent regulations and legislation as would be a drug study (Medicines and Healthcare 
Products Regulatory Agency, n.d). Furthermore, as an awareness of the potential role of 
AVGs refines, industry support is likely to assist in the funding of larger multicentre 
RCTs, which are expensive to run. It is vital that such studies remains clinician led and 
industry-supported, to ensure that the most appropriate and clinical relevant questions are 
asked.  
 
This thesis includes three novel randomised clinical trials of vascular access (operative 
technique, anaesthetic technique and a new device/product) each of which, unlike many 
other studies in renal medicine, had a positive result. The study presented in Chapter 6, 
which demonstrated superior patency at 3 months in AVF created under brachial plexus 
block compared to local anaesthesia, was recently published in the The Lancet and is one 
of only three vascular access publications ever published in a journal with impact factor 
>45. 
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The focus of this thesis has been on optimising vascular access in incident haemodialysis 
patients. It acknowledges the significant impact that vascular access has on early dialysis 
mortality and the legacy of poor early vascular access decision-making.  The importance 
“getting it right from the start” cannot be overemphasised (Lok, 2007). Mortality rates on 
haemodialysis are highest within the first year, with catheter-related infection the principal 
cause of death among these patients (UK Renal Registry, 2014.; USRDS, 2006.; Pietro 
Ravani et al. 2013). Patients who start dialysis via a line are more likely to remain with a 
line (Weber et al. 2009; UK Renal Registry, 2014.; National Kidney Care, 2012.). Data 
from the UK Renal Registry indicate that 59.8% of patients starting on a TCVC continue 
to dialyse via a TCVC at 3 months (UK Renal Registry, 2014) and the presence of a CVC 
at the time of dialysis commencing is associated with poorer AVF maturation (Brunori et 
al. 2005). Central venous stenosis can occur with just a few days of line exposure and has 
significant impact on longevity of future vascular access (Agarwal et al. 2007; Moist et al. 
2012; Jackson et al. 2014).  Within this thesis five distinct areas of practice relevant to 
incident vascular access creation have been explored: 
 
1. Central vein stenosis and avoidance of future problems. 
2. Predicting maturation of autologous access. 
3. Promotion of maturation of autologous access. 
4. Individualising vascular access provision. 
5. The problem of “crashlanders” . 
Chapters 5 and 6 describe randomised controlled trials of modifications in operative and 
anaesthetic technique aimed at optimising maturation of autologous AVF. Interventions to 
improve AVF maturation should minimise the number of unnecessary vascular access 
procedures and improve autologous vascular access usage amongst incident patients.  
Previous observational studies have demonstrated that modifications to suturing technique 
may affect anastomotic haemodynamics and affect early AVF thrombosis rates (Hong et 
al. 2013; Moini et al. 2009; Zeebregts et al. 2004), however the study presented in this 
thesis is the first RCT of a suturing technique to demonstrate differential outcomes in AVF 
patency. It has shown improved early (6-week) patency rates in radiocephalic fistulae 
created using an interrupted suturing technique compared to a continuous suturing 
technique. Similarly, prior observational studies have demonstrated improved blood flow 
at 8 weeks in AVF created under brachial plexus block (BPB) compared to local 
anaesthesia (LA) (Sahin et al. 2011), however the results presented in Chapter 6 are the 
first to demonstrate improvements in the clinically relevant end point of  primary patency 
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at 3 months in a randomised controlled trial comparing BPB to LA.  
The importance of tailoring vascular access to the individual is repeatedly highlighted 
throughout this thesis. The concept of the arteriovenous fistula as a ‘gold standard” 
vascular access (Fluck & Kumwenda, 2011) is challenged. Whilst, arteriovenous fistulae 
have traditionally been the access of choice, changing patient demographics and the 
evolution of graft technologies means that ‘the subject is in a perpetual state of evolution 
(therefore) gold standards are, by definition, almost never reached’ (Duggan, 1992 pp. 
1569) and may necessitate refining the definition of ‘gold standard’ towards a more 
patient-centred strategy. 
Chapter 2 describes the local experience in the West of Scotland with TCVC use and the 
changes that occurred following aggressive intervention to reduce line usage. These 
observational data demonstrated that, whilst in prevalent patients it was possible (with 
aggressive surgical intervention) to convert 20% of patients who were dialysing via a 
TCVC to an AVF, the majority (over two-thirds) were subjected to multiple failed 
interventions and associated morbidity with no resultant autologous AVF. This highlighted 
two important issues: firstly the difficulty in obtaining autologous access in prevalent 
patients after several failed attempts and the importance of getting it right from the start 
with incident patients; and secondly, that blindly enforcing a policy of “Fistula First” is not 
necessarily in the best interests of the individual patient (Drew & Lok, 2014). A fistula 
primacy at all costs approach will inevitably lead to inadvertent surgical fatigue and 
prolonged catheter dependence (Lok, 2007) and patient-centred care must therefore be 
considered “best practice” for vascular access provision (Drew & Lok 2014).  The 
emphasis of the research in this thesis is directed towards finding pragmatic, patient-
focussed solutions to clinically relevant problems. Likewise, Chapter 3 describes the 
legacy of poor vascular access decision-making in incident patients and highlights the 
difficulties in achieving sustainable vascular access in patients with bilateral central vein 
stenosis. A targetted and individualised approach is necessary in these patients with “end-
stage” vascular access also. Despite the difficulties, lower limb vascular access and HeRO 
grafts can prove effective in these complex patients, however an “exit strategy” in terms of 
cure through renal transplantation (expedited or otherwise) is necessary for long-term 
survival in most of these patients. 
Chapter 4 evaluated uraemia and renal function as a predictor for AVF maturation in pre-
dialysis patients. No association was found between eGFR at the time of access creation 
and either short or long-term patency. However increasing serum urea was associated with 
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worse clinical patency at 6 weeks and poorer long-term outcomes from RCF, suggesting 
for that the timing of AVF creation in pre-dialysis patients may actually influence AVF 
outcome. 
Chapters 7, 8 and 9 describe our work with ecAVGs and highlight the role that these novel 
devices may play in clinical practice, particularly in relation to incident haemodialysis 
patients and “crashlanders”. The evolution of a practice is described from the initial case 
series, through modification of the technique, development of a concept in the “virtual 
study”, to implementation in a RCT. The early case series with Gore® ACUSEAL 
highlights the versatility of the graft in a range of clinical settings including “end-stage” 
complex vascular access patients and as a “bridge” to alternative vascular access. The 
potential role of an ecAVG as an alternative to TCVC in “crashlanders” and incident 
patients requiring expectant vascular access was highlighted. Complication rates, 
particularly venous stenosis, infection and pseudoaneurysm, were high in the early patient 
cohort and modifications of operative and cannulation technique acquired through 
experiential learning and education have been described (Chapter 7). The “virtual study” 
(Chapter 8) represents progression of the concept of the role of ecAVGs by demonstrating, 
in a feasibility study, that ecAVG can provide an acceptable, practicable and cost-effective 
alternative to TCVCs. Finally the randomised controlled trial (Chapter 9) confirms a 
significantly lower rate of access related bacteraemia at 6 months in patients requiring 
“urgent” vascular access with ecAVG compared to TCVC. 
Traditionally TCVC have been considered default in patients without mature autologous 
access who require to start haemodialysis. From the outset of the work with ecAVG it was 
anticipated that the implementation of ecAVG into clinical practice for this purpose would 
necessitate a “paradigm shift”(Rodriguez et al. 2000) in thinking on vascular access. In 
fact, a gradual “mission creep” (Anon., 2016) of practice change has been observed. In the 
past five years, as the combined local experience of ecAVG has grown, there has been a 
gradual shift away from TCVCs in favour of ecAVGs. This is an excellent example of how 
the research described in this thesis has rapidly shaped clinical practice. Moreover, I was 
surprised and intrigued to observe the almost symbiotic relationship between the research 
described in this thesis and practice development, particularly in relation to ecAVG. A few 
“early adopters” who modified the operative technique through experiential learning 
initially embraced the concept. Education was vital in those early stages. Further uptake 
and adoption of ecAVGs into routine clinical practice in our unit was expedited by the 
existence of the randomised trial. The clinical trial drew interest to an otherwise 
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underrecognised area of practice and many clinicians became engaged in discussion on the 
role of ecAVG. Whilst it is evident that the RCT could not have progressed were it not for 
a rapid expansion in the clinical service, it is also my belief that the service would not have 
expanded so rapidly were it not for engagement with the clinical trial. This highlights the 
importance of the integration of clinical research into clinical practice with gains and 
benefits evident for both parties. Research, quality improvement and practice development 
are not independent of each other and may actually draw mutually beneficial conclusions. 
 
10.2. MOVING FORWARD: IMPLEMENTATION INTO CLINICAL PRACTICE 
 
Locally, the findings of the RCTs on suturing and anaesthetic techniques have been almost 
universally adopted into clinical practice as examples of evidence-based medicine 
informing clinical practice. Resource issues regarding the availability of trained 
anaesthetists and additional time added to the procedure are currently limiting the universal 
adoption of BPB for simple AVF creation. 
 
As described above, the implementation of an ecAVG practice has been exponential. The 
early adaptations to practice involved modification of operative or cannulation technique, 
however the latter changes relate to the evolution and modification of an entire service. 
Over the past few years, during which this research was conducted, the number of AVGs 
used in prevalent patients in the West of Scotland has increased from 0.8% (October 2011) 
to 5.9% (October 2016). Nearly 10% of incident patients now commence dialysis via an 
ecAVG (P. Thomson, personal communication). Such a change in practice has, and will, 
necessitate redistribution of resources, away for the radiology service, that traditionally 
inserted TCVCs, to the surgical service to support an increase in the number of ecAVG 
procedures. Furthermore, the unpredictable nature of the need to insert and 
thrombectomise grafts requires a previously unnecessary flexibility in access to theatre 
time and manpower. The ecAVG “package” is an excellent example of the importance of 
“process”, rather than simply a procedure, in driving change and improving quality of care 
(Stevenson et al. 2007). Currently this remains a fluid situation and is likely to continue to 
evolve as the exact role for ecAVGs in clinical practice emerges. 
As alluded to previously, the research presented in this thesis forms part of the work to 
develop a fledgling Vascular Access Service in Glasgow. The clinical and academic 
aspects of this service have developed in parallel. In 2011 only 42% of incident patients at 
our institution commenced HD via an AVF; the Staph.aureus bacteraemia rate was 1.8 per 
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1,000 access days; >10% of patients had bilateral CVS (the legacy of years of poor 
vascular access decision-making); and there was one Vascular Access Nurse Specialist 
(whose role it was to co-ordinate TCVC insertion). There was an ethos of absolute 
autologous primacy. Now, despite the fact that still fewer than half of our incident patients 
commence dialysis via an AVF, the Staph.aureus bacteraemia rate is only 0.8 per 1,000 
catheter days; only 3% of patients have bilateral CVS; and there is a dedicated Vascular 
Access Multidisciplinary Team. The focus is now on individualised care with the aim to 
provide every patient a “personal vascular access solution”. The local service has expanded 
rapidly and the team has taken a coordinating role in the improvement of vascular access 
services nationally with the publication of the Scottish Haemodialysis Vascular Access 
Appraisal (Oliver et al. 2015). 
Personally, it has been an exciting time to be involved in vascular access research. Locally, 
the rapid expansion of a service has provided me with great scope to undertake varied 
research and also take an active role in service development and quality improvement. 
Globally, the last couple of years have brought increased recognition of the need for and 
opportunities that research into vascular access provides. Since 2011, there have been over 
2,000 peer-reviewed publications (including 15 RCTs) on vascular access. 20% of the 
randomised controlled trials in the vascular access world literature in the past 5 years are 
presented in this thesis.  
 
10.3.  FUTURE RESEARCH 
 
Our work on ecAVGs and incident patients has highlighted the lack of standardised 
definitions for access infection and functional patency in patients not yet established on 
dialysis. Whilst definitions of catheter-related bacteraemia (Taylor et al. 2002; Thomson et 
al. 2010) and functional patency in maintenance dialysis patients (Sidawy et al. 2008) are 
well established, terminology for graft infection and functional patency in pre-dialysis 
patients is not. In our studies, we have used a combination of the ultrasound-based “rule of 
6s” (NKF-KDOQI, 2006) and clinician assessment to define functional patency in pre-
dialysis patients. We found 100% concordance between the two measures; however both 
are arbitrary, historical and have not been validated. Similarly we have observed that, 
whilst systemic bacteraemia rates associated with AVGs are significantly lower than 
TCVCs, the pattern of infective complications differs significantly and would caution 
against using similar terminology to compare the differ access modalities as definitions of 
systemic bacteraemia are likely to underestimate the burden of infection associated with 
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AVGs. Instead we propose a range of terms to fully characterise graft infections: a. local 
vs. systemic; b. culture proven vs. suspected; c. temporal (early infections are commonly 
localised associated with post-operative haematoma; late infections are generally 
associated with inoculation from cannulation and often lead to systemic bacteraemia) 
(Kingsmore, 2016). 
 
One of the limitations of current research in vascular access is the heterogeneous nature of 
the patient cohort. Whilst this is reflective of the “real-world” practice encountered by the 
clinician, the “dirty data” obtained from research in a mixed patient cohort limits 
reproducibility and can lead to difficulties in publication. (Certainly this author has often 
received feedback from reviewers that the variation in the patient cohort limits 
transferability and clinical applicability). Future research is likely to need to target more 
specific patient groups e.g. “crashlanders” or “end stage access”. Clearly defined 
terminology for these patient cohorts will also be necessary, particularly since recruitment 
of patients from small, specific patient cohorts is likely to need greater collaboration and 
multicentre trials (thus far lacking in vascular access). 
Future randomised controlled trials need to ask clinically relevant questions of the right 
patient groups. We have demonstrated the benefit of ecAVGs over TCVCs in provided 
immediate vascular access for dialysis, however it is likely the AVGs have an additional 
role in other clinical settings. The demographic of the dialysis population is changing. 
Elderly, co-morbid patients are now the norm (Scottish Renal Registry, 2015). Previously 
held-beliefs, for example the ‘gold standard’ standard arteriovenous fistula and start 
distally and work proximally when planning autologous access need to be challenged 
(Fluck & Kumwenda, 2011; NKF-KDOQI, 2006). The previously published RCTs 
comparing AVGs to AVFs failed to address true clinical problems, instead comparing BBF 
to forearm loop grafts (Keuter et al. 2008) and forearm loops with primary RCF in patients 
with suboptimal vessels (Rooijens et al. 2005). At the time, both studies found that the 
prosthetic graft required more interventions to maintain patency, adding support to the 
ethos of “Fistula First”.  Latterly however, the high primary failure rate of autologous 
access in an aging, co-morbid dialysis population, coupled with a resurgence in interest in 
the role of AVGs, mean that the scene may once again be set for a multicentre RCT of 
prosthetic versus autologous access.  
In my opinion the following are the most important contemporaneous clinical questions in 
vascular access that could be answered via RCT: 
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1. Brachiobasilic fistula versus brachioaxillary graft in patients with no or failed 
cephalic options? 
2. Pre-emptive AVF or “watch-and wait” (±ecAVG) for pre-dialysis patients over 70 
years old 
3. “Distal first” versus “single best option” for autologous access 
It is my intention to continue clinical research in vascular access, taking forward these 
questions into multicentre randomised controlled trials in the coming year. 
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APPENDIX 1: KIRKPATRICK’S MODEL OF TRAINING 
EVALUATION ADAPTED FOR ecAVG COURSE 
 
 
The model uses four levels: reaction, learning, behaviour and results to evaluate the 
success of any training intervention. The description below outlines how the model was 
adapted specifically to evaluate outcome of the graft courses. 
 
1. Reaction: Participants completed questionnaires immediately following the course 
and six weeks later to evaluate their reactions and response to the course. A 
combination of closed (outlined below) and open questions (with opportunity for 
free text responses) were used. Participants were asked to answer each response as 
strong agree; agree; neutral; disagree or strongly disagree. 
 
The course was well organized 
The course was clear and easy to understand 
The course improved my knowledge concerning the subject 
The course improved my skills concerning the subject 
The course developed my ability to think critically about the subject 
I will be able to apply the knowledge and skills from my course to my job 
The course was a good use of my time 
I would recommend the course to others 
 
 
2. Learning: Nurses knowledge of arteriovenous grafts and early cannulation grafts 
was assessed prior to and following the course by asking five simple questions: 
 
x Can you describe the anatomy of a brachioaxillary graft? 
x Where is the venous outflow? 
x How should the graft be assessed prior to cannulation? 
x Which needles should be used to cannulate an ecAVG? 
x How long should you press for after the needles come out of an ecAVG? 
 
Additionally participants were asked to comment on what they had learned 
following the course. Common themes in the domains of knowledge, skills and 
attitudes were identified. 
 
3. Behaviour: The transfer of skills back into the workplace was assessed. Surgeons 
and dialysis nurses were contacted 3 months following participation in the course. 
Surgeons were asked if they had inserted any ecAVGs in their practice and if so 
how many. Dialysis nurses were asked if had they cannulated any ecAVGs and did 
they do so on a regular basis (i.e. more than once a week)?  
 
Additionally, given that at the second course, a whole team of surgeons, 
nephrologists and vascular access nurses attended from Belfast an evaluation of 
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practice in Belfast prior to and following the course was assessed to evaluate 
dissemination of practice from one institution to another. 
 
4. Outcomes: Prior to the course we perceived a relatively high rate of graft 
complications locally (as has been reported in the early Gore®ACUSEAL cohort 
(Aitken et al. 2014c)). The number of graft complications (infection, stenosis, 
thrombosis, pseudoaneurysm/ rupture) in the three years prior to (early cohort) and 
the six months following the course (later cohort) were compared to evaluate if 
change in behaviour translating into change in clinical outcomes. 
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APPENDIX 2: PHOTOGRAPHS FROM THE ecAVG COURSE 
 
 
 
A model was used to demonstrate the anatomy of upper and lower limb grafts and 
highlight where needles should be sited. 
 
 
Patients with grafts attended help teach vascular access examination skills 
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APPENDIX 3: BLAND ALTMAN PLOTS OF BRACHIAL ARTERY 
BLOOD FLOW AND VESSEL DIAMETER 
Bland Altman plots showing intraobserver variability in the measurement of brachial 
artery diameter, cephalic vein diameter and brachial artery blood flow. Dashed line 
represents bias and the dotted-dashed line represents 95% limits of agreement. A. 
Brachial artery diameter (95% limit of agreement: -0.31, 0.33mm). B. Cephalic vein 
diameter (95% limit of agreement: -0.53, 0.47mm). C. Brachial artery blood flow 
(95% limit of agreement: -10.9, 7.6mL/min).  A. 
 B. 
  C. 
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